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Optimising polymeric nanocarrier environments to encapsulate and deliver highly potent 
anti-cancer drug SN-38 
Chemotherapy is undeniably a highly effective cancer treatment, which has saved or 
prolonged many patients’ lives.  However, its indiscriminate nature, acute toxicities and low 
aqueous solubility has limited the ability to achieve maximum therapeutic effectiveness and 
usage clinically. Irinotecan, a water-soluble prodrug of highly potent SN-38, is used clinically 
to treat multiple cancers. The active metabolite, SN-38, exhibits 100- to 1000- fold more 
cytotoxicity compared to irinotecan, but the metabolism of irinotecan to SN-38 is highly 
inefficient with significant interpatient variability. Direct administration of SN-38 is highly 
desirable; however, the extreme hydrophobicity exhibited by SN-38 has prevented its clinical 
use. Herein, branched vinyl copolymer nanoparticles have been utilised to encapsulate SN-
38, offering sustained release profiles and superior in vitro cytotoxic behaviour compared to 
irinotecan. Co-nanoprecipitation has proven to be a fast, reproducible and efficient 
nanoformulation technique for the preparation of sterically stabilised SN-38 loaded 
branched vinyl copolymer aqueous nanoparticle dispersions. The preparation of which 
involved the simultaneous nanoprecipitation of highly branched hydrophobic vinyl 
copolymers with amphiphilic PEG-based AB block copolymers and SN-38. Methanolic atom 
transfer radical polymerisation, a versatile polymerisation technique, was used for the 
production of novel hydrophobic branched vinyl polymers and AB block copolymers; this 
provided an easy synthetic strategy to impart different polymer characteristics through 
varying different monomer chemistries. Fundamental studies were carried out to gain an 
understanding of how these differing polymer chemistries affected the formation of the 
nanoparticles and their stability, and in-turn influenced the drug loading capabilities and 
subsequent in vitro and in vivo pharmacological behaviour. The SN-38 loaded nanoparticles 
were characterised with small sizes (< 180 nm), slight negative charges (< -20 mV) and 
respectable drug loadings (< 10 wt.%) with high drug encapsulation efficiencies (> 88%) and 
extremely low IC50 values following in vitro analyses in both human and murine cancer cell 
lines. Radiometric labelling of SN-38 allowed for the release profiles to be accurately 
determined and highlighted that the particles offer sustained, slow release at physiological 
relevant conditions (< 17% release).  Overall, it has been demonstrated that SN-38 can be 
successfully encapsulated within aqueous branched vinyl copolymer nanoparticle 
dispersions, which display promising in vitro behaviour; thereby providing an opportunity to 
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1.1 Cancer  
The term cancer is given to a group of diseases in which there is an accumulation of 
abnormal cells as a consequence of a mutation to one or more genes.1 This usually 
results in the uncontrollable proliferation of the cancerous cells and the rapid growth 
of the malignant tumour - a clear violation to the maintenance of a healthy cell 
system. These tumours are also capable of metastasis, where cells from the primary 
tumour can relocate to secondary sites within the body, thereby causing the spread 
of the disease.  The World Health Organisation (WHO) reported that in 2018, cancer 
was the second leading cause of death globally and accounted for 9.6 million deaths.2 
There are over 200 different variants of the disease and it can be noted that there is 
an increasing prevalence and diagnosis within economically developed countries.  In 
the UK, there was 367,000 incidences of cancer (2017)  and the four most common 
diagnosed were  breast, prostate, lung and bowel; cumulatively, they accounted for 
over half (53%) of all new  cancer cases, as highlighted in Figure 1.1.3   
 
Figure 1.1 The 20 most common cancers in the UK (2017) and their respective numbers of 
cases for both males (blue bar) and females (pink bar). Graphic Credit: Cancer Research UK. 
It is predicted that the number of new cancer cases diagnosed in the UK will rise to 
over half a million per year by 2035, an increase of over 40% compared to 2015.4,5 
Whilst the risk of developing cancer depends on many different factors including 




lifestyle choices, increasing populations and rising life expectancies. Although the 
quality of services available to cancer patients has dramatically improved UK survival 
rates in recent decades, with a 10-year survival rate progressing from 1-in-4 during 
the 1970s to 1-in-2 in 2010, the UK still finds itself with a lower five-year survival rate 
in comparison to other developed countries such as Australia, Sweden, New Zealand 
and Canada.6 It is believed that this difference is likely due to the variances in the 
treatments given to patients, together with the fact that diagnoses in the UK are 
typically made later in the disease development.6 Clearly, cancer has a huge and 
devastating impact on human life, but it also places huge financial stress on to the 
National Health Service (NHS), with the National Audit Office estimating an annual 
expenditure of approximately £6.7 billion in 2009; given that the incidence of cases 
has increased, it is certain that this figure of expenditure will have increased too.7 
In 2011, the Department for Health and Social Care aimed to address these issues by 
launching the National Cancer Strategy in partnership with cancer charities, research 
institutes and healthcare professionals.8 The aims of the strategy were to: (1) raise 
further awareness of the disease and increase screening processes to enable earlier 
diagnosis, (2) provide funding opportunities for researchers to improve the range and 
efficacy of available treatments, and finally, (3) challenge societal unhealthy lifestyles 
and advocate the reduction in risk factors, such as occupational exposure to harmful 
materials.  By investing into the research and development of new and existing 
treatments and diagnostic tests, and generating resources to educate society about 
lifestyle choices, it could help to reduce the financial outlay on the NHS. Successful 
research in those areas could lower the cost by: reducing the overall incidence of 
cancer; increasing the number of cancer cases detected early in the disease 
development, thereby providing opportunity for more cost-effective treatment 
options; reducing the therapeutic dose by improving the efficiency of existing 
treatments.  
Whilst providing financial relief to the NHS is clearly advantageous, the ultimate 
driving force behind research investments comes from our societal conscience to 
improve the outcomes for patients diagnosed with cancer, not just in the UK but 




1.1.2 Bowel Cancer 
The continual regeneration of the epithelial cells lining the bowel is essential to 
maintaining good health; however, gene mutation can result in the formation of 
polyps, common amongst the older population.9 Most polyps are not typically 
cancerous and can be removed easily. However, bowel cancer, alternatively referred 
to as colorectal cancer (CRC), arises from a polyp that has shown abnormal behaviour 
and has developed into an advanced adenoma.10 
In 2018, approximately 1.8 million new cases of CRC were diagnosed worldwide, 
making it the third most commonly diagnosed malignancy.11 CRC incidence has been 
growing steadily worldwide and is forecast to rise to 2.2 million cases annually by 
2030,12 indicating that there is a growing demand for effective treatments of CRC.13 
The main contributing factors to the increase in incidence cases are: sedentary 
lifestyles, rising prevalence of obesity, and excessive alcohol, tobacco and red meat 
consumption. Case numbers are rapidly rising in developing countries who are 
undergoing speedy economic and societal changes and transitioning to a more 
western lifestyle.14  
As previously mentioned, CRC is the fourth most commonly diagnosed cancer within 
the UK, accounting for approximately 11% of all new cancer cases (2017), but it is the 
second most common cause of cancer death within the UK, accounting for 10% of all 
UK cancer deaths (2017).15 As with all cancers, when a tumour has developed in CRC, 
the course of treatment recommended will depend on what stage the cancer is and 
the individual patient. 
1.1.3 Conventional Cancer Treatments  
Cancer treatment’s first aim is to cure the disease where possible by shrinking, or 
stopping the progression of cancer cells. Should that not be possible due to advanced 
disease then the treatment should look to palliate.16, 17 There are many different 
types of cancer treatments available and the type of cancer and how advanced it is 
will dictate which treatment option is most applicable. The most commonly known 
options are: radiation therapy, chemotherapy and surgery, which is appropriate in 
cases where physical tumour mass can be accessed, with minimal risk, and removed. 




tissue, if localised.18, 19  Other alternative, lesser known treatments include, hormone 
therapy, immunotherapy and stem cell therapies. 18, 19 
The inherent ability of metastasis from cancer cells usually means that the most 
applicable form of treatment is chemotherapy, since the cancer is no longer localised. 
This involves the intravenous (IV) administration of cytotoxic drugs, henceforth 
referred to as chemotherapeutics, which are designed to kill cells. The mechanism of 
which is complex and drug dependent, but in brief they typically disrupt the cells 
ability to divide. This is achieved by causing damage to the RNA or DNA which is 
responsible for informing a cell’s replication during the division process.20 Simply, if 
the cancer cells cannot divide they will die. IV infusion allows for the rapid entry of 
molecules into the systemic circulation. It also provides predictable 
pharmacokinetics and offers the quickest drug absorption time compared to other 
methods, such as oral administration.21  
Chemotherapy is often administered in cycles to patients and a combination of 
chemotherapeutics can be used. Which chemotherapeutic is used is decided based 
on a number of different factors such as: the type of the cancer cells, the rate of cell 
division and also whether there are any secondary cancer sites present.22 There are 
two different types of chemotherapeutics: cell-cycle specific therapies, which target 
the cancer cell when they are dividing and, on the contrary, cell-cycle nonspecific 
therapies, which kill the cells when they are at rest. Chemotherapeutics can be 
typically categorised as platinum based or non-metallic,23, 24 the latter leading to the 
discovery and development of a number of organic chemotherapeutics, such as: 
doxorubicin, fluorouracil, taxanes and campothecin derived agents.  
1.1.3.1 Bowel Cancer Treatments  
There have been significant advances made in the treatment of CRC over the past 30 
years, which have resulted in patients having a higher chance of cure and, when cure 
is not achievable, longer survival times with their disease.25 The choice of treatment 
for bowel cancer is based on several factors, including stage at presentation, location, 
and the conditions of the patient.  The preferential and most common treatment 




CRC receiving surgery as part of their primary cancer treatment.15   Surgery is 
dependent on a substantial proportion of the tumour being able to be removed. 
Often, this is done in combination with a cycle of chemotherapy to cause tumour 
shrinkage (and therefore make the surgery easier) or to reduce the risk of the cancer 
returning after tumour removal. However, when surgery is not a viable option, 
chemotherapy is the secondary preferred route of treatment. Approximately 31% of 
bowel cancer patients will receive some form of chemotherapy as part of their 
primary cancer treatment. Reasons why surgery is not viable include late stage 
diagnosis meaning that the cancer has spread to other parts of the body, such as the 
liver or lungs, or that the patient is not a suitable candidate for surgery due to other 
health complications or poor recovery predictions.  
There are many different chemotherapeutic agents that can be administered for the 
treatment of CRC but the most common are 5-fluorouracil (5-FU), oxaliplatin and 
irinotecan (IR).26 Often, these are administered in combination and can be given as a 
tablet or intravenously infused. IR, a prodrug which is converted in vivo to biologically 
active metabolite 7-ethyl-10-hydroxy-campothecien (SN-38; Scheme 1.1), has also 
been established as an effective treatment as a single agent.27  
 
Scheme 1.1 Schematic representation of the conversion of inactive prodrug irinotecan to the active metabolite 
SN- 38. 
It has been shown that the potent anti-cancer activity of IR is due to this rapid 
formation of SN- 38.  The potency of SN-38 relative to IR varies between patients but 
it is reported to have 100- to 1000-fold higher cytotoxic activity compared to the 
original parent drug dependant on conversion rates.28 29 Although, conversion 
between the prodrug and SN-38 suffers from interindividual variability and the 




are discussed in more detail in Chapter 4.30 Direct administration of SN-38, although 
desirable, is not possible due to the extremely low water solubility and other 
associated pharmacological problems it presents. 
1.1.3.2 Limitations to Chemotherapy Treatments  
Whilst the use of chemotherapeutics has played a major role in the reduction to 
morbidity and enhancement of the quality of patients’ lives, there are often concerns 
associated with their use and other factors which decrease the clinical effectiveness 
of these agents.  
The nonspecific distribution of chemotherapeutics within the body can result in 
severe off-target toxicities and, as effective as chemotherapeutics are at causing cell 
death, the chemotherapeutics unfortunately cannot distinguish between healthy 
and non-healthy (or cancerous) cells; thereby accumulation of these highly toxic 
drugs also occurs within healthy cells. This results in some adverse side effects such 
as: diarrhoea, nausea, mouth sores, low blood counts and hair loss. These are the 
most commonly experienced side effects since the cells found in hair follicles, bone 
marrow, gut epithelium and skin often display high mitotic activity and thereby are 
most likely to respond to chemotherapeutics that affect cell division.31 These side 
effects are caused by most chemotherapeutics, but there are some side effects which 
are  drug-specific, such as cardiotoxicity experienced by administration of 
anthracyclines (a class of chemotherapeutics).32  
In addition to the poor specificity chemotherapeutics display, they are also presented 
with a variety of different obstacles upon their administration into the body which 
also limits their effectiveness. Chemotherapeutics often will extensively bind to body 
tissues and serum proteins upon administration in an unpredictable manner in 
comparison to other drug classes. This offers unique problems and unfavourable 
pharmacokinetic profiles such as short half-life in blood circulation, high clearance 
rates and susceptibility to induce drug resistance within cancer cells.33  
Other factors which constrain the clinical effectiveness of chemotherapeutics also 
include the suboptimal penetration into tumour tissue and their poor aqueous 




Approximately 40% of developed pharmaceuticals are practically insoluble in water, 
rendering them unsuitable for purpose and many of the commonly used 
chemotherapeutics are no exception, often displaying high lipophilicity and low 
water-solubility characteristics.34 As specified by the Biopharmaceuticals 
Classification System a drug is considered to be poorly water soluble “if the maximum 
dose strength is insoluble in 250 mL or less aqueous media over a pH range from 1 – 
7.5.” 35 This poor water solubility typically arises due to two reasons: (1) the 
hydrophobic nature of the drug molecule meaning that they have limited ability to 
form hydrogen bonds with surrounding water molecules and (2) the typical bulky 
cyclic nature of most chemotherapeutics and the subsequent high lattice energy 
required to break down the solid molecule. This poor water solubility is one of the 
main reasons why most new drug molecules fail to fulfil their potential as therapeutic 
candidates and do not make it to clinic. Given that chemotherapeutics are generally 
administered in aqueous solutions, this poses a problem.  
Currently, to overcome the poor solubility issues displayed, the chemotherapeutics 
are often mixed with various different solubilisers or co-solvents in order to maximise 
their water solubility and improve their therapeutic efficacy. However, the efficiency 
of solubilisation is directly related to the polarity of the compound which can limit 
the use of this technique.36-38 Also, when using co-solvents and stabilising agents, it 
is important to consider the effects that these may have to the overall toxicity 
experienced directly or indirectly by the patient.39   
Whilst the use of solubilizers or co-solvents may improve the observed saturation 
solubility, it does not address the other aforementioned issues associated with the 
use of chemotherapeutics. The combination of inherent problems results in only a 
small fraction of the administered dose reaching the tumour site and thereby 
reducing the therapeutic efficacy and increasing systemic drug toxicity. These 
challenges are diverse and complex and must be overcome by the 
chemotherapeutics in order to successfully perform their anti-cancer functions in a 




To overcome the aforementioned problems associated with the administration of 
chemotherapeutics, an attractive strategy that has received considerable interest 
and research development over the last few decades involves the formulation of 
chemotherapeutics within nanoscale drug carrying platforms, which will be discussed 
in detail in Section 1.2. Such systems have been used for disease treatment and 
prevention and some of the key advantages of using these drug carrying platforms 
include improved pharmacokinetics, longer circulation half-lives and targeted drug 
delivery thereby decreasing off-target toxicity.40  
1.2 Nanomedicine 
Given the huge scientific and technological developments that have been made in 
the last 60 years, it would be fair to assume that this would have aided new drug 
discovery. However, it has somewhat had the opposite effect with more drugs failing 
during their clinical development now than in the 1970s.41 A combination of stricter 
regulations, reproducibility issues and rising research and development costs can all 
be assumed to be contributing factors. As disease incidence continues to rise, 
pressures of finding new drugs to “cure” disease, particularly cancer, remains at the 
forefront of discussion. Yet due to the complexity of the stages involved in drug 
discovery, research has slowed with limited outputs. There are also significant 
financial and time costs associated with new drug discovery.  
Nanomedicine provides an attractive strategy to overcome these limitations. The 
main objective is not to discover new drugs but to improve therapeutic outcomes of 
existing medicines or those that have failed late stage clinical tests, and to develop 
new therapeutic strategies of administration. 
1.2.1 What is Nanomedicine? 
Nanomedicine is an evolving sub-discipline of nanotechnology, but its official 
definition continues to be an area of controversy and one would find many different 
definitions. For the clarity of the work being presented within this thesis, 
nanomedicine is the use and application of a material, whose size exists within a 
region between 1-1000 nm, within a medicinal environment.35, 42 The concept of 
working at the nanoscale is not novel, but the developments in the ability to be able 




are organised at the nanoscale has propelled the area into becoming one of the key 
areas of research in the 21st century,43 receiving significant attention from funding 
agencies, regulatory bodies, academic research groups and global government 
agencies.44, 45  
Developing a nanomedicine is a time-consuming process which is usually divided into 
three main stages: development of a proof-of-concept demonstration, clinical 
development and investigations, followed by the generation of a commercialised 
product.46 The first stage generally occupies the most time, typically up to 20 years, 
since it can be subdivided into three sections: preliminary research, development of 
the intended application followed by preclinical animal studies. There are many 
biomedical applications which exploit the use of nanomedicines such as diagnosis 
and treatment of disease, regenerative medicine and molecular imaging. 47, 48 
One area in which nanomedicine has proven to be particularly advantageous is its 
application within the field of oncology.49 The utilisation of such has seen 
improvements made to imaging and treatments of cancer.50 The inherent problems 
conventional cancer treatments possess - low specificity, rapid drug clearance, 
biodegradation and limited targeting - can be potentially addressed by the use of 
nanocarriers.51, 52 Nanocarriers can be referred to as drug delivery systems (DDS), 
which are engineered materials in the nanoscale size region used for the targeted 
delivery and/or release of therapeutic agents.53 The DDS utilised may offer several 
advantageous attributes and opportunities such as, size, high surface area to volume 
ratio, targeting modifications and stimuli responsive behaviour, all of which can 
favourably work in unison or complement each other to deliver drugs in a stable, 
controlled manner.51, 54 There are many different type of nanocarriers, with the most 
relevant examples being discussed below.   
1.2.2 The Different Types of DDS 
DDS can be applied to a wide range of different disease treatments including: Human 
Immunodeficiency Virus (HIV),55 respiratory disease,56 Alzheimer’s disease,57 




The desire to deliver potent therapeutic agents intact to their intended site of action 
whilst minimising adverse side effects can be achieved by utilising a DDS.60 Other 
advantages include improving the drug bioavailability, enhancing therapeutic effect, 
improved permeation of drugs across biological barriers (e.g. gut and blood brain 
barrier), and the alteration of the pharmacological properties of the drugs (e.g. 
stability) in the hope to see improvements without altering the active drug molecule 
itself.61, 62 There are a wide variety of material platforms being investigated as DDS 
candidates: inorganic,63 lipid-based,64 polymer-based65 and drug conjugates (Figure 
1.2). 66-68  
 
Figure 1.2 Overview of the material platforms currently being investigated as drug delivery systems. Figure 
adapted from reference 69. 
An example of a lipid-based DDS is a liposome, which is formed when phospholipids 




Bangham and co-workers in the 1960s, who observed the spontaneous formation of 
a three-dimensional intricate structure that was formed when egg lecithin was 
exposed to water.71 A liposome consists of a phospholipid bilayer which is 
amphiphilic in nature, thereby providing liposomes with the capability to encapsulate 
both hydrophilic and hydrophobic payloads. They also exhibit high levels of 
biocompatibility.72 In addition to this, liposomes, like other DDS, can protect drug 
molecules from degradation and reduce the premature removal from the body by 
opsonisation.35  This is the process, whereby opsonin proteins can bind to the surface 
of the nanoparticles, allowing immune recognition and subsequently trigger 
clearance from the body by various different mechanisms.73  
Some of the drawbacks associated with the use of liposomes include: their complex 
manufacture, leakage of encapsulated drugs/molecules, low solubility and the 
potential for oxidation and hydrolysis of the phospholipids.74  
In 1995, a liposome-based DDS, known as Doxil, was approved by the Food and Drug 
Administration (FDA) for use in anti-cancer treatments. The formulation 
encapsulated the chemotherapeutic, Doxorubicin.75 The success of Doxil is owed to 
its prolonged systemic circulation that enables the DDS to exploit the Enhanced 
Permeation and Retention effect (EPR) - a pharmacokinetic principle that will be 
discussed in further detail in Section 1.2.3. In 2017, there were fifteen clinically 
available liposomal formulations being used to treat a variety of diseases, seven of 
which were specific to anti-cancer treatments.76 In addition to these, there are 
numerous other formulations that have made it through to various stages of clinical 
trial. One of interest is a liposomal encapsulation of SN-38 (LE-SN38) developed by 
Neopharm for the treatment of late stage CRC. The work was inspired by the clinical 
success of Camptosar (irinotecan) that had been developed by Pfizer, and aimed to 
directly encapsulate SN-38. It was hoped that this formulation would improve 
efficacy of the treatment whilst ensuring that the overall toxicity of the drug was not 
increased. LE-SN38 was evaluated successfully in phase I, but failed phase II trials.77,78 
Despite the formulation preventing any further disease growth, the tumours did not 
display any sign of shrinkage and it was concluded that the formulation did not meet 




Another example of a lipid-based DDS is a solid lipid nanoparticle (SLN), which 
consists of a solid lipid core, which can carry lipophilic payloads, that is typically 
stabilised by a range of polymer-based surfactants to prevent particle agglomeration. 
The main advantages of SLNs include: the water-based synthesis thus avoiding 
organic solvent use; the ease of scale-up compared to liposomal formulations; the 
cost of manufacturing is typically less than other polymer-based DDS; and finally, 
their excellent biodegradability and biocompatibility.80 However, one disadvantage 
of SLNs is that they typically display low drug loadings due to the limited solubility of 
the drug in the lipid melt: if the structure of the lipid matrix comprises molecules that 
are too similar in nature, a highly crystalline matrix is formed that hinders drug 
encapsulation. Therefore, more complex lipids are required in order to facilitate high 
drug loadings. There are many different types of lipids that can be used to yield SLNs. 
These include triglycerides, steroids, waxes and fatty acids, all of which offer different 
opportunities to the formulation. A lot of research has been conducted into SLNs and 
they have many applications ranging from gene vector carriers to cosmeceuticals to 
applications in agriculture. The use of SLNS within cancer research has been 
extensively researched, examples including docetaxel, doxorubicin and SN-38.33, 81  
Micelles based DDS are formed from the self-assembly of amphiphilic molecules, 
including block copolymers, upon their addition to water. Amphiphilic block 
copolymers are comprised of 2 segments: one hydrophobic and one hydrophilic. The 
self-assembly is driven by the unfavourable interaction between water and the 
hydrophobic segment of the block copolymer. 82 The shape of these DDS is dictated 
by: (1) the head group size and the degree of steric hinderance, (2) the length of the 
hydrophobic tail, and (3) whether the surfactant is ionic or non-ionic in nature. 
Typical shapes include spheres, cylinders and rods. It is possible for micelles to 
encapsulate hydrophobic drug molecules within their cores.83 This has resulted in this 
form of DDS receiving significant attention as drug nanocarriers in the treatment of 
many cancers. Examples include the encapsulation of paclitaxel for the treatment of 
ovarian, breast and small cell lung cancer.84, 85 These formulations showed high drug 
loading capacities and good treatment efficiency in patients.86 Similarly this was also 




associated with the use of micelles as DDS include: (1) the potential for drug-leakage 
from the polymer assembly, thereby reducing drug circulation half-life, and (2) the 
poor stability of the micelles within the blood stream.88, 89 
A leading class of DDS system for clinical translation are solid drug nanoparticles 
(SDNs). They do not employ a guest-host mechanism, as the active pharmaceutical 
ingredient is not encapsulated but instead forms the solid core of the nanoparticle, 
which is stabilised by polymers and surfactants.90  This, in principle, means that 
higher drug loadings, relative to stabilisers, can be achieved in comparison to systems 
made up of other chemical entities which simply host the payload, such as micelles 
and liposomes. One method of preparation for SDNs is the emulsion templated 
freeze-drying method, which is a relatively simple process.91-94 Firstly, the formation 
of an oil-in-water emulsion is achieved by sonication. Following this, it is then rapidly 
frozen in liquid nitrogen, thereby entrapping droplets within a solid emulsion 
template. Then, the sample is subjected to freeze drying to remove the aqueous and 
non-aqueous phase leaving behind a monolith of water-soluble polymers and 
surfactants, with particles of drug dispersed within the solid. This monolith is then 
re-dispersed in water to form aqueous nanodispersions, thereby generating an 
aqueous nano-dispersion.  Materials of similar nature can also be formed using a 
spray drying technique.95-97  Due to the relative ease and scalability of these 
formulations, SDNs have become attractive candidates as DDS in the treatment of 
various diseases and infections such as HIV and cancer.98-101  
Drug nanocrystals are also a class of SDN that are commonly researched. They are an 
attractive class of DDS as they also consist solely of drug particles stabilised by 
polymers and surfactants. Nanocrystals can be obtained by adopting a top-down or 
bottom-up approach. Top down technologies typically use high energy methodology, 
such as milling, to break down larger drug crystals into smaller drug crystals. Whereas 
bottom up processes see the formation of drug nanocrystals from dissolved drug 
molecules. In the production of commercial drug nanocrystals, it is not common to 
utilise bottom up technologies as difficulties in controlling the process can be 




and most drugs exhibit poor solubility in both aqueous and organic media, often 
rendering this processing technique unsuitable. 
1.2.3 Passive Targeting of DDS in Tumours via Enhanced Permeation Retention 
(EPR) Effect 
A pharmacokinetic principle which is often exploited in the design of DDS for cancer 
therapies is the EPR effect, see Figure 1.3. It was initially discovered in the 1950s 
following in vivo studies involving the administration of small molecule dyes into 
tumour bearing animals; the results showed extravasation from systemic circulation 
and accumulation within tumour tissue.102-104 
 
Figure 1.3 Passive targeting of DDS via the EPR effect. 
This was subsequently developed further in 1986 by Matsumura and Maeda whose 
initial publication has since been cited within > 6500 publications.105 The study 
investigated the mechanism of accumulation of radioactive proteins within tumour-
bearing mice. It found that there was noticeable accumulation of proteins within the 
tumour tissue and it was speculated, and later confirmed, that the accumulation was 
due to the high degree of vasculature within the tumour microenvironment and its 
increased permeability compared to that within healthy cells. The results also 
highlighted little lymphatic recovery of the macromolecules from the tumour tissue. 
The article concludes that the findings presented were of “potential value” to 




contribution to the development of drug delivery, specifically by recognising the 
opportunity for enhanced passive targeting capabilities of drug nanocarriers.  
In principle, when a tumour grows, the centre of the tumour gets further away from 
the supply of blood supply, oxygen and nutrients, all of which are required to 
promote growth. As a result of this, the cancerous cells send out an angiogenic signal 
which encourages new blood vessels to form within that area, thereby providing the 
tumour with the vasculature necessary for further growth as depicted in Figure 1.3. 
However, the fast, dysregulated nature of the growth of this tumour vasculature 
leads to structural and physiological defects. These defects often lead to 
hyperpermeability within the tumour tissue and give rise to the increased 
permeation of macromolecules. The tumour vasculature can be described as ‘leaky’; 
typically, macromolecules with prolonged circulation will exploit this characteristic 
the most. Another unique property of the tumour microenvironment is the lack of a 
properly functioning lymphatic recovery system, which is responsible for the 
clearance of macromolecules; this results in poor lymphatic drainage and the 
retention of macromolecules within the tumour tissue.106 These unique 
characteristics presented within the tumour environment can be utilised to help 
increase the delivery of nanoparticles via passive targeting, provided the 
nanoparticle can remain stable and avoid clearance, the strategies of which will be 
discussed later.   
1.2.3.1 Limitations Associated with the EPR Effect  
The EPR effect has been described as the “pillar of cancer nanomedicine research” 
and has been validated for particles up to 400 nm in size.107, 108 However, the 
development of such nanomedicines is somewhat stalling and the relevance of the 
EPR effect has been under considerable debate.108-112 The main drawback of the EPR 
dogma is that it has been somewhat over-generalised. There is no question that the 
EPR effect does exist,51, 113-117 but it should be recognised that the effect cannot be 
simply generalised as a feature of all cancers, and that there is a degree of variance 
exhibited due to the heterogenous nature of the disease. Variances of the effect can 
also occur between patients and different types of cancers.118,119 For example,  a 




both breast cancer and Kaposi’s sarcoma found that the nanoparticle accumulation 
was different between the two cancers due to the differences in the degree of 
“leakiness” in the vasculature. The extent of deformation of the endothelial 
membrane in the case of Kaposi’s sarcoma was larger than in the case of the breast 
cancer tumour, resulting in a more effective accumulation of nanoformulated 
doxorubicin for the Kaposi’s sarcoma. 120 
The preclinical investigations of DDS have often been conducted using animal 
models, typically murine, to assess the EPR effect in tumours. These tumours are 
systematically grown within the model in a controlled environment. However, since 
the tumours have been forced to grow rapidly, it is thought that the blood vessels 
that have developed are somewhat leakier than those developed within a tumour 
under normal conditions, which can often take many years. This can lead to an 
overestimation of the actual passive targeting capabilities of the formulated 
nanomedicines, as seen when radio-labelled soluble (2-
hydroxypropyl)methacrylamide copolymers were administered to different tumour 
models. The results showed an increased accumulation (0.5% per gram 
administered) observed for the tumour model which had grown by one centimetre 
in two weeks compared to the accumulation observed (0.2% per gram administered) 
in a tumour model which had taken over a year to grow by one centimetre.121, 122   
Despite these limitations, pre-clinical data on DDS for anti-cancer treatments has 
undergone meta-analysis for the past 10 years and the results seem to suggest that 
delivery efficiency of chemotherapeutics from DDS is higher than the delivery 
efficiency of most chemotherapeutics which dominate the clinic. Calculations 
suggest that a median of about 0.7% of the injected dose of DDS reaches the target 
tumours.123  Whilst this number may seem small, this delivery efficiency is higher than 
that of conventionally used chemotherapeutics. A study conducted by Vlerken et al. 
on nanoformulated paclitaxel compared to free paclitaxel, showed that the delivery 
efficiency increased from 0.2%  to 0.6% of injected dose when the chemotherapeutic 
was formulated into DDS.124 The study concludes that this is encouraging and clearly 




The delivery efficiency of DDS can be improved to maximize their therapeutic benefit. 
An alternative method of increasing the accumulation of polymeric nanoparticles 
within tumour sites is the utilisation of a strategy known as active targeting. 
Whereby, a ligand which is complimentary in nature to an over expressed receptor 
on the tumour surface can be incorporated onto the nanoparticle corona so that an 
increase in binding and affinity of polymeric nanoparticles to a tumour is observed.125  
1.3 Polymeric Nanoparticles   
Advancements made within the polymer chemistry field has provided opportunities 
for chemists to generate macromolecular structures with a high degree of control. 
These structures can then be utilised to generate nanoparticles. Their attractiveness 
as DDS stems from a variety of different reasons but mainly from the ability to design 
and control the polymer functionality to compliment individual drug properties and 
delivery requirements. This makes polymers a desirable material platform to utilise 
in the development of new/improved disease treatments with pre-existing drug 
candidates. Incorporation of drug molecules within polymeric nanoparticles can be 
achieved by adsorption, covalent linkage, entrapment and encapsulation. Polymer 
nanoparticle preparation, in short, utilises polymeric material that is hydrophobic in 
nature, which spontaneously collapses upon addition to water. The hydrophobic core 
of these nanoparticles would therefore provide a suitable environment for a 
hydrophobic guest molecule to reside, in this case a hydrophobic drug. This type of 
encapsulation is classified as non-covalent since there are no chemical bonds created 
to entrap the drug, only supramolecular interactions based on hydrophobic 
interactions, and if applicable, π-π interactions.126  
The formation of nanoparticles can be categorised into two strategies: in situ 
synthesis of nanoparticles starting from solubilised small molecules; or the creation 
of polymeric nanostructures via various different preparative techniques such as 
spray drying, milling processes and nanoprecipitation. The latter is a facile, low 
energy and mild technique which can be used to generate nanoparticular material of 
organic, inorganic or hybrid nature.127-129 This simple and highly convenient 
technique offers applicability to wide field applications, since the incorporation of 




nature of this method. In non-specific terms, it is the precipitation of dissolved 
material, of low or high molecular weight, as nanoparticles, upon the rapid exposure 
to a non-solvent environment. Given the context of this thesis, the discussion will be 
focussed on the nanoprecipitation of polymeric material. The applications of which 
can be generalised into two main category types: a formulation technique to create 
value-added desired end-products, such as pay loaded nanoparticles, or as an 
intermediate step during polymer processing. 
1.3.1 Nanoprecipitation  
The process of nanoprecipitation originated long before the emergence of 
nanotechnology as a concept, and its applicability was verified by the broad scope of 
patents that were filed during the latter half of the 19th century.129-133 For some time 
after, however, interest in the technique waned until it was utilised as a cost-
effective purification technique for polyolefins.129 The use of nanoprecipitation was 
also patented by Fessi et al in 1992, following the presentation of a simple, novel 
procedure to synthesise indomethacin loaded polylactic acid  nanoparticles (200 nm) 
via the deposition of poly(lactic acid) (PLA) polymer at an oil-water interface 
following acetone displacement from the oily nanodroplets.134, 135 The inventors of 
the patent highlight that the main advantage of the technique was the 
instantaneous, reproducible way of producing monodisperse nanoparticles with 
long-term stability.134 The versatility of this procedure was demonstrated by the 
extension of the study to include the nanoprecipitation of different polymeric species 
(polyvinylacetate, polyvinylchloride and polycaprolactone) and the incorporation of 
various hydrophobic moieties (essential oils, anticancer drugs and  magnetic 
resonance imaging contrast agents), thereby reflecting the extended potential of 
such a technique.136, 137   
Polymers which possess charge can also be used to form nanoparticles via 
nanoprecipitation and examples of such have been used for efficient gene 
delivery.138 The theory and mechanism of nanoparticle formation is discussed in 




1.3.2 Nanoprecipitation Theory   
Nanoprecipitation as a preparative method is a simple and easy way to generate 
nanoparticles from polymers or small molecules in solution.139 Theoretically, 
nanoprecipitation is based on the reduction of the quality of the solvent in which the 
polymer is dissolved, which subsequently causes the precipitation of this material 
into nanoparticles.  This can be achieved by various strategies such as: altering the 
pH, varying the salt concentration or introducing a non-solvent phase, such as water. 
Formation of nanoparticles via the latter strategy can be broken down into four 
different steps which will be discussed in more detail below: 1) the generation of a 
supersaturated solution, 2) nucleation, 3) growth, and finally, 4) stabilisation as 
outlined in Figure 1.4.  
 
Figure 1.4 Schematic representation of the formation of nanoparticles via nanoprecipitation. Following i) the 
addition of polymer to water, ii) generation of state of supersaturation, iii) nucleation of polymer chains, iv) 
growth via 2 mechanisms: A) nucleation and diffusion or B) coagulation. Followed by v) stabilisation via C) charge 
repulsion of cationic nuclei or D) steric repulsion. 
Each of these steps play a role in the control of the particle size and morphology.140-
142 It is worth noting that the mechanistic understanding of these four stages are 
complex, and often in literature, scientists will suggest that the primary principle of 
nanoprecipitation is based on the classical nucleation theory (CNT). However, this 
has been criticised with suggestions that CNT over-simplifies the process and 
Gebauer and Colfen provide a detailed review on non-classical nucleation.143 These 
alternative mechanisms suggest that the CNT is based on the assumptions that 
supersaturation is uniformly distributed in the solution. However, in a state of 
precipitation, supersaturation is often not uniformly distributed throughout the total 
solution volume and it is local fluctuations in concentration, caused by 
supersaturation, which leads to the formation of the primary nuclei. Regardless, 




into the mechanistic detailing, for the purpose of this thesis, the reader will be 
redirected back to the typical representation of the mechanism of nanoprecipitation.  
1.3.2.1 Supersaturation and Nucleation    
The initial step of the mechanism involves the formation of a supersaturated solution 
following the rapid addition of polymeric materials which are dissolved in a ‘good’ 
solvent to an anti-solvent, typically water (Figure 1.5).140  
 
Figure 1.5 Schematic representation of  the initial stages of the nanoprecipitation mechanism, i) polymer 
dissolved in ‘good’ solvent, ii) polymer in ‘good’ solvent added to anti-solvent (water), iii) exchange of anti-solvent 
and ‘good’ solvent causing polymer chains to collapse, iv) generation of a supersaturated solution, where Sr > 1, 
followed by the nucleation of polymer chains to form v) polymer nuclei. 
This occurs because the addition of the organic solution to the non-solvent phase 
decreases the solvent potency for the dissolved polymer solute and creates a solution 
with a dissolved solute concentration that is greater than the thermodynamic 
solubility limit, thereby creating a system defined as a state of supersaturation. The 
extent of which can be represented by the simple equation Sr = C/Ceq, where Sr 
represents the supersaturation limit, C is the concentration of the polymer in the 
nanoprecipitation medium, and Ceq is the thermodynamic equilibrium solubility limit. 
The extent of supersaturation can influence the final nanoparticle properties, such 
as the particle size.144 Only when a state of supersaturation is achieved (i.e. the value 
of Sr > 1) will the spontaneous formation of nuclei occur in order to gain 
thermodynamic stability within the system. The formation of nuclei occurs through 
the random collapsing of the polymer chains in order to minimise the interfacial 
energy between the polymer and the surrounding solvent environment (Figure 1.5iii 
and iV). The nuclei that are initially formed increase in size by association of solute 




against dissolution (Figure 1.5v). Once this is achieved these nuclei will then continue 
to grow until a state of colloidal stability is established.  
1.3.2.2 Growth   
The mechanism of growth can be described by either: 1) nucleation and diffusion 
limited growth, or 2) coagulation or the diffusion limited cluster-cluster aggregation 
(Figure 1.6).145, 146  
 
 
Figure 1.6 Schematic representation of the growth mechanisms which follow after the initial formation of 
polymer nuclei. Growth via i) nucleation and diffusion limited mechanism and ii) coagulation mechanism. 
Growth by nucleation and diffusion limited growth mechanism involves the addition 
of solute molecules to the particle surface and proceeds via two steps.147 Initially, 
solute molecules diffuse from the bulk fluid through the solution to the surface of 
the nuclei, then a deposition step occurs where the adsorbed solute molecules are 
integrated onto the nuclei matrix (Figure 1.6i). This growth will continue until the 
non-adsorbed solute concentration is reduced to that of the equilibrium saturation 
concentration. This mechanism is limited by the rate of nucleation and the diffusion 




Alternatively, growth may occur by coagulation, which in short is the adhesion of 
particles to one another following a random collision (Figure 1.6ii).148 Typically, this 
adhesion will occur when the attractive interactions are stronger than that of the 
repulsive interactions of the particles.  This is controlled and limited by the collision 
frequency, which is dependent on the rate of diffusion and can be affected by the 
particle concentration and the particle size. The collision efficiency is primarily 
dependent on the attractive and repulsive forces between the particles.   
The mechanism of growth that is favoured is typically dependent on two factors: 1) 
the initial nuclei concentration, and 2) the extent of supersaturation.149 If the degree 
of supersaturation is high, the mechanism of growth is predominantly coagulation 
driven.146 This is because the rate of nucleation is enhanced. Since there is a high 
concentration of nuclei and that the probability of collisions is proportional to the 
square of the number of nuclei present, the chances of random collisions between 
nuclei increases.150 If the degree of supersaturation is low, the mechanism of growth 
will proceed by nucleation and diffusion. Since the nucleation rate is lower, there is 
less chance of random collisions occurring between particles; instead, the particle 
growth will be limited by the diffusional rate of solute molecules. Preferentially, to 
obtain small particle sizes with narrow particle size distributions, it would be 
desirable if the growth mechanism followed coagulation.150, 151 
1.3.2.3 Stabilisation   
In order to minimise the thermodynamically unfavourable high total surface energy 
that nanoparticles possess, the particles will tend to agglomerate leading to 
macroscopic precipitates, rendering them useless for nanoscale applications. To 
prevent this from occurring, it is typical that a stabiliser will be introduced into the 
formulation or the polymeric material will have been designed to possess 
characteristics that provide stability. Stability can be provided to the colloidal 
suspension by two main methods: steric stabilisation and electrostatic stabilisation 
(Figure 1.7). Both works to ensure that the attractive Van der Waals (VDW) forces are 
exceeded by the repulsive forces, preventing the particles coming together and 




Stabilisation by electrostatic charge is based on the mutual repulsion of like charges 
and can be described by the well-known Derjaguin-Landau-Verwey-Overbeek (DLVO) 
theory.152-155 This theory is well understood for aqueous suspensions and assumes 
that there are two main forces acting on the particle within the medium: attractive 
VDW forces and repulsive electrostatic forces (Figure 1.7A). As previously mentioned, 
the interplay between these two is the driving force behind the stabilisation. The 
origin of the repulsive forces is caused by the overlapping of the electrical double 
layer, which surround the particles in the medium. This double layer consists of two 
different layers: (1) the stern layer, which is generated by counter ions attracted to 
the particle surface to maintain electrical neutrality, and (2) the diffuse layer, which 
is a result of the diffusion of ions.156-158 One parameter that can be used to predict 
suspension stability is the zeta potential, which is defined as the electrical potential 
at the boundary between the diffuse layer and the bulk liquid. Solutions which have 
a high zeta potential (negative or positive) will generally exhibit more stability than 
the solutions which have a lower value.159  
 
Figure 1.7 Schematic representation of nanoparticle stabilisation mechanism via A) electrostatic repulsion 
between two cationic nanoparticles and B) steric repulsion caused through extended solvated polymer chains. 
On the contrary, steric stabilisation is achieved by a solvation effect and the presence 
of a well solvated polymer chain on the particle surface (Figure 1.7B).160 This can be 
attained by the incorporation of an amphiphilic copolymer into the formulation 




species.161, 162 Coagulation of particles is prevented through the unfavoured 
interactions of the solvated surface polymer chains as two particles approach each 
other.163 These stabilising segments may interpenetrate, which can cause a 
compression to the surface polymer chains and a subsequent increase in osmotic 
pressure that ejects solvent molecules located within the inter-particulate space into 
the bulk medium.164 This is thermodynamically unfavoured, since this would result in 
an increase in the Gibbs free energy of the system. This process is minimised when 
the bulk solvent is a good environment for that of the stabilising block. These 
extended solvated polymeric chains do not get within a close enough distance of 
each other to allow for the attractive VDW forces to act. Stabilisation via this 
mechanism offers some benefits which are of interest if the particles are intended 
for biomedical applications. A common stabilising segment used in such applications 
is polyethylene glycol (PEG); this polymer functionality has increased systemic 
circulation of nanoparticles within the blood stream by providing them with stealth 
properties, which will be discussed in more detail in Section 1.4.  Rannard and co-
workers have demonstrated the applicability and ease of the incorporation of PEG 
functionalities into nanoprecipitating polymers that were subsequently included 
within nanoprecipitations to produce sterically stabilised polymeric nanoparticles.165-
167 Consideration of the length, and subsequent surface density, of the stabilising 
block is something to be taken into consideration to ensure that particle-particle 
interactions are minimised through the steric barrier.168  
1.4 Nanoparticles in the Body    
When designing nanoparticles for use in drug delivery, it is important to acknowledge 
that the nanoparticles are faced with a variety of different physiological barriers as 
soon as they are administered. The success of a DDS will depend on how well it can 
overcome these barriers. The DDS must circulate within the body for an extended 
period of time to allow it to ultimately reach the site of therapeutic need. The journey 
of any IV administered DDS injected directly into the blood stream is the same as any 
foreign matter; however, it is their interactions with the cells within the body that 
differs and it is these interactions which can be the DDS’s biggest limitation when 




The journey begins with the injection of the DDS directly into the blood, where the 
nanoparticles are immediately covered in biomolecules which can modify their size 
and physiochemical properties.170 These molecules are adsorbed onto the external 
surface of the nanoparticles to form a corona; the composition of this corona will 
include proteins and other extracellular components, which will be discussed in 
further detail below. The DDS is then transported via venous networks to the heart, 
specifically into the right ventricle. From here, it will be pumped into the lungs where 
it will then enter pulmonary circulation. The capillaries that line the lungs are the 
smallest blood vessels within the body, approximately 2-13 µm in diameter, and act 
as the first initial sieving process for removing any foreign material from the blood 
stream; it is therefore the first hurdle a DDS must overcome. If the DDS is too large 
or rigid in nature, this will result in the DDS being sequestered in the lungs. If the DDS 
passes through it is then transported back to the heart, specifically the left ventricle, 
where it is then pumped into systemic circulation. Here, the DDS continues to face 
interactions with the different components of the blood.  
Blood consists of leukocytes (white blood cells), erythrocytes (red blood cells), 
thrombocytes (platelets), and a solution of proteins and low molecular weight 
solutes commonly known as plasma. Typically, interactions between blood cells and 
DDS are minimal, as red blood cells and platelets exhibit a non-phagocytic nature and 
the defence mechanism of white blood cells will only be activated at the site of an 
injury. However, it is the proteins found in plasma that will interact with the DDS and 
it is the physicochemical properties of the DDS, specifically the particle size and 
surface functionality, that will determine to what extent these interactions 
occur.14,171 These interactions, if significant, can subsequently influence the 
behaviour of the DDS within the body.   
The plasma proteins form a dynamic corona on the particle surface and can increase 
or decrease the clearance of the DDS by the mononuclear phagocyte system (MPS) - 
the system responsible for the elimination of foreign material.172, 173 This interaction 
of proteins with the surface of the DDS can either be minimised or exploited during 
the design of the nanocarrier.173, 174 An example of using surface protein as an 




protein found in plasma and acts as a carrier for many different molecules whilst also 
regulating osmotic pressure.175 Compared to other proteins, it exhibits a long half-
life (~22 days) as it is protected from elimination by recognition from neonatal 
receptors, which ensure the reabsorption of the protein during liver filtration. The 
non-specific interactions of albumin and the surface of the DDS can be exploited to 
increase the circulatory time of a nanoparticle therapy.176 However, since these 
interactions are transient, albumin can be displaced easily by proteins that have a 
higher affinity for the nanoparticle surface.177 There have been studies that have 
physically adsorbed albumin to the surface of the DDS, but these show only a 
marginal increase in circulation time.178  
DDS that have avoided clearance this far, and have therefore remained in systemic 
circulation, are now exposed to different filtration mechanisms within the kidney, 
liver and spleen, all of which are usually size dependent.179  
The kidney is responsible for blood filtration and, in short, is made up of about a 
million filtering units called nephrons, which are comprised of a glomerular capillary 
network. Simplistically, this network has fenestrations present in their endothelium 
layer that are typically around 60-80 nm in size. The molecules that are able to pass 
through these gaps are passed into the tubule where they will either be reabsorbed 
into the blood or they will be excreted as waste in urine.180 Molecules with larger 
sizes will not pass through these gaps and will subsequently remain in the blood 
unless there has been prior biodegradation.181 
It is approximated that around 60-90% of nanomaterials are sequestered by the 
liver.182 The liver receives the blood from the gut and brain via the portal and hepatic 
veins respectively, and it engages in numerous endocrine, metabolic and 
immunological functions. To enter these veins and subsequently the liver, blood 
circulates through a permeable discontinuous network known as the sinusoids, 
which have fenestrations present (100-150 nm).183, 184 These sizes will typically allow 
for unrestricted passage of most plasma components, including most DDS, into the 
presinusoidal space. Within this space, there are hepatocytes that have multiple 




hepatocytic cell type present within the space is the Kupffer cell, which is responsible 
for phagocytotic behaviour within the liver.186 Phagocytosis occurs between cells and 
DDS when there is recognition of opsonins on the particle surface. The macrophage 
will spread its cell membrane around the particle and engulf it.  Once engulfed, the 
particle will be degraded by digestive proteins and the acidic internal environment 
that these cells possess. Following this process, the degradation products are 
released for excretion as waste. For DDS, this type of capture by the Kupffer cells 
needs to be minimised in order to sustain a long circulatory time and subsequent 
enhanced tumour accumulation. The most common synthetic strategy to minimise 
this is to coat the particle surface with an antifouling agent such as PEG or through 
manipulation of particle size and shape.187, 188 An alternative study which sought to 
improve the delivery efficiency of DDS has investigated whether removal of the 
macrophage cells within the liver would increase the delivery efficiency of DDS to 
tumour sites.  The results showed that the depletion of the macrophage cells in the 
liver increased the delivery efficiency from the median value of 0.7% to maximum 
value of 2%.182  
In selected cases of anti-cancer treatments where the liver is the target organ, this 
large accumulation of DDS in the liver can be advantageous, enabling the 
pharmacological effects to be exerted provided the DDS is not engulfed by the 
phagocytes.189  
It is commonly thought that the spleen does not play a role in the clearance of 
classical drug molecules, but instead its physiological roles are: removal of old blood 
cells, immunological surveillance and the regulation of blood volume.189, 190 However, 
this perspective has changed since the development of nanomaterials for drug 
delivery, with the current understanding that the spleen is actually accountable for 
taking up approximately 2 – 20% of DDS from the blood stream. 189 This is likely due 
to the increased size of nanoparticles and their complex chemical structures 





This therefore highlights the additional physicochemical responses that need to be 
accounted for when designing DDS, and the parameters that need to be considered 
to achieve accumulation within different tumour sites.  
1.4.1 Design Considerations for Nanoparticles in the Body    
When designing nanoparticles for drug delivery purposes, it is important to take into 
consideration how a nanoparticle behaves when administered into systemic 
circulation and how the nanoparticle will behave in a physiological environment. The 
physicochemical properties of a nanoparticle determine the immediate 
pharmacological response and the pharmacokinetics observed. These physiological 
barriers are typically the main limiting factor for the efficacy of nanoparticles.191, 192 
A number of parameters must be considered when generating polymer materials 
intended for drug delivery, all of which will collectively contribute to the action and 
fate of the nanoparticle within the body (Figure 1.8). 
 
Figure 1.8 A schematic summary of the design considerations of the properties of polymeric nanoparticles. 
Information from ref193.  
Firstly, the most important parameter to consider is whether the polymer is deemed 
“safe” for such an application. To determine this, toxicology studies would need to 
be performed to assess the suitability of the bulk material with respect to the 
possible detrimental effects it could have on the body. Additionally, it is also 




understand the potential detrimental or beneficial effects it may have, which is often 
thought of as a materials biocompatibility. These two observations lead to the 
understanding of the materials safety.194  
Secondly, consideration must also be given to the route of administration and the 
different physiological barriers that each present. As previously mentioned, the 
primary administrative route of chemotherapeutics is via IV injection. This is 
advantageous when designing drug nanocarriers as it avoids the complex issues often 
associated with oral dosing. These often refer to how the nanocarrier will enter the 
systemic circulation and whether its structural integrity will remain intact upon 
administration after being subjected to the harsh acidic environment of the GI tract.  
IV administration is the most efficient and reproducible route of administration but 
it does present different obstacles and negative side effects compared to oral dosing. 
These include pulmonary complications, thrombophlebitis and infection risks.195  
One of the primary obstacles to overcome in the delivery of nanoparticles is to 
prevent their premature removal from systemic circulation, whilst maintaining 
stability within blood and ensuring optimum biodistribution and bioavailability. The 
size, shape, charge and surface functionality of nanoparticles can all contribute to the 
fate of the nanoparticle. Polymeric nanoparticles can be modified to circumvent 
some of these challenges.   
1.4.1.1 Nanoparticle Size 
When designing polymeric nanoparticles for applications in drug delivery, there 
really isn’t a ‘one size fits all’ approach that can be adopted; instead, the intended 
use and the delivery target should be carefully considered.  It has been reported 
previously that nanoparticles designed for use in cancer treatments should have 
particle sizes between 70 – 200 nm.115, 193 If the particles are too small (< 30 nm) they 
will be cleared rapidly by the renal system,196 too large and the particles will be taken 
up by the MPS.197 The liver and spleen will often accumulate nanoparticles that are 
between 150-300 nm, whilst particles below 150 nm will generally locate in the heart, 
kidney, stomach and bone marrow.198 Hobbs et al determined that most tumours 




1.4.1.2 Charge of Nanoparticle 
The charge exhibited by the surface of nanoparticles can influence: (1) the degree of 
opsonisation, (2) the degree of particle stability in biological media, and (3) the 
degree of cytotoxicity.200 Particles of high charge, negative or positive, will promote 
protein adsorption and therefore increase the particle’s recognition and subsequent 
clearance by the MPS.115, 201 The magnitude of charge can also determine how stable 
the nanoparticles are when exposed to various ions and proteins present in biological 
media. 165 
Particles of positive charge typically exhibit high levels of toxicity and have 
demonstrated deleterious effects when administered in vivo, since their ability to 
rupture cells is enhanced due to the electrostatic attractions between the particles 
and the negatively charged cell membranes.202  Particles which display negative 
surface charge are generally less toxic and have shown decreased recognition and 
subsequent clearance by the MPS when compared to positively charged particles. 
This is due to their repulsion from the negatively charged cell membranes.203, 204 
Although, other studies have suggested that this is model-dependent: when 
negatively charged formulations were administered to rats rather than mice, little 
increase in circulatory time was observed compared to formulations of neutral 
charge.205, 206 The administration of particles with neutral charge have shown 
minimal interactions within the body. 207 
1.4.2 Incorporating Stealth Properties  
Drug containing nanoparticles must circulate within the blood stream for as long as 
possible if they are to deliver adequate concentrations of therapeutic payloads to 
tumour tissue.  Once in the blood stream, however, opsonin proteins can bind to the 
surface of the nanoparticles, allowing immune recognition and subsequently trigger 
clearance from the body by various different mechanisms.73 The macrophages 
involved with this process of removal have the capabilities to remove nanoparticles 
from the bloodstream within minutes of administration, thus rendering them 
ineffective with regard to drug delivery.208 One method to overcome this rapid 
clearance is to incorporate an inert polymer on to the surface of the nanoparticle, 




and therefore help to avoid immune recognition. There are several different 
polymers that have been used for this purpose: poly(acrylic acid)209, poly(vinyl 
alcohol) and polysaccharides.210 However, the most widely used polymer to impart 
stealth properties onto nanoparticles is PEG and is termed PEGylation.208, 211-213 This 
hydrophilic polymer contains subunits which are capable of forming tight 
associations with water molecules, creating a hydrating layer that prevents protein 
adsorption on the surface of the nanoparticle, therefore reducing the recognition by 
the MPS.214 This was demonstrated for the first time when PEG was covalently 
attached to bovine serum albumin, resulting in an increase in circulation time due to 
a lack of an immunological response.213  Additionally, incorporation of PEG chains 
within the nanomaterial whilst increasing circulation time, can also help to provide 
steric stabilisation to the particles and prevent aggregation, as described in Section 
1.3.2.4. The PEG chains at the surface help to form a sterically hindering layer to 
stabilise the surface charge exhibited by charged nanoparticles and providing 
stability.73 
There are different factors that can influence the circulation time of PEGylated 
nanoparticles, one of which is the chain length of the PEG chains. In a study of 
PEGylated micelles, it was found that an increase in circulation time in vivo was 
observed as the MW of the PEG was increased (from 2 to 20 kg mol-1).215 Likewise, 
when liposomes were PEGylated with PEG of MW 5 kg mol-1, a prolonged blood 
circulation and reduced clearance was observed when compared to the non-
PEGylated and liposomes bearing PEG with an MW = 750 g mol-1; the latter behaved 
almost identically to the liposomes without PEG.216 Whilst modification of a liposome 
surface with PEG is known to increase circulation time by reducing the opsonisation 
clearance and increase accumulation within tumours via the EPR effect, it has been 
demonstrated that it can inhibit cellular uptake capabilities and reduce endosomal 
escape - this is known as the PEG dilemma.217-219 In addition to this, the dense 
PEGylated shell may also prevent targeting ligands on the nanoparticle surface from 
binding to the desired receptor. This dilemma means that a balance is required 
between having a long enough PEG chain present to reduce opsonisation and 




chain is not too long that the cellular uptake is impacted. Synthetically, there are 
strategies for overcoming this dilemma, but generally the most utilised is designing 
a cleavable PEG linker.217  
Despite the early literature reports suggesting that all these strategies discussed to 
improve the fate of nanoparticles in the body were shown to be very promising 
strategies at overcoming some of the described problems.220 Progress has somewhat 
stalled in the development of clinically relevant materials and paradoxically, the 
upsurge in published papers does not compliment with therapeutic advances.121, 221, 
222 This is likely due to the fact that the pathophysiological and physiological 
interactions between nanoparticles and biological systems are somewhat complex 
and often unique between patients, thereby hindering the clinical translation. Simple 
chemical modifications that can be made to the nanoparticles seem to offer easy 
ways to strategically overcome the bodies response systems, and when investigated 
in animal models, most will show potential.223 However, it is typical that when these 
systems are extended to human models, they will fail because our understanding of 
how the body actually responds to nanoparticles is somewhat still in its infancy. An 
interesting article eloquently summarised that the clinical success of nanoparticles is 
limited by: 1) the biobarriers, 2) fate at the disease site, and 3) safety issues.222  
1.5 Research Hypothesis  
For the successful treatment of cancer, chemotherapeutic agents need to be 
delivered in a safe and effective manner but as previously discussed there are still 
some challenges associated with the delivery of these potent, hydrophobic 
molecules. It has been shown that the use of nanocarriers offers the opportunity to 
encapsulate and deliver these drugs in aqueous media. The use of DDS also provides 
opportunities to nano-formulate drugs which previously have had to be administered 
in a prodrug formulation to overcome insolubility issues. Of interest in this thesis is 
SN-38, which is the active metabolite of irinotecan administered for the treatment of 
CRC. Research has shown that high molecular weight branched hydrophobic 
polymers can be utilised to generate nanoprecipitate nanocarriers. This branched 
material has numerous chemical modification options. It is hypothesised that 




through the manipulation of the chemical structure of this branched material and 
subsequent polymer-drug interactions of the nanoparticles. 
1.5.1 Project Aim  
The aim of the research presented within this thesis is to investigate and optimise 
the encapsulation of the anti-cancer drug SN-38, within a novel polymeric based drug 
delivery platform and assess its applicability as a biologically relevant pharmaceutical 
candidate (Figure 1.9).  
 
Figure 1.9 Schematic representation of the aims of this research project. Highlighting the formation of SN-38 
loaded polymeric nanoparticles formed via co-nanoprecipitation of AB block and branched copolymers indicating 
the various different modifications that can be made.   
Building from previous reports, it is proposed that by combining highly branched, 
high molecular weight methacrylate-based copolymers and amphiphilic AB block 
copolymers, sterically stabilised polymeric nanoparticles can be generated via co-
nanoprecipitation. Thereby, presenting opportunity for the potential encapsulation 
and delivery of guest molecules, such as therapeutic agents. 165-167, 224, 225  Methanolic 
ATRP, a proven robust synthetic strategy, will be utilised to generate a large library 
of polymeric materials including, linear homo and statistical copolymers, statistical 
branched and AB block copolymers. The chemical compositions of these materials 
will be varied through the incorporation of different monomer, divinyl monomer and 
initiator chemistries (Figure 1.9A). The effects of these chemical alterations on the 




also be studied. Nanoprecipitation and co-nanoprecipitation studies will then follow 
the successful synthesis of this broad range of polymer materials (Figure 1.9B). Co-
nanoprecipitation presents an opportunity to generate sterically stabilised 
nanoparticles under controlled conditions through the addition of an AB block 
copolymer. Previously, this steric stabilisation has been achieved through the 
incorporation of an AB block copolymer which possessed complimentary chemistry 
on the B block to the branched methacrylate polymer. However, the aim here is to 
investigate the effects on nanoparticle formation when the chemistry of the B Block 
on the AB block copolymer is varied. Additionally, variance in the nanoparticles’ 
composition of branched polymer: AB block copolymer ratio, will also be explored to 
determine the optimum ratio to achieve steric stabilisation. Given the intended 
application for these nanoparticles their stability in vitro is essential for 
pharmacological assessment; therefore, to mimic physiological conditions 
nanoparticles stability to PBS addition will also be tested.  
The ultimate aim of the nanoparticles is to encapsulate the hydrophobic anti-cancer 
drug SN-38. Given, the role of an additional hydrophobic guest within the co-
nanoprecipitation has not been explored, SN-38 will be included in all polymer co-
nanoprecipitate regimes to determine whether it has any influence on the outcome. 
The evaluation of drug loading capacity and efficiency will be assessed for the 
successful drug loaded nanoparticles. It is anticipated that the different physical 
properties of the polymers, imparted through chemical variance during synthesis, 
will in turn effect polymer-drug interactions. These differing interactions and the 
relationship between the physical properties of the polymers and its effects on drug 
loading and release rates will be explored via radiometric release experiments.  
Promising candidates of stable SN-38 loaded polymer nanoparticles will have their 
pharmacological behaviour explored in vitro and in vivo to determine their potential 
and suitability as a CRC treatment (Figure 1.9C). The PhD is funded by Cancer 
Research UK and sees the collaboration between the Departments of Chemistry and 
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Synthesis of Methacrylate Based Polymers via Copper 






2.1 Introduction  
2.1.1 Controlled Polymer Synthesis  
The desire to produce well-defined functional materials under simple reaction 
conditions led to the development of controlled radical polymerisation (CRP) 
techniques.1 These were formed from a combination of the principles of ‘living’ 
polymerisation and conventional free radical polymerisations (FRP).2 Unlike FRP, 
however, CRP offers the potential to synthesise macromolecular structures with 
control over the molecular weight, molecular weight distribution, chain-end 
functionality, polymer architecture and composition.3-5 These advantages 
complement the existing advantages associated with FRP, such as mild reaction 
conditions and the applicability to a wide range of monomers. 1, 6-9  
The success of CRP can be attributed to two general characteristics: firstly, all the 
polymer chains are formed at the same time via initiation which is faster than 
propagation and secondly, the number of active species has to be constant 
throughout the reaction (i.e. termination reactions have to be minimal). This can be 
achieved by minimising the concentration of active radical species to suppress any 
undesirable side reactions. 
The combination of these two factors allows the equal growth rate of polymer chains, 
producing polymers with narrow molecular weight distributions. These attributes 
have steered CRP into becoming a widely researched synthetic route since its 
discovery in the 1990s, contributing to the development of numerous materials with 
potential applications ranging from coatings, adhesives, personal care products, 
biomaterials and many more.10, 11  
 Since 2010, the international union of pure and applied chemicals (IUPAC) 
recommends that CRP is referred to as reversible-deactivation radical polymerisation 
(RDRP),12 which is how it will be referred to throughout the remainder of this thesis.  
2.1.2 Atom Transfer Radical Polymerisation  
Atom transfer radical polymerisation (ATRP) is a specific type of RDRP that is 




applicable to a wide range of monomers and presents opportunity to introduce site 
specific tailored functionalities.6 The first reports of ATRP were published in 1995 
describing the work conducted by Wang and Matyjaszewski,13 and Sawamoto and 
co-workers.14 These seminal studies were built on the concept of atom transfer 
radical addition (ATRA), which is an efficient and well recognised method in organic 
chemistry for the formation of carbon–carbon bonds between olefins and alkyl 
halides. These studies showed that transition metal catalysts commonly employed in 
ATRA could also be employed in ATRP to polymerise vinyl monomers with a high 
degree of control.13, 15  
The control exerted by ATRP arises from the equilibrium between dormant species 
(R-X) and propagating radicals (R ), outlined in Scheme 2.1.10, 16 ATRP is a reversible 
redox process which is catalysed by a transition metal complex TMn/L (TMn 
represents the transition metal species in oxidation state n and L represents the 
ligand). The most commonly used complexes are Cu-based, but other studies have 
been conducted using different metals such as Fe, Ru and Mo.17  
 
Scheme 2.1 General mechanism for transition metal catalysed ATRP.   
The reaction proceeds via the activation of the dormant species R-X, which involves 
the abstraction of the halide atom and the simultaneous one-electron oxidation of 
the transition metal complex to form the species X – TMn+1/ L and the active radical 
R ; this activation step proceeds via the rate constant kact. The active radical species 
R  can then propagate with vinyl monomer (rate constant kp) to grow the polymer 
chain. A reverse reaction (rate constant kdeact) sees the deactivation of the active 
radical by capping it with the halide to form the dormant species once more. 
Termination reactions of the activated radical species can also occur (rate constant 




of active radical species is minimised since the rate of deactivation is much greater 
than the rate of activation (kdeact >> kact). Additionally, the occurrence of any 
termination reactions minimises further termination reactions by what is known as 
the persistent radical effect.18, 19 Here, the irreversible formation of a radical-radical 
species generates two equivalents of the halide complex, X – Mtn +1 / L, and thus 
further drives the equilibrium towards the dormant species in accordance with Le 
Chatelier’s principle.  
The values of the rate constants can all be strongly influenced by experimental 
parameters such as:  reaction solvent, temperature, pressure, and the chemical 
structure of the monomer, the initiating species and the ligand. The main control 
over the polymerisation arises from two factors: (i) the rate of deactivation (kdeact) is 
much larger than the rate of propagation (kp) and therefore only a small number of 
monomer units are added to the chain at each time i.e. the propagating radical is 
only active for a short period of time before capping. And (ii) the rate of deactivation 
(kdeact) is far greater than the rate of activation (kact), which means that the dormant 
dominates and the local concentration of active radicals is kept low. Due to the 
nature of the mechanism it is extremely important that the reaction is completed 
without the presence of oxygen as this would lead to: (i) the poisoning of the 
transition metal catalyst, and (ii) the scavenging of the active radicals. The control of 
ATRP can be studied through kinetic experiments and detailed proton nuclear 
magnetic resonance (1H NMR) spectroscopy and triple detection size exclusion 
chromatography (TD- SEC) analysis. A semi-logarithmic plot of ln([M]
0
/[M]) vs. time, 
where [M]0 represent monomer concentration at t=0 and [M] represent monomer 
concentration and a plot of number average molecular weight (Mn) vs. conversion 
should both yield linear correlations, which would highlight that a constant radical 
concentration was maintained throughout the polymerisation and that termination 
and chain-transfer reactions were negligible. 
ATRP has attracted both research and commercial interest for the following reasons: 




of different monomers, use of readily available and inexpensive catalytic 
components and commercially available or easily prepared (macro)initiators.20 
2.1.3 The Synthesis of Various Polymer Compositions and Architectures by ATRP 
The use of ATRP has facilitated the straightforward synthesis of a wide range of 
polymeric architectures including: stars, brushes, linear polymers and branched 
(co)polymers.20 The design of polymeric compositions and architectures can involve 
the variation of: the monomer functionality, the number of monomer types, their 
distribution within a polymer chain and how the polymer chains are arranged, i.e. the 
polymer topology (Figure 2.1).21, 22 There are many different types of copolymers 
such as: alternating copolymers, statistical copolymers and block copolymers.23, 24    
 
Figure 2.1 Schematic representation of the different examples of polymer structures: a) examples of the different 
compositions, and b) examples of the different polymer architectures achievable via ATRP.   
2.1.3.1 Controlled Polymerisation for the Synthesis of Amphiphilic Block 
Copolymers 
Block copolymers, as previously discussed (Chapter 1.2.1), are copolymers consisting 




given chain. There is huge scope for their use as advanced materials in different 
applications that include their use as porous materials, electronics, and drug 
delivery.25 Significant research interest arises from the inherent ability of amphiphilic 
block copolymers to self-assemble, which is a process that requires well-defined 
polymers with distinct block functionalities and narrow molecular weight 
distributions. In addition to the relative functionalities of the block segments, the 
length and ratio of each are also important contributory factors to the formation of 
such self-assembled structures. Therefore, the required method of synthesis must 
control these characteristics and ATRP has already proven to be a particularly 
attractive route for their synthesis. 26, 27 There are two main methodologies for the 
synthesis of block copolymers via ATRP, both of which involve growth from a pre-
existing polymer chain.  
The first approach involves the sequential addition of two monomer, A and B. with 
the propagation of B from the end of the first chain comprising of monomer A 
residues. This type of approach is typically referred to as chain extension to produce 
an A-B di-block copolymer structure, as depicted in Figure 2.2. 
Figure 2.2 Schematic representation of the generation of an AB di-block copolymer via chain extension. Whereby, 
the (re)initiation of polymer A that has retained its alkyl halide chain-end functionality occurs via sequential 
polymerisation with monomer B to generate AB block copolymers.  
The order of monomer addition plays an important role since the reactivity of the 
carbon-halogen bond of the dormant species will depend on the chemical structure 
of the first monomer used. The reactivity decreases as follows: acrylonitrile > alkyl 
methacrylate > styrene ~ alkyl acrylate > acrylamide.28 Further sequential additions 
can be made under suitable conditions following the chain extension method, which 
provides an opportunity to generate a wide variety of different block copolymer 




terpolymers (Figure 2.3ii).  The success of chain extension is dependent on the 
preservation of the alkyl halide chain-end functionality, and the successful and 
efficient re-initiation of the polymer chains. 
 
Figure 2.3 Schematic representation of the generation of ABA block copolymers and ABC triblock terpolymers via 
tertiary polymerisation of an AB block copolymer. 
The second approach to A-B block copolymer formation involves the chain-end 
modification of polymer A in order to generate a macro-initiator capable of initiating 
an alternative polymerisation (Figure 2.4i). This macro-initiator can then be used to 
produce an AB di-block copolymer by initiating a polymerisation of monomer B 
(Figure 2.4ii).27, 28  
 
Figure 2.4 Schematic representation of the generation of an AB block copolymer following the synthesis of a PEG 
macro-initiator. The figure shows i) the post polymerisation modification of poly(ethylene glycol) monomethyl 
ether (polymer A) with α-bromoisobutyryl bromide (or another initiating species) and ii) its subsequent utilisation 
within ATRP of methacrylate-based monomer B.  
Polymers that have been synthesised from alternative methods such as ring-opening 




used to generate macro-initiators, which therefore increases the scope and chemical 
variability of the available block co-polymers. 
There are several potential limitations of this model of macro-initiator synthesis. 
Firstly, poor efficiency of the end group modification on the primary polymer chain; 
if the modification of the end group is not efficiently achieved, and if purification is 
difficult, this could result in the presence of polymer chains which are incapable of 
initiating the subsequent polymerisation. Secondly, if the initiator efficiency is low, 
this would result in the generation of a mixture of unreacted original polymer and AB 
block copolymer. Additionally, the rate of initiation can also be a limitation. If it is 
slow then the polydispersity of the resulting AB block copolymer will be broad and 
will result in undesirable variability of the ratio of the segments. 
It is common for amphiphilic block copolymers intended for drug delivery 
applications to incorporate a hydrophilic PEG component. The successful 
incorporation of PEG within AB block copolymers can be achieved by the use of a PEG 
isobutryl bromide macroinitiator, which can be utilised to initiate ATRP 
polymerisations of different monomers, examples of which include hydrophilic,33-35 
hydrophobic and ionic chemistries.36, 37  
2.1.3.2 Synthesis of Branched Statistical Copolymers by ATRP  
A branched polymer can be defined as a macromolecule with chains or branches of 
significant length bonded to the main chain at branching points (Figure 2.5). Such 
species can be characterised by the size and number of branches. Branched 
polymeric materials, although architecturally complex, are relatively economical and 
facile to synthesise compared to other complex branched architectures such as 





Figure 2.5 Schematic representation of different branched polymer architectures. 
Branched copolymer materials can be synthesised through the copolymerisation of 
a monofunctional monomer and a bifunctional monomer (Figure 2.6).  A bifunctional 
monomer, as the name suggests, is a monomer that contains two functional groups 
which are capable of partaking in propagation reactions between separate growing 
polymer chains. This inclusion between two propagating chains generates a single 
branching point, with the generation of further intermolecular branching points 
resulting in a large number of primary polymer chains being covalently linked 
together.  
 
Figure 2.6 Schematic formation of a branched copolymer. Figure adapted from reference40  
In the initial stages of the copolymerisation of a monofunctional and bifunctional 
monomer, the incorporation between the two monomers is statistical and results in 
the formation of linear primary polymer chains presenting unreacted pendant double 




monomer is much greater than that of pendant vinyl bonds, and only at high 
conversion of the monovinyl monomer does the spontaneous intermolecular 
coupling of the chains begin – subsequently producing branched polymers.40 This 
generates materials with significantly higher molecular weights and broader 
molecular weight distributions compared to that of  the corresponding primary 
chains synthesised in the absence of divinyl monomer.  Gelation of a polymer can 
occur when primary polymer chains forms large interconnected networks via cross-
linking through the incorporation of more than one on average divinyl monomers per 
polymer primary chain (Figure 2.7).  
 
Figure 2.7 Schematic representation illustrating a: A) branched polymer and B) cross linked polymer. 
The initial quantitative description of gelation was developed in the 1940s by Flory 
and Stockmayer, which is termed the Flory-Stockmayer theory.41-45 Which allows for 
the identification of a gel point of a polymerisation between monomer A and B and 
is based on three assumptions: 1) all vinyl groups are equally reactive, 2) that all 
reactions occur between monomer A and B and 3) there are no intramolecular 
reactions.  
There are several synthetic strategies that can be utilised in the synthesis of branched 
materials, which include chain transfer mediated FRP, reversible addition-
fragmentation chain-transfer (RAFT) polymerisation and ATRP.11, 46-53   
Characteristically, FRP proceeds in an uncontrolled manner, and high molecular 




propagation compared to a slow rate of initiation; and due to the highly reactive 
nature of the free radicals, termination and chain transfer are inevitable. When even 
a small percentage of divinyl monomer is incorporated, these high molecular weight 
chains are very easily cross-linked i.e. an average two or more branch points per chain 
has been introduced into each chain resulting in gelation as described by Flory.54 Due 
to the polydisperse nature of the polymers produced via FRP, gelation can occur even 
at low monomer conversions since some chains will be significantly longer than 
average, making cross-linking even easier.55 This has somewhat limited the 
production of branched polymers via FRP.  To try and avoid gelation, high dilution 
could be employed.  
Alternatively, Sherrington and co-workers reported the synthesis of branched vinyl 
polymers via FRP but with the inclusion of a chain transfer agent (CTA) (typically a 
thiol) to a copolymerisation of a vinyl and divinyl monomer. Scheme 2.2 illustrates an 
example of how chain transfer occurs when a radical from a propagating styrene 
chain is transferred to a chain transfer agent, butyl mercaptan, in exchange for a 
proton, terminating the chain.    
 
Scheme 2.2 Schematic representation of how butyl mercaptan, a CTA, can be used to transfer a radical from a 
propagating styrene chain.   
The incorporation of a chain transfer agent within a copolymerisation of a vinyl and 
divinyl monomer suppresses gelation by limiting the molecular weight of the primary 
polymer chains by transferring the radical of a growing polymer chain to another 
molecule and therefore reducing the average number of branch points per chain 





Scheme 2.3 Schematic representation of copolymerisation of a vinyl and divinyl monomer with and without the 
presence of a CTA.  
This is known as the “Strathclyde” technique, which was built upon pre-existing 
knowledge that chain transfer agents could be used to supress gelation by ensuring 
that primary chain length is too short.56 However, Sherrington and co-workers were 
the first to show that this method could be used to generate soluble branched 
copolymers of high molecular weight with high monomer conversion.57-61 The 
branched polymers produced, contain a large number of conjoined primary chains 
and due to the statistical nature of branching possess a broad molecular weight 
distribution. The Strathclyde methodology has received significant attention in the 
literature with the majority of the work focussing on the polymerisation of 
hydrophobic monomers.62-65    
ATRP can be utilised for the synthesis of high molecular weight soluble branched 
copolymers as part of a modified Strathclyde technique.66-68  These branched 
copolymers can be prepared via the statistical copolymerisation between a vinyl and 
divinyl monomer without the need of a CTA. Gelation is minimised in the case of 
ATRP since the degree of polymerisation (i.e. primary chain length) can be controlled 
without CTA presence, through adjustment of monomer and initiation molar ratio. 
Since the amount of initiator is known, gelation can also be controlled through the 
accurate incorporation of a divinyl monomer. Additionally, the relatively low 
polydispersity values minimise the probability of primary polymer chains 
incorporating more than two branching units. Whilst ATRP does provide a degree of 




polymer, the molar ratio of divinyl monomer: initiator should be less than 1. This is 
in keeping with the Flory Stockmayer theory.41-45 Employing ATRP to obtain soluble 
branched copolymers provides several advantages. Firstly, the degree of branching, 
and therefore the number of primary chains which are joined together, can be varied 
by targeting various [B]/[I] molar ratios, where [B] represents brancher concentration 
and [I] represent initiator concentration. Secondly, the degree of polymerisation of 
the primary polymer chain can be varied by simply targeting different [M]/[I] ratios, 
where [M] represents monomer concentration. Finally, since polymers prepared by 
ATRP contain two chain ends: the α-end derived from the initiator and the ω-end, 
which is normally a labile end-group, such as a bromine atom, an array of different 
chain-end functionalities is possible, through careful design and synthesis of the 
initiator (Figure 2.8).  
 
Figure 2.8 Schematic representation of a primary polymer chain highlighting the two different chain ends and 
how different functionalities can be introduced.  
First reports of soluble branched polymers produced via ATRP and utilising a 
modified Strathclyde methodology was published in 2004 when Isaure et al. reported 
the copolymerisation of methyl methacrylate and divinyl monomer ethylene glycol 
dimethacrylate (EGDMA) in a one pot synthesis to produce p(MMAx-co-EGDMAy).69 
Other reports of soluble branched material being synthesised by ATRP include 
p(HPMAx-co-EGDMAy) 40 and p(styrene-co-divinylbenzene).70  
2.2 Research Aims of Chapter 2   
Literature reports have shown that ATRP is a versatile technique which exhibits 
compatibility with a wide range of functional monomers. The synthetic process, 
methanolic ATRP, has already proven to be robust and efficient at generating well-




the polymer materials which have been previously reported, by synthesising a wide 
range of methacrylate-based hydrophobic polymers via methanolic ATRP. Three 
different methacrylate hydrophobic monomers with varying hydrophobicity will be 
used: butyl methacrylate (BuMA), 2-ethyl hexyl methacrylate (EHMA) and 2-
hydroxylpropyl methacrylate (HPMA) (Figure 2.9i). Employing the monomer 
chemistries outlined above, polymers of varying architectures will be targeted. These 
include: linear homopolymers, branched copolymers through copolymerisation of a 
vinyl and divinyl monomer using the modified Strathclyde approach following the 
Flory-Stockmayer theory; amphiphilic A-B block copolymers by incorporating a 
macroinitiator and statistical copolymers, both linear and branched through mixing 
of monomers (Figure 2.9ii). These materials in-turn, would later be utilised generate 
hydrophobic amphiphilic polymer nanoparticles. 
 
Figure 2.9 Schematic representation of i) the different methacrylate monomers selected and ii) the varying 
polymer architectures.  
This chapter also aims to explore how different functionalities can be imparted into 
the polymer species during the synthesis of high molecular weight branched 
copolymers using six different divinyl monomers: bisphenol A dimethacrylate 
(BPDMA), bisphenol glycerol dimethacrylate (BPGDMA), Bis(2-methacryloyl)oxyethyl 
disulphide dimethacrylate (DSDMA), ethylene glycol dimethacrylate (EGDMA), 
glycerol dimethacrylate (GDMA) and urethane dimethacrylate (UDMA). Polymers of 
different primary chain lengths will also be synthesised. The polymer materials 
generated will be characterised by 1H NMR and TD-GPC and their thermal 
characteristics analysed via DSC.  
57 
 
2.3 Results and Discussion 
2.3.1 Synthesis of Linear p(BuMA)n Homopolymers via Methanolic ATRP 
A series of polymerisations were performed using a method previously reported by 
Dwyer et.al, whereby linear poly(n-butyl methacrylate) p(BuMA)n was synthesised 
via  methanolic ATRP to yield p(BuMA)n of controlled molecular weight and low 
dispersity values.51,53 Therefore, the monomer BuMA was chosen as a control to 
verify the controlled nature of ATRP.  
The homopolymerisation of commercially available monomer BuMA was performed 
in anhydrous methanol (MeOH) at 50 °C using a copper (I) chloride (Cu(I)Cl): 2,2-
bipyrine (bpy) catalytic system and a commercially available initiator, ethyl α-
bromoisobutyrate (EBiB). A molar ratio of BuMA:EBiB:Cu(I)Cl:bpy of X:1:1:2 was used 
for all reactions, were X also represents the targeted DPn of the resulting linear 
polymer. The amount of MeOH added was set to 50 wt. % wrt to total solids content. 
The DPn was varied and targeted 20, 60, 80 and 100 monomer units (Scheme 2.4), 
which was achieved by increasing the monomer concentration relative to initiator 
and catalyst within the reactions and maintaining the 50 wt.% total solids content. 
All of the polymerisations remained as homogenous dark brown solutions 
throughout the reactions and achieved high vinyl conversions (≥ 98%), as calculated 
by 1H NMR (Table 2.1).  
 
Scheme 2.4 Linear polymerisation of hydrophobic BuMA monomer via Cu-catalysed methanolic ATRP. 
As the targeted DPn value increased, the reaction time required to reach these high 
monomer conversions also increased from 18 hours to 75 hours to allow for the 
longer polymer chain length to be generated. The reactions were then poisoned via 
the addition of THF and exposure to oxygen to prevent further reaction. A change in 
colour was observed for all the polymerisations from dark opaque brown to a 




from oxidation state +1 to +2. The polymers were then purified via a two-stage 
process. Firstly, the catalytic system was removed by passing the diluted reaction 
mixture through a neutral alumina column using THF as the mobile phase. The 
removal of catalyst is evident by the presence of a green band at the top of the 
column, and the catalyst-free polymer solutions were subsequently concentrated in 
vacuo and precipitated into cold MeOH to remove any unreacted monomer, residual 
initiator and free ligand. The polymers were obtained as white solids and were then 
dried in vacuo at 35 °C for 24 hours to ensure complete solvent removal. Analysis of 
the polymers was conducted via 1H NMR (CDCl3) to confirm the complete removal of 
residual initiator, unreacted monomer and free ligand. 1H NMR analysis of the vinyl 
monomers are presented in the Appendix Figure A1-3.  Subsequent analysis via TD- 
SEC using a THF/TEA (98/2 v/v %) eluent, was used to determine the molecular 
weights and dispersities of the synthesised linear homopolymers (Table 2.1).  
Table 2.1 Methanolic Cu-ATRP of BuMA at 50 °C for linear polymer synthesis targeting various DPn. 


















20 18 > 99 3 010 5 100 6 400 1.24 0.591 
60 24 98 8 550 10 930 12 110 1.11 0.735 
80 48 > 99 11 460 18 850 20 910 1.11 0.807 
100 75 > 99 14 280 20 200 23 050 1.14 0.676 
a Target DPn calculated [BuMA] / [EBiB], b Calculated by 1H-NMR spectroscopy of polymerisation mixture at 
t=final. c Theoretical Mn calculated as ((target DPn x MW monomer) x (conversion/100)) + initiator residue. d 
Calculated by TD-SEC using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1mL min-1. 
Analysis by TD-SEC revealed monomodal chromatograms that indicated that the 
polymerisations had proceeded in a controlled manner to yield well-defined 
polymers with narrow molecular weight distributions (1.11 ≤ Ð ≤ 1.24). The obtained 
Mn values (5,100 – 20,200 g mol-1) increased as the targeted DPn increased, and all 
showed an appreciable targeting of the molecular weights; however, these values 
did vary slightly from that of the theoretical values, which could be attributed to a 
lower initiator efficiency of EBiB than expected. Overlay of the refractive index 




polymer chain length relative to the shortest DPn targeted of 20 monomer units 
(Figure 2.10). 
 
Figure 2.10 Overlaid TD-SEC refractive index chromatograms of p(BuMA) at varying different degrees of 
polymerisation: a) 100 (black solid line), b) 80 (red dashed line), c) 60 (blue long dashed line) and c) 20 (red solid 
line) monomer units showing molecular weight distributions. 
Confirmation of linear architectures was provided by analysis of the Mark-Houwink 
α values; these values are obtained from the Mark-Houwink-Sakurada equation 
(Equation 2.1). The analysis describes the relationship between the molecular weight 
(M), the intrinsic viscosity (η) of a polymer in a given solvent and α, which represents 
parameters which depend on the nature of the interaction with the polymer and 
solvent. 
[𝜂] =  ΚΜ𝛼            (2.1) 
Typically, when in solution, a linear polymer will adopt a random coil conformation 
and the polymer will experience a high level of solvent interaction. Therefore, values 




p(BuMA)n homopolymers (0.591 - 0.807) are consistent with values expected of 
linear polymers.  
In summary, methanolic ATRP has been utilised successfully as a technique to 
synthesise p(BuMA)n, where n represents a varying degree of polymerisation. The 
polymers produced were generated with a high level of control and the experiment 
has shown that ATRP is a suitable polymerisation technique for targeting polymers 
with different DPn values. 
2.3.2 Kinetic Studies on the Formation of Linear p(BuMA)60 in Anhydrous Methanol 
via ATRP 
Kinetic experiments are performed on controlled polymerisations to confirm that 
reactions proceed via first order kinetics with respect to monomer concentration. It 
provides evidence that control was maintained throughout the polymerisation and 
that termination reactions were negligible. Monitoring the evolution of molecular 
weight with respect to monomer conversion can also provide evidence that chain 
transfer reactions were negligible and that predictable number average molecular 
weights may be achieved. Methanolic ATRP reactions were conducted as previously 
described at 50°C for 24 hours, but aliquots were removed at nine different time 
points and analysed by 1H NMR and TD- SEC. It is important that throughout the 
kinetic experiment the reaction mixture is not poisoned via exposure to oxygen and 
that a dark brown homogenous solution remains in order to maintain the validity of 
the experiment. The kinetic study targeting p(BuMA)
60 was homogeneous 
throughout the polymerisation and the reaction was terminated at 98 % conversion 
after 24 hours. The data provided linear correlations of both ln([M]
0
/[M]) vs. time, 
and M
n 
vs. conversion (Figure 2.11), indicating that the polymerisation of BuMA 
followed first order kinetics and that the concentration of active species remained 
constant throughout the polymerisation and irreversible termination reactions were 
negligible. The linear plot of M
n 
vs. conversion (Figure 2.11b) provides an indication 
that all the chains were formed at the same time i.e. the initiation was faster than 








Figure 2.11 Kinetic studies of targeted p(BuMA)60
 
by ATRP in anhydrous MeOH at 50 °C: (a) conversion and semi-






2.3.3 Synthesis of AB Block Copolymers 
Given the success of the methanolic ATRP of BuMA to yield p(BuMA) homopolymers, 
this method was considered as an attractive synthetic strategy to synthesise AB 
diblock copolymers with well-defined structural characteristics. The only difference 
between the preparations was the replacement of the commercially available EBiB 
initiator with a synthesised polymer-based macro-initiator. Therefore, the 
generation of the amphiphilic AB diblock copolymer consisted of two stages: firstly, 
the synthesis of a poly(ethylene glycol) monomethyl ether bromo isobutyrate macro-
initiator (MeO-PEG114-Br) via an end group modification that involved a reaction 
between α-bromoisobutyryl bromide and the hydroxyl chain-end functionality of 
poly(ethylene glycol) monomethyl ether (PEG114-OH).  The chain length of the 
macroinitiator (MeO-PEG114-Br) was chosen as it is widely used within nanomedicine 
and detailed in literature that the higher molecular weight chain can reduce the 
likelihood of opsonisation from the body as discussed in Section 1.5.72, 73 From 
previous data obtained, it has also been shown that AB block copolymers which are 
comprising of PEG114 compared to PEG45 produce nanoparticles which are smaller in 
size.36 Following successful synthesis, the second stage is the methanolic ATRP of 
BuMA, initiated by the synthesised PEG macro-initiator, thereby yielding an 
amphiphilic AB diblock copolymer consisting of a hydrophilic PEG block covalently 
bonded to a hydrophobic p(BuMA) block. The targeted DPn of the BuMA B block 
segment was fixed at DPn 100 monomer units for consistency. Since the intended use 
of the AB block copolymer is to be used to provide steric stabilisation to 
nanoparticles, the DPn of the hydrophobic segment needs to be long enough to 
ensure that the chances of its incorporation within the nanoparticle core is 
maximised and therefore can provide maximum stabilisation. The synthesis and 
characterisation of the macroinitiators and copolymers will be discussed below.  
2.3.4 Synthesis of PEG114 Macroinitiator   
The PEG114-Br macroinitiator, (MeO-PEG114-Br), was synthesised as previously 
reported via an esterification reaction between poly(ethylene glycol) monomethyl 
ether (MeO-PEG114-OH; average molecular weight ~5000 g mol-1)  and 





Scheme 2.5 Synthesis of MeO-PEG114-Br macroinitiator via an esterification of poly(ethylene glycol) monomethyl 
ether. 
The monomethoxy PEG, MeO-PEG114-OH (Mn ~5000 g mol-1) was dissolved in 
anhydrous toluene with the addition of triethylamine and the reaction mixture was 
heated to 45 °C to aid solubilisation. The solution was degassed with argon for 
30 minutes and then allowed to cool to room temperature before α-bromoisobutyryl 
bromide was added drop-wise over a period of 30 minutes. The formation of a white 
precipitate indicated the progress of the reaction and the formation of a 
triethylammonium bromide salt. The reaction medium was left to stir for 24 hours at 
room temperature under Ar. After reaction completion, a hot filtration (50 °C) was 
performed and the crude product was washed with small amounts of hot toluene (~ 
10 mL, 50 °C).  The solvent was then concentrated in vacuo.  The resulting product 
was diluted in THF and passed through a short basic alumina column before further 
purification by precipitation into room temperature hexane.  The precipitation 
process was repeated and the product (white powder) was dried under vacuum at 
35 °C for 24 hours. -The MeO-PEG114-Br macro-initiator was characterised using a 
number of analytical techniques: 1H-NMR, 13C-NMR and TD-SEC (Figures 2.12-2.13). 
1H-NMR analysis of the macro-initiator and assignment of environments was 
obtained by normalising the integration of the methoxy group (Figure 2.8, proton a, 
δ = 3.38 ppm) to 3H. Assignment of the MeO-PEG114-Br is assigned to two methylene 
groups i.e. 4 protons, (Figure 2.12, protons b-f, δ = 3.65 ppm) gave an integration 
value of 452, which is expected for a ~5000 g mol-1 MeO-PEG114-Br macroinitiator. 
The two methyl groups (6 protons) of the initiator end group (Figure 2.8, protons h, 
δ = 1.94 ppm) and its relative intensity compared to the methoxy, provide 
confirmation that the end group modification had been successful and confirmed the 
structure of the desired compounds. The integral ratio theoretically should be 6:3 for 
the two methyl groups and the methoxy respectively, however the integration value 




% which may be indicative that there may have been an impurity present within the 
sample, likely to be the starting material, MeO-PEG114-OH. The success of the 
reaction however was further supported by 13C NMR and the assignment of the 
resonances attributed to the two methyl groups (Figure 2.13, carbons j, δ = 30 ppm). 
 
Figure 2.12 1H NMR (CDCl3) spectrum of MeO-PEG114-Br macro-initiator.  
 









It is noted that the carbon associated with the carbonyl group (h) is absent from the 
13C NMR spectra, which is likely due to the polarity of the CDCl3. However, all other 
expected resonances are present. TD-SEC analysis of MeO-PEG114-Br (Table 2.2) 
showed that monomodal traces were observed and that the macro-initiator had a 
narrow molecular weight distribution (Đ = 1.03), and a Mn value (4 950 g mol-1) was 
obtained which was in good agreement compared to the Mn theory (5 150 g mol-1).  
2.3.5 Synthesis of AB Diblock Copolymers via Methanolic ATRP of BuMA 
The ATRP polymerisations of BuMA initiated by the PEG macroinitiator (MeO-PEG114-
Br) targeted a DPn of 100 monomer units and was carried out at 50 °C in anhydrous 




Scheme 2.6 A reaction scheme for the methanolic ATRP synthesis of AB block copolymer using MeO-PEG114-Br as 
macroinitiator and BuMA as the monomer with a target DPn of 100 monomer units.   
The reaction was conducted at 50 wt. % solids in MeOH, as done previously. The 
polymerisation proceeded homogenously with the typical dark brown colour 
associated with Cu catalysed ATRP. The reaction proceeded for 96 hours and was 
terminated via exposure to oxygen before an aliquot was taken and diluted with 
CDCl3 for 1H NMR analysis to determine the monomer conversion. As before, the 
catalytic system was removed via a neutral alumina column and the polymer solution 
was concentrated in vacuo before being precipitated into ice cold hexane to yield a 
white solid. The polymer was then dried in vacuo at 35 °C for 24 hours to ensure 
complete solvent removal. Analysis of the AB block copolymer was conducted via 1H 
NMR (CDCl3) and confirmed the complete removal of the unreacted monomer by the 
disappearance of the resonances associated with the vinyl protons (c.a. 6.09 and 5.54 
ppm (CDCl3)). Characterisation of the purified AB diblock copolymer was conducted 




Table 2.2 TD-SEC data of PEG5k macroinitiator and AB block copolymer synthesised via methanolic ATRP of BuMA 
at 50 °C targeting a DPn of 100 monomer units. 













(g mol-1) Đ 
MeO-PEG114-Br - 5 150 4 950 5 100 1.03 
p(PEG114-b-BuMA100) 98 19 200 27 700 37 300 1.21 
a Calculated by 1H-NMR spectroscopy of polymerisation mixture at t=final. b Theoretical Mn calculated as 
((target DPn x MW monomer) x (conversion/100)) + initiator residue. c Calculated by TD-SEC using THF/TEA 
mobile phase (98/2 v/v%) at 35 °C, flow rate of 1mL min-1. 
 
The polymerisation achieved a high monomer conversion (98%) to yield a 
well-defined AB diblock copolymer with a narrow molecular weight distribution 
(Đ = 1.21), suggesting the polymerisation had proceeded with control. The calculated 
Mn (NMR) value (21 150 g mol-1) correlated well with the Mn theory (19 200 g mol-1) 
based on monomer conversion.  However, the calculated Mn (TD-SEC) value 
(27 700 g mol-1) was higher (by a factor of 1.4) than the Mn theory (19 200 g mol-1), 
which may indicate a poor initiation efficiency. An approximate estimation of initiator 
efficiency can be determined using a simple calculation of ((Theoretical Mn)/ 
(Observed Mn (TD-SEC)) x 100 %), which in this case gave a value of 70% for 
MeO-PEG114-Br; this is consistent with a previously reported value of 73%.53 One 
possible reason for this is that not all chain-ends of the macro-initiator were bromide 
functionalised and therefore exist as dead chains (i.e. not capable of initiating 
polymerisations). Ideally, these dead chains should have been removed during the 
purification step of the macro-initiator synthesis, but the almost identical nature of 
the starting material and the final product rendered this very difficult. The initiator 
efficiency has also been calculated using 1H NMR (91%), which is higher than that 
calculated by TD-SEC (70 %).  This is likely due to residual amount of unreacted 
macroinitiator in the sample, highlighted by the slight shoulder in the overlaid RI 
chromatograms (Figure 2.14). However, the relative success of the polymerisation is 
highlighted in the overlaid RI chromatograms through the elution of AB block 






Figure 2.14 TD-SEC analysis of p(PEG114-b-BuMA100) generated via polymerisation from MeO-PEG114-Br initiator 
with BuMA using Cu-ATRP. Overlaid TD-SEC chromatograms showing molecular weight distributions of a) 
p(PEG114-b-BuMA100) (red) and b) MeO-PEG114-Br (black). 
2.3.6 Synthesis of Linear Polymers via Methanolic ATRP of Various Methacrylate 
Monomers  
The physicochemical properties of polymers are largely determined by the chemistry 
of their monomer repeat units.77 Therefore, the methanolic ATRP of other 
hydrophobic monomers was investigated in order to expand the library of linear 
polymers already synthesised by this method. The two monomers that were chosen 
were EHMA and HPMA (Figure 2.15), both of which are commercially available. Their 
chemistries differ by the pendant group and therefore their hydrophobicity. These 
variations in the monomer chemistry, such as the presence of a hydroxy group in the 
HPMA monomer and the longer alkyl chain in the EHMA monomer, is hoped to 
introduce different polarities, hydrophobicity and hydrogen bonding to the polymer 
and the subsequent nanoparticles that are to be generated (Chapter 3.3.1). Optimum 
polymerisation conditions of HPMA via ATRP had previously been determined from 
research within the Rannard group to produce p(HPMA).74, 78-80   
 




Polymerisations generating p(EHMA)n via methanolic ATRP had not been 
investigated in significant detail at the time of this study. Although, recent reports 
from the Rannard group have described the synthesis of both linear and branched 
(co)polymers of p(EHMA) in MeOH.50  
2.3.6.1 Synthesis of Linear Homopolymers via Methanolic ATRP  
The polymerisations of EHMA and HPMA with a targeted DPn of 100 and 20 monomer 
units per chain were conducted as previously described. The polymerisations were 
carried out at 50 °C in anhydrous MeOH with Cu(I)Cl:(bpy) as the catalytic system 
(Scheme 2.7). An initial molar ratio of monomer:EBiB:Cu(I)Cl:bpy was set at 100:1:1:2 
for the reactions targeting a DPn of 100 monomer units, and 20:1:1:2 for those 
reactions targeting a DPn of 20 monomer units. The amount of MeOH added was set 
to 50% wrt to total solid mass, as before.  
 
Scheme 2.7 Linear homopolymerisation of EHMA and HPMA methacrylate monomers via copper catalysed 
methanolic ATRP targeting DPn of 20 and 100 monomer units. 
The polymerisations of HPMA and EHMA with DPn = 20 monomer units proceeded 
for 24 hours, whereas when the DPn was increased to 100 monomer units the 
reactions proceeded for a longer period of time of 48 and 72 hours for the HPMA and 
EHMA polymerisations, respectively.  
The HPMA polymerisation reactions all proceeded with the classic Cu-ATRP 
characteristic of a dark brown homogenous solution being observed throughout the 
polymerisation. Interestingly, however, the EHMA polymerisations targeting the DPn 




of the reactions. More specifically, the polymerisation medium had turned biphasic 
with an opaque dark brown liquid above a cream solid-like layer. In light of previous 
studies in the group investigating the UCST behaviour of pBuMA in various 
monomer-MeOH mixtures, the differences observed between the homogeneity 
between the polymerisations could be due to the poor solubility of p(EHMA) in the 
monomer-MeOH mixtures. It is likely that in the early stages of the polymerisation, 
low molecular weight oligomers/polymers are retained in solution due to the co-
solvency effect of the EHMA monomer. However, as the polymerisation progresses, 
and the monomer is depleted, the co-solvency effect may not be enough to retain 
the polymer in solution. Phase separation observed early on in the polymerisations 
highlights that the co-solvency effect was minimal in its thermodynamic contribution 
to the Gibbs free energy of mixing. 81  
After the HPMA polymerisations had reached high monomer conversions (≥ 98%), 
determined by 1H-NMR analyses, the polymerisations were terminated by exposure 
to air and addition of THF solvent. Due to the biphasic nature of the EHMA 
polymerisations, they were terminated via the addition of CDCl3 instead of THF, 
which enabled a crude NMR sample to be taken directly from the reaction mixture 
once solubilised. Integration of the resonances attributed to the vinyl protons within 
the 1H NMR spectra showed that despite the biphasic nature, the polymerisation was 
still able to achieve high monomer conversions (≥ 99%). A change in colour was 
observed for both the HPMA polymerisations from dark opaque brown to a 
transparent green solution. This colour change was also observed for the EHMA 
polymer mixture but with the additional observation that the biphasic mixture only 
became solvated and homogenous with stirring for 1 hour. The polymers were then 
purified via a two-stage process. Firstly, the catalytic system was removed by passing 
the diluted reaction mixture over a neutral alumina column using either CHCl3 or THF 
as the mobile phase for the purifications of p(EHMA) and p(HPMA), respectively. The 
polymer solutions were then precipitated, as before, to remove any unreacted 
monomer, residual initiator and free ligand. The linear p(EHMA) homopolymers were 
precipitated into cold MeOH and the linear p(HPMA) homopolymers into room 




ensure complete solvent removal. Analysis of the polymers was then conducted via 
1H-NMR spectroscopy to confirm the complete removal of any residual initiator, 
unreacted monomer and free ligand.  Subsequent analysis via TD-SEC in THF/TEA 
(98/2 v/v %), was used to determine the molecular weights and dispersities of the 
synthesised linear homopolymers (Table 2.3). 
Table 2.3 Methanolic Cu-ATRP of hydrophobic monomers, EHMA and HPMA, for linear polymer synthesis at 50 °C 
with target DPn of 100 and 20 monomer units. 
    
TD-SEC (THF)d 

















p(EHMA)20 24 > 99 % 4 050 7 530 10 450 1.38 0.486 
p(EHMA)100 72 99 % 19 850 23 900 35 300 1.48 0.621 
p(HPMA)20 24 98 % 3 000 4 300 7 200 1.67 0.480 
p(HPMA)100 48 99 % 14 500 24 500 30 400 1.24 0.526 
a Target DPn calculated by [Monomer]/[EBiB]. b Calculated by 1H NMR spectroscopy of polymerisation mixture at t=final. c 
Theoretical Mn calculated as ((target DPn x mw monomer) x (conversion/100)) + initiator residue). d Calculated by TD-SEC 
using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1mL min-1. 
The TD-SEC analysis of the polymers revealed that the Mn values did vary slightly from 
that of the theoretical values, which again may be attributed to the initiator efficiency 
of EBiB. The initiator efficiencies were calculated as previously described and values 
were obtained as follows: p(EHMA)20 (54%), p(EHMA)100 (84%), p(HPMA)20 (70%) and 
p(HPMA)100 (60%).  The dispersity values obtained for these homo-polymerisations 
were higher compared to that of the BuMA homo-polymerisations. It is not surprising 
that p(EHMA)n possessed higher dispersity values of Đ = 1.38 and 1.48 for the DPn 20 
and 100 monomer units, respectively. This is because it is likely to be a result of the 
phase separation that occurred during the polymerisation, which would have 
isolated polymer chains from the monomer/MeOH solution and subsequently 
impeded further growth. Whereas, the higher dispersities of p(HPMA)n compared to 
that of p(BuMA)n could be due the equilibrium of ATRP being impacted by the relative 
reactivity of the two monomers. Although higher than that of p(BuMA), the dispersity 
value of p(HPMA)100 (Đ = 1.24) suggested that the polymerisation still proceeded with 
control. However, the dispersity value obtained for p(HPMA)20 (Đ=1.69) is 
significantly higher than what would be anticipated for that of a controlled 




a higher dispersity values due to the nature of the calculation. The Mark-Houwink α 
values obtained for the homopolymers (0.480 - 0.621) are consistent with that 
expected of linear polymers. 
2.3.7 Synthesis of Statistical Linear Copolymers via Methanolic ATRP 
Statistical copolymers can be generated by using a mixed monomer feed of different 
monomers before initiation and is typically done to manipulate the chemical and 
physical properties of the copolymers that are produced. In this study, linear 
statistical copolymers were generated by blending 2 of the 3 monomers with the 
target DPn set to 100 and the comonomers selected were used at an equal molar 
ratio to generate 50 monomer units each with respect to the initiator concentration.  
The polymerisations were conducted as before via methanolic ATRP at 50 ˚C using 
the same catalytic system as that used in earlier polymerisations. The reactions all 
proceeded for 72 hours and were terminated by exposure to oxygen and via addition 
of THF, with the exception of p(BuMA50-co-EHMA50); this was poisoned with CDCl3 
due to the biphasic nature of the polymerisation. Purification was conducted as 
before, passing the crude polymers through a neutral alumina column before 
conducting a precipitation into an appropriate antisolvent. TD-SEC and 1H NMR 
analyses were conducted on the purified polymers (Table 2.4).  
Table 2.4 Methanolic Cu-ATRP of hydrophobic monomers at 50 °C to generate statistical linear copolymers with 
overall target DPn of 100 monomer units. 
   
TD-SEC (THF)d 














p(BuMA50-co-EHMA50) > 99 % 16 900 19 800 22 500 1.13 0.686 
p(BuMA50-co-HPMA50) 98 % 14 000 18 100 22 200 1.22 0.620 
p(EHMA50-co-HPMA50) 99 % 17 100 22 100 26 100 1.18 0.628 
a Target DPn calculated [Monomer] / [EBiB], b Calculated by 1H-NMR spectroscopy of polymerisation mixture at t=final. 
c Theoretical Mn calculated as ((target DPn x mw monomer) x (conversion/100)) + initiator residue. d Calculated by TD-SEC 
using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1mL min-1. 
The reactions all reached high monomer conversions (> 98%) and the polymers 
produced were generated with control, as indicated by the low dispersity values 
(1.13 ≤ Đ ≤ 1.22). As previously observed, the Mn values (19 800 – 22 100 g mol-1) did 




still highlighted a reasonable control of the molecular weight of the primary polymer 
chains. The obtained Mark-Houwink α values (0.620 ≤ α ≤ 0.686) indicated that the 
polymers were linear in architecture. 
Interestingly, p(HPMA50-co-EHMA50) did not precipitate from the reaction medium, 
and instead remained homogenous and yet for the polymerisation of p(BuMA50-co-
EHMA50), biphasic behaviour was observed at the late stages of the polymerisation. 
Homopolymerisation of EHMA have been shown to proceed with a biphasic nature.50 
However, from the inclusion of HPMA monomer this behaviour was altered. The 
difference in behaviour observed could be rationalised by the simple fact that MeOH 
is a much better solvent for HPMA than EHMA and therefore the HPMA monomer 
residues in the polymer chain enable the chain to remain solvated. Despite the 
polymerisation of p(BuMA50-co-EHMA50) yielding a biphasic reaction mixture, a low 
dispersity value (1.13) was still obtained.   The biphasic nature was only observed 
after the reaction had proceeded for at least 60 hours, so it is likely the 
polymerisation had already reached high conversion. The obtained Đ value for 
p(HPMA50-co-EHMA50) (1.18) was also lower than the values obtained for the 
corresponding homopolymerisation of HPMA and EHMA, which could be as a result 
of the polymer remaining in solution for longer and therefore was more likely to 
polymerise better.  
2.3.8 Synthesis of PEG114 AB Diblock Copolymers via Methanolic ATRP using EHMA 
and HPMA as the Monomers 
In order to expand the library of the amphiphilic AB block copolymers available, the 
synthesis of p(PEG114-b-EHMA100) and p(PEG114-b-HPMA100) was conducted. The 
ATRP polymerisations were initiated by the PEG macroinitiator (MeO-PEG114-Br), 
targeting a DPn of 100 monomer units and was carried out at 50 °C in anhydrous 
MeOH. The same catalytic system of Cu(I)Cl:bpy (1:2) was used as discussed in 
Section 2.3. The MeOH concentration was set to 50% with respect to total solid mass, 





Scheme 2.8 Schematic representation of the synthesis of a) p(PEG114-b-EHMA100) and b) p(PEG114-b-HPMA100). 
The polymerisation proceeded homogenously with the typical dark brown colour 
associated with Cu catalysed ATRP and was terminated via exposure to oxygen 
before an aliquot was taken and diluted with CDCl3 for 1H NMR analysis to determine 
the monomer conversion. As before, the catalytic system was removed via a neutral 
alumina column and the polymer solution was concentrated in vacuo before being 
precipitated into ice cold hexane to yield a white solid. The polymer was then dried 
in vacuo at 35 °C for 24 hours to ensure complete solvent removal. Analysis of the AB 
block copolymer was conducted via 1H-NMR (CDCl3) (Appendix, Figure A4 and A5) 
and confirmed the complete removal of any residual initiator, unreacted monomer 
and free ligand. Characterisation of the purified AB diblock copolymer was conducted 
via 1H NMR spectroscopy and TD-SEC (Table 2.5).  
Table 2.5 TD-SEC data of AB block copolymers synthesised via methanolic ATRP at 50 °C with target DPn of 100 
monomer units. 
The polymerisations proceeded for 72 hours until high monomer conversions were 
reached, determined by 1H NMR. Both polymerisations proceeded under 
   
TD-SEC (THF)d 










p(PEG114-b-EHMA100) > 99 % 24 400 32 400 39 000 1.19 
p(PEG114-b-HPMA100) 98 % 14 000 18 100 22 200 1.71 
a Target DPn calculated [Monomer] / [EBiB], b Calculated by 1H-NMR spectroscopy of polymerisation mixture 
at t=final. c Theoretical Mn calculated as ((target DPn x mw monomer) x (conversion/100)) + initiator residue. 




homogeneous reaction conditions with a dark brown colour observed throughout; in 
the case of the EHMA polymerisation, this observation was in contrast to that 
observed during the synthesis of the p(EHMA) homopolymers, which proceeded with 
a biphasic nature. It is believed that the hydrophilic PEG functionality had a significant 
effect on retaining the block copolymer within the methanolic solution. The 
refractive index trace obtained for p(PEG114-b-HPMA100) showed a small shoulder on 
the right-hand side of the peak at a higher retention time that had a significant 
contribution to this high dispersity value (Figure 2.16).  
 
Figure 2.16 TD-SEC overlay of a) PEG113-b-p(BuMA100) vs PEG113-b-p(HPMA100) obtained with DMF containing 
0.01M LiBr at 60  Cͦ, 1 mL min-1 flow rate and b) PEG114-b-p(EHMA100) obtained with THF containing 2% TEA (v/v) 
at 35  ͦC, 1 mL min-1 flow rate. 
This shoulder was believed to be unreacted MeO-PEG114-Br macro-initiator that has 
not been successfully removed during the purification via precipitation. This was 
further confirmed by overlaying the RI traces of p(PEG114-b-HPMA100) and MeO-
PEG114-Br (Figure 2.17), which showed that the shoulder eluted at a very similar 
retention time to that of the macro-initiator. The purification of the AB block 
copolymers involved the precipitation into an antisolvent of hexane. This is also an 
anti-solvent for the macro-initiator, meaning purification was challenging. It could 
also be presence of MeO-PEG114-OH which was not removed successfully during the 
purification of the macro-initiator and has subsequently been carried forward in the 





Figure 2.17 Overlaid TD-SEC chromatograms of p(PEG114-bHPMA100) (black line) and MeO-PEG114-Br (red line). 
Obtained with THF containing 2% TEA (v/v) at 35  Cͦ, 1 mL min-1 flow rate. 
2.3.9 Synthesis of Statistical Branched Copolymers with EGDMA via Methanolic 
ATRP 
Having established the viability of methanolic ATRP as technique suitable for the 
controlled synthesis of linear polymers varying in functionality and composition, this 
technique was extended towards the synthesis of high molecular weight branched 
statistical copolymer architectures. These materials were synthesised following a 
modified Strathclyde approach via Cu-catalysed ATRP of BuMA. The polymerisation 
was conducted as described previously for the generation of linear p(BuMA) 
homopolymers (Section 2.4.1) but with the addition of small amounts of a divinyl 
monomer - ethylene glycol dimethacrylate (EGDMA) - within the synthesis, which led 
to the inter-chain branching of primary polymer chains (Scheme 2.9). It is important 
to note that the equivalence of the divinyl monomer had to be on average less than 
one equivalent per primary chain to avoid gelation of the polymeric material, as 





Scheme 2.9 The methanolic ATRP of BuMA with the inclusion of divinyl monomer EGDMA at equivalence X (0.85-
1) using the EBiB initiator, targeting a DPn =100 monomer units, to yield branched copolymer p(BuMA100-co-
EGDMAx).  
The incorporation of EGDMA with [EGDMA]/[EBiB] molar equivalences varying 
between 0.85 and 0.95 yielded materials with varying molecular weights. The weight 
average number of chains within the branched species was calculated via a crude 
calculation, by dividing the Mw value of the branched copolymers by the Mn of the 
linear counterpart (Table 2.6).  The polymerisations targeting a DPn of 100 monomer 
units proceeded via Cu-catalysed methanolic ATRP at 50 ˚C. An initial molar ratio of 
BuMA:EGDMA:EBiB:CuCl:bpy was set at 100:X:1:1:2, where X represents the varying 
equivalences of the divinyl monomer. All the reactions proceeded for 72 hours with 
the characteristic brown homogenous solution as previously observed for 
p(BuMA)100. The monomer conversions were high for all polymerisations (≥ 98%), as 
determined by 1H-NMR analysis. This is essential for the formation of high Mw 
branched copolymers following a modified Strathclyde method, as the propagation 
through the pendent vinyl group only occurs during the latter stages of the reaction 
(Section 2.2.3).40 Reactions were terminated following exposure to oxygen and 
subsequent dilution with THF, the catalytic system was removed by passing the 
polymer solution through a neutral alumina column and all polymers were purified 
by precipitation into MeOH. The branched copolymers were then characterised by 





Table 2.6 Methanolic Cu-ATRP of BuMA at 50 °C using varying equivalences of divinyl monomer EGDMA to 
generate branched statistical copolymers with a targeted DPn of 100 monomer units. 
  
TD-SEC (THF)c 















p(BuMA100-co-EGDMA0.85) > 99 % 35 950 99 100 2.76 0.430 4 
p(BuMA100-co-EGDMA0.90) 98 % 39 700 271 250 6.83 0.405 11 
p(BuMA100-co-EGDMA0.95) > 99 % 125 700 2 140 000 17.02 0.428 105 
p(BuMA100-co-EGDMA1.00) Insoluble Gel 
a Target DPn calculated by [nBuMA] / [EBiB], b Calculated by 1H NMR spectroscopy of polymerisation mixture at t=final. c 
Calculated by TD-SEC using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1mL min -1. d Calculated by Mw of 
branched copolymer (TD-SEC)/Mn of corresponding linear polymer (TD-SEC).  
Analysis of the branched p(BuMA-co-EGDMA) copolymers by TD-SEC (THF) showed 
that the Mw and Mn values were significantly higher than the linear homopolymer 
analogues (Section 2.3.1, Table 2.1), which clearly indicates that the incorporation of 
the divinyl monomer EGDMA had an influence on the polymer architecture and that 
branched structures have been generated. Furthermore, an increase in Mw and Mn 
values was observed as the [EGDMA]/[EBiB] molar ratio was increased. The branched 
copolymer, p(BuMA100-co-EGDMA0.95) exhibited the highest molecular weight (Mn = 
125 kg mol-1; Mw = 2140 kg mol-1) within the series. As expected, when the molar 
equivalence of EGDMA relative to EBiB was increased to 1, the formation of an 
insoluble gel occurred. The molecular weight distributions (2.76 ≤ Đ ≤ 17.02) were 
significantly broader than that of the linear homopolymer (Đ = 1.14), which again 
indicates the statistical inter-chain branching of the primary polymer chains in the 
presence of EGDMA. The Mark-Houwink α values (0.405-0.430) were significantly 
lower compared to the linear analogue (0.676). It has been reported that for 
branched polymers, depending on the degree/extent of branching within the 
branched architecture, that the α value will typically vary between 0.2 and 0.5, which 
further validates that branched copolymer architectures have been obtained. From 
a crude calculation, the weight average number of chains within the branched 
species was calculated by dividing the Mw value of the branched copolymers by the 
Mn of the linear counterpart. The number of chains branched together increased 
considerably with the increasing ratios of EGDMA, further validating that the EGDMA 




that the branched polymers structures consisted of at least 4 conjoined primary 
polymer chains and this increased to 105 as the equivalence of EGDMA increased.  
Overlays of the TD-SEC refractive index (RI) (Figure 2.18A) and right-angle light 
scattering (RALS) (Figure 2.18B) chromatograms obtained for p(BUMA)100 and 
p(BuMA100-co-EGDMA0.95), highlights the difference between the linear and 
branched architectures obtained. Analysis of RI traces illustrates narrow monomodal 
molecular weight distribution for linear p(BuMA)100 and broad multi-modal 
distributions for branched p(BuMA100-co-EGDMA0.95) copolymer. This is typical for 
the analysis of branched polymers synthesised in this way due to the statistical 
nature of incorporating EGDMA into the polymer species. A range of species is 
generated; linear, lightly branched and highly branched architectures which has been 
reported for polymers synthesised in this way.80 This is further confirmed by the close 
correlation between the overlays of the RI traces of the linear homopolymer and the 
lower Mw species of the branched material. The differences between the obtained 
RALS chromatograms provides evidence for the presence of large size (high Mw) 
species since material which has larger size will scatter significantly more light than 





Figure 2.18 Overlaid TD-SEC analysis of a) RI chromatograms and b) RALS chromatograms for p(BuMA100-co-
EGDMA0.95) (black) and p(BuMA)100 (red).  
The copolymerisation of BuMA with varying equivalences of EGDMA was also 




polymerisations proceeded for 24 hours.  Compared to the DPn of 100 monomer 
units, this copolymerisation required a lower equivalence (0.85 eqv.) of divinyl 
monomer EGDMA relative to EBiB in order to avoid gelation and yield a soluble 
branched polymer. Equivalences above this value generated insoluble polymeric gels. 
Since the monomer mass is fixed during the polymerisations, the lower gelation point 
could be explained by the increased density of pendant vinyl bonds, which has 
increased from 1 in 100 to 1 in 20 and hence the potential for intermolecular reaction 
has increased and loop formation (cyclisation) is less likely. Analysis by TD-SEC 
showed that p(BuMA20-co-EGDMA0.85) was highly branched with an Mw value of 4856 
kg mol-1(Table 2.7). 
Table 2.7 Methanolic Cu-ATRP of hydrophobic monomer BuMA and varying equivalences of divinyl monomer 
EGDMA for branched statistical copolymers synthesis at 50 °C with target DPn 20 monomer units. 
Calculation of the weight average number of chains revealed that there were 952 
primary polymer chains branched together, which is significantly more than that 
calculated for p(BuMA100-co-EGDMA0.95) that had 105 primary polymer chains 
branched together.   The Mark-Houwink α value (0.402) is indicative of a branched 
polymer. The broad dispersity value (Đ = 85) was consistent with that expected for a 
branched polymer produced by this technique (i.e. modified Strathclyde.) The broad 
value suggests that there is a wide variety of species present within the sample.  
2.3.9.2 Variation of the Hydrophobic Monomer to Produce Branched Statistical 
Copolymers  
Statistical branched copolymers were also generated using EHMA and HPMA as the 
monomers. Both DPn = 100 and 20 monomer units were targeted for the primary 
chain length and, as before, varying equivalences of EGDMA were incorporated into 
the polymerisations. For the polymerisations targeting a DPn of 100 monomer units, 
  TD-SEC (THF)c 
















p(BuMA20-co-EGDMA0.85) > 99 % 57 050 4 856 000 85. 14 0.402 952 
p(BuMA100-co-EGDMA0.90) Insoluble Gel 
p(BuMA20-co-EGDMA0.95) Insoluble Gel 
a Target DP calculated [nBuMA] / [EBiB],   b Calculated by 1H NMR spectroscopy of polymerisation mixture at t=final hr. c 
Calculated by TD-SEC using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1mL min -1. d Calculated by Mw of 




a molar ratio of monomer:EGDMA:EBiB:Cu(I)Cl:bpy was set at 100:X:1:1:2. The 
polymerisations proceeded for 48 and 72 hours for HPMA and EHMA, respectively, 
during which the observed phase behaviours were identical to that of the 
corresponding linear polymerisations as previously described; the polymerisation of 
HPMA remained homogeneous in nature throughout the reaction, whereas the 
polymerisation of EHMA induced a phase-separation during the reaction. Analysis of 
the polymerisation mixtures by 1H NMR showed that the polymers had achieved high 
monomer conversions (97 - 99%) (Table 2.8). Polymers were purified by removal of 
the Cu(I)Cl:Bpy catalytic system by passing through a neutral alumina column and 
subsequent precipitation into an anti-solvent. The purified branched copolymers 
were characterised by TD-SEC (Table 2.8) and 1H NMR (Appendix, Figure A7 and A8).  
Table 2.8 Methanolic Cu-ATRP of hydrophobic monomers, EHMA and HMPA, with varying equivalences of divinyl 
monomer EGDMA for branched statistical copolymers with target DPn = 100 monomer units at 50 °C. 
  
TD-SEC (THF)c 
a Target Polymer 











p(EHMA100-co-EGDMA0.80) 97 % 44 100 687 950 15.60 0.419 20 
p(EHMA100-co-EGDMA0.85) Insoluble Gel 
p(HPMA100-co-EGDMA0.85) > 99 % 60 350 359 500 5.96 0.314 12 
p(HPMA100-co-EGDMA0.90) > 99 % 71 500 1 427 000 19.97 0.359 47 
p(HPMA100-co-EGDMA0.95) Insoluble Gel 
a Target DP calculated [Monomer] / [EBiB], b Calculated by 1H NMR spectroscopy of polymerisation mixture at t=final. c 
Calculated by TD-SEC using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1mL min-1. d Calculated by Mw of 
branched copolymer (TD-SEC)/Mn of corresponding linear polymer (TD-SEC).  
In both cases, soluble high molecular weight copolymers were obtained, p(EHMA100-
co-EGDMA0.80) (Mw = 687 950 g mol-1) and p(HPMA100-co-EGDMA0.90) (Mw = 1427 kg 
mol-1). It was observed that the branched copolymerisation of EHMA required a 
much lower equivalence of EGDMA (0.80 eqv.) compared to the polymerisations of 
BuMA and HPMA in order to avoid gelation and generate soluble branched material. 
As oligomers and polymers concentrate during phase separation, it is likely that they 
are swollen by the monomer mixture and a relative high concentration of EGDMA is 
present that may lead to higher incorporation in some chains and the potential for 




Despite the lower molecular weight, analysis of the Mark-Houwink α value (0.419) 
and the broad dispersity (Đ = 15.60) still indicate that the polymer is branched with 
approximately 20 primary chains attached together. Analysis of p(HPMA100-co-
EGDMA0.90) showed that branched copolymer architecture had been obtained with 
a broad dispersity value (19.97) with approximately 47 primary chains attached 
together.  
The polymerisations targeting a reduced DPn of 20 monomer units were also 
conducted as described above using a molar ratio of monomer:EGDMA:EBiB:Cu(I)Cl: 
bpy was set at 20:X:1:1:2. The reactions all proceeded for 24 hours and the same 
phase behaviour was observed. The polymerisations were poisoned via the exposure 
to oxygen and via the addition of THF for p(HPMA20-co-EGDMAx) and CDCl3 for 
p(EHMA-co-EGDMAx). Analysis of the polymerisations via 1H-NMR spectroscopy 
showed that high monomer conversions (> 99%) were achieved. The catalytic system 
was removed by passing the polymeric solution over a neutral alumina column and 
subsequent precipitation into an appropriate anti-solvent. The polymers were 
characterised by TD-SEC and 1H NMR spectroscopy (Table 2.9).  
Table 2.9 Methanolic Cu-ATRP of hydrophobic monomers, EHMA and HMPA, with varying equivalences of divinyl 
monomer EGDMA for branched statistical copolymers with target DPn = 20 monomer units at 50 °C. 
  
TD-SEC (THF)c 















p(EHMA20-co-EGDMA0.80) > 99 18 900 1 200 000 63.16 0.372 159 
p(EHMA20-co-EGDMA0.85) Insoluble Gel 
p(HPMA20-co-EGDMA0.80) > 99 21 300 119 900 5.63 0.365 28 
p(HPMA20-co-EGDMA0.90) > 99 138 950 1.02 x 107 73.74 0.179 2 372 
p(HPMA20-co-EGDMA0.95) Insoluble Gel 
a Target DP calculated [monomer] / [EBiB], b Calculated by 1H NMR spectroscopy of polymerisation mixture at t=final.                                
c Calculated by TD-SEC using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1 mL min -1. d Calculated by Mw of 
branched copolymer (TD-SEC)/Mn of corresponding linear polymer (TD-SEC).  
The obtained Mw and dispersity values indicated that branched polymeric structures 
had been synthesised: p(EHMA20-co-EGDMA0.80) (Mw = 1200 kg mol-1, Đ = 63.16) and 
p(HPMA20-co-EGDMA0.90) (Mw =10 200 kg mol-1, Đ = 73.74). The weight average 




p(HPMA20-co-EGDMA0.90), respectively. Additionally, the corresponding Mark-
Houwink α values obtained for the EHMA and HPMA branched copolymers (0.372 
and 0.179, respectively) also provide indication that the materials are branched in 
nature. As observed for the copolymerisation of EHMA and HPMA with EGDMA 
targeting the higher DPn of 100 monomer units, the required molar equivalences of 
EGDMA to avoid gelation and produce soluble branched material varied between the 
polymerisations of the two monomers. Polymerisation of EHMA incorporated a 
maximum of 0.80 equivalences ([B]/[I] ratio) of EGDMA, whereas the polymerisation 
of HPMA incorporated a maximum of 0.90 equivalences of EGDMA.  
2.3.10 Synthesis of Statistical Branched Copolymers  
Since the viability of methanolic ATRP has been proven for the synthesis of high 
molecular weight branched polymers following a modified Strathclyde approach, the 
synthesis was extended to the generation of statistical branched copolymers using 
two monofunctional monomers in the presence of the divinyl monomer, EGDMA, 
and targeting an overall DPn of 100 monomer units for the primary chains. This 
resulted in each monovinyl monomer being set to 50 equivalences with respect to 
the initiator concentration. The polymerisations were conducted as before via 
methanolic ATRP at 50 ˚C using the same catalytic system as previously described. 
The reactions all proceeded for 72 hours and were terminated by exposure to oxygen 
and via addition of THF. Interestingly, there was no phase separation observed for 
any of these polymers. Purification was conducted by passing the polymer mixture 
through a neutral alumina column before performing a precipitation into an 
appropriate antisolvent. Once again, the formation of branched statistical 
copolymers was confirmed by TD-SEC and 1H-NMR spectroscopy (Table 2.10). In all 
cases high monomer conversions (≥ 98%) were achieved and the calculated Mw (≥ 
501.6 kg mol-1) and Mn (≥ 51.3 kg mol-1) values were significantly higher than the 
values obtained for the linear statistical copolymers (Section 2.4.3.3). Broad 
molecular weight distributions were also observed (Đ = 7.51 – 20.75) and the 
calculated Mark-Houwink α values were highly indicative of branched copolymer 




Table 2.10 Methanolic Cu-ATRP of hydrophobic monomers at 50 °C to generate statistical branched copolymers 
with overall target DPn = 100 monomer units. 












p(BuMA50-co-EHMA50-co-EGDMA0.95) 98 % 51 250 1 060 000 20.75 0.389 
p(BuMA50-co- HPMA50-co-EGDMA0.95) 99 % 66 750 939 000 14.07 0.399 
p(HPMA50-co-EHMA50-co-EGDMA0.95) 99 % 66 800 501 600 7.51 0.423 
a Target DP calculated [monomer] / [EBiB], b Calculated by 1H NMR spectroscopy of polymerisation mixture at t=final hr. c 
Calculated by TD-SEC using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1 mL min-1.  
 
2.4 Determining the Glass Transition Temperature of the Polymers 
The physical properties of polymers such as rigidity and viscosity in the bulk state can 
be influenced by temperature. Polymeric materials that are semi-crystalline in 
nature, such as p(caprolactone), p(lactic acid) and PEG, will exhibit two characteristic 
thermal transitions in the solid state.82 One of the thermal transitions is associated 
with a first order phase change of the polymer and occurs at the temperature at 
which the crystalline polymer (or domain) melts thereby increasing the molecular 
motion of the polymer chains. This is known and reported as the crystalline melting 
temperature (Tm). This transition is only present in (semi-)crystalline species and is 
absent from materials that are amorphous in nature.  The other thermal transition is 
known as the glass-transition and is represented by the glass transition 
temperature (Tg). The Tg represents a second order transition and can be thought of 
as the temperature at which local segmental motion starts to occur within an 
amorphous polymer. It is important to note that Tg proceeds over a certain 
temperature range and not as a discrete temperature value. The Tg value is affected 
by the mobility and flexibility of the polymer chains, which in turn is governed by the 
free volume and the backbone and pendent group chemistry. The free volume 
describes how much space a polymer chain has to move and achieve different 
physical conformations with respect to other polymer chains. If the free volume 
around the polymer chain is large, the polymer chain can move and undergo 
conformational changes more freely with a lower energy input and will exhibit a low 
Tg value. On the contrary, if the polymer chain has limited free volume (i.e. the 
mobility of the chain is restricted), more energy is required for the polymer chains to 




There are many different factors that can affect the Tg of a polymer including: 
molecular weight, molecular structure, intermolecular forces, chain stiffness and 
cross-linking. In general, factors that increase the energy required for the onset of 
molecular motion will increase Tg; factors that decrease the energy required will 
lower Tg. Polymers of different architectures and monomer composition will also 
typically exhibit different Tg values.  It has been reported that even minimal changes 
such as increasing the carbon number by one on the pendant group of the repeat 
unit can have a dramatic impact on the Tg value. As seen when comparing analyses 
of poly(methyl methacrylate) and poly(ethyl methacrylate); in the latter case, there 
is a significant decrease in the recorded Tg by approximately 40 °C.83 This observed 
change illustrates how easily the thermal characteristics of any polymer can be 
altered by relatively small manipulations of polymer structure and chemistry. 
Changes to the primary polymer chain length and therefore the molecular weight will 
also alter the Tg value. The relationship between polymer molecular weight and Tg 
can be explained by the Flory-Fox approximation, which describes the relationship 
between Tg and Mn (Equation 2.2).84, 85  
𝑇𝑔(𝑀𝑛) ≈  𝑇𝑔,∞ − 𝐾/𝑀𝑛           (2.2) 
Where Tg,∞ represents maximum Tg temperature at a theoretical infinite molecular 
weight and K is the empirical parameter relating to polymer free volume. This Tg 
dependence on Mn can be explained with the free volume theory; chain ends typically 
exhibit greater mobility than chain segments, and consequently free volume 
increases with the number of chain-ends in a given volume.  Higher DPn values yield 
polymers with higher Mn values and lower numbers of chain-ends for any given mass, 
thereby reducing the free volume and mobility that can be exhibited and increasing 
the Tg value. Tg will continue increasing with molecular weight until it reaches a 
limiting value (Tg,∞) at moderate to high molecular weights. However, the Flory-Fox 
equation does not give accurate estimations for the entire range of molecular 
weights; at short chain lengths (low molecular weight oligomers), the accuracy of the 
prediction is much lower. This is because there is a strong dependency on the 




polymer is not precisely defined, but it is generally accepted that this point will be 
located at around 50 to 100 monomer units.86  
2.4.1 Determining the Thermal Behaviour of Linear Homopolymers via Differential 
Scanning Calorimetry 
The thermal characteristics of the linear homopolymers were assessed using a DSC Q 
2000 TA Instrument (Table 2.11). The instrument was calibrated for heat flow and 
temperature using an indium reference. All samples were purged with pure nitrogen 
at a flow rate of 50 mL min- 1 and the thermal history was erased by an initial 
heat/cool cycle and then the Tg values were determined from the second heat cycle 
by taking the inflection point of the heat flow curve.   
Table 2.11 Tg temperatures (°C) obtained for linear homopolymers of DPn 20 and 100 monomer units.   
 
For all of the polymers within the series, a single Tg endotherm was obtained without 
the presence of any additional transitional temperatures (such as melting), 
suggesting that the polymers are amorphous in nature. Examples thermograms are 
provided for p(EHMA)20, p(HPMA)20, p(BuMA)100 and p(HPMA)100 (Appendix, Figure 
A9-A12). The Tg values obtained for the linear homopolymers all varied for the DPn = 
20 monomer units, (-34 ≤ Tg ≤ 39 ℃) and DPn = 100 monomer units (-17 ≤ Tg ≤ 53 ℃).  
Literature values have been reported as -10 ℃ for EHMA, 24 ℃ for BuMA and 76 ℃ 
for HPMA based polymers,87 but it is important to note that literature values are 
usually reported as Tg,∞ and at much higher Mn values than these materials. The Tg 
values obtained for all of the linear homopolymers are consistently lower than the 
Polymer Composition aObtained Tg Value (°C) 
p(EHMA)20 - 34 
p(BuMA)20 8 
p(HPMA)20 39 
p(EHMA)100 - 17 
p(BuMA)100 24 
p(HPMA)100 53 
a Tg values were determined from the second heat cycle by taking the inflection point of the heat flow 
curve. Thermogram was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and 
temperature using an indium reference and all samples were purged with pure nitrogen at a flow rate of 
50 mL min-1. Measurements were obtained via two heat/cool/heat cycles between 25 and 250 °C at a heating 




literature values reported, with the exception of p(BuMA)100 and it is likely that the 
values that have been experimentally obtained for the polymer series described 
above have not yet reached Tg,∞.  
When comparing the functionality of the homopolymers, it is not surprising that 
those consisting of HPMA monomer residues exhibited the highest Tg values for both 
the targeted DPn 20 and 100 chain lengths, which were 39 °C and 53 °C, respectively. 
This can be explained by the presence of the hydroxyl groups on the pendant chain 
of the repeat units, which increases the intermolecular interactions between the 
polymer chains and therefore decreases their mobility and flexibility. This decrease 
in free volume increases the energy required to impart conformational changes on 
the polymer chains and subsequently increases the observed Tg value. As expected, 
the polymers consisting of EHMA monomer residues exhibited the lowest Tg values 
for both the targeted DPn 20 and 100 chain lengths, which were -34 °C and -17 °C, 
respectively. Since the EHMA repeat units contain a long aliphatic side group, this 
creates more free volume between the polymeric chains and thus in turn decreases 
the energy required for chain mobility and therefore decreases the Tg value.   
2.4.2 Determining the Thermal Characteristic Behaviour of the Branched 
Copolymers via Differential Scanning Calorimetry 
The DSC thermograms of the branched copolymer series consisting of EGDMA divinyl 
monomer residues were also acquired under identical DSC conditions, and provided 
insight into Tg changes associated with changing the polymer architecture from linear 
to branched (Table 2.12). Examples of DSC thermograms obtained for branched 









Table 2.12 Tg temperatures (°C) obtained for EGDMA branched statistical copolymers of DPn 20 and 100 monomer 
units compared to the Tg temperatures obtained for linear homopolymers DPn 20 and 100 monomer units.   
In general, the observed Tg values were higher for all branched polymers compared 
to the corresponding linear homopolymers with same targeted DPn value. The 
rationalisation of this increase could follow the very classic approach of using the 
Flory-Fox equation, since the actual Mn of the copolymers had increased with the 
introduction of the divinyl monomer. However, it is important to note that Tg studies 
reported in the literature that also follow this trend are typically of linear samples 
that are relatively monodisperse with unimodal molecular weight distributions. In 
this study, the branched polymeric materials have broad molecular weight 
distributions and therefore the effects of this distribution on the Mn value and 
therefore Tg must be accounted for. Rannard and co-workers have shown that a more 
general equation can be applied to consider samples that have a wide variation in Mn 
and Mw (Equation 2.3).88  
𝑇𝑔 = 𝑇𝑔,∞ −
𝐾
√𝑀𝑛𝑀𝑤
    (2.3) 
Polymer Composition 
Obtained Tg Value 
(°C) 
Mn (SEC) 
(g mol-1) Đ 
p(EHMA)20 - 34 7 530 1.38 
p(BuMA)20 8 5 100 1.24 
p(HPMA)20 39 4 300 1.67 
p(EHMA20-co-EGDMA0.80) - 16 18 900 63 
p(BuMA20-co-EGDMA0.95) 24 57 050 85 
p(HPMA20-co-EGDMA0.85) 58 138 950 74 
p(EHMA)100 - 17 19 850 1.48 
p(BuMA)100 24 20 200 1.14 
p(HPMA)100 53 14 500 1.24 
p(EHMA100-co-EGDMA0.80) - 6 44 100 16 
p(BuMA100-co-EGDMA0.95) 26 125 700 17 
p(HPMA100-co-EGDMA0.90) 78 71 500 20 
aTg values were determined from the second heat cycle by taking the inflection point of the heat flow 
curve. Thermogram was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and 
temperature using an indium reference and all samples were purged with pure nitrogen at a flow rate of 50 mL 
min-1. Measurements were obtained via two heat/cool/heat cycles between 25 and 250 °C at a heating rate 





Clearly, when incorporating a branching agent within a polymerisation, the Mn and 
Mw values will increase. Therefore, an increase in Tg value could be expected until 
values of Tg, ∞ are obtained due to the molecular weight dependency. When Tg∞ is 
obtained, increases in molecular weight can no longer be the only contributory factor 
to changes in the Tg. However, what is of interest is the influence of changing the 
polymer architecture from linear to branched from an architectural perspective once 
Tg is no longer dependant on molecular weight. Rannard and co-workers reported 
that variations to Tg of polystyrene based materials were observed when branched 
polymers were produced.88 Initially, these variations were clearly due to molecular 
weight influence. However, once the observed Tg values were at Tg∞, an interesting 
observation was made; when the DPn was increased to 100 monomer units, the Tg 
value observed for the branched polystyrene materials were systematically lower 
than the respective linear counterpart despite the significant increase in MW of the 
branched species. This suggested that architecture may be now playing a 
contributory role in the influence over Tg. The paper concludes that there was no 
direct correlation with branched polymer molecular weight but instead highlighted a 
strong relationship between the primary polymer chain length of the individual 
chains and its influence on Tg.88  
Studying the DSC analyses of the polymers presented here, higher Tg values were 
observed for the branched copolymers targeting a DPn of 20 monomer units 
compared to their linear homopolymer analogues, which can be explained by their 
higher molecular weights. These increases in Tg values when changing from linear to 
branched architectures are consistent with that reported by Rannard and co-workers 
for a linear polystyrene homopolymer of DPn = 10 monomer units (Tg = 37 °C) 
compared to the corresponding branched polystyrene with primary chains of DPn = 
10 monomer units (Tg = 62 °C).  
The Tg values obtained for all branched materials containing primary chains of 
DPn = 20 monomer units are lower than the reported Tg literature values, which is 




consistent with the work by Rannard and co-workers for the linear and branched 
polystyrene materials containing primary chains of DPn = 10 monomer units. This 
significant difference with Tg,∞ for high molecular weight species can be explained by 
the significant population of unbranched linear polymers within the branched 
polymer samples are believed to act as plasticisers at short primary chain lengths, 
which therefore decreases the Tg values.88 
With reference to the Alhilfi et al. paper once more, when the DPn was increased to 
100 monomer units, the reported Tg value for the branched material was lower than 
that of the corresponding linear homopolymer.88 In the study presented here, 
however, the Tg of the branched materials of DPn = 100 monomer units are still higher 
than the corresponding linear homopolymers. In the present work, the values 
obtained for the different linear homopolymers of DPn = 100 monomer units are 
systematically lower than the reported Tg,∞ and therefore it is believed that the 
overall molecular weight is still the primary parameter influencing Tg as would be 
expected in a classic Flory-Fox model. It is also worth noting that the polymers 
produced within this study are synthesised via a much less controlled polymerisation 
technique (ATRP) compared to the method of synthesis used by Alhilfi  et al. (living 
anionic polymerisation) and therefore samples containing primary chains with much 
broader molecular weight distributions were obtained. As expected, branched 
polymers with DPn = 100 monomer units exhibited higher Tg higher than branched 
DPn = 20 monomer units. HPMA still had the highest Tg value and branched 
copolymers of EHMA still had the lowest Tg values following the incorporation of 
EGDMA divinyl monomer residues. However, no clear conclusion regarding this can 
be drawn given the complexity of the systems and the varying molecular weights, 
composition and architecture.  We have shown that Tg can be varied by using 
different monomers, varying the primary chain length and changing the polymer 
architecture by incorporation of a divinyl monomer. It is now of interest to see how 
the Tg can be influenced following the mixing of two monomers to produce statistical 
linear copolymers and mixing of two monomers with EGDMA incorporation to 




polymer chains within linear and branched statistical copolymers through the 
copolymerisation of two monofunctional monomers. 
2.4.3 Determining the Thermal Characteristic Behaviour of Linear and Branched 
Statistical Copolymers via Differential Scanning Calorimetry  
The thermal characteristics of the linear statistical copolymers were assessed by DSC 
using the same conditions as previously described (Table 2.13).  
Table 2.13 Tg temperatures (°C) obtained for statistical linear copolymers of DPn = 100 monomer units. 
The thermograms showed a single transition with no melting point observed, 
therefore we can conclude that these materials are amorphous (Appendix, Figure 
A18-A20). Only one Tg value was recorded for each of the statistical copolymers. This 
is indicative of a copolymer that has a statistical distribution of the two monomer 
functionalities along the chain and has not developed polymer blocks of each 
individual monomer functionality.  
Finding comparative values of Tg for these type of materials within the literature is 
difficult since the combination of monomers and polymer composition vary 
significantly.  One relationship that can be used to calculate the theoretical Tg of 
statistical copolymers is the DiMarzio-Gibbs equation. This relationship links the 
molar composition of statistical copolymers and the Tg of each component to the Tg 
of the final material (Equation 2.4).  Where m represents the mole fraction of each 
monomer (A and B). This equation was used to calculate the theoretical Tg values of 
the linear statistical copolymers (Table 2.14).  
𝑇𝑔(𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙) = 
(𝑚(𝑀𝑜𝑛𝑜𝑚𝑒𝑟𝐴)𝑥𝑇𝑔𝑀𝑜𝑛𝑜𝑚𝑒𝑟𝐴) + (𝑚(𝑀𝑜𝑛𝑜𝑚𝑒𝑟𝐵)𝑥𝑇𝑔𝑀𝑜𝑛𝑜𝑚𝑒𝑟𝐵) (2.4) 




a Tg values were determined from the second heat cycle by taking the inflection point of the heat flow curve. Thermogram 
was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and temperature using an indium reference 
and all samples were purged with pure nitrogen at a flow rate of 50 mL min-1. Measurements were obtained via two 





Table 2.14 Table of theoretical Tg values calculated using the Dimarzio-Gibbs relationship compared to the 














p(BuMA50-stat-EHMA50) 20 -10 5 5 
p(HPMA50-stat-EHMA50) 76 -10 33 40 
p(BuMA50-stat-HPMA50) 20 76 48 53 
a, Tg values were obtained from literature. b Tg calculated via the Dimarzio-Gibbs relationship.c Tg values 
were determined from the second heat cycle by taking the inflection point of the heat flow 
curve. Thermogram was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and 
temperature using an indium reference and all samples were purged with pure nitrogen at a flow rate of 
50 mL/min. Measurements were obtained via two heat/cool/heat cycles between 25 and 250°C at a 
heating rate of 5°C/min. 
 
There seemed to be a good correlation between experimental and theoretical Tg 
values. Interestingly, the experimental Tg values for the two statistical copolymers 
containing HPMA monomer residues were both observed to be above the theoretical 
Tg values. The rationale for this is beyond the scope of this manuscript, but it could 
be speculated that perhaps the hydrogen-bonding capabilities of the HPMA 
monomer residues were having a strong influence on Tg compared to the other 
monomer residue functionalities. Especially when considering that the Tg,∞ of the 
statistical copolymers may not have been reached.  
Despite it being a complicated relationship, it is clear that simple manipulation of the 
polymer composition has resulted in considerable differences between experimental 
Tg values of the linear statistical copolymers and the respective linear homopolymers. 
For example, when comparing the difference between p(BuMA50-stat-EHMA50) and 
p(BuMA50-stat-HPMA50) a difference of 48 °C was observed.  
The thermal characteristics of branched statistical copolymers were assessed using 
DSC under the same conditions (Table 2.15). Incorporation of EGDMA within the 
statistical copolymers produced amorphous materials as only one Tg value was 
recorded for each of the statistical copolymers (Appendix, Figure A21-A23). Once 
again, it was observed that a considerable difference between Tg values can be 




the architecture was changed from linear to branched, which may be related to the 
changes in free volume associated with the architectural change.  
Table 2.15  Tg temperatures (°C) obtained for statistical branched copolymers of DPn = 100 monomer units. 
2.4.4 Determining the Thermal Characteristic Behaviour of AB Block Copolymers 
via Differential Scanning Calorimetry 
When considering AB block copolymers which incorporate a PEG segment, the 
copolymer may be described as semi-crystalline. Therefore, it would be expected 
that both a Tm and a Tg value would be observed. The thermal characteristics of AB 
block copolymers were determined using DSC as previously described (Table 2.16).  
Table 2.16  Tm temperatures (°C) obtained for AB block copolymers and MeO-PEG114-Br. 
Analysis of the obtained thermograms showed the presence of only one thermal 
transition, which can be assigned as the Tm of the PEG block (Appendix, Figure A24-
A26). In comparison to the MeO-PEG114-Br macroinitiator, the effect of 
polymerisation with a B block seemed to lower the melting point of the PEG block. 
The lack of Tg recorded from the B block could be due to the endotherm dwarfing the 
Tg transition or the PEG domain restricting the mobility of the hydrophobic domain.  
Polymer Composition aObtained Tg Value (°C) 
p(BuMA50-stat -EHMA50-co-EGDMA0.95) 17 
p(HPMA50-stat-EHMA50-co-EGDMA0.95) 47 
p(BuMA50-stat-HPMA50-co-EGDMA0.90) 58 
a Tg values were determined from the second heat cycle by taking the inflection point of the heat flow curve.  Thermogram 
was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and temperature using an indium reference and 
all samples were purged with pure nitrogen at a flow rate of 50 mL min-1. Measurements were obtained via two 
heat/cool/heat cycles between 25 and 250 °C at a heating rate of 5 °C min-1. 
Polymer Composition aObtained Tm Value (°C) 
MeO-PEG114 -Br 57 
p(PEG114 -b-BuMA100) 52 
p(PEG114 -b-HPMA100) 52 
p(PEG114 -b-EHMA100) 43 
a Tg values were determined from the second heat cycle by taking the inflection point of the heat flow curve. Thermogram 
was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and temperature using an indium reference 
and all samples were purged with pure nitrogen at a flow rate of 50 mL min-1. Measurements were obtained via two 




2.5 Varying the Divinyl Methacrylate Monomer in the Synthesis of Branched 
Copolymers   
As has been shown above, changes to the polymer architecture and monomer 
composition resulted in changes to the polymer bulk characteristics. It was therefore 
of interest to investigate whether changes to the functionality of the divinyl 
monomer residues would also result in such changes to the polymer bulk 
characteristics. The monomer composition of the primary polymer chain was fixed to 
EHMA and five different divinyl monomers were incorporated into the branched 
copolymerisations: bisphenol A dimethacrylate (BPDMA), bisphenol A glycerolate 
dimethacrylate (BPGDMA), bis(2-methacrylol)oxyethyl disulphide dimethacrylate 
(DSDMA), glycerol dimethacrylate (GDMA) and urethane dimethacrylate (UDMA) 
(Figure 2.19).  
 
 
Figure 2.19 Chemical structures of divinyl monomers; a) BPDMA, b) BPGDMA, c) DSDMA, d) GDMA and f) UDMA. 
Once again, these polymerisations targeted a DPn of 20 and 100 monomer units.  The 
reason why EHMA was selected as the monofunctional monomer instead of BuMA 
or HPMA was because it would yield polymers with the lowest Tg value, and therefore 
any changes to this value as a result of the divinyl monomer residue would be easily 
observable. Also, since the intended use of the polymer nanoparticles is to act as 
drug carriers and release chemotherapeutics in vivo, working with a polymer that is 





The divinyl monomers were chosen as they all had differing chemical structures, 
which would in turn influence the bulk polymer properties in different ways.  The 
different branching agents allowed for the introduction of: bulkiness, rigidity, 
aromaticity, hydrophilicity, hydrogen bonding and possible degradation sites (S-S 
bonds).  
 
As previously indicated, it is well established that the level of branching that occurs 
during the copolymerisation of monofunctional and bifunctional monomers is 
significantly impacted by the molar ratio of divinyl monomer to initiator. As 
previously outlined for the copolymerisation of the monofunctional monomers with 
EGDMA, the molar ratio of these divinyl monomers relative to the initiator must be 
less than 1 to avoid gelation in the absence of significant cyclisation. Given the 
differences in chemical structure for these divinyl monomers, it is likely that their 
subsequent incorporation into the primary polymer chains, and therefore their 
gelation point, will vary. This was studied for all of the divinyl monomers and EHMA 
combinations at the two different DPn values by conducting copolymerisations at 
decreasing divinyl monomer: initiator ratios starting from 0.95 equivalences. The 
polymerisations were carried out following the same experimental methods as 
before, that is at 50 °C in MeOH using Cu(I)Cl: bpy as the catalytic system. An initial 
molar ratio of monomer: EBiB: CuCl: bpy : divinyl monomer was set at 100:1:1:2:X for 
the reactions targeting a  DPn of 100 monomer units and 20:1:1:2:X for those 
reactions targeting a DPn of 20 monomer units. The reaction was completed with 50 
wt. % solids in MeOH as before. All of the copolymerisations proceeded with a dark 
brown colour and under biphasic reaction conditions. Termination occurred after 72 
hours (DPn = 100) and 48 hours (DPn = 20) via exposure to oxygen and dilution with 
CDCl3, which enabled the monomer conversion to be determined by 1H-NMR. 
Polymer mixtures were passed through a neutral alumina column, concentrated in 
vacuo and precipitated into ice-cold MeOH. Analysis via 1H-NMR and TD-SEC was 
conducted. Subsequent comparison of copolymer compositions and molecular 
weight distributions were made and show that varying equivalences of the different 
divinyl monomers were copolymerised with EHMA monomer to produce soluble 




Table 2.17 Table of EHMA branched copolymers synthesised via methanolic Cu-ATRP at 50 °C with varying divinyl 
monomer incorporated.  
  TD-SEC (THF)c 
 
















p(EHMA100-co-BPDMA0.85) > 99 57 100 832 300 14.58 0.362 42 
p(EHMA100-co-BPGDMA0.85) >99 36 750 197 400 5.37 0.443 8 
p(EHMA100-co-DSDMA0.75) >99 85 100 1 386 000 16.28 0.487 58 
p(EHMA100-co-GDMA0.85) 98 44 600 306 600 6.89 0.390 13 
p(EHMA100-co-UDMA0.85) 98 50 800 377 000 7.42 0.426 16 
p(EHMA20-co-BPDMA0.85) >99 16 250 148 000 9.11 0.341 19 
p(EHMA20-co-BPGDMA0.80) 99 208 200 1 791 000 8.60 0.572 243 
p(EHMA20-co-DSDMA0.75) >99 41 650 1 986 000 47.27 0.403 267 
p(EHMA20-co-GDMA0.85) >99 12 100 117 300 9.68 0.366 16 
p(EHMA20-co-UDMA0.90) >99 19 100 502 100 26.28 0.80 67 
a Target DP calculated [EHMA] / [EBiB], b Calculated by 1H NMR spectroscopy of polymerisation mixture at t = final. c 
Calculated by TD-SEC using THF/TEA mobile phase (98/2 v/v%) at 35 °C, flow rate of 1 mL min -1. d Calculated by Mw of 
branched copolymer (SEC)/Mn of corresponding linear polymer (SEC). 
The results presented within the table are those of the soluble branched polymers 
that were obtained using the highest possible concentration of divinyl monomer; 
higher concentrations yielded insoluble gel network structures. The results show that 
the polymerisations involving each divinyl monomer had different gelation points, 
and that the [B]/[I] ratios for each varied between 0.75 and 0.9. As expected, the 
incorporation of the different divinyl monomers into the copolymerisations yielded 
soluble branched copolymers with significantly higher molecular weights and 
broader molecular weight distributions compared to the corresponding linear 
homopolymer of EHMA. This was observed by TD-SEC with the Mw, Ð, Mark-Houwink 
α value, and the weight averaged number of primary chains incorporated into the 
branched architecture via intermolecular branching reactions confirming that the 
material produced was indeed branched in nature, therefore suggesting that the 




2.5.1 Determining the Thermal Characteristic Behaviour of Branched Copolymers 
with Varying Divinyl Monomer 
The thermal characteristics of the EHMA branched copolymers with DPn = 20 
monomer units were assessed via DSC using a DSC Q 2000 TA Instrument (Table 
2.18).  
Table 2.18 Glass transition (Tg) temperatures (°C) obtained for EHMA branched copolymers with varying divinyl 
monomers with a targeted of DPn = 20 monomer units. 
The instrument was calibrated for heat flow and temperature using an indium 
reference. All samples were purged with pure nitrogen at a flow rate of 50 mL min-1 
and the Tg values were determined from the second heat cycle by taking the 
inflection point of the heat flow curve.  
For all of the polymers, a single Tg endotherm was obtained without the presence of 
any additional transitional temperatures (such as melting), suggesting that the 
polymers are amorphous in nature (Appendix, Figure A27-A30). The Tg values 
obtained for the branched copolymers all varied, (-16 ≤ Tg ≤ 6 ℃). Using EGDMA as a 
reference point, the comparison of the different divinyl monomers showed that 
different thermal properties of the resulting polymer could be obtained when this 
was varied. The effect was quite dramatic when comparing EGDMA to UDMA. The 
magnitude of difference was large (ΔTg = 22 °C). However, when considering the mass 
contribution (%) of the divinyl monomer to the polymer mass, UDMA has the highest 
mass contribution (11%) compared to the mass contribution of EGDMA (5%) (Table 
2.19). The incorporation of UDMA is likely to have increased the hydrogen bonding 
within the polymer. This increase in intramolecular bonding between the polymer 







aTg values were determined from the second heat cycle by taking the inflection point of the heat flow curve.  Thermogram 
was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and temperature using an indium reference 
and all samples were purged with pure nitrogen at a flow rate of 50  mL min-1. Measurements were obtained via two 




chains may result in it behaving more like an entangled network, therefore having 
less chain mobility and less free volume. This would mean that more energy is 
required to exhibit conformational changes to the polymer segments and therefore 
an increase in Tg. 
Table 2.19 Mass contributions of the divinyl monomers to the overall mass of polymer at DPn = 20 monomer 
units. 
Divinyl Monomer 
Mw of Divinyl 
Monomer (g mol-1) 
a Mass Contribution of Divinyl Monomer (%) 
EGDMA 198.22 4.76 
GDMA 228.24 5.44 
DSDMA 290.44 6.82 
BPDMA 364.4 8.41 
UDMA 470.53 10.61 
BPGDMA 484.54 10.89 
aCalculated by Mw (divinyl monomer)/ (Mw (divinyl monomer) + DPn* Mw(monomer)) 
The magnitude of difference between EGDMA and the differing divinyl monomers 
did decrease. It has already been shown how complex it is to rationalise material 
thermal characteristics when architecture and molecular weight have an influence. 
This study is even more complex due to the incorporation of an additional monomer 
which can influence intermolecular bonding, hydrogen bonding strength and the 
rigidity of the polymer chains. The effect of which was more noticeable for the DP 
20, since the ratio of divinyl monomer to monomer is greatest at this lower DP value. 
 The thermal characteristics of the EHMA branched copolymers with DPn = 100 









Table 2.20 Glass transition (Tg) temperatures (°C) obtained for EHMA branched copolymers with varying divinyl 
monomers with a targeted of DPn = 100 monomer units.    
Again, when using EGDMA as a reference (-6 °C), varying the divinyl monomer 
changed the Tg behaviour. However, the difference between the divinyl monomers 
was not as significant in magnitude compared to the DP 20 analogues. (ΔTg DPn = 100 = 
12 °C) This observation is in line with what would be expected for the increase in 
polymer primary chain length since the percentage contribution of brancher to 
monomer is now significantly less (Table 2.21). 
Table 2.21 Mass contribution of divinyl monomer to the overall polymer mass  
Divinyl Monomer 
Mw of Divinyl 
Monomer (g mol-1) 
a Mass Contribution of 
Divinyl Monomer (%) 
EGDMA 198.22 0.99 
GDMA 228.24 1.14 
DSDMA 290.44 1.44 
BPDMA 364.4 1.80 
UDMA 470.53 2.32 
BPGDMA 484.54 2.39 
aCalculated by Mw (divinyl monomer)/ (Mw (divinyl monomer) + DPn* Mw (monomer)) 
Generally, as before, the Tg for polymers with DPn = 20 monomer units was lower 
than when the polymers were DPn = 100 monomer units, except for UDMA which 
goes against this trend.  When the primary polymer chain length was decreased from 
100 to 20 monomer units, the Tg did not decrease like we have observed for every 
other polymer but instead it increased (6 to -5 °C), so the Tg value actually decreased 
with a decrease in free volume which is counter intuitive to what would be expected.  







a Tg values were determined from the second heat cycle by taking the inflection point of the heat flow curve. Thermogram 
was obtained on a DSC Q 2000. The instrument was calibrated for heat flow and temperature using an indium reference 
and all samples were purged with pure nitrogen at a flow rate of 50  mL min-1. Measurements were obtained via two 




The main observation from this is that through the synthetic manipulation of 
incorporating different divinyl monomer chemistries within the polymer imparts 
different physical properties. This in turn may or may not influence the behaviour of 
this material with respect to the encapsulation and release of the drug. 
2.6 Conclusion  
Methanolic ATRP has proven to be a robust way of generating hydrophobic 
methacrylate-based polymers and expanding on the library which has been 
previously reported. A range of linear homopolymers were synthesised using 
monofunctional monomers BuMA, EHMA and HPMA with control over primary 
polymer chain length (DPn = 100 and 20 monomer units), low Đ values and targeted 
molecular weight. Statistical linear copolymers were also obtained by the mixing of 
these monomers. Soluble high molecular weight branched statistical copolymer 
architectures (2.1 x 106 g mol-1) were generated with relative ease through the 
incorporation of divinyl monomer EGDMA at low concentrations. Variations to the 
divinyl monomer chemistries using BPGDMA, BPDMA, DSDMA, UDMA and GDMA 
yielded, to the best of authors knowledge, the first report on the preparation of these 
branched statistical copolymers containing EHMA monomer residues using 
methanolic Cu-ATRP. Through the incorporation of a PEG based macro-initiator 
within a linear polymerisation at the expense of EBiB, amphiphilic AB block 
copolymers were obtained with varying hydrophobic block chemistry. The thermal 
characteristics of these materials was assessed via DSC and it was seen that the bulk 
polymer materials had different properties.    
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Preparation of Branched Vinyl Copolymer Nanoparticles 








Nanoprecipitation is a technique that can be used to generate polymer nanoparticles 
from a wide range of polymer materials. These nanomaterials are of particular 
interest as they possess different chemical and physical properties to that of the bulk 
materials, which in turn renders them useful for many applications. The mechanism 
of nanoparticle formation and stabilisation via nanoprecipitation was discussed in 
detail Chapter 1, Section 1.3.1. Nanoprecipitation has been a successful technique 
for the large-scale generation of polymeric nanoparticles under clinically relevant 
conditions.1-3 The majority of nanoprecipitations reported in the literature use 
biodegradable polyesters and polystyrenes.4-6 Over recent years, however, there has 
been an increase in research studies that utilise more hydrophobic polymers to 
generate aqueous polymer nanoparticle dispersions via nanoprecipitation.7-9 
As previously discussed, it is essential that polymer nanoparticles possess some form 
of stabilisation mechanism, either steric or charge, in order to avoid the polymeric 
nanoparticles being unstable and prone to aggregation and sedimentation. Rannard 
and co-workers showed that the utilisation of a polymer that generates electrostatic 
charge at the nanoparticle surface can prevent particle-particle aggregation via 
electrostatic repulsion and yield stable nanoparticles without the requirement of 
additional stabilisers.7-9 However, these nanoparticle dispersions were prone to 
aggregation upon exposure to salts, likely due to the masking of the electrostatic 
charges on the surface of the nanoparticle. Consequently, this rendered them 
unsuitable for drug delivery applications as it is vital that such nanoparticle 
formulations remain stable in biological media. To overcome this issue, Rannard and 
co-workers reported the first example of the simultaneous nanoprecipitation of 
linear AB block copolymers, specifically PEG-based amphiphilic block copolymers, 
and hydrophobic branched copolymers to yield sterically stabilised branched vinyl 
copolymer nanoparticles. This approach was termed ‘co-nanoprecipitation’.10 
3.1.1 Co-nanoprecipitation 
Co-nanoprecipitation describes the precipitation of a polymer with a secondary 
polymer that can act as a stabilising species. This differs from conventional 




system. There are two methods in which the mixing of these two polymers can occur. 
The first method involves the mixing of the polymer and the stabilising polymer 
within the good solvent phase prior to precipitation into water. Whereas, the second 
method involves dissolving the polymer in the good solvent and the stabilising 
polymer (or surfactant) in water prior to the mixing of the two phases. The first 
method has greater relevance to the research presented in this thesis and will 
therefore be discussed in greater detail below. The second method is beyond the 
scope of this research and the reader is directed to publications by McDonald and 
co-workers for further details.11  
The formation of branched vinyl copolymer nanoparticles via co-nanoprecipitation is 
presented in Figure 3.1. The experimental process of which is nearly identical to that 
of nanoprecipitation, as discussed in Chapter 1.3.1. The only difference is the 
inclusion of an amphiphilic AB block copolymer, which is solvated with the branched 
copolymer in a water-miscible good solvent.  
 
Figure 3.1 Schematic representation of the formation of branched vinyl copolymer nanoparticles via co-
nanoprecipitation. (A) The rapid addition of AB block copolymers and hydrophobic branched copolymers - both 
dissolved in a good solvent - to water. (B) Nanoparticle formation immediately following the addition to the bad 
solvent (water), yielding swollen nanoparticles. (C) Subsequent solvent evaporation over time, giving aqueous 




Rannard and co-workers reported that the addition of the AB block copolymer within 
the nanoprecipitation did not interfere with the nanoprecipitation process of 
poly(hydroxypropyl methacrylate) (p(HPMA)) but instead yielded highly 
monodisperse nanoparticles with intensity-derived hydrodynamic diameters ranging 
between 70 – 300 nm.10 These nanoparticles were sterically stabilised and could 
tolerate the addition of sodium chloride at high concentrations, thereby showing that 
this method can be utilised to generate polymer nanoparticles with potential 
applications as drug delivery vehicles.  In brief, the co-nanoprecipitation technique 
enables the one pot production of sterically stabilised branched vinyl copolymer 
nanoparticles by mixing the branched vinyl copolymer with the amphiphilic AB block 
copolymer within a good solvent. This is rapidly added to water (a bad solvent 
environment), which causes a state of supersaturation and subsequent nucleation of 
both polymers. Nanoparticle formation then occurs via a growth mechanism, details 
of which are described in Chapter 1.3.2.3. As demonstrated by the authors, 
nanoparticle formation occurs immediately after addition of the solution of polymers 
to the anti-solvent (water) and solvent evaporation leads to an aqueous dispersion 
of sterically stabilised branched vinyl copolymer nanoparticles. 
More recent work conducted by Rannard and co-workers expanded the scope of co-
nanoprecipitation as a technique and investigated the branched vinyl copolymer 
nanoparticle formation from differing hydrophobic vinyl polymers such as poly(hexyl 
methacrylate), poly(lauryl methacrylate), poly(butyl methacrylate) (p(BuMA)) and 
poly(ethylhexyl methacrylate) (p(EHMA)).12 Stabilisation was provided by the 
incorporation of AB block copolymers that had a matching hydrophobic domain 
derived from the same hydrophobic monomer that produced the branched vinyl 
copolymers. This preliminary study further illustrated the attractiveness of co-
nanoprecipitation as a nano-formulation technique since, with the exception of 
p(HPMA) previously reported, none of the hydrophobic branched polymers studied 
alone (i.e. without amphiphilic blocks copolymers) were capable of forming stable 
aqueous nanoparticle dispersions, but were successful with the inclusion of the 
respective AB block copolymer.12 In addition to this advantageous attribute of co-




the composition of the nanoparticle and degree of steric stabilisation can be pre-
determined prior to synthesis. This is due to the ability to vary the branched vinyl 
copolymer and AB block copolymer weight ratios within the initial good solvent 
mixture. Secondly, in order to drive nucleation, co-nanoprecipitation utilises high 
molecular weight branched copolymers. This opens up an opportunity to utilise 
complex macromolecular architectures that have been prepared by RDRP 
techniques, such as those discussed in Chapter 2. The design space of these materials 
can be explored to produce polymeric nanoparticles that have been specifically 
designed to facilitate and maximise incorporation of guest molecules, such as drugs. 
And thirdly, since steric stabilisation is achieved by the utilisation of the hydrophilic 
domains of the amphiphilic AB block copolymers, this also presents an opportunity 
for improving the behaviour of the polymer nanoparticle within the body and 
therefore the suitability of the polymeric nanoparticle as a drug delivery platform.   
3.2 Chapter Aims  
The primary aim of the work presented within this chapter is to build on the 
successful co-nanoprecipitations of hydrophobic vinyl-based copolymers and AB 
block copolymers that have been previously reported. The initial report focused on 
the co-nanoprecipitation of hydrophobic branched copolymers, comprised 
predominantly of p(HPMA) containing a low molar concentration of EGDMA, in the 
presence of an amphiphilic linear AB block copolymer to yield sterically stabilised 
aqueous vinyl polymer nanoparticles. As discussed, the co-nanoprecipitation process 
relies upon the simultaneous nucleation between amphiphilic block copolymers and 
hydrophobic vinyl branched copolymers. This has been previously achieved by 
ensuring that both hydrophobic domains of the copolymers are derived from the 
same monomer residue functionality. However, in this study we aim to vary the 
hydrophobic B block of the amphiphilic block copolymer to investigate any changes 
that this may impart to the co-nanoprecipitation process and the resulting polymeric 
nanoparticles. The library of polymer materials synthesised in Chapter 2 are to be 
utilised herein and their ability to form stable nanoparticle dispersions in aqueous 
media via co-nanoprecipitation will be assessed. The impact of the two different DPn 




nanoparticle formation will be explored. Given the contrasting role that each 
polymers plays, investigative studies into the optimal composition will be conducted 
and their stability to dilution with PBS will be evaluated. Another important aim of 
this study is to try and encapsulate a guest molecule, pyrene, as a model system to 
explore: (i) whether the presence of a hydrophobic guest molecule, which may 
crystalise, within the co-nanoprecipitation process has any significant influence on 
the mechanism of co-nanoprecipitation, and (ii) whether these polymer 
nanoparticles have encapsulation capabilities and therefore can be eventually 
utilised as a potential drug delivery system. In-turn, pyrene encapsulation will also 
provide opportunity to obtain information about the nanoparticle core polarity.  
3.3 Results and Discussion  
3.3.1 Nanoprecipitation Studies  
Co-nanoprecipitation is more complex than a traditional nanoprecipitation process, 
since there is no longer just one polymer contributing to the formation of 
nanoparticles.10 Therefore, it was important to gain an understanding of the 
behaviour (e.g. solubility, particle formation or aggregation) of each individual 
polymer component under nanoprecipitation conditions before assessing how they 
each contributed to the formation of polymer nanoparticles during the co-
nanoprecipitation process.  Each polymer was therefore nanoprecipitated as a single 
component to act as a control experiment.  
3.3.1.1 Single-component Nanoprecipitation Studies  
As previously discussed, nanoprecipitation is a reproducible and efficient synthetic 
technique to generate polymeric nanoparticles.13, 14 There are many different 
parameters that can control and influence the population, particle size, particle size 
distribution and ultimately whether it is successful in producing polymer 
nanoparticles. These parameters include the solvent:water ratio, the 
polymer:solvent ratio, the polymer molar mass and the selection of the organic 
solvent.  
Regarding the selection of solvent, it must be water-miscible and ideally volatile. 




bad solvents and for the easy removal of the good solvent under ambient conditions 
to yield aqueous polymeric nanoparticles and avoid the need for lengthy dialysis. 
There are many organic solvents that meet these criteria including: acetone, 
acetonitrile, MeOH, isopropyl alcohol and tetrahydrofuran (THF). It has been 
reported that the mean size of nanoparticles is dependent on the nature of the 
organic solvent used to solubilise the polymer before nanoprecipitation. The impact 
of solvent miscibility with water and its effect on nanoparticle size has been 
investigated by Cheng et al. who reported that a decrease in mean nanoparticle size 
was observed with increasing water/solvent miscibility.1 It has also been reported 
that when comparing the use of THF and acetone under identical nanoprecipitation 
conditions, nanoparticles obtained from acetone solutions had smaller particle sizes 
regardless of the polymer used.15, 16 Acetone has a lower viscosity and higher 
diffusion coefficient in water compared to THF, and it has been suggested that this 
could promote faster mixing of acetone and water. This faster mixing would result in 
a more uniform supersaturation. Acetone would therefore make an obvious solvent 
choice. However, since the co-nanoprecipitation process would hopefully advance to 
include a chemotherapeutic drug (SN-38) solubilised within the polymer mixture, 
discussed in Chapter 4, the solubility of the chemotherapeutic drug in the organic 
solvent also needed to be considered. SN-38 exhibits extremely limited solubility in 
most organic solvents, however, it is soluble in THF. Therefore, the solvent selected 
as the good solvent for all aqueous nanoprecipitations and co-nanoprecipitations 
conducted throughout this research was THF.  
Solubility of all the polymers was tested in THF and was conducted by preparing 
polymer solutions at an initial polymer concentration ([P]0) = 5 mg mL-1 in THF. It has 
been reported previously that the hydrodynamic diameter of the polymer 
nanoparticles can be influenced by the polymer concentration within the organic 
solvent.17 We have reported in our group that nanoparticles produced via co-
nanoprecipitation had intensity-average hydrodynamic diameters (Dz) in the range 
of 50 – 200 nm, which was dependent on the chemical nature of the polymer. These 
nanoparticles were produced at [P]0 = 5 mg mL-1.  7-10, 18 The effect of varying [P]0 in 




0.5 mg mL-1 to 5 mg mL-1 and a small decrease in hydrodynamic diameter was 
observed as the [P]0 decreased; although this change was modest and was again 
dependent on the chemical nature of the polymer.  
In addition, the nanoprecipitation process also involves careful consideration of 
other design parameters, such as the good solvent/bad solvent volume ratio and the 
final polymer concentration in water ([P]f), both of which contribute to the success 
of the technique. It has been established and demonstrated for a number of 
polymers with similar functionalities and structures that [P]f = 1 mg mL-1 is sufficient 
to facilitate the nucleation and subsequent nanoparticle formation. With this is mind, 
and given that the nanoparticles produced from [P]0 = 5 mg mL-1 were within the size 
range that is optimal for anti-cancer DDS, this was the initial polymer concentration 
used within this study. Solutions were sealed and placed on a roller mixer overnight 
to ensure complete solubilisation of polymer. In all cases, the polymers showed full 
solubility in THF as clear solutions were obtained.  
Nanoprecipitation of all materials synthesised in Chapter 2 was conducted following 
the general protocol outlined below and depicted in Figure 3.2. The polymer was 
dissolved in THF (the good solvent) until complete solubilisation was achieved. Into 
5 mL of stirred deionised (DI) water, 1 mL of the polymer stock solution 
([P]0 = 5 mg mL-1) was rapidly added using a manual air displacement pipette. The 
solution was allowed to stir at ambient temperature for 24 hours to facilitate the 
evaporation of the THF solvent.  Confirmation of complete THF removal was 
conducted by performing the nanoprecipitation in D2O and then analysing via 1H-
NMR spectroscopy, which showed that no THF was remaining. To ensure the final 
concentrations were targeted accurately, the mass of water was recorded before and 
after evaporation and topped up as required. Aqueous nanoparticle dispersions were 





Figure 3.2 Schematic representation of how nanoprecipitations of 1) linear homopolymers, 2) AB block 
copolymers, 3) statistical linear copolymers, 4) statistical branched copolymers and 5) branched copolymers were 
conducted via co-nanoprecipitation. A) Good solvent containing polymer at [P]0=5 mg mL-1 rapidly added to 5 mL 
H2O with stirring, (B) nanoparticle formation and (C) evaporation of THF over 24 hours yielding aqueous 
nanoparticle dispersion at [P]f =1 mg mL-1.  
Sole nanoprecipitation of all 31 polymers, with the exception of p(HPMA)100, 
p(HPMA)20, p(HPMA100-co-EGDMA0.90), p(HPMA-co-EGDMA0.95) and p(PEG114-b-
HPMA100), were unsuccessful in forming stable polymer nanoparticles; a mere 
success rate of 13%. The other 87% of nanoprecipitated samples failed, which was 
evident after the THF had evaporated leading to macroscopic polymer precipitation 
and subsequent sedimentation within the glass vial. The successful 
nanoprecipitations of p(HPMA) based polymers agreed with the literature and its 
success is owed to its ability to provide electrostatic stabilisation, discussed in more 
detail below. Turbid aqueous nanoparticle dispersions were obtained for p(HPMA)100 
and p(HPMA)20, whilst transparent aqueous nanoparticle dispersions were obtained 
for p(HPMA100-co-EGDMA0.90), p(HPMA20-co-EGDMA0.85) and p(PEG114-b-HPMA100), 





Figure 3.3 Photograph of the successful sole nanoprecipitations of the HPMA based polymeric systems.  
Particle size distributions of the p(HPMA) based polymer nanoparticles were 
obtained by dynamic light scattering (DLS) (Table 3.1, Figure 3.4). Differences 
between polymer architectures yielded different hydrodynamic diameters. Linear 
homopolymers had larger hydrodynamic diameters and significantly increased 
polydispersity values compared to the branched copolymers; for example, 
p(HPMA)20 (Dz = 570 nm, PDI = 0.217) compared to p(HPMA20-co-EGDMA0.85) 
(Dz = 80 nm, PDI = 0.047).  This result is not surprising, since it has been reported 
previously that high molecular weight p(HPMA-co-EGDMA) copolymers play an 
important role in promoting homogenous and rapid nucleation, which leads to 
smaller hydrodynamic diameters and narrower particle size distributions.8, 9 It was 
also observed that the sole nanoprecipitation of p(HPMA)20 when compared to 
p(HPMA)100 produced particles with a significantly larger hydrodynamic diameter 
(570 vs 190 nm). This is likely due to p(HPMA)20 having a higher thermodynamic 
equilibrium solubility limit and therefore a lower degree of supersaturation. This may 
have, in turn led to a slower nucleation rate and a small number of nuclei. 
Table 3.1 DLS analysis of the stable aqueous nanoparticle dispersions produced via sole nanoprecipitation of the 






(kcps)a ζ (mV)b 
Attenuator 
Value 
p(HPMA)100* 190 0.154 286 323 -31.2 4 
p(HPMA)20* 570 0.217 21 800 -37.1 7 
p(HPMA100-co-EGDMA0.90) 60 0.047 99 734 -32.6 6 
p(HPMA20-co-EGDMA0.85) 80 0.080 238 220 -40.4 5 
p(PEG114-b-p(HPMA)100) 40 0.042 10 000 -12.9 8 
a Measured using DLS analysis at a concentration of 1 mg mL-1, Dz values have been rounded to the nearest 5 nm. b Obtained 
via measurement of the electrophoretic mobility of aqueous nanoparticle dispersions within zeta cell. *Samples were not 
stable 7 days after generation and sedimentation had occurred.  
The success of the nanoprecipitations of p(HPMA) based polymers is often attributed 




(ζ) obtained for the HPMA-based polymer nanoparticles (avg. -35 mV) is considered 
of a sufficient magnitude to be able to provide charge stabilisation to a moderate 
level and would explain why these were successful at forming nanoparticles without 
the addition of stabilisers (e.g. AB block copolymers or additional surfactants).  
 
Figure 3.4 Nanoparticle size distributions obtained by DLS analysis of the successful sole nanoprecipitations: a) 
p(HPMA)20, b) p(HPMA100), c) p(HPMA-co-EGDMA0.85), d) p(HPMA100-co-EGDMA0.90) and e) p)PEG114-b-HPMA100)  
obtained at 1 mg mL-1 with no filtration.  
It is worth emphasising that the nanoparticle dispersions obtained from linear 




noticed after several days without stirring. This difference in behaviour observed 
between linear homopolymers and branched copolymers is consistent with that 
previously reported, whereby, our group have shown that the architecture of the 
nanoprecipitated polymer can have a large influence on the production of stable 
nanoparticles and that stability is greatly facilitated by high molecular weight 
branched material.7 
When the sole nanoprecipitations of the AB block copolymers were conducted, it was 
assumed that the addition of the hydrophilic PEG group would provide the 
nanoparticles with steric stabilisation and thereby produce stable polymer 
nanoparticles from polymers with differing methacrylate-based B block domains 
varying in hydrophobicity.  However, the only successful nanoprecipitation of AB 
block copolymers was that of p(PEG114-b- HPMA100), producing a transparent 
dispersion with no visible aggregates present (Figure 3.5a). The other AB block 
copolymers were unsuccessful in forming stable nanoparticles and generated fine 
white macroscopic aggregates in solution (Figure 3.5b&c).  
 
Figure 3.5 Photographs showing the successful sole nanoprecipitation of a) p(PEG114-b-HPMA100) producing a 
transparent aqueous nanoparticle dispersion compared to the unsuccessful nanoprecipitation of b) p(PEG114-b-





From this experiment, it was evident that the sole nanoprecipitation of each 
individual polymer component was not a feasible method for producing stable 
aqueous nanoparticle dispersions, with the exception of HPMA-based branched 
copolymer systems. To potentially produce stable aqueous nanoparticle dispersions 
of the hydrophobic branched copolymers consisting of BuMA and EHMA monomer 
residues, there is a need for the addition of a stabilising species, such as an AB block 
copolymer. Co-nanoprecipitation is a technique whereby two polymers can be mixed 
to potentially generate sterically stabilised nanoparticles and therefore further 
studies focussed on utilising this approach.  
3.4 Determining Co-Nanoprecipitation Parameters 
Despite the failure to nanoprecipitate the majority of the polymer library individually, 
it was of interest to conduct co-nanoprecipitations on the full material library 
generated in Chapter 2 but with the inclusion of an AB block co-polymer in each case. 
This would provide insight into whether or not the material behaved differently 
during co-nanoprecipitation when combined with an AB block co-polymer, whilst 
also providing a greater understanding of the co-nanoprecipitation process and the 
different types of polymer material that can be used to generate nanoparticles.  In 
particular, it was of interest to gain an understanding of how the nanoparticle 
composition, specifically branched copolymer:AB block copolymer weight ratio, 
could affect the size and stability of the polymer nanoparticles.  Given that the 
hydrophobic linear polymers exhibited limited stability during the sole 
nanoprecipitations (Section 3.3.1), this study focussed on the co-nanoprecipitation 
of hydrophobic branched copolymers and amphiphilic linear AB block copolymers 
only, and aimed to determine an optimum weight ratio of branched copolymer:AB 
block copolymer that could then be utilised in the rest of the studies.   
3.4.1 Varying the Weight Compositional Ratio of Each Polymeric Component 
Within Co-nanoprecipitation  
When two polymers are co-nanoprecipitated, they must associate simultaneously in 
order to avoid the formation of two different species, which may also result in two 
distinct size populations or visible macroscopic aggregation from unstabilised 
nanoparticles. Given the contrasting roles of each polymer component within the 




composition and the AB block provides stabilisation, it could be expected that by 
varying the weight percentages (wt. %) of these components with respect to the total 
polymer mass that it would alter or impact the properties of the final polymer 
nanoparticle. Specifically, the particle stability, size, dispersity and core 
characteristics. Therefore, there is a need to select consistent values to provide direct 
comparisons and aid identification of the role of varying polymer chemistry and 
structure. In order to successfully form stabilised nanoparticles, the concentration of 
AB block copolymer must be sufficient enough to provide steric stabilisation, but low 
enough to avoid also forming nanoprecipitates that comprise predominantly AB 
block copolymer.   
Co-nanoprecipitations were conducted following the same protocol as previously 
described. Initial polymer concentration was maintained at [P]0 = 5 mg mL-1 and the 
ratio of branched copolymer and AB block copolymer incorporated within the good 
solvent varied systematically between 100:0 to 0:100 wt.% with respect to total solid 
mass (Figure 3.6). It is worth noting that the weight percentages discussed below 
correspond to branched copolymer:AB block copolymer, respectively.  
 
Figure 3.6 Schematic representation of the experimental design used to vary the weight ratio of branched 
copolymer: AB block copolymer within the initial THF solution.  Co-nanoprecipitation conducted as before to yield 
varying nanoparticle compositions containing i) 100 wt.% branched copolymer, (ii) 50 wt.% branched copolymer 




Given that p(PEG114-b-HPMA100)  is stable when nanoprecipitated on its own, it was 
the ideal choice of AB block copolymer to conduct this study as it would allow for the 
full range of weight ratios to be explored. It would also help develop an 
understanding of the influence of monomer chemistry from the branched 
(co)polymers on the co-nanoprecipitation process, as only one polymer component 
would be changing. Three branched vinyl copolymers were selected: p(HPMA100-co-
EGDMA0.90), p(BuMA100-co-EGDMA0.95) and p(EHMA100-co-EGDMA0.80). Rapid 
addition of polymer stock solution (1 mL) was added to DI water (5 mL) and left to 
evaporate for 24 hours for complete THF removal. Particle size distributions of the 
aqueous nanoparticle dispersions were obtained using DLS at a concentration of 
1 mg mL-1 (Table 3.2, Figure 3.7). Samples where visible macroscopic aggregation had 
occurred, for example like the sole nanoprecipaiton of p(EHMA100-co-EGDMA0.80) and 
p(BuMA100-co-EGDMA0.95), were passed through a 1 µm fibreglass filter prior to DLS 
analysis, as indicated by an Asterix and red italic font (Figure 3.8). These samples 
would normally be classified as a failed nanoprecipitation but have been utilised 












Table 3.2 DLS analyses of branched vinyl copolymer nanoparticles produced by co-nanoprecipitation with 
p(PEG114-b-HPMA100) at varied branched and AB block copolymer compositions from 100-0 wt.%, respectively.  
Monomer Residue 
Wt. % of 
Branched 
Polymer 











a(kcps) Day 01 Day 10 Day 01  Day 10 
HPMA 
100 0 60 60 0.210 0.207 119 330 
90 10 60 60 0.159 0.154 99 990 
80 20 60 60 0.121 0.110 97 500 
70 30 60 60 0.149 0.135 122 100 
60 40 60 60 0.112 0.100 89 700 
50 50 55 55 0.093 0.083 110 700 
40 60 55 55 0.068 0.055 103 400 
30 70 55 55 0.055 0.046 100 800 
20 80 55 55 0.066 0.061 89 500 
10 90 50 50 0.082 0.090 57 850 
0 100 40 40 0.060 0.048 19 150 
BuMA 
100* 0 190 - 0.111 - 263 100 
90* 10 170 - 0.122 - 321 700 
80* 20 160 - 0.098 - 426 900 
70* 30 150 - 0.081 - 578 100 
60 40 140 140 0.068 0.091 567 500 
50 50 130 130 0.090 0.083 463 700 
40 60 130 130 0.108 0.090 458 600 
30 70 120 120 0.106 0.118 316 400 
20 80 110 110 0.126 0.130 230 000 
10 90 80 80 0.148 0.0157 108 250 
0 100 40 40 0.060 0.048 19 150 
EHMA 
100* 0 220 - 0.179 - 186 900 
90* 10 165 - 0.107 - 445 000 
80* 20 160 - 0.091 - 465 600 
70* 30 145 - 0.078 - 586 200 
60* 40 170 - 0.133 - 318 300 
50* 50 140 - 0.099 - 481 150 
40* 60 125 - 0.089 - 371 100 
30 70 125 125 0.137 0.095 358 600 
20 80 110 110 0.140 0.135 233 150 
10 90 95 100 0.187 0.172 130 850 
0 100 40 40 0.060 0.048 19 150 
a Measured using DLS analysis at a concentration of 1 mg mL -1, Dz values have been rounded to the nearest 5 nm. *Sample 





Figure 3.7 Graphical representation of the impact of varying the branched copolymer wt.% in the initial THF 
solution on the Dz (nm) (closed circles) and the PDI (open triangles) of the branched vinyl copolymer nanoparticles 
generated via co-nanoprecipitation: A) p(HPMA100-co-EGDMA0.90), B) p(BuMA100-co-EGDMA0.95) and C) 
p(EHMA100-co-EGDMA0.80). The wt. % ratios of branched copolymer at which visible aggregation was observed is 





Figure 3.8 A photograph of the co-nanoprecipitations of p(PEG114-b-HPMA100) and i) p(HPMA100-co-EGDMA0.90), 
ii) p(BuMA100-co-EGDMA0.95) and iii) p(EHMA100-co-EGDMA0.80) at varying wt.% ratios of AB block decreasing from 
left to right. The wt.% at which macroscopic aggregation occurred is illustrated with the red box.   
In all cases, DLS analysis of the aqueous nanoparticle dispersions showed 
monomodal particle size distributions consisting of highly monodisperse 
nanoparticles with Dz values ranging from 40 to 220 nm. A general trend was 
observed where the nanoparticle hydrodynamic diameters decreased linearly as the 




this decrease was dependent on the chemical nature of the branched copolymer 
utilised within the co-nanoprecipitation. Interestingly, the extent of this decrease in 
hydrodynamic diameter was small whilst the AB block copolymer composition was 
between 0 and 50 wt.%, but became more significant as the composition increased 
beyond 50 wt.%. For example, when analysing the results of the co-nanoprecipitation 
of p(HPMA100-co-EGDMA0.90) with p(PEG114-b-HMPA100), an increase in the AB block 
copolymer composition from 0 to 50 wt.% resulted in a decrease in hydrodynamic 
diameter from 60 to 55 nm - a relatively insignificant change. However, as the 
composition of AB block copolymer increased from 50 to 100 wt.%, the change in 
hydrodynamic diameter was more significant, decreasing from 55 to 40 nm. This was 
also observed for the other two polymer systems. The rationale for this is that the 
increasing composition, and therefore mass, of AB block copolymer within the 
system results in a decrease in composition, and therefore mass, of hydrophobic 
branched copolymer. As the role of the AB block copolymer is to provide steric 
stabilisation, nanoparticle growth would likely be arrested at an earlier stage 
resulting in smaller hydrodynamic diameters.   
In all cases, the co-nanoprecipitation of p(HPMA100-co-EGDMA0.90) and p(PEG114-b-
HMPA100) was successful in forming sterically stabilised polymer nanoparticles 
regardless of the weight ratio of AB block copolymer utilised. DLS analysis of the 
aqueous nanoparticle dispersions showed monomodal size distributions with 
hydrodynamic diameters ranging from 40 – 60 nm. The hydrodynamic diameter of 
the nanoparticles remained consistent (60 nm) as the composition of hydrophobic 
branched copolymer decreased from 100 to 60 wt.%. This control in size could be 
derived from the electrostatic stabilisation that p(HPMA100-co-EGDMA0.90) provides 
during the nanoparticle growth capping mechanism, even at low wt.% ratios of AB 
block copolymer. The PDI values (0.210 – 0.055) decreased as the wt.% of AB block 
copolymer increased from 0 – 70 wt.% and branched copolymer decreased from 100 
– 30 wt.%, but then began to increase at 80 wt.% AB block copolymer and above.   
When the branched copolymer was changed to p(BuMA100-co-EGDMA0.95), samples 




macroscopic aggregation was observed (Figure 3.8). This suggests that the 
nanoparticles generated at these compositions had an insufficient density of PEG 
stabilising chains to achieve steric stabilisation and colloidal stability. This is also in 
line with what was observed during the sole nanoprecipitation of p(BuMA100-co-
EGDMA0.95) without the presence of AB block copolymer, which also resulted in 
macroscopic aggregation. However, these samples were still analysed via DLS 
following filtration to provide some indication about size trends. There was a large 
decrease in hydrodynamic diameter (190 to 40 nm) as the composition of AB block 
copolymer increased from 0-100 wt.%. Again, this is likely due to the increasing levels 
of steric stabilisation afforded to the polymer nanoparticles. Interestingly, however, 
the magnitude of change in hydrodynamic diameter was significantly larger (ΔDz = 
150 nm) than what was observed for p(HPMA100-co-EGDMA0.90). This is likely due to 
the lack of electrostatic stability provided to the growing nuclei by p(BuMA100-co-
EGDMA0.95). When 50 - 90 wt.% of AB block copolymer was present and sterically 
stabilised nanoparticles were formed, the PDI values increased up to a value of 0.148. 
This broader PDI and decrease in size suggests a loss of control during the co-
nanoprecipitation may be occurring. This is likely due to differences in 
supersaturation within the co-nanoprecipitations. As the amount of AB block 
copolymer increases and the amount of branched vinyl copolymer decreases, there 
is a decrease in the levels of supersaturation of the core-forming material. This 
decrease in supersaturation causes a slower nucleation relative to the growth phase 
and hence produces samples that have a broader PDI.  As before, the stability of the 
branched vinyl polymer nanoparticles was checked by repeating the DLS 
measurements on the original samples following 10 days of storage under ambient 
conditions. These measurements showed a lack of significant variation from the 
original nanoparticle diameters, suggesting that the samples all remained stable.  
Finally, when changing the polymer to p(EHMA100-co-EGDMA0.80), co-
nanoprecipitations with ≤ 60 wt.% of AB block copolymer present resulted in 
macroscopic aggregation and failed co-nanoprecipitations. The boundary between 
the success and failure of these co-nanoprecipitations was observed at higher 




series. As previously explained, EHMA is more hydrophobic than BuMA, therefore 
the EHMA branched copolymer may possibly require more stabiliser to achieve steric 
stabilisation. Those samples with visible polymer aggregates were still studied using 
DLS, following filtration. Particle hydrodynamic diameters decreased (220 to 40 nm) 
as the composition of AB block copolymer increased.   
The results of the study highlighted that each polymer species has different roles 
within the co-nanoprecipitation process, with the hydrophobic branched copolymers 
driving the particle nucleation and the amphiphilic AB block copolymer arresting 
particle growth through steric stabilisation. In the cases of the p(BuMA100-co-
EGDMA0.95) and p(EHMA100-co-EGDMA0.80) series, a combination of these 
components was essential in order to generate colloidally stable nanoparticles. In the 
case of the p(HPMA100-co-EGDMA0.90) series, such a combination was not essential 
and colloidally stable nanoparticles consisting of 100 wt.% hydrophobic branched 
copolymer could be obtained through charge stabilisation; however, the presence of 
the AB block copolymer is still deemed necessary if such nanoparticles are to fulfil 
their potential as drug delivery vehicles, for the reasons discussed previously. 
Furthermore, the results highlighted that the AB block copolymer composition had a 
direct impact on the particle size and the success of the co-nanoprecipitations, with 
the p(EHMA100-co-EGDMA0.80) nanoprecipitates requiring a greater content of 
p(PEG114-b-HPMA100) (≥ 70 wt.%) compared to the p(BuMA100-co-EGDMA0.95) 
nanoprecipitates (≥ 40 wt.%) in order to achieve colloidal stability. With regard to the 
latter point, it was assumed that the nanoprecipitates of the EHMA-based polymers 
may be unsuitable candidates as DDS unless their behaviour is altered when a guest 
molecule is introduced to the co-nanoprecipitation process. 
3.4.2 Stability of Co-nanoprecipitated Nanoparticles Upon the Addition of PBS 
To be considered as a potential drug delivery vehicle, it is important that the 
nanoparticles can maintain their structural integrity upon exposure to physiological 
relevant conditions. These conditions include high dilution and the presence of salts. 
Failure of the nanoparticles to withstand these conditions is likely to result in the 
faster clearance from systemic circulation and the uncontrolled release of the 




studies within our group have reported the stability of branched p(HPMA) based 
nanoparticles upon addition of salt (NaCl).10 It was shown that nanoparticles without 
AB block copolymer present were immediately prone to aggregation and 
sedimentation following this addition due to the screening of the electrostatic 
charges that otherwise provided stability.19 However, it was found that incorporation 
of AB block copolymer (≥ 20 wt.%) led to greater stability of the polymer 
nanoparticles upon addition of the salt.  It is likely that this was due to the steric 
stabilisation of the hydrophilic PEG domain of the AB block copolymer. This 
stabilisation effect was seen to diminish when ≥ 70 wt.% AB block copolymer was 
incorporated, as particle size began to increase dramatically. This indicated that 
branched vinyl copolymer nanoparticles should compromise ≤ 60 wt.% AB block 
copolymer if they are to be utilised as DDS.   
Given that these polymer nanoparticles were to be assessed in both in vitro and in 
vivo pharmacological evaluations, it is important to understand their behaviour when 
diluted in buffered media and it was therefore necessary to conduct a study to 
determine the effects of the addition of phosphate buffer solution. Experimentally, 
p(HPMA100-co-EGDMA0.90) was co-nanoprecipitated into DI water with p(PEG114-b-
HPMA100); as before, the compositions varied from 100:0 – 50:50 wt.%, respectively. 
The volatile organic solvent was allowed to evaporate and Dz, PDI and derived count 
rate were determined via DLS at [P]f = 1 mg mL-1.  The stability of these branched 
vinyl copolymer nanoparticles in response to dilution and exposure to salts was 
assessed via a serial dilution with PBS over a 100-fold dilution factor to produce final 
polymer concentrations at 0.5, 0.25, 0.1 and 0.01 mg mL-1.  The aqueous nanoparticle 
dispersions were left to gently mix overnight following dilution and then assessed 
using DLS (Table 3.3). The samples that were diluted to 0.1 and 0.01 mg mL-1 have 
been omitted from this discussion as the DLS data obtained was not credible due to 





Table 3.3 DLS analyses of p(HPMA100-co-EGMDA0.90) co-nanoprecipitates varying in wt. % of p(PEG114-b- HPMA100) 
from 0 – 50 wt.%, respectively, following the serial dilution with PBS addition. Dz values have been rounded to the 
















1 mg mL-1 
(no PBS) 
100 0 65 0.261 47 900 6 
90 10 60 0.197 46 500 6 
80 20 75 0.239 54 550 6 
70 30 70 0.170 69 950 6 
60 40 60 0.152 40 720 6 
50 50 60 0.115 31 800 7 
0.5 mg mL-1 (PBS) 
100 0 Polymer aggregation 
90 10 Polymer aggregation 
80 20 180 0.277 249 700 5 
70 30 90 0.093 81 050 6 
60 40 60 0.097 19 500 7 
50 50 60 0.113 18 300 7 
0.25 mg mL-1 (PBS) 
100 0 Polymer aggregation 
90 10 Polymer aggregation 
80 20 180 0.272 84 600 5 
70 30 95 0.195 38 300 6 
60 40 105 0.269 11 000 7 
50 50 90 0.291 10 600 7 
1Italic numbers represent sample which resulted in polymer aggregation. 
As expected, the sample without AB block co-polymer present precipitated 
immediately upon dilution with PBS to a polymer concentration of 0.5 mg mL-1. It was 
also observed that the nanoprecipitates consisting of 10 wt.% of AB block copolymer 
also precipitated (Figure 3.9). These two samples were consequently not diluted 
further. However, stability was observed when ≥ 20 wt.% of AB block copolymer was 
incorporated. Although precipitation was not observed, it is thought that 20 wt.% 
may be on the cusp of providing a sufficient density of surface PEG chains from the 
AB block copolymer for steric stabilisation since an approximate doubling in Dz was 
observed (75 to 180 nm). It is worth noting, however, that little variation was seen 





Figure 3.9 Photographs showing the effects of the addition of PBS to the samples of p(HPMA100-co-EGDMA0.90) 
with varying amounts of AB block copolymer from 0-50 wt.% from left to right. Measured at A) polymer 
concentration = 1 mg mL-1 in H2O and B) polymer concentration = 0.5 mg mL-1 following dilution with PBS.  
 
Further increases in AB block copolymer composition (≥ 30 wt.%) led to greater 
stability of nanoparticles upon exposure to PBS, as demonstrated by the smaller 
changes in Dz values observed before and after PBS addition. Although, the sample 
with 30 wt.% AB block copolymer did increase in size from 70 to 90 nm upon dilution 
to 0.5 mg mL-1. The size and PDI values of samples with 60:40 and 50:50 wt.% 
branched copolymer:AB block copolymer were the least affected by addition of PBS. 
This study has indicated that ≥ 40 wt.% of AB block copolymer is required to provide 






Figure 3.10 Graphical representation of changes to the hydrodynamic diameter (nm) following the dilution of 
p(HPMA-co-EGDMA) nanoparticles with varying % wt. of p(PEG114-b-HPMA100) with PBS from 1 mg mL-1 to 0.25 
mg mL-1. 
3.5 Co-nanoprecipitation of Varying Polymer Architectures with Varying 
Amphiphilic AB Block Copolymers.  
The co-nanoprecipitations were attempted using combinations of the (co)polymers 
and varying AB block copolymers that had been previously described in Chapter 2. In 
total, there were 48 different co-nanoprecipitation combinations. 
Co-nanoprecipitations were attempted using: 1) linear homopolymers, 2) linear 
statistical copolymers, 3) branched copolymers and 4) branched statistical 
copolymers (Figure 3.11). Each of which were co-nanoprecipitated with an AB block 
copolymer. Previous reports of co-nanoprecipitation saw the use of compatible AB 
block copolymers, where the hydrophobic domain of the AB block copolymer 
matched the hydrophobic domain of the branched vinyl copolymer. This study 
incorporated AB block copolymers with varying hydrophobic domains that 
sometimes differed from that of the hydrophobic vinyl copolymer. This approach was 
taken to determine if this would have any effect on the formation of colloidally stable 
co-nanoprecipitates.  
% wt. AB block copolymer 

































Figure 3.11 Schematic representation of the co-nanoprecipitation process. Combinations of polymers include 1) 
linear homopolymer and AB block copolymer, 2) Linear statistical copolymer and AB block copolymer, 3) 
branched statistical copolymer and AB block copolymer and 4) branched polymer and AB block copolymer. Co-
nanoprecipitation proceeded as A) addition of 1 mL of polymer-THF solution into 5 mL DI water, B) rapid 




3.5.1 Co-nanoprecipitation of Linear Homopolymers with Varying Amphiphilic AB 
Block Copolymers.  
Co-nanoprecipitations were conducted in an identical manner to those reported in 
Section 3.4. Linear homopolymers were combined with AB block copolymers in THF 
to form a solution with polymer concentration of 1 mg mL-1, and the THF solution 
(1 mL) was added into stirred DI water (5 mL) (Figure 3.12). Solutions were left for 
24 hours for THF removal via evaporation. In all cases, the combination of 
hydrophobic linear homopolymer:AB block copolymer consisted of a 60:40 wt.% 
ratio, respectively. This ratio was chosen as it had been previously suggested by Ford 
et al that incorporation of AB block copolymer above 60 wt.% may lead to a loss of 
control within the nanoprecipitation process and potentially form a secondary 






Figure 3.12 Schematic representation of the co-nanoprecipitation of varying linear homopolymers with a) 
different monomer chemistry and b) different degrees of polymerisation, and with differing AB block copolymers: 
i) p(PEG114-b-BuMA100), ii) p(PEG114-b-EHMA100) and iii) p(PEG114-b-HPMA100). 
Aqueous nanoparticle dispersions were assessed via DLS and zeta potential analysis 
(Table 3.4). With the exception of the linear p(HPMA) homopolymers, all co-
nanoprecipitations of p(BuMA) and p(EHMA) linear homopolymers with the three 
varying AB block copolymers were unsuccessful and resulted in macroscopic 
aggregation. Unsurprisingly, the co-nanoprecipitation of p(HPMA)20 and p(HPMA)100 
with p(PEG114-b-HPMA100) yielded sterically stabilised nanoparticles with 
hydrodynamic diameters of 90 and 120 nm, and PDI values of 0.310 and 0.093, 
respectively. These hydrodynamic diameters were lower than those from sole 
nanoprecipitations of p(HPMA)20 and p(HPMA)100 (= 570 and 190 nm, respectively), 
suggesting that the AB block copolymer has capped the growth of the nanoparticles 
during the co-nanoprecipitation process and provided steric stabilisation. Negative 





Table 3.4 DLS characterisation of linear homopolymers with varying AB block copolymers.  
 AB Block Copolymer (40 wt.%) 

























p(BuMA)20 Polymer Aggregation Polymer Aggregation Polymer Aggregation 
p(EHMA)20 Polymer Aggregation Polymer Aggregation Polymer Aggregation 
p(HPMA)20 Polymer Aggregation Polymer Aggregation 90 0.310 79 200 -33 
p(BuMA)100 Polymer Aggregation Polymer Aggregation Polymer Aggregation 
p(EHMA)100 Polymer Aggregation Polymer Aggregation Polymer Aggregation 
p(HPMA)100 215 0.294 329 350 -27 175 0.235 351 200 -24 120 0.093 358 100 -17 
aMeasured using DLS analysis at a concentration of 1 mg mL-1, Dz values have been rounded to the nearest 5 nm. b Obtained 
via measurement of the electrophoretic mobility of aqueous nanoparticle dispersions within zeta cell. 
Interestingly, p(HPMA)100 successfully co-nanoprecipitated with the contrasting AB 
block copolymers p(PEG114-b-BuMA100) and p(PEG114-b-EHMA100) to form turbid and 
translucent aqueous nanoparticle dispersions with hydrodynamic size diameters of 
215 and 175 nm and PDI values of 0.294 and 0.235, respectively. The sole 
nanoprecipitations of these two AB block copolymers were unsuccessful, so this 
observation once again highlights the importance of the hydrophobic polymers 
within the co-nanoprecipitation process. However, p(HPMA)20 did not co-
nanoprecipitate successfully with p(PEG114-b-BuMA100) or p(PEG114-b-EHMA100), but 
instead yielded polymer aggregates.  
The failure of the co-nanoprecipitations involving the linear p(BuMA) and p(EHMA) 
homopolymers, both DPn 100 and 20 monomer units, is not that surprising. The role 
of high molecular weight copolymers in promoting rapid homogeneous nucleation in 
co-nanoprecipitation has been reported previously.  
3.5.2 Co-nanoprecipitation of Linear Statistical Copolymers with Varying 
Amphiphilic AB Block Copolymers.  
Co-nanoprecipitations were conducted with statistical linear copolymers and varying 
AB block copolymers as before. Both were solvated in THF and added to stirred water 
with [P]f = 1 mg mL-1. Following the evaporation of THF overnight, aqueous polymer 




and zeta potential analysis (Table 3.5). These co-nanoprecipitations proved more 
successful than the co-nanoprecipitations of the linear homopolymers (Section 
3.5.1). Interestingly, the presence of HPMA monomer residues within the statistical 
linear copolymers appeared to provide additional stabilisation and enabled the 
formation of colloidally stable nanoparticles. 
 
Table 3.5 DLS and zeta potential analyses following the co-nanoprecipitations of linear statistical copolymers with 
varying AB block copolymers. 
 
The resulting Dz values were in the range of 100 – 165 nm, where p(BuMA50-s-
HPMA50) and p(HPMA50-s-EHMA50) produced smaller particles than p(BuMA50-s-
EHMA50), likely due to the stabilisation from HPMA monomer residues providing 
some charge stabilisation through the adsorption of hydroxide ions and therefore 
preventing further growth of the particle. Uniform and narrow particle size 
distributions were obtained (< 0.102), which is indicative of a homogenous 
nucleation and rapid growth period. In all cases, ζ values were low (-7.95 to -13.3 
mV), which suggests that the stabilisation of the nanoparticles is not entirely 
maintained by electrostatic forces, as previously observed, but is instead likely 
provided by steric stabilisation from the hydrated PEG coronas.   
Interestingly, it was observed that the co-nanoprecipitation of p(BuMA)n with 
p(PEG114-b-HPMA100), and the co-nanoprecipitation of p(EHMA)n with p(PEG114-b-
HPMA100) both failed, but the co-nanoprecipitation of p(BuMA50-s-EHMA50) with 
p(PEG114-b-HPMA100) was a success. This may be as a result of the compatibility being 
 AB Block Copolymer (40 wt.%) 























(kcps)a ζ (mV)b 
p(BuMA50-s-
EHMA50) 
Polymer Aggregation Polymer Aggregation 165 0.102 773 250 -13.3 
p(BuMA50-s-
HPMA50) 
100 0.056 359 300 -7.95 125 0.015 804 550 -8.04 105 0.082 329 300 -11.7 
p(HPMA50-s-
EHMA50) 
Polymer Aggregation 140 0.033 523 000 -10.6 90 0.310 79 200 -33 
aMeasured using DLS analysis at a concentration of 1 mg mL -1, Dz values have been rounded to the nearest 5 nm. b Obtained 




improved between the statistical copolymer and the AB block copolymer compared 
to the homopolymers. 
3.5.3 Co-nanoprecipitation of EGDMA-Based Branched Copolymers with Varying 
Amphiphilic AB Block Copolymers.  
Co-nanoprecipitations were conducted with EGDMA-based branched copolymers 
that were described in Chapter 2. Branched vinyl copolymers were each combined 
with an AB block copolymer in THF. Co-nanoprecipitations were completed following 
the same protocol as previously used, whereby polymer-THF solution (1 mL) at [P]0 = 
5 mg mL-1 was added to stirred DI water (5 mL). Again, the solutions consisted of 
60:40 wt.% ratio of branched copolymer: AB block copolymer. Co-nanoprecipitations 




Figure 3.13 Schematic representation of the co-nanoprecipitations of varying branched copolymers with a) 
different monomer chemistry and b) different degrees of polymerisation, with differing AB block copolymers: i) 
p(PEG114-b-BuMA100), ii) p(PEG114-b-EHMA100) and iii) p(PEG114-b-HPMA100). 
Co-nanoprecipitations of branched copolymers and AB block copolymers were 




following THF evaporation, with the exception of: p(BuMA20-co-EGDMA0.85) and 
p(EHMA20-co-EGDMA0.80) when co-nanoprecipitated with p(PEG114-b-BuMA100), and 
p(EHMA100-co-EGDMA0.80) when co-nanoprecipitated with p(PEG114-b-EHMA100) and 
p(PEG114-b-HPMA100), which did not remain stable following THF evaporation; 
macroscopic polymer aggregation was observed with subsequent sedimentation. 
The other combinations formed turbid aqueous nanoparticle dispersions, which 
were assessed via DLS and zeta potential analysis (Table 3.6).  
Table 3.6 DLS and zeta potential analyses of aqueous branched copolymer nanoparticle dispersions produced via 
co-nanoprecipitation with varying AB block copolymers.  
The polymer nanoparticles that were generated were uniform and had monomodal 
particle size distributions without the need for sample filtration. The nanoparticles 
that were obtained had varying hydrodynamic diameters (70 < Dz < 155 nm) and 
polydispersity values (0.024 < PDI < 0.135). Compared to the sole nanoprecipitation 
of these branched materials, whereby all but HPMA-based polymers failed, 
incorporation of an AB block copolymer within the polymer-THF solution yielded 
much more successful results. Only four out of the eighteen co-nanoprecipitations 
failed. This observation highlights how important the AB block copolymer is and how 
it can provide sufficient levels of steric stabilisation to prevent nanoparticle-
nanoparticle aggregation. This steric stabilisation was once again confirmed by the 
 AB Block Copolymer (40 wt.%) 






















Polymer Aggregation 95 0.024 387 500 -14.7 155 0.098 788 000 -10.8 
p(EHMA20-co-
EGDMA0.80) 
Polymer Aggregation 95 0.065 341 000 -17.7 150 0.133 592 300 -12.2 
p(HPMA20-co-
EGDMA0.85) 
100 0.088 325 600 -10.1 115 0.067 400 000 -4.34 110 0.111 397 500 -8.0 
p(BuMA100-co-
EGDMA0.95) 
80 0.135 116 100 -14.1 95 0.039 346 100 -12.7 145 0.088 481 250 -10.8 
p(EHMA100-co-
EGDMA0.80) 
85 0.120 239 150 -11.6 Polymer Aggregation Polymer Aggregation 
p(HPMA100-co-
EGDMA0.90) 
70 0.088 75 050 -16.5 75 0.056 102 200 -17.9 60 0.112 89 700 -11.9 
aMeasured using DLS analysis at a concentration of 1 mg mL -1, Dz values have been rounded to the nearest 5 nm.  




moderately negative ζ values obtained for the aqueous polymer nanoparticle 
dispersions (-8.0 to -17.9 mV). SEM analyses of the nanoparticles produced via co-
nanoprecipitation of p(BuMA100-co-EGDMA0.95):p(PEG114-b-HPMA100) and p(EHMA20-
co-EGDMA0.80):p(PEG114-b-HPMA100) at 60:40 wt.% ratio respectively, indicated 
spherical particle morphology (Figure 3.14). 
Figure 3.114 SEM images of co-nanoprecipitates produced using (A and B) p(BuMA100-co-EGDMA0.95):p(PEG114-b-
HPMA100) and (C-E) p(EHMA20-co-EGDMA0.80):p(PEG114-b-HPMA100) at 60:40 wt.% ratio, respectively. 
Co-nanoprecipitations of branched statistical copolymers with varying AB block 
copolymers were also conducted following the same standard protocol. Stable 
aqueous nanoparticle dispersions were analysed via DLS (Table 3.7). With the 
exception of p(BuMA50-s-EHMA50-co-EGDMA0.95):p(PEG114-b-BuMA100), all cases gave 
monomodal particle size distributions with intensity-averaged hydrodynamic 
diameters ranging from 90-175 nm. In the case of p(BuMA50-s-EHMA50-co-
EGDMA0.95):p(PEG114-b-BuMA100), visible aggregation occurred. In the majority of 
cases, narrow PDI values were obtained (< 0.1), indicating that the nanoparticles are 
monodisperse. Nanoparticle stability obtained through steric stabilisation conferred 





 Table 3.7 DLS and zeta potential analyses of aqueous branched statistical copolymer nanoparticle dispersions 
produced via co-nanoprecipitation with varying AB block copolymers. 
Clearly, when developing polymer nanoparticles for DDS, the ability to generate 
stable aqueous dispersions is essential. As shown throughout all of the studies, co-
nanoprecipitation offers the opportunity to generate sterically stabilised aqueous 
nanoparticle dispersions. In order to assess the potential of the co-nanoprecipitates 
as DDS of therapeutic compounds, the next stage of the research and development 
is to investigate whether the identified co-nanoprecipitation options can be used 
successfully to encapsulate small hydrophobic guest molecules.    
3.6 Encapsulating a Hydrophobic Guest Molecule via Co-nanoprecipitation 
For polymer nanoparticles to be utilised as DDS they must be able to encapsulate 
hydrophobic drug molecules within their core. The following experiments aimed to 
investigate whether it was possible to encapsulate a hydrophobic guest molecule 
within the core of branched vinyl copolymer nanoparticles prepared via co-
nanoprecipitation before utilising this strategy for encapsulation of hydrophobic 
drug molecules to generate DDS. Encapsulation of such can be achieved by dissolving 
the hydrophobic guest molecule within the copolymer-THF solution before addition 
to water. Pyrene was used as the selected guest molecule in the following studies 
(Figure 3.15). 
 AB Block Copolymer (40 wt.%) 



































115 0.071 320 250 -8.6 135 0.037 690 000 -9.8 125 0.099 444 900 -10.1 
aMeasured using DLS analysis at a concentration of 1 mg mL-1, Dz values have been rounded to the nearest 5 nm.  






Figure 3.15 Schematic representation of the encapsulation of the hydrophobic guest molecule, pyrene, via co-
nanoprecipitation. 
 
Pyrene is a hydrophobic aromatic molecule consisting of four fused benzene rings, 
and has been used as a fluorescent probe to evaluate solvent polarity (Figure 3.16).20. 
 
Figure 3.16 The chemical structure of pyrene. 
The fluorescence of pyrene (π → π*) generates an emission spectrum consisting of 
five vibrational bands that are sensitive to solvent polarity. The first vibrational band 
(373 nm, I1) of pyrene is enhanced in polar solvents (or environments) relative to the 
third vibrational band (385 nm, I3). Therefore, the ratio of intensities between these 
two bands (I1/I3) can be used to provide information on the local environment of the 
pyrene molecules (i.e. the internal environment of nanoparticles). I1/I3 values 
obtained for pyrene in polar solvents such as water have been reported at 1.87. 
Which decreases significantly to 0.58 when the solvent is changed to the non-polar 




polarity can also be assessed using fluorescence emission spectroscopy of pyrene. 
Pyrene can be encapsulated at low loadings (1 wt.% with respect to total polymer 
mass) during the co-nanoprecipitation process, and its fluorescence emission spectra 
can help to provide insight into where the hydrophobic guest molecule locates itself 
(i.e. within the core or on the surface) and subsequent information about the 
characteristics of that environment.  
The co-nanoprecipitation studies that were conducted using pyrene aimed to provide 
information on the following: 1) did the incorporation of pyrene alter the co-
nanoprecipitation process, 2) can a hydrophobic molecule be encapsulated within 
the core, and 3) how was the polarity of the nanoparticle core altered when varying 
the monomer residue functionality, the AB block copolymer and the divinyl 
monomer residue functionality. In addition to this, results obtained from the 
fluorimetry measurements could also provide indication of how the AB block 
copolymer is interacting with the nanoparticle during the co-nanoprecipitation 
process.   
3.6.1 Evaluation of the Impact of Pyrene Encapsulation During Co-
nanoprecipitation 
Encapsulation experiments were conducted in an identical manner to those in 
previous co-nanoprecipitation studies but with the addition of pyrene into 
copolymer-THF solutions. Given the hydrophobic nature of pyrene, it was anticipated 
that it would become entrapped and therefore encapsulated within the core of the 
polymeric nanoparticles during its co-nanoprecipitation with the AB block copolymer 
and branched vinyl copolymer. Pyrene was incorporated within the copolymer-THF 
solutions with a 1 wt.% loading with respect to total polymer mass. As before, the 
copolymer-THF solutions consisted of [P]o = 5 mg mL-1 and contained 60:40 wt.% 
branched vinyl copolymer:AB block copolymer. Co-nanoprecipitations were 
conducted by addition of copolymers and pyrene/THF solutions (1 mL) into stirred DI 
water (5 mL). Samples were left stirring overnight to allow for THF evaporation to 
yield aqueous nanoparticle dispersions with [P]f = 1 mg mL-1 and a pyrene 
concentration of 1 µg mL-1. Nanoparticle size distributions were obtained via DLS 




Table 3.8 DLS of aqueous branched copolymer nanoparticle dispersions produced via co-nanoprecipitation with 
varying AB block copolymers and pyrene. 
In all of the cases, turbid aqueous nanoparticle dispersions were obtained which 
closely resembled those obtained without pyrene present. Monomodal particle size 
distributions were obtained, and pyrene loaded nanoparticles were produced with 
hydrodynamic diameters between 50 - 165 nm and PDI values between 0.032 - 0.287.  
Different observations were made regarding the impact of loading pyrene within the 
nanoparticles.  
Firstly, and most commonly, was that there was no difference in the hydrodynamic 
diameters of pyrene loaded polymer nanoparticles compared to unloaded versions 
of the same polymer composition. For example, pyrene loaded p(HPMA100-co-
EGDMA0.90):p(PEG114-b-HPMA100) nanoparticles had a hydrodynamic diameter of 
60  nm and a PDI of 0.101, whereas in the absence of pyrene the polymer 
nanoparticles had a hydrodynamic diameter of 60 nm and a PDI of 0.112. Another 
example is pyrene loaded p(BuMA100-co-EGDMA0.95):p(PEG114-b-HPMA100) 
nanoparticles having a hydrodynamic diameter of 145 nm and a PDI of 0.088, 
whereas in the absence of pyrene the nanoparticles had a hydrodynamic diameter 
of 145 nm and a PDI of 0.088 (Figure 3.17).  
 AB Block Copolymer (40 wt.%) 


















65 0.071 77 200 80 0.032 266 300 135 0.088 304 600 
p(EHMA20-co-
EGDMA0.80) 
75 0.071 117 350 90 0.035 325 550 70 0.156 59 200 
p(HPMA20-co-
EGDMA0.85) 
110 0.287 77 450 90 0.287 80 700 165 0.087 749 250 
p(BuMA100-co-
EGDMA0.95) 
80 0.143 230 100 90 0.094 300 250 145 0.088 578 300 
p(EHMA100-co-
EGDMA0.80) 
75 0.090 128 400 90 0.070 409 300 145 0.100 542 100 
p(HPMA100-co-
EGDMA0.90) 
50 0.166 105 900 50 0.143 118 500 60 0.101 117 500 






Figure 3.17 Overlaid nanoparticle size distributions obtained by DLS analysis of unloaded (solid lines) and 0.1 wt.% 
pyrene loaded (dashed lines) aqueous nanoparticle dispersions prepared by co-nanoprecipitation of a) 
p(HPMA100-co-EGDMA0.95), and b) p(BuMA100-co-EGDMA0.95), with p(PEG114-b-HPMA100) at a composition of 60:40 
wt.%, respectively.  
There were four cases where the incorporation of pyrene within the co-
nanoprecipitation caused a significant decrease in the hydrodynamic diameters 
observed. Pyrene loaded p(HPMA100-co-EGDMA0.90):p(PEG114-b-BuMA100) 
nanoparticles had a hydrodynamic diameter of 50 nm and a PDI of 0.166, but in the 
absence of pyrene, the polymer nanoparticles had a hydrodynamic diameter of 
70 nm and a PDI of 0.088. A decrease in hydrodynamic diameter of approximately 
20 nm. Another example of this is pyrene loaded p(HPMA100-co-
EGDMA0.95):p(PEG114-b-EHMA100) nanoparticles having a hydrodynamic diameter of 
50 nm and a PDI of 0.143, but in the absence of pyrene the nanoparticles had a 
hydrodynamic diameter of 75 nm and a PDI of 0.056. This was also observed for 
nanoparticles comprising of p(BuMA20-co-EGDMA0.85): p(PEG114-b-HPMA100), which 
also saw a decrease in hydrodynamic diameter from 155 nm to 135 nm when pyrene 
was loaded. Finally, this was also observed for p(EHMA20-co-EGDMA0.80): p(PEG114-b- 
HPMA100), which saw a decrease in hydrodynamic diameter from 150 nm to 70 nm 
when pyrene was loaded. These observations suggest that pyrene may be playing a 
positive role in driving the nucleation process. Its incorporation within the co-
nanoprecipitation process may lead to an increase in the number of nuclei formed in 
the initial stages which may lead to a greater nucleation rate and a consequent 
decrease in nanoparticle size.   
Perhaps the most interesting observation was that not only did the incorporation of 




previously failed in its absence. For example, the co-nanoprecipitation of p(BuMA20-
co-EGDMA0.85) with p(PEG114-b-BuMA100) in the absence of pyrene resulted in 
macroscopic aggregation (Section 3.5.3). When pyrene was incorporated, however, 
a monomodal particle size distribution was obtained consisting of monodisperse 
nanoparticles with a hydrodynamic diameter of 65 nm and PDI of 0.071.  Another 
example is the co-nanoprecipitation of p(EHMA100-co-EGDMA) with p(PEG114-b-
HPMA100) without pyrene, which once again resulted in macroscopic aggregation 
(Section 3.5.3); however, when pyrene was included, a monomodal particle size 
distribution was obtained consisting of monodisperse nanoparticles with a 
hydrodynamic diameter of 145 nm and PDI of 0.100.  Since these co-
nanoprecipitations were conducted at the standard 60:40 branched copolymer:AB 
block copolymer wt.% ratio, the full range of ratios from 0-100 wt.% were studied to 
see if this influence of pyrene was observed throughout the whole series of 
compositions (Section 3.6.2) 
In contrast, there was one example, p(HPMA20-co-EGDMA0.85):p(PEG114-b-HPMA100) 
nanoparticles, where incorporation of pyrene caused an increase in hydrodynamic 
diameter compared to the blank nanoparticles, from 110 to 165 nm.  Both 
chemistries of the branched copolymer and the AB block copolymer consist of HPMA 
hydrophobic monomer residues. Hydrophobic interfaces have been shown to 
promote the adsorption of hydroxide ions and leading to a negative ζ values.22-24   This 
adsorption may confer some charge stabilisation to the resulting nanoparticles. 
Therefore, the increase in particle size could have arisen from some incompatibilities 
between the pyrene and the charge exhibited from these species.   
3.6.2 Varying the Composition of the Nanoparticle Core and the Effect on the 
Encapsulation of Pyrene 
In the co-nanoprecipitations described above, the ratio of branched copolymer and 
AB block copolymer was set at a constant 60:40 wt.%, respectively, unless otherwise 
stated. It has been shown that each constituent copolymer plays a different role 
during the co-nanoprecipitation process and that the manipulation of this ratio 
between the two polymers in the initial THF solution has an effect on particle stability 




guest molecule, the outcome of some co-nanoprecipitations differed from that of the 
respective co-nanoprecipitation without a guest molecule present (Section 3.6.1). It 
was of interest to see whether this effect was observed at the full range of 
compositional ratios and whether such compositional manipulation also impacted 
the nanoparticle internal polarity. Therefore, a range of co-nanoprecipitations were 
conducted as previously described, with pyrene incorporated within copolymer-THF 
solution with a loading of 1 wt.% with respect to total polymer mass. As before, 
copolymer/THF solutions consisted of [P]o = 5 mg mL-1 and branched vinyl copolymer: 
AB block copolymer was systematically varied from 0-100 wt.%, respectively. The AB 
block copolymer utilised in this study was p(PEG114-b-HPMA100), given its stability 
when solely nanoprecipitated. Co-nanoprecipitations were conducted by addition of 
copolymers and pyrene/THF solution (1 mL) into stirred DI water (5 mL). Samples 
were left stirring overnight to allow for THF evaporation to yield aqueous 
nanoparticle dispersions with [P]f = 1 mg mL-1 and a pyrene concentration of 1 µg 
mL- 1. The effects of the encapsulation of pyrene within branched vinyl copolymer 
nanoparticles during co-nanoprecipitation was confirmed using DLS (Figure 3.18) and 
fluorescence emission spectroscopy (Figure 3.19). Analysis via DLS for all the stable 
pyrene loaded polymer nanoparticles showed that the co-nanoprecipitations 
produced monodisperse nanoparticles with monomodal particle size distributions, 
and that the particle sizes did not vary with any significance compared to their 








Figure 3.18 Nanoparticle sizes from DLS analysis of blank nanoparticles (black circles) and with 1 wt.% pyrene 
encapsulated (red circles) for A) p(HPMA100-co-EGDMA0.90), B) p(BuMA100-co-EGDMA0.95) and C) p(EHMA100-co-




Encapsulation of pyrene within all p(HPMA100-co-EGDMA0.90) nanoparticles was 
successful and had little, if any, effect to the nanoprecipitation regime regardless of 
the wt.% of AB block copolymer present. Interestingly, when the polymer was 
changed to p(EHMA100-co-EGDMA0.80), the wt.% of AB block copolymer required to 
produce sterically stabilised nanoparticles changed when comparing the co-
nanoprecipitations with and without pyrene.  When pyrene was incorporated, all 
wt.% of AB block copolymer produced stable co-nanoprecipitates of p(EHMA-co-
EGDMA). This is a stark contrast to what was observed when no pyrene was included, 
which required at least 70 wt.% AB block copolymers to yield sterically stabilised 
nanoparticles. This observation suggests that the incorporation of a guest molecule 
such as pyrene has had an influence on the co-nanoprecipitation process to produce 
stabilised nanoparticles. The guest molecules may be coming together to form zoned 
areas which may be presented on the surface (or partially presented) which could be 
providing additional stabilisation through charge.  
Analysis of the pyrene fluorescence spectra showed two different trends between 
nanoparticle internal polarity and the wt.% ratio of AB block copolymer present 
within the co-nanoprecipitation (Figure 3.19). In the case of p(HPMA100-co-
EGDMA0.90), increasing the weight composition of the AB block copolymer had little 
impact on the internal polarity of the nanoparticle core. The I1/I3 ratio increased 
slightly from 1.69 when the polymer nanoparticle consisted entirely of p(HPMA100-
co-EGDMA0.90), to 1.71 as the environment was changed to consist solely of p(PEG114-
b-HPMA100). This result is consistent with what would be expected since there is little 
change to the chemical composition of the nanoparticle core; both of the 
hydrophobic domains within each polymer component contain hydroxyl functional 
groups and therefore bring an associated level of polarity to the nanoparticle core. 
Changing the polymer to those with more hydrophobic monomer residues, BuMA 
and EHMA, presented a different trend. Increasing the content of AB block copolymer 
from 0 to 100 wt.% caused a general increase to the I1/I3 value, suggesting that the 
core of polymeric nanoparticle was increasing in polarity with the increasing AB block 




from 1.22 to 1.71 and p(EHMA100-co-EGDMA0.80) increased from 1.07 to 1.71. 
Interestingly, this influence on the internal core polarity seemed to begin when the 
AB block composition was > 50 wt.%. This observation suggests that when the AB 
diblock copolymer composition is < 50 wt.%, the chemical composition of the 
nanoparticle core is dominated by the branched copolymer and not the AB block 
copolymer. 
Figure 3.19  Graphical representation of how the I1/I3 ratio changed as the wt.% of p(PEG114-b-HPMA100) increased 
within co-nanoprecipitates of p(HPMA100-co-EGDMA0.90) (black line, circles), p(BuMA100-co-EGDMA0.95) (red line, 
triangles) and p(EHMA100-co-EGDMA0.80) (blue line, open squares). 
Clearly, increasing the amount of AB block copolymer altered the nanoparticle core 
polarity, suggesting that the hydrophobic domain of the AB block copolymer was in 
fact anchored within the core of the particle in some way and the hydrophilic 
counterpart was located on the surface. Incorporation of AB block copolymer within 
co-nanoprecipitation clearly changes the nanoparticle core otherwise it could be 
expected that the I1/I3 values would remain the same. Also, it is worth reiterating 
that since the I1/I3 values do change, it further confirms that some of the 
encapsulated pyrene is located within the core of the particle and not present on the 




3.6.3 The Evaluation of Nanoparticle Core Polarity of EGDMA Branched Vinyl 
Copolymers with Varying Monomer compositions and Varying AB block 
Copolymers via the Encapsulation of Pyrene 
The encapsulation of pyrene within branched vinyl co-polymer nanoparticles enabled 
investigations into the physical properties of the internal environment. This was 
achieved through analysis of the fine structure of the fluorescence emission of 
pyrene, specifically the I1 and I3 vibrational bands. It was hypothesised that 
comparison of the fluorescence spectra of pyrene within co-nanoprecipitates of 
varying composition, including different branched vinyl copolymers and different AB 
block copolymers, would potentially provide information of the core environment 
(specifically polarity) and a more-clear indication on the role of AB block copolymer 
within the co-nanoprecipitation process. 
To compare the I1/I3 values of the co-nanoprecipitates derived from the three 
different monomers, pyrene was encapsulated within p(HPMA100-co-EGDMA0.90), 
p(BuMA100-co-EGDMA0.95) and p(EHMA100-co-EGDMA0.80) co-nanoprecipitated with 
p(PEG114-b-HPMA100), p(PEG114-b-BuMA100) and p(PEG114-b-EHMA100), (60:40 wt.%). 
The nanoparticles were prepared as previously described in Section 3.6.  A similar 
study has been previously conducted for hyp-polydendron nanoparticles.9 In all 
cases, the fluorescence emissions of the aqueous nanoparticle dispersions, obtained 
following excitation at λ = 335 nm, showed that the encapsulation of pyrene during 
co-nanoprecipitation had been successful. This was confirmed by the lower I1/I3 
values obtained for pyrene encapsulated polymer nanoparticles (I1/I3 = 1.10-1.62) 
compared to that of pyrene dissolved in water (I1/I3 = 1.81) (Table 3.9).  
Table 3.9 Polarity data obtained from pyrene emission spectroscopy for aqueous nanoparticle dispersions 
obtained via co-nanoprecipitation of varying branched polymers, AB block copolymers and pyrene. 
  AB block copolymer 
 p(PEG114-b-HPMA100) p(PEG114-b-BuMA100) p(PEG114-b-EHMA100) 
Branched Copolymer a I1/I3 
p(EHMA100-co-
EGDMA0.80) 
1.10 1.12 1.10 
p(BuMA100-co-
EGDMA0.95) 
1.22 1.17 1.12 
p(HPMA100-co-
EGDMA0.90) 
1.62 1.26 1.14 
a Obtained using fluorescence emission spectroscopy of aqueous nanoparticle dispersions following attempted encapsulation 




The lower I1/I3 values obtained suggests that pyrene is located in an environment 
which is of lower polarity than water, indicating that pyrene may be located within 
the core of the polymer nanoparticles (i.e. it has been successfully encapsulated 
during co-nanoprecipitation). Polymer nanoparticles produced with p(PEG114-b-
HPMA100) as constant but with varying branched vinyl polymer showed varying I1/I3 
values (Figure 3.20).  
 
Figure 3.20 Fluorescence emissions spectra for pyrene loaded p(HPMA100-co-EGDMA0.90) (Black line), p(BuMA100-
co-EGDMA0.95) (red line) and p(EHMA100-co-EGDMA0.80) (green line) branched copolymers with AB block 
copolymer, p(PEG114-b-HPMA100) (60:40 wt. % composition respectively). Showing the difference in I1 and I3 values 
between the branched copolymers.  
 
Since the AB block copolymer composition was kept constant during the co-
nanoprecipitation process, the changes to the I1/I3 ratio value has provided indication 
that the monomer residue chemistry is having an impact on the nanoparticle core 
chemistry and therefore the internal polarity. This was also observed when the AB 
block was changed to p(PEG114-b-BuMA100) and p(PEG114-b-EHMA100). Analysis of the 
values obtained for p(PEG114-b-HPMA100) co-nanoprecipitates showed that polymer 
nanoparticles consisting of branched copolymers with HPMA monomer residue 




highest I1/I3 value (1.62). This value decreased when the monomer residue of the 
branched copolymer was changed to BuMA (1.22) and then to EHMA (1.10). This 
suggests that when varying monomer residue chemistry, a decrease in polarity of the 
nanoparticle core is observed with increasing monomer residue hydrophobicity. As 
previously discussed, BuMA and EHMA functionalities are more hydrophobic than 
that of HPMA and therefore it would be expected that a less polar core would be 
generated. The difference in values between BuMA and EHMA functionalities further 
suggests that the increasing hydrophobicity between the two has an impact on the 
core polarity. This increase in hydrophobicity can be readily rationalised as being due 
to the longer and branched aliphatic chains that are present in p(EHMA) and the 
subsequent changes this would have on the calculated octanol-water partition 
coefficients (cLogP). 
To provide some indication of the mode of AB block copolymer incorporation during 
co-nanoprecipitation, the AB block copolymer was changed to p(PEG114-b-BuMA100) 
and p(PEG114-b-EHMA100). If the hydrophobic segment of the AB block locates within 
the core of the polymer nanoparticle, then changing the hydrophobic segment on 
the AB block copolymer should alter the nanoparticle core polarity and, in turn, the 
I1/I3 ratios. Polymer nanoparticles were prepared with pyrene, as described 
previously. The fluorescence emissions of the aqueous nanoparticle dispersions, 
obtained following excitation at λ = 335 nm, showed that the encapsulation of pyrene 
during these co-nanoprecipitations had been successful.  
Different I1/I3 values were obtained for the nanoparticles prepared with different AB 
block copolymers (Table 3.9). The polymer nanoparticles that were prepared with 
p(PEG114-b-EHMA100) produced the lowest I1/I3 ratios, which is consistent with this 
being the most hydrophobic AB block copolymer. These differing values presented 
here demonstrate that the nanoparticle internal core is comprised not just of 
branched copolymer, but also the hydrophobic segment from the AB block 
copolymer. Additionally, it also indicates that the hydrophilic PEG-based domain is 
not located within the core of the nanoparticle as these values suggest that pyrene 




3.6.4 Evaluation of Stability of Pyrene Loaded p(EHMA-co-EGDMA) Nanoparticles 
Following the Addition of PBS. 
As previously mentioned, the co-nanoprecipitation of p(EHMA100-co-EGDMA0.85) 
seemed to be improved by the incorporation of the guest molecule, pyrene. It was 
of interest to see how the co-nanoprecipitates incorporating pyrene behaved 
following the addition of PBS.  Experimentally, p(EHMA100-co-EGDMA0.85) was co-
nanoprecipitated with pyrene into DI water with p(PEG114-b-HPMA100) at varying 
compositional ratios of 100:0 – 50:50 wt. %, respectively. Solvent was allowed to 
evaporate and Dz, PDI and derived count rate were determined via DLS at a [P]f =1 
mg mL-1.  The stability to dilution and exposure to salts of these branched vinyl 
copolymer nanoparticles was assessed via a serial dilution with PBS over a 100-fold 
dilution factor to produce final polymer concentrations at 0.5, 0.25, 0.1 and 0.01 mg 
mL-1. Aqueous nanoparticle dispersions were diluted and left to gently mix overnight 
before being analysed via DLS (Table 3.10).  
The sample without AB block co-polymer present was translucent but contained 
visible aggregation on the stirrer bar before addition of PBS, again indicating that the 
AB block copolymer is required to provide a degree of steric stabilisation during the 
co-nanoprecipitation process (Figure 3.21).  The importance of such steric 
stabilisation was also evident as the sample was diluted with PBS to 0.5 mg mL-1, 
which resulted in a dramatic increase in particle hydrodynamic diameter from 140 to 
306 nm, coupled with a decrease in count rate from 72 700 to 15 400 kcps, which 
suggests that the sample was precipitating out of solution and sedimenting, resulting 
in a reduced scattering of light. The samples that contained ≥ 20 wt.% AB block 
copolymer remained stable upon addition of PBS up to a dilution of 0.01 mg mL-1, 
with minimal variation in hydrodynamic diameter observed (Figure 3.22). The sample 
with 10 wt.% AB block copolymer showed signs of instability and polymer 
aggregation at 0.25 mg mL-1 as a multimodal DLS trace was obtained; no further 
dilution was conducted with this sample (Appendix, Figure A31). Interestingly, the 
sample that showed the least difference between measurements was that consisting 





Table 3.10 DLS analyses of pyrene loaded p(EHMA100-co-EGMDA0.90) polymer nanoparticles conanoprecipitated 
at varying wt. % of p(PEG114-b-HPMA100) from 0-50 wt.%, respectively, following the serial dilution with PBS. Dz 
values have been rounded to the nearest 5 nm. 
Polymer 
Concentration 
Wt.% of Branched 
Polymer 











1 mg mL-1 
(no PBS) 
100* 0 140 0.073 72 700 6 
90 10 175 0.093 781 300 4 
80 20 175 0.239 773 500 4 
70 30 175 0.170 816 700 4 
60 40 160 0.152 781 300 4 
50 50 140 0.115 579 800 4 
0.5 mg mL-1 
(PBS) 
100* 0 305 0.115 15 400 7 
90 10 185 0.130 518 900 4 
80 20 180 0.118 305 100 5 
70 30 170 0.126 340 300 5 
60 40 160 0.106 389 850 4 
50 50 150 0.089 276 150 5 
0.25 mg mL-1 
(PBS) 
100 0 Polymer aggregation 
90** 10 215 0.233 260 100 5 
80 20 175 0.088 227 100 5 
70 30 175 0.078 248 150 5 
60 40 160 0.099 222 750 5 
50 50 140 0.095 93 510 6 
0.1 mg mL-1 
(PBS) 
100 0 Polymer aggregation 
90 10 Polymer aggregation 
80 20 175 0.106 61 750 6 
70 30 180 0.105 59 200 6 
60 40 160 0.099 58 100 6 
50 50 140 0.104 43 100 6 







Figure 3.21 Photographs showing the effects of the addition of PBS to the samples of p(EHMA100-co-EGDMA0.85) 
with varying amounts of p(PEG114-b-HPMA100) from 0-50 wt.% from left to right. Measured at A) polymer 
concentration = 1 mg mL-1 in H2O and B) polymer concentration = 0.5 mg mL-1, following dilution with PBS. 
 
 
Figure 3.22 A graph showing the hydrodynamic diameters (nm) obtained for the pyrene loaded p(EHMA100-co-
EGDMA0.85) nanoparticles with varying amounts compositions of p(PEG114-b-HPMA100) from 0-50 wt.%. Data 
collected at different final polymer concentrations: 1 mg mL-1 (black closed circles), and 0.5 mg mL-1 (blue open 




3.7 Co-nanoprecipitation of p(PEG114-b-HPMA100) and Branched Copolymers with 
Varying Divinyl Monomer Residue Chemistries 
Co-nanoprecipitations were conducted by fixing the AB block copolymer as 
p(PEG114-b-HPMA100) and by using branched copolymers consisting of EHMA 
monomer residues but varying in divinyl monomer residue chemistries. A ratio of 
branched copolymer:AB block polymer of 60:40 wt.% was used, as before. Co-
nanoprecipitations were conducted as previously described (Section 3.5.3). Co-
nanoprecipitation of all the branched p(EHMA) with varying divinyl monomer residue 
chemistry was successful except for p(EHMA100-co-EGDMA0.80), which resulted in 
macroscopic aggregation, as previously described. Analysis via DLS showed 
monomodal distributions for all the aqueous nanoparticle dispersions obtained 
(Table 3.11).   
Table 3.11 DLS and zeta potential analyses of aqueous nanoparticle dispersions produced via co-
nanoprecipitation of the AB block copolymer, p(PEG114-b-HPMA100), with branched p(EHMA) varying in divinyl 
monomer residue chemistry. 
Nanoparticles were produced with varying hydrodynamic diameters (110 ≤ Dz ≤ 165 
nm) and polydispersity values (0.018 ≤ PDI ≤ 0.133).  Repeat analyses were performed 
on p(EHMA100-co-GDMA0.85), p(EHMA20-co-GDMA0.85), p(EHMA100-co-UDMA0.85) and 
p(EHMA20-co-GDMA0.90) after 80 days of storage following co-nanoprecipitation, 
which showed little deviation from the original data collected and that all samples 
  AB Block copolymer: p(PEG114-b-HPMA100) 









(kcps)a ζ (mV)b 
20 
EGDMA 150 0.133 592 300 -17.7 
BPDMA 150 0.066 698 750 -10.7 
GDMA 150 0.090 738 500 -11.7 
BPGDMA 110 0.018 456 000 -13.5 
UDMA 155 0.090 785 700 -9.86 
DSDMA 145 0.042 790 350 -13.2 
100 
EGDMA Polymer Aggregation 
BPDMA 165 0.087 637 150 -11.1 
GDMA 160 0.084 833 450 -11.2 
BPGDMA 150 0.063 731 550 -8.64 
UDMA 155 0.080 785 400 -8.58 
DSDMA 165 0.086 815 600 -11.9 
a Measured using DLS analysis at a concentration of 1 mg mL-1. b Obtained via measurement of the electrophoretic mobility of 




were stable (Appendix, Table A.2). Therefore, suggesting that changes in the 
branching agent chemistry imparted minimal differences on the nanoparticle 
formation.  
3.7.1 Investigating the Effect of Divinyl Monomer Residue Chemistries on 
Nanoparticle Core Polarity  
Pyrene was encapsulated within EHMA-based branched copolymers consisting of 
varying branching agent chemistries to study its effect on the core properties of the 
polymer nanoparticles. Co-nanoprecipitations with pyrene were conducted as 
previously described with p(EHMA20-co-EGDMA), p(EHMA20-co-BPGDMA), 
p(EHMA20-co-GDMA), p(EHMA20-co-UDMA), p(EHMA20-co-DSDMA) and p(EHMA20-
co-BPDMA) combined with p(PEG114-b-HPMA100). Co-nanoprecipitations with pyrene 
were also conducted with EHMA-based branched copolymer analogues with DPn of 
100 monomer units. All co-nanoprecipitations were conducted at 60:40 wt.% ratio of 
branched copolymer:AB block copolymer, respectively, and produced stable aqueous 
nanoparticle dispersions following THF evaporation. Analysis of these dispersions by 
DLS showed minimal differences in the hydrodynamic diameters compared to their 
unloaded counterparts. Fluorescence emission spectroscopy confirmed the 
encapsulation of pyrene in the core of the polymer nanoparticles (Table 3.12).  
Table 3.12 Polarity data obtained from pyrene emission spectroscopy for aqueous nanoparticle dispersions 
obtained via co-nanoprecipitation of varying branched EHMA polymers at DPn = 20 and 100 monomer units with 
p(PEG114-b-HPMA100) and pyrene (1 wt.%). 
  p(PEG114-b-HPMA100) 




















a Obtained using fluorescence emission spectroscopy of aqueous nanoparticle dispersions following attempted encapsulation 




I1/I3 values were determined for DPn = 20 monomer units (1.09 - 1.11) and for DPn = 
100 monomer units (1.06 - 1.10). The slightly higher I1/I3 values obtained for the 
polymers of DPn = 20 monomer units is likely to be as a result of the higher 
concentration of branching comonomers for any given mass of branched copolymer.  
However, these results showed that the variations in the branched copolymer core 
chemistries had negligible effect on the nanoparticle core polarity. 
3.8 Conclusion  
The work completed within this chapter aimed to expand on the scope of materials 
that have been previously reported to produce polymer nanoparticles via co-
nanoprecipitation. The initial findings from model co-nanoprecipitation studies of 
linear and branched copolymers with AB block copolymers reiterated previous 
findings in that there is a clear advantage to using high molecular weight branched 
vinyl polymer material to promote faster rates of nucleation for the formation of 
sterically stabilised nanoparticles with narrow and monomodal size distributions. 
This provided an opportunity to utilise complex macromolecular architectures that 
have been prepared by RDRP techniques, such as those discussed in Chapter 2. The 
design space of these materials was explored and the impact on producing polymeric 
nanoparticles and the effect this may have on the nanoparticle properties, such as 
size, appeared to be dependent on chemical nature of the polymer materials used. 
The results also reinforced that co-nanoprecipitation was a viable technique to 
produce polymer nanoparticles consisting of BuMA and EHMA functional 
copolymers, whose sole nanoprecipitation regimes failed to produce stable 
nanoparticles in the absence of AB diblock copolymers. Previously, the chemistry of 
the AB block copolymer hydrophobic domain has always been complimentary to that 
of the branched vinyl copolymer. However, systematically varying the AB block 
copolymer chemistries within the co-nanoprecipitation process allowed for the 
previously unreported co-nanoprecipitation of linear and branched vinyl 
(co)polymers whose functionality differed from that of the hydrophobic domains of 
the AB block copolymer. This in turn developed a further understanding of how the 




It was also of interest to gain an understanding of whether these polymer 
nanoparticles would be suitable candidates for the encapsulation of hydrophobic 
guest molecules. The use of pyrene as a hydrophobic guest molecule demonstrated 
that these polymer nanoparticles have the capability to encapsulate small 
hydrophobic molecules within their core during the co-nanoprecipitation process 
and that this approach may therefore be suitable for the use of encapsulating 
chemotherapeutics.  It was also indicated through this incorporation that the co-
nanoprecipitation process is a complex mechanism, which can be influenced by the 
presence of small molecules. The presence of pyrene may be introducing a degree of 
charge stabilisation through the possible adsorption of hydroxide ions, as has been 
previously reported for hydrophobic polymers with HPMA monomer residue 
functionalities. 
The chemical nature of pyrene also allowed for the probing of the internal 
environment of the polymer nanoparticles via fluorescence spectroscopy, which 
showed that the nanoparticle core polarities were influenced by the monomer 
residue chemistries and the hydrophobic domain chemistries of the AB block 
copolymer. These sterically stabilised pyrene loaded branched vinyl copolymer 
nanoparticles withstood dilution with biological media, which was relevant for future 
pharmacological investigations. This also suggests that the encapsulated guest 
molecules will remain within the nanoparticles and release at a rate dependent on 
diffusion and not by the degradation of the polymer nanoparticles.  
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Encapsulation of the Anti-Cancer Drug SN-38 via Co-












One of the most common treatments for a wide range of cancers is systemic 
chemotherapy, however, high doses are required to achieve a high drug 
concentration in target tissues, and thus a therapeutic effect, which frequently 
results in a broad toxicity experienced by the patients. Additionally, many 
chemotherapeutics exhibit poor aqueous solubility and stability issues. Over the last 
few decades there has been an increase in the preparation of drug loaded 
nanocarriers that have shown promising potential in overcoming the inherent 
problems associated with conventional dosing of chemotherapy drugs. Examples of 
such nanocarriers include liposomes, dendrimers, micelles and polymeric 
nanoparticles, which were discussed in detail in Chapter 1 section 1.2.1. When 
compared to conventional administration, encapsulation of chemotherapeutics 
offers several specific advantages, such as protection from degradation in systemic 
circulation, enhanced drug stability and solubility, decreasing toxic side effects and 
improved pharmacokinetic and pharmacodynamic profiles.  
4.1.1 Irinotecan - An Anticancer Chemotherapy Drug 
Camptothecin-11, more commonly known as irinotecan (IR), is a non-metallic 
chemotherapeutic that is commonly administered as a single agent or in combination 
therapy for the treatment of colorectal and small cell lung cancer.1 It is derived from 
the natural compound, camptothecin (CPT), a plant alkaloid that is found in the 
Chinese ornamental tree, Camptotheca acuminate. CPT was first discovered in the 
1960s and demonstrated positive anti-tumour effects in mice with experimental 
tumours.2 However, its clinical development was halted as it exhibited unpredictable 
and severe toxicity in both animal experiments3 and clinical trials.4-6  These 
unpredictable toxic effects were determined to be as a result of the water insolubility 
CPT exhibited.7 Therefore, CPT is not utilised as a clinical chemotherapeutic. 
However, an analogue with increased water solubility and more predictable toxicity 
was created, which led to the development of IR (Figure 4.1).8, 9 IR demonstrated 
potent anti-tumour activity in multiple murine models10-12 and became commercially 
available in Japan (1994) for the treatment of lung, cervical and ovarian cancers, and 
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soon after gained approval for treatment of metastatic colorectal cancer in the USA 
(1996).8 
 
Figure 4.1 Chemical structures of camptothecin (CPT) and irinotecan (IR). 
The use of IR prevents cells from dividing by inhibiting topoisomerase I, a nuclear 
enzyme.13 More specifically, it prevents the DNA from re-ligating by binding to 
topoisomerase I through hydrogen bonding, therefore causing DNA damage and 
resulting in apoptosis. However, IR itself actually possesses limited anti-tumour 
activity and its pharmacological profile is dependent on an extensive and complex 
metabolic conversion in vivo by varying enzyme systems (Figure 4.2).  
 
Figure 4.2 Metabolic pathway of IR showing the esterase mediated formation of the active metabolite SN-38 and 
its subsequent conversion to a glucuronide derivative (SN-38G) by enzymes UGT1A and 1A7. SN-38G can undergo 
deglucuronidation by β-glucuronidase. IR can also undergo enzyme mediated oxidation to form APC and NPC, the 
latter can be hydrolysed by carboxylesterase to form SN-38. Figure adapted from reference.7   
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The enzymatic hydrolysis of IR in the liver by carboxylesterase leads to the formation 
of the active metabolite, SN-38, which is 100-1000 times more potent than IR.14 
Unfortunately, only 1-9% of an injected dose of IR is converted to SN-38 in humans 
due to the low rates of carboxylesterase mediated cleavage which occurs in the 
liver.15, 16  
IR is also metabolised by cytochrome enzymes into less active metabolites, 7-ethyl-
10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin (APC) and 
7-ethyl-10-[4-amino-1-piperidino] carbonyloxycamptothecin (NPC). The latter can be 
further converted to SN-38 by carboxylesterase. SN-38 is inactivated by 5′-
diphospho-glucuronosyltransferase enzymes (UGT) into SN-38G, which increases the 
polarity of the drug and promotes its elimination from the body.17  
 
The high potency of SN-38 makes it a highly desirable chemotherapeutic for the 
treatment of lung, ovarian, breast and colorectal cancer, but the clinical applications 
have been significantly limited due to the poor solubility in aqueous solutions 
(< 5 µg mL-1)18, 19 and most pharmaceutically accepted solvents.20 However, the 
preparation of SN-38 within DDS offers an opportunity to formulate and evaluate it 
as a directly administrated therapy.  
4.1.2 SN-38 Nanoformulations  
Currently, SN-38 is not directly administered due to its hydrophobic nature. In 
addition, SN-38 also possesses pH sensitivity, whereby SN-38 is converted from 
closed-lactone ring form to the open carboxylate form at physiological pH, the latter 
of which is inactive (Figure 4.3).21 The rate of this hydrolysis is dependent on pH22, 
ionic strength23 and protein concentration.24, 25 This consequently limits its clinical 
application. 
 




Figure 4.3 Conversion of the lactone and carboxyl forms of SN-38. 
The preparation of SN-38 DDS is fairly limited as a consequence of these factors; 
however, a variety of different DDS have been developed and reported, which 
include polymer-drug conjugates,26, 27 liposomes,28-30 micelles31, and polymer 
nanoparticles.32-35  
Perhaps the most significant DDS of SN-38 to date is NK012, which has been 
evaluated in Phase II clinical trials.36  NK012 is a micellar formulation of SN-38, which 
was prepared by the self-assembly of a PEG-poly(glutamic acid)  based block 
copolymer. Binding of SN-38 to the poly(glutamate) block via an ester bond saw SN-
38 incorporated at ca. 20% (w/w), and generated mean particle sizes of 20 nm with 
narrow size distributions.  Release rates of SN-38 were determined in PBS at 37 °C, 
and were 57% and 74% at 24 and 48 hours, respectively. In comparison to treatment 
with IR, NK012 demonstrated significantly greater anti-tumour activity in a wide 
variety of pre-clinical experimental tumours such as: lung,36-38 pancreatic,39 renal,40 
gastric,38 and colorectal cancer.41 Another polymer-drug conjugate that progressed 
to Phase I clinical trials is EZN-2208, synthesised via PEGylation of SN-38 with drug 
loadings between 2.5-3.7 wt.%, which showed potent in-vitro cytotoxicity against 
human cell lines.42, 43 
Alternatively, there have been reports of SN-38 loaded polymer nanocarriers, which 
have been prepared via different methods including thin film hydration44 or 
nanoprecipitation.25, 26 Whereas, Roger et al formulated SN-38 within a liposomal 
formulation using a variety of different excipients, which had a mean particle size of 
40 nm and a drug loading of approximately 0.43 mg g-1; release of SN-38 was 
determined to be 10% after 6 hours at pH 1.2.45 Gu et al described loading SN-38 into 
micelles (ca. 125 nm) consisting of Pluronic F-108 and p(PEG114-b-PCL), at an 
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estimated drug loading of 20 wt.%. Release of SN-38 was determined to be < 68% in 
PBS after 24 hours.31 Polymer nanoparticles prepared from PLGA and a PVA stabiliser 
with a drug loading of approximately 6 wt.% SN-38  and an average diameter of 170 
nm have also been reported.16 Although, the preparation of these required the 
presence of DMSO as a co-solvent to increase SN-38 solubility.    
Each of these different strategies have their own merits and demerits. For example, 
polymer-drug conjugates improve the drug bioavailability, but the preparation 
involves multiple complex reaction steps, which in-turn can result in low product 
yields. Co-nanoprecipitation of hydrophobic branched vinyl copolymers and AB block 
copolymers, as previously demonstrated, offers a potentially facile way to 
incorporate hydrophobic guest molecules, which may in turn provide a route to 
encapsulate SN-38 at clinically-relevant drug loadings and offer sustained release 
profiles.    
4.1.3 Chapter Aim 
In Chapter 3, the preparation of sterically stabilised polymer nanoparticles with 
varying chemical composition was explored. It was highlighted that co-
nanoprecipitation was a versatile way of generating aqueous nanoparticle 
dispersions. It was also shown that the chemistry of both branched vinyl polymer and 
AB block copolymer had an influence on the nanoparticle properties, such as size, 
core polarity and stability. The ability to tune the chemistry means that the 
nanoparticle can be tailored for the encapsulation of a desired hydrophobic drug 
molecule.   This research chapter ultimately aims to assess and optimise the 
encapsulation capabilities of the co-nanoprecipitated materials explored in Chapter 
3 using the potent chemotherapeutic SN-38 and to assess the rate of drug release 
from the nanoparticles. These studies will determine the maximum drug loading of 
SN-38 attainable without causing significant disruption to the co-nanoprecipitation 
process or generating large quantities of un-encapsulated drug. The influence of 
different parameters that may modulate the drug loading, encapsulation efficiency 
(EE), such as polymer functionality and composition, and nanoprecipitation 
environment (pH), will also be studied. Following this, investigations will be 
conducted to determine whether encapsulating SN-38 within polymer nanoparticles 
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enables sustained release profiles by quantifying the release rate of SN-38 using 
radiometric analysis.  
4.2 Preparation of SN-38 Loaded Aqueous Nanoparticles  
Co-nanoprecipitation as a technique has been shown to produce sterically stabilised 
branched vinyl copolymer nanoparticles capable of encapsulating hydrophobic guest 
molecules (Chapter 3.6). Since SN-38 is a small hydrophobic guest, it is theorised that 
it could be encapsulated during the co-nanoprecipitation process. However, as 
previously discussed, SN-38 exhibits extremely limited solubility in most organic 
solvents and the solubility is limited to acetonitrile, dimethyl sulfoxide (DMSO) and 
THF. The 1H-NMR and 13C-NMR analysis of SN-38 in deuterated DMSO is presented 
in the Appendix, Figure A32 & A33. SEM analyses of the sole nanoprecipitation of SN-
38 [1 mg mL-1] from THF (1 mL) into water (5 mL) shows the crystalline nature of the 
drug (Figure 4.4).  
 
Figure 4.4  SEM images of nanoprecipitated SN-38 from THF into water.  
4.2.1 Preparation of SN-38 Loaded Aqueous Nanoparticles via Co-
nanoprecipitation 
SN-38 encapsulation experiments were conducted by the co-nanoprecipitation of 
branched vinyl polymers and AB block copolymers in the presence of SN-38. Since 
there was a large number of co-nanoprecipitation options, a standard set of 
conditions were determined for all co-nanoprecipitations involving SN-38. Following 
on from the successful conditions developed in Chapter 3.4, all of these 
co-nanoprecipitations were conducted from THF (1 mL, [P]o= 5 mg mL-1) into stirred 
water (5 mL, [P]f= 1 mg mL-1).  SN-38 was incorporated within the initial THF solution 
to target drug loadings of 2.5 and 5 wt.% wrt. the total solid mass. All co-
nanoprecipitations were conducted using a 60:40 wt.% composition of branched 
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vinyl polymer:AB block copolymer, respectively.  A general overview of the SN-38 
encapsulation experiments is presented in Figure 4.5.  
 
Figure 4.5 Schematic representation of the co-nanoprecipitation of branched vinyl copolymers and AB block 
copolymers with SN-38 to produce SN-38 loaded branched vinyl copolymer nanoparticles.  
In all cases, the addition of the polymer/SN-38 THF solution to water resulted in the 
instantaneous formation of a turbid mixture. The mixtures were left to stir for 24 
hours at ambient temperature to allow for the evaporation of THF. The success of 
the co-nanoprecipitations was determined initially by visual observations. There 
were 3 different observations made regarding the formulations. Firstly, there were 
formulations that showed macroscopic aggregation of polymer, suggesting the co-
nanoprecipitation had not been successful and that stable polymer nanoparticles had 
failed to be generated. Secondly, there were formulations that did not show 
macroscopic aggregation but appeared ‘opalescence’, which suggested that polymer 
nanoparticles had been formed but the encapsulation of SN-38 had not been entirely 
successful and instead ‘free SN-38’ (i.e. un-encapsulated SN-38) drug crystals may be 
present within the aqueous nanoparticle dispersions (Figure 4.6). SEM imaging of 
these samples confirmed this theory by showing the presence of polymer 
nanoparticles on large drug crystals (Figure 4.7). 




Figure 4.6 Photographs showing the opalescence appearance of several nanoformulations.  
 
Figure 4.7 SEM images of co-nanoprecipitations that were described as ‘opalescence’. The images show the 
successful formation of branched vinyl polymer nanoparticles but the unsuccessful encapsulation of SN-38.  
Thirdly, and most importantly, there were formulations that remained turbid without 
the presence of an ‘opalescence’ effect or macroscopic aggregation of polymer. This 
suggests that the encapsulation of SN-38 within branched vinyl polymer 
nanoparticles had been successful (Figure 4.8).  




Figure 4.8 Photographs showing (A) the successful encapsulation of SN-38 within branched vinyl polymer 
nanoparticles, and (B) its unsuccessful encapsulation, described as ‘opalescence’ in appearance.  
Based on these observations, it was clear that the success of the encapsulation 
experiments was dependent on the monomer residue functionalities of the AB block 
copolymers and branched vinyl copolymers, with HPMA monomer residue 
functionalities proving to be necessary for successful formulation. It is unclear why 
HPMA was important; however, the potential for strong hydrogen bonding may play 
a role in interacting with the drug and generating stabilisation or positive interactions 
that impeded macroscale phase separation. It is important to note that the presence 
of HPMA did not guarantee success.  
The DLS analyses of the aqueous nanoparticle dispersions are presented in Table 4.1. 
The DLS analyses revealed monomodal intensity-derived particle size distributions 
(with the exception of one), whereby the nanoparticles had hydrodynamic diameters 








Chapter 4  
167 
 
Table 4.1 DLS analyses of SN-38 loaded branched vinyl copolymer nanoparticle dispersions formed via co-
nanoprecipitation with varying AB block copolymers. Drug loadings of 2.5 and 5 wt. % wrt. total solid mass was 
targeted.  
These successful nanoprecipitates showed slight deviations in the hydrodynamic 
diameters and PDI values when compared to the blank nanoparticles (no SN-38) and 
the 1 wt.% pyrene loaded nanoparticles. In all cases the particle size increased and 
the particle size distribution became broader for the SN-38 loaded nanoparticles. This 
effect was more significant for the polymers with a short primary polymer chain 
length. For example, when comparing blank and SN-38 loaded co-nanoprecipitations 
of p(BuMA20-co-EGDMA0.85):p(PEG114-b-HPMA100), the Dz values increased from 
155 nm to 185 nm and the PDI values increased from 0.098 to 0.333 when SN-38 was 
encapsulated. Whereas, the same comparisons for p(BuMA100-co-
EGDMA0.95):p(PEG114-b-HPMA100) showed a small increase in Dz from 145 to 160 nm 
and the PDI showed minimal deviation from 0.088 to 0.099 when SN-38 was 
introduced into the co-nanoprecipitation. Again, the direct rationale for this 
behaviour is unclear. 
  AB Block Copolymer (40 wt.%) 






















5 Opalescence Polymer Aggregate 185 0.333 531 700 
p(EHMA20-co-
EGDMA0.80) 
5 Opalescence Polymer Aggregate 190 0.186 325 150 
p(HPMA20-co-
EGDMA0.85) 





160 0.099 771 100 





175 0.123 706 450 





5 Polymer Aggregate 
a Measured using DLS analysis at a concentration of 1 mg mL-1, Dz values have been rounded to the nearest 5 nm. 
*Non-monomodal size distribution obtained. 




Figure 4.9 DLS size distribution by intensity traces for SN-38 loaded polymer nanoparticles for i) p(BuMA100-co-
EGDMA0.95): p(PEG114-b-HPMA100) (2.5 wt. % SN-38), ii) p(EHMA20-co-EGDMA0.80): p(PEG114-b-HPMA100) (5 wt. % 
SN-38), iii) p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) (5 wt. % SN-38), and iv) p(EHMA100-co-EGDMA0.80): 
p(PEG114-b-HPMA100)  (2.5 wt. % SN-38).  
The SN-38 co-nanoprecipitations utilising p(PEG114-b-EHMA100) generated aggregates 
in all cases, with the exception of combinations containing p(HPMA100-co-
EGDMA0.90). This is in contrast to the blank and pyrene loaded co-nanoprecipitations 
with this AB block copolymer, which generated sterically stabilised nanoparticles. 
Clearly the incorporation of SN-38 has impacted the co-nanoprecipitation process of 
this material. The successful co-nanoprecipitation of p(EHMA20-co-
EGDMA0.85):p(PEG114-b-HPMA100) with 5 wt.% SN-38 was studied using SEM. The 
images obtained provided evidence for nanoparticle formation and showed that SN-
38 had been successfully encapsulated since there were no observable free drug 
crystals outside of the nanoparticles (Figure 4.10).  




Figure 4.10 SEM images showing the successful SN-38 encapsulation (5 wt.% drug loading) in p(EHMA20-co-
EGDMA0.85): p(PEG114-b-HPMA100) nanoparticles at 60:40 wt.% composition, respectively (SEM images obtained 
at 0.50 mg mL-1).  
4.2.2 Determining the Encapsulation Efficiency of SN-38 Co-nanoprecipitations  
When encapsulating SN-38 during a co-nanoprecipitation process it is assumed that 
all of the drug is located within the core of the branched copolymer nanoparticles. 
Clearly, it is desirable for this process to be as efficient as possible; however, it is likely 
that there are small amounts of SN-38 dissolved in the water at the concentration of 
its thermodynamic equilibrium solubility limit or drug crystals which have not been 
encapsulated and sedimenting from the saturated aqueous medium.  Therefore, 
quantitative analysis was required in order to evaluate the efficiency and success of 
the SN-38 encapsulations within the co-nanoprecipitations. The encapsulation 
efficiency (EE), as described in Equation 4.1, is the concentration of the incorporated 
material (SN-38) detected in the final formulation divided by the initial concentration 
used to make the formulation.  
EE (%)  = (
Mass of drug loaded in nanoparticles
Total mass of drug loaded 
) × 100                (4.1) 
EE was determined by measuring the concentration of SN-38 that remained within 
the final aqueous nanoparticle dispersion after the nanoparticles were filtered 
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through an Amicon® ultra-15 centrifugal spin filter tube (MWCO = 30 kDa) and 
centrifuged (6000 g for 1 hour at 20 °C). The final concentration of SN-38 was 
determined by monitoring the absorbance at 390 nm using UV-Vis spectroscopy after 
the water was removed by freeze drying, with a pre-established SN-38 calibration 
curve (Appendix, Figure A34). The calibration curve was prepared from 8 standard 
solutions with samples prepared by dissolving the appropriate mass of SN-38 in THF. 
A linear calibration plot for the above method was obtained over 0 μg mL-1 to 15 μg 
mL-1, with a correlation coefficient of 0.99.  
The EE was determined for the 2.5 wt.% SN-38 loaded p(BuMA100-co-EGDMA): 
p(PEG114-b-HPMA100) nanoparticles and both the 2.5 and 5 wt.% SN-38 loaded 
p(EHMA100-co-EGDMA):p(PEG114-b-HPMA100) nanoparticles. The determined EE 
values were greater than 98% in all 3 cases. These high values suggest that the SN-38 
encapsulation within the branched copolymer co-nanoprecipitates is highly efficient.  
4.2.3 Studying SN-38-loaded Nanoparticle Formation via DLS 
As stated earlier, co-nanoprecipitations containing SN-38 using the library of 
polymers synthesised in Chapter 2, led to either a clear failure, an opalescent 
dispersion or a turbid aqueous nanoparticle dispersion with no observable 
particulate material. To study the process of co-nanoprecipitation under these 
conditions, three combinations of branched and A-B block copolymers were selected 
with different loadings of SN-38. These were: 1) the opalescent combination of 
5 wt.% SN-38 loaded p(HPMA100-co-EGDMA0.90):p(PEG114-b-HPMA100), 2) the turbid 
combination of 5 wt.% SN-38 loaded p(EHMA100-co-EGDMA0.80):p(PEG114-b-
HPMA100),  and the unloaded comparison 3) p(HPMA100-co-EGDMA0.90):p(PEG114-b-
HPMA100).  
During the process of nanoprecipitation and solvent evaporation, DLS analysis was 
conducted on each sample and compared (Table 4.2).  The drug loaded p(EHMA100-
co-EGDMA0.80):p(PEG114-b-HPMA100) and unloaded p(HPMA100-co-EGDMA0.90): 
p(PEG114-b-HPMA100) co-nanoprecipitations followed a similar trend after addition to 
water and during the evaporation of THF, leading to monomodal size distributions. 
Specifically, the hydrodynamic diameters decreased steadily during THF removal 
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(Figure 4.11), starting at approximately 400 nm for the SN-38 loaded (EHMA100-co-
EGDMA0.80):p(PEG114-b-HPMA100) nanoparticles and ending at 180 nm. The unloaded 
particles comprising p(HPMA100-co-EGDMA0.90):p(PEG114-b-HPMA100) decreased 
from 110 nm to 70nm over the same timescale. The decrease is a result of the initial 
nanoparticles being swollen with good solvent and collapsing to a final more dense 
structure as the good solvent is removed. Observation of the same behaviour in 
presence and absence of SN-38 suggests that the drug substance is compatible with 
the nanopreciptation timescales, mechanism and environment within (EHMA100-co-
EGDMA0.80):p(PEG114-b-HPMA100) combination. Importantly, drug loaded 
nanoparticles do have a broader size distribution and a larger Dz value which may 
indicate that the polymer is not fully dominating the process and the drug compound 
is having a significant influence; however, the distribution was consistent during the 
evaporation stages. 
The behaviour of the p(HPMA100-co-EGDMA0.90):p(PEG114-b-HPMA100) 
nanoprecipitation in the presence of 5 wt% SN-38 is in stark contrast with both the 
unloaded combination and the loading of SN-38 into p(EHMA100-co-
EGDMA0.80):p(PEG114-b-HPMA100). Immediately after THF solution addition, a very 
broad distribution of particles was observed with hydrodynamic diameters of 
approximately 0.5 μm. The variation in observed hydrodynamic diameter during 
solvent evaporation was highly irregular although a general trend to smaller values 
was seen and sedimentation of unstable material was visually observed (Figure 4.12). 
This suggests a poorly compatible co-nanoprecipitation of polymer and drug, and 
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Table 4.2 DLS analyses of 5 wt.% SN-38 loaded p(HPMA100-co-EGDMA0.90): p(PEG114-b-HPMA100), p(EHMA100-co-
EGDMA0.80): p(PEG114-b-HPMA100) co-nanoprecipitate regimes and non-loaded p(HPMA100-co-EGDMA0.90): 
p(PEG114-b-HPMA100) co-nanoprecipitate over a period of 24 hours. 










0 110 0.055 66 350 
1 110 0.052 71 000 
2 100 0.043 43 100 
4 95 0.045 74 250 
5 95 0.042 33 500 
8 85 0.083 64 150 




0 400 0.188 18 900 
1 320 0.124 5200 
2 295 0.163 5600 
4 260 0.170 6400 
5 230 0.185 251 700 
8 235 0.206 122 800 




0 500 0.597 83 700 
1 1215 0.938 78 550 
2 600 0.620 76 300 
4 260 0.307 60 850 
5 415 0.498 62 600 
8 315 0.395 108 900 
24 130 0.287 69 850 
a Measured using DLS analysis at a concentration of 1 mg mL -1. 





Figure 4.11 Graphical representation of the changes in hydrodynamic diameter and PDI over 24 hours for A) non-
loaded p(HPMA100-co-EGDMA0.90): p(PEG114-b-HPMA100), B) 5 wt. % SN-38 loaded p(EHMA100-co-EGDMA0.80): 
p(PEG114-b-HPMA100) and C) 5 wt. % SN-38 loaded p(HPMA100-co-EGDMA0.90): p(PEG114-b-HPMA100) co-
nanoprecipitate regimes. 
 





Figure 4.12 A photograph of 5 wt.% SN-38 loaded p(HPMA100-co-EGDMA0.90): p(PEG114-b-HPMA100) co-
nanoprecipitate regime over 24 hours during THF evaporation.   
4.2.4 Stability of SN-38 Loaded Nanoparticles  
The colloidal stability of the SN-38 loaded nanoparticle formulations of p(BuMA100-
co-EGDMA0.95):p(PEG114-b-HPMA100) (2.5 wt.% SN-38) and p(EHMA100-co-
EGDMA0.80):p(PEG114-b-HPMA100) (2.5 and 5 wt.% SN-38) was studied by measuring 
the hydrodynamic diameter, PDI and derived count rate by DLS analysis over a total 
of 13 weeks of storage (Table 4.3).   
Table 4.3 DLS analyses of SN-38 loaded polymer nanoparticles sterically stabilised with AB block copolymer 
p(PEG114-b-HPMA100) over an extended period of time.  
Nanoparticle dispersions were stored under ambient conditions out of direct light. In 
general, monomodal size distributions were observed throughout the storage period 
(Figure 4.13) and the aqueous SN-38 loaded nanoparticle dispersions remained 











Day 1 Day 8 Day 91 Day 1 Day 8 Day 91 Day 1 Day 8 Day 91 
p(BuMA100-co-
EGDMA0.95) 
2.5 160 160 160 0.099 0.103 0.121 771 100 739 950 757 100 
p(EHMA100-co-
EGDMA0.80) 
2.5 175 175 170 0.123 0.117 0.103 706 450 836 900 767 000 
5 180 180 175 0.177 0.125 0.134 758 450 836 900 829 350 
a Measured using DLS analysis at a concentration of 1 mg mL -1. 




Figure 4.13 Overlaid DLS size distribution by intensity traces for SN-38 loaded polymer nanoparticles i) p(BuMA100-
co-EGDMA0.95): p(PEG114-b-HPMA100) (2.5 wt.% SN-38), ii) p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) (2.5 
wt.% SN-38) and iii) p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) (5 wt.% SN-38) from day 1, day 8 and 13 
weeks.  
There was almost no deviation in measured hydrodynamic diameter, PDI and derived 
count rate compared to the original samples that were measured.  These 
observations confirmed that the SN-38 loaded nanoparticles remained colloidally 
stable over extended periods of time, as observed for non-drug loaded nanoparticles 
(Chapter 3.5). The data suggests that the particles maintain their structural integrity 
during storage and, presumably, after administration which is clearly of importance 
for DDS. As a comparison, it has been shown that Doxil takes approximately 3-7 days 
for peak level of drug accumulation within a tumour46 and other literature reports 
have shown changes in DDS sizes in much shorter timeframes (< 7 days).47 Slight 
decreases in zeta potential values were observed for all 3 of the SN-38 loaded 
polymer systems from day 1 to day 91. For example, the zeta potential of p(BuMA100-
co-EGDMA0.95):p(PEG114-b-HPMA100) (2.5 wt.% SN-38) decreased from -7.29 mV (day 
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1) to -11.3 mV (day 91), and that of p(EHMA100-co-EGDMA0.80):p(PEG114-b-HPMA100) 
(5 wt.% SN-38) decreased from -12.4 mV (day 1) to -14.2 mV (day 91). These 
variations are too small to be considered significant. 
4.2.5 Reproducibility of SN-38 Loaded Nanoparticles  
Polymer nanoparticle production is often associated with having poor batch-to-batch 
variability. Clearly, this is a disadvantage for robust clinical translation as its poor 
reproducibility will potentially lead to variable pharmacokinetics. It was of 
importance to check the reproducibility of the SN-38 loaded polymer nanoparticles; 
therefore, three repeats of the 5 wt.% SN-38 loaded p(EHMA100-co-
EGDMA0.80):p(PEG114-b-HPMA100) co-nanoprecipitations (60:40 wt.%) were 
conducted under identical conditions, as previously described, but using three 
different stock solutions to model different manufacturing batches. In all cases, 
turbid aqueous nanoparticle dispersions were obtained, which were analysed via DLS 
and zeta potential measurements (Table 4.4). Monomodal size distributions were 
obtained in all cases, with identical hydrodynamic diameters (Dz = 180 nm) and the 
PDI values varied between 0.167 – 0.196. Zeta potential measurements were all 
consistent and in the range of -11.3 to -14.2 mV. The results that were obtained 
suggest that there is very little batch-to-batch variability between the polymer 
nanoparticles and their physical characteristics.   
Table 4.4 DLS and zeta potential analyses of 5 wt. % SN-38 loaded p(EHMA100-co-EGDMA0.80): p(PEG114-b-
HPMA100) nanoparticles that were prepared from three different stock solutions.  
4.2.6 Preparation of SN-38 Loaded Nanoparticles Using Statistical Branched 
Copolymers  
The effect of the branched copolymer composition on the degree of SN-38 















1 180 0.167 628 900 -11.3 
2 180 0.189 744 600 -12.4 
3 180 0.196 699 750 -14.2 
a Measured using DLS analysis at a concentration of 1 mg mL -1.Dz values have been rounded to the nearest 5 nm. 
b Obtained via measurement of the electrophoretic mobility of aqueous nanoparticle dispersions within zeta cell.  
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the co-nanoprecipitation process whilst targeting a 5 wt.% drug loading. For these 
experiments, the following SN-38 encapsulated co-nanoprecipitated particles were 
targeted: 1) p(BuMA50-s-EHMA50-co-EGDMA0.95), 2) p(BuMA50-s-HPMA50-co-
EGDMA0.90) and 3) p(HPMA50-s-EHMA50-co-EGDMA0.95). All were co-nanoprecipitated 
with 3 AB block copolymers: p(PEG114-b-BuMA100), p(PEG114-b-EHMA100) and 
p(PEG114-b-HPMA100) (Figure 4.14).   
 
Figure 4.14 Schematic representation of the co-nanoprecipitation of branched statistical copolymers and AB 
block copolymers with SN-38 to produce SN-38 loaded branched vinyl copolymer nanoparticles. 
SN-38 was prepared, as before, in a THF stock solution (1 mg mL-1) that was allowed 
to equilibrate for 24 hours before addition to the polymer-THF solutions. When this 
polymer/SN-38 THF stock was co-nanoprecipitated into water, the concentrations of 
the polymer and drug were [P]f = 1 mg mL-1 and [SN-38] = 0.05 mg mL-1. In all cases, 
the addition of the polymer/SN-38 THF solution resulted in the instantaneous 
formation of a turbid mixture. The mixtures were left to stir for 24 hours at ambient 
temperature for THF evaporation and the success of the co-nanoprecipitation was 
determined by visual observations as previously described. All samples co-
nanoprecipitated with p(PEG114-b-EHMA100) resulted in the formation of visual 
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aggregation, as previously observed (Chapter 4.2.1). In all other cases, except for 
p(BuMA50-s-HPMA50-co-EGDMA0.90):p(PEG114-b-HPMA100), the co-nanoprecipitations 
resulted in the formation of an opalescent sample, suggesting that the formation of 
polymeric nanoparticles but the inefficient encapsulation of SN-38. These samples 
were analysed via DLS for information (Table 4.5). 
Table 4.5 DLS analyses of 5 wt.% SN-38 loaded statistical branched copolymers co-nanoprecipitated with varying 
AB block copolymers (60:40 wt.% respectively). 
The hydrodynamic diameters obtained for these opalescent samples ranged 
between 100 ≤ Dz ≤ 180 nm and the recorded PDI values were relatively high 
(PDI ≥ 0.250). In addition, all samples also contained a secondary peak in the particle 
size distribution at approximately 5 µm, although the intensity of this peak was 
significantly less than that of the main population.  
The SN-38 loaded p(BuMA50-s-HPMA50-co-EGDMA0.90):p(PEG114-b-HPMA100) sample 
produced nanoparticles with a monomodal size distribution, hydrodynamic diameter 
of 120 nm and a PDI of 0.073. Long term stability (> 70 days) was also seen for this 
sample, as shown by the negligible deviation in hydrodynamic diameter (Figure 4.15). 
This is an interesting observation since the corresponding homopolymers did not 
successfully encapsulate 5 wt. % SN-38 under the same conditions. This further 
  AB Block Copolymer (40 wt.%) 


































5 100 0.318* 139 200 Polymer Aggregate 165 0.258* 399 200 
a Measured using DLS analysis at a concentration of 1 mg mL -1. * Sample was opalescent and secondary peak present within 
particle size distribution. 
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suggest that the environment of the core of the nanoparticles is very important for 
the successful encapsulation of SN-38. 
 
Figure 4.15 Overlaid DLS size distribution by intensity for 5 wt.% SN-38 loaded p(BuMA50-s-HPMA50-co-
EGDMA0.90): p(PEG114-b-HPMA100) 60:40 wt. % respectively at day 0 and day 70.  
 
4.2.7 Preparation of SN-38 Loaded Nanoparticles Using EHMA Based Branched 
Polymers with Varying Divinyl Monomer Chemistries 
The encapsulation of SN-38 within branched copolymers consisting of EHMA 
monomer residues at DP 20 and 100 but with varying divinyl monomer residue 
chemistry was also studied to understand the potential role for drug 
compatibilization by the branching monomer. Co-nanoprecipitations were 
conducted as before with p(PEG114-b-HPMA100) as the stabilising block copolymer and 
a ratio of branched copolymer:AB block polymer of 60:40 wt.%. All of the co-
nanoprecipitations were successful in forming colloidally stable nanoparticles 
encapsulating 5 wt.% SN-38. Analysis via DLS showed monomodal particle size 
distributions for all of the aqueous nanoparticle dispersions (Table 4.6).   
Chapter 4  
180 
 
Table 4.6 DLS and zeta potential analyses of 5 wt.% SN-38 loaded aqueous nanoparticle dispersions produced via 
co-nanoprecipitation of the AB block copolymer, p(PEG114-b-HPMA100), with branched p(EHMA) varying in divinyl 
monomer residue chemistry of with varying primary polymer chain length of DP20 and DP100 monomer units. 
Drug-loaded nanoparticle dispersions were produced with similar hydrodynamic 
diameters (180 ≤ Dz ≤ 195 nm) and polydispersity values (0.200 ≤ PDI ≤ 0.296). 
Comparing these hydrodynamic diameters with that of their unloaded counterparts 
showed only minor differences in particle size.  In all cases, the obtained zeta 
potential values were relatively low (-13.8 to -20.8 mV), which indicates that colloidal 
stability was achieved primarily through steric stabilisation. Again, when compared 
to the range obtained for the comparative blank (no SN-38) polymer nanoparticles 
(-8.58 to -13.5 mV), a slight decrease (i.e. more negative) zeta potential was 
observed, although these differences are not highly significant. This may be due to a 
portion of SN-38 present on the surface of the nanoparticles. Due to the equilibrium 
between the two forms of SN-38, closed lactone and open carboxylate, this in turn 
may increase the concentration of charged groups that exist at the nanoparticle 
surface.   
 PEG114-b-HPMA100 
Polymer Composition SN-38 wt. % 
Dz 






p(EHMA100-co-BPDMA0.85) 5 195 0.279 447 000 -14.4 
p(EHMA100-co-GDMA0.85) 5 185 0.234 821 300 -20.4 
p(EHMA100-co-BPGDMA0.80) 5 180 0.238 806 150 -15.9 
p(EHMA100-co-UDMA0.85) 5 190 0.243 693 850 -15.8 
p(EHMA100-co-DSDMA0.75) 5 190 0.200 781 150 -13.8 
p(EHMA20-co-BPDMA0.85) 5 180 0.258 455 300 -14.1 
P(EHMA20-co-GDMA0.85) 5 185 0.296 673 900 -16.3 
p(EHMA20-co-BPGDMA0.80) 5 180 0.202 729 500 -14.6 
p(EHMA20-co-UDMA0.85) 5 195 0.270 759 000 -15.5 
p(EHMA20-co-DSDMA0.75) 5 180 0.221 511 300 -20.8 
aMeasured using DLS analysis at a concentration of 1 mg mL-1. b Obtained via measurement of the electrophoretic mobility 
within zeta cell.   
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4.3 Optimising Drug Loading with Co-nanoprecipitated particles 
When considering DDS and how effective they are, drug loading is one of the key 
characteristics which should be considered. Drug loading refers to the mass of drug 
present with respect to the total mass of solids which contribute to making polymer 
nanoparticles. The drug loading can be influenced by the physical and chemical 
properties of the DDS and, ideally, the drug loading should be as high as possible. 
High drug loadings, have a range of advantages such as: lower administered dosing 
volume and a lower concentration of excipients/polymers relative to the dosed drug.  
Additionally, a high drug loaded nanoparticle dispersion can deliver more active drug 
to the tumour per particle and may offer improvements to the efficiency and 
efficacy.48 However, a challenge that is often associated with  polymer nanoparticles 
is the low drug loading values which plague their development. Often in literature, 
improvements to the drug loading have required different materials or excipients 
which can impart specific polymer-drug interactions such as donor-acceptor 
interactions49, hydrogen bonding50 and π–π interactions51.  In studies described 
above, drug loadings of 5 wt. % SN-38 have been achieved with the polymers studied 
here (Section 4.2.1); however, there is a need to establish the range of drug loadings 
that may be available in order to optimise the clinical relevance of the materials 
under investigation.  
4.3.1 Increased SN-38 Concentrations within the Co-nanoprecipitation   
To increase the drug loading of SN-38 within the polymer nanoparticles without 
material manipulation or compositional changes simply involved increasing the 
concentration of SN-38 within the SN-38/polymer THF stock solutions over a range 
of values. Since p(EHMA100-co-EGDMA0.80):p(PEG114-b-HPMA100) had proven 
successful with the incorporation of 5 wt.% SN-38, it was used to study whether 
higher drug loadings could be achieved. Co-nanoprecipitations were conducted as 
before using a range of targeted drug loadings: 2.5, 5, 6, 7.5, 10, 20 and 30 wt.%. 
Immediately following the addition of the stock solutions into water, the initial 
observations were that turbid dispersions were formed. However, after the 
evaporation of THF, visible differences between the samples were observed. Samples 
with drug loadings ≥ 10 wt.% had a white precipitate on the side of each vial, which 
became more significant as the targeted drug loading increased (Figure 4.16 iv and 
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v) and may be attributed to free SN-38 that was not successfully encapsulated within 
the polymer nanoparticles. This white precipitate was not observed for the samples 
with targeted loadings of ≤ 7.5 wt.% SN-38.  
 
Figure 4.16 Photographs of p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) co-nanoprecipitations targeting 
various drug loadings of SN-38, varying from i) 2.5, ii) 5, iii) 10, iv) 20 and v) 30 wt.% SN-38. 
The aqueous nanoparticle dispersions were analysed without filtration via DLS and 
zeta potential measurements (Table 4.5).  
Table 4.5 DLS analyses of p(EHMA100-co-EGDMA0.80) branched vinyl copolymer nanoparticle dispersions formed 
via co-nanoprecipitation with PEG114-b-p(HPMA)100. Drug loadings varied between 2.5 and 30 wt.% wrt. total solid 
mass. 
Polymer Composition SN-38 (wt.%) 
Dz 
(nm)a PDIa 
Derived Count  
Rate (kcps) ζ(mV)b 
p(EHMA100-co-
EGDMA0.80) 
:  p(PEG114-b-HPMA100) 
2.5 175 0.123 706 450 -11.9 
5 180 0.164 760 300 -12.4 
6* 195 0.264 564 800 -12.5 
7.5* 215 0.288 771 550 -12.3 
10* 220 0.305 829 600 -12.6 
20* 245 0.481 774 300 -13.4 
30* 320 0.736 622 000 -14.9 
a Measured using DLS analysis at a concentration of 1 mg mL -1. b Obtained via measurement of the electrophoretic 
mobility in 0.01M KCl aqueous nanoparticle dispersions.  *DLS particle size distributions were not monomodal. 
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The results showed that as the targeted drug loadings increased from 2.5 to 30 wt.%, 
the Dz increased from 175 to 320 nm and the PDI increased from 0.123 to 0.736. It is 
worth highlighting that samples targeting ≥ 6 wt.% SN-38 did not possess monomodal 
particle size distributions, as there was a presence of additional peaks between 1000-
5000 nm (Figure 4.17). Although these additional peaks were representative of 
populations that are low in number, their intensities increased significantly as higher 
drug loadings were targeted and consequently had a greater bearing on the 
calculated PDI values. 
 
Figure 4.17 DLS analyses of the SN-38 loaded p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) at 60:40 wt. % co-
nanoprecipitate regimes with increasing drug loading from 2.5 - 30 wt. %. 
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The zeta potential measurements were in the range of -11.9 to -14.9 mV, which also 
increased in negativity as the drug loading increased but show no meaningful 
differences.   
The co-nanoprecipitates targeting the various drug loadings were also studied using 
SEM (Figure 4.18).  
 
Figure 4.18 SEM images of SN-38 loaded p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) at 60:40 wt. % co-
nanoprecipitate regimes. Images obtained of A+B) 5 wt.%, C+D) 7.5 wt.%, E+F) 10 wt.%, G-J) 20 wt.% and K-N) 30 
wt.%. 
Images obtained for the samples targeting ≤5 wt.% SN-38 showed near-spherical 
nanoparticles and SN-38 crystals were not observed, suggesting that the SN-38 
encapsulations had high efficiency and that there were very low concentrations of 
free SN-38 within the aqueous phase of the dispersion.  
This is consistent with the high encapsulation efficiency values that were determined. 
However, as the drug loading increased beyond 5 wt.%, long spindle-like crystals 
Chapter 4  
185 
 
appeared in addition to the polymer nanoparticles, the concentration of which 
increased as higher loadings were targeted. Whilst it is likely that these crystals are 
associated with SN-38 that had not been encapsulated and were present as drug 
crystals in the aqueous dispersion, the crystals could also be as a result of the drying 
phase of the SEM sample preparation.  
Although EE of these co-nanoprecipitations were not determined experimentally, the 
results of this study strongly suggest that the maximum drug loading that can be 
successfully achieved is 5 wt.% SN-38. When targeting loadings above this value, a 
limit to the encapsulation appears to be reached resulting in the formation of 
multiple populations comprising polymer nanoparticles and free drug crystals. The 
reasons for this failure may well be due to a saturation of the available polymer 
encapsulation capacity and the uncontrolled nucleation and growth of SN-38. 
Additionally, particle density has been reported to have an influence on the degree 
of encapsulation of hydrophobic guest molecules.52 Calculations completed by 
Ribeiro and co-workers on coumarin-6 loaded PCL nanoparticles suggest that the 
assemblies are loosely packed and represent soft structures compared to hard 
compact spheres. If this is applicable to the polymer system described here, and the 
polymer chains are loosely packed, they could be highly swollen by water molecules 
thereby limiting the degree of encapsulation of SN-38.  
4.3.2 Varying the Poor Solvent pH during Co-nanoprecipitation and its effects on 
the Drug Loading  
As previously discussed, SN-38 exists in an equilibrium between two forms at pH 7; a 
closed-ring lactone form and an open-ring carboxylate form. The lactone form is 
more hydrophobic than the carboxylate form and therefore, has a lower solubility in 
water.53, 54  It was hypothesised that through manipulating the pH of the water used 
in the co-nanoprecipitation process, this could impact the relative concentrations of 
these two forms; if the pH of the water was acidic, the closed-lactone ring would be 
present and its greater hydrophobicity would enhance the encapsulation of SN-38 
and potentially increase the drug loading. This hypothesis was tested by acidifying 
the aqueous poor solvent phase to pH 4 before conducting co-nanoprecipitations 
targeting a 5 wt.% SN-38 loading. However, the results in all cases caused a disruption 
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to the co-nanoprecipitation process and therefore wasn’t studied in any greater 
detail. It is not clear why the pH was so disruptive to the formation of 
nanoprecipitated particles; however, the presence of a small concentration of 
carboxylic acid groups may enable the stabilisation and compatibility of SN-38 during 
precipitation. 
4.3.3 Evaluation of SN-38 Pro drugs as options for increased Drug Loadings:  SN-38 
Pentanoate   
Within the literature it has been shown that specific chemical modifications of SN-38 
can result in enhanced solubility or lipophilicity of pro-drug formulations compared 
to their parent compound. These simple chemical modifications involved the 
esterification at the C10 position of SN-38 with different fatty acids of varying length 
of hydrocarbon chains.55  It was therefore hypothesised that such lipophilic pro-drugs 
of SN-38 may enable a more efficient encapsulation within the co-nanoprecipitation 
process and offer an opportunity to increase the drug loading of the active 
component, SN-38. This hypothesis was investigated by incorporating SN-38 
pentanoate within co-nanoprecipitations of the AB block copolymer, p(PEG114-b-
HPMA100), and various branched vinyl copolymers. SN-38 pentanoate was 
synthesised by Dr Andrew Dwyer through the esterification of SN-38 and valeroyl 
chloride in anhydrous THF, using 4-dimethylaminopyridine (DMAP) as a catalyst and 
N,N-diisopropylethylamine (DIPEA) as a base (Figure 4.20).  
 
Figure 4.20 Reaction scheme of the esterification of SN-38 to SN-38 pentanoate.  
Andrew is a post-doctoral research associate working in the department of chemistry 
at the University of Liverpool and was preparing such materials for the use in a 
different project. He kindly synthesised and supplied SN-38 pentanoate for the use 
within this experiment.  
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Co-nanoprecipitations were conducted with the following combinations of polymers: 
p(BuMA100-co-EGDMA0.95), p(EHMA100-co-EGDMA0.80) and p(HPMA100-co-EGDMA0.90) 
were each co-nanoprecipitated with the AB block copolymer p(PEG114-b-HPMA100) at 
a 60:40 wt.% composition. SN-38 pentanoate was incorporated into the co-
nanoprecipitations with a targeted drug loading of 2.5 and 5 wt.%. The SN-38 
pentanoate/polymer THF stock solution (1 mL) was added to stirred DI water (5 mL). 
Samples were left for 24 hours to allow for THF evaporation. After evaporation, those 
samples that did not contain any visible aggregation were analysed via DLS and zeta 
potential measurements (Table 4.6).  
Table 4.6 DLS analyses of SN-38 pentanoate loaded branched vinyl copolymer nanoparticle dispersions formed 
via co-nanoprecipitation with AB block copolymer, p(PEG114-b-HPMA100). Targeted drug loadings of 2.5 and 5 
wt.% wrt. total solid mass. 
SN-38 pentanoate loaded branched vinyl nanoparticles were produced with 
hydrodynamic diameters in the range of 155 ≤ Dz ≤ 180 nm and PDI values between 
0.092 – 0.190. The co-nanoprecipitate of p(EHMA100-co-EGDMA0.80) with 2.5 wt.% 
SN-38 pentanoate was successful and produced a monomodal size distribution with 
a low PDI value of 0.092 (Figure 4.21A). Interestingly, however, the co-
nanoprecipitation with 5 wt.% SN-38 pentanoate did not yield an aqueous 
nanoparticle dispersion, but instead visible aggregation was observed. This 
observation was surprising for this co-nanoprecipitate regime since it has already 
been shown that 5 wt. % of the parent drug SN-38 could be incorporated. This may 
suggest that the phenol ring may play a role in making the drug compatible with the 
EHMA core, although it is unclear why. 











2.5 155 0.092 801 500 -14.3 
p(BuMA100-co-
EGDMA0.95)* 
2.5 160 0.145 816 350 -15.2 
p(BuMA100-co-
EGDMA0.95)* 
5 180 0.190 855 150 -16.3 
a Measured using DLS analysis at a concentration of 1 mg mL-1. Dz values obtained have been rounded to the nearest 5 
nm. *Secondary peak present on size distribution by intensity (Figure 4.21B). 
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Co-nanoprecipitates with p(BuMA100-co-EGDMA0.95) targeting both 2.5 and 5 wt.% 
SN-38 pentanoate produced near monodisperse particles, but with the presence of 
small secondary peaks representative of populations with hydrodynamic diameters 
> 5000 nm (Figure 4.21B). The intensity of which increased as the pro-drug loading 
increased from 2.5 to 5 wt.%, suggesting that the encapsulation of SN-38 pentanoate 
within this co-nanoprecipitate combination was also not optimum. 
 
Figure 4.21 DLS size distribution by intensity traces for SN-38 pentanoate loaded polymer nanoparticles for A) 
p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA)100 (2.5 wt.% SN-38 pentanoate) and B) p(BuMA100-co-EGDMA0.95): 
p(PEG114-b-HPMA)100 2.5 wt.% (blue, dashed line) and 5 wt.% SN-38 pentanoate (pink, solid line).  
Both the targeted 2.5 and 5 wt.% SN-38 pentanoate loadings failed to produce 
nanoparticles (i.e. aggregation was observed) with the p(HPMA100-co-EGDMA0.90) co-
nanoprecipitate regime, which was an interesting observation since p(HPMA100-co-
EGDMA0.90) has been shown to both solely nanoprecipitate and co-nanoprecipitate 
successfully, presumably due to its charge stabilisation. 
Although SN-38 pentanoate was successfully encapsulated within 2 different co-
nanoprecipitate regimes with a maximum drug loading that matched that of SN-38, 
the difference in mass of the active component did not make the pro-drug approach 
particularly viable or attractive i.e. 5 wt. % SN-38 pentanoate does not equal 5 wt. % 
SN-38. Therefore, further studies with more lipophilic pro-drugs were not 
undertaken. 
4.4 Increasing the Concentration of SN-38 via Multiple Co-nanoprecipitation   
SN-38 was successfully loaded at 5 wt.% into branched p(EHMA) based systems 
(Section 4.2.1) but attempts to increase the drug loading were unsuccessful and had 
a negative impact on the efficiency and simplicity of the co-nanoprecipitation process 
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(Section 4.3). When evaluating the viability of these DDS and their potential 
application within a clinical setting, there are three key factors that need to be 
considered: 1) drug loading, 2) efficiency of drug loading and 3) the administration 
dose.  
The drug loading achieved within the co-nanoprecipitate regimes appeared modest, 
but SN-38 is a very potent chemotherapeutic agent and is not currently administered 
in clinical practice. Therefore, these systems may still be an attractive option for 
clinical treatments.  The candidate therapies containing 5 wt.% drug loaded 
nanoparticles offered an SN-38 concentration of 0.050 mg mL- 1. Increasing this 
concentration without having to adapt the drug loading of the branched vinyl 
copolymer nanoparticles will only strengthen the attractiveness of the system from 
a pharmacological perspective as the administered dose required for therapy would 
be reduced. 
Ford et al. demonstrated that co-nanoprecipitations involving multiple additions of a 
polymer solution to a single aqueous phase was possible. This multiple co-
nanoprecipitation generated higher concentrations of branched vinyl copolymers 
within the water phase without any significant impact to the nanoparticle size, but 
slight increase on particle size distribution which increased from 0.08 to 0.103.56 This 
is likely due to the fact that the nanoparticle growth is terminated via the steric 
stabilisation mechanism. Multiple additions of polymer and drug stock may be an 
attractive way to increase the drug concentration within the aqueous polymeric 
nanoparticle system without having to alter the drug loading capabilities of the 
polymer nanoparticles. Therefore, the multiple co-nanoprecipitation of 5 wt.% SN-
38 loaded p(EHMA20-co-DSDMA0.80):p(PEG114-b-HPMA100) nanoparticles was 
attempted for the first time. The selection of this specific formulation will be 
discussed in Chapter 5. 
The conditions of the multiple co-nanoprecipitations were kept consistent with 
previous experiments. The first addition of SN-38/polymer THF stock solution ([P]0 = 5 
mg mL- 1, [SN-38]0 = 0.25 mg mL-1) was rapidly added to stirred DI water (5 mL) to give 
aqueous SN-38 loaded branched vinyl copolymer nanoparticles ([P]f = 1 mg mL- 1, and 
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final SN-38 concentration, [SN-38]f = 0.05 mg mL-1). Following THF evaporation 
overnight, the co-nanoprecipitation was analysed via DLS. The subsequent additions 
were carried out into the same SN-38 loaded aqueous nanoparticle dispersions a 
further three times to yield aqueous SN-38 loaded branched vinyl copolymer 
nanoparticles ([P]f = 4 mg mL- 1, [SN-38]f = 0.20 mg mL-1). These turbid aqueous 
nanoparticle dispersions were assessed via DLS at a concentration of [P]f = 1 mg mL-
1 following every addition (Table 4.7).  It is worth noting that after the first addition, 
[P]f = 1 mg mL-1, so DLS is obtained as normal. However, following the second, third 
and fourth addition [P]f increases to 2, 3 and 4 mg mL-1 respectively. The aliquot of 
the nanoparticle dispersion used for DLS analysis was diluted as required and the 
aqueous nanoparticle dispersion was topped up by mass to 5 mL by mass before the 
next addition of polymer/drug stock solution to ensure a constant volume.  
Table 4.7 DLS analyses of 4 sequential multiple co-nanoprecipitations for 2 individual samples of p(EHMA20-co-
DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% and 5 wt.% SN-38 loaded for p(EHMA20-co-DSDMA0.80): p(PEG114-b-
HPMA100) 60:40 wt. %.  
 
 

















5 wt.% SN-38 
1 160 0.173 797 700 170 0.229 783 200 
2 165 0.269 513 800 165 0.205 747 300 
3 175 0.217 773 000 185 0.219 716 300 
4 185 0.233 626 750 185 0.204 534 400 
No Drug 
1 115 0.055 460 000 120 0.036 469 900 
2 140 0.079 466 050 140 0.075 826 250 
3 145 0.058 426 500 145 0.058 739 450 
4 150 0.072 594 800 155 0.116 697 500 
a Measured using DLS analysis at a concentration of 1 mg mL -1 
The recorded Dz values were similar for all four of the additions of the 5 wt.% SN-38 
loaded nanoparticle regimes with an observed increase from 160 to 185 nm for 
sample 1 and from 170 nm to 185 nm for sample 2 after the 1st to the 4th addition, 
respectively (Figure 4.22).  




Figure 4.22 Graphical representation of the changes in hydrodynamic diameter for 5 wt.% SN-38 loaded 
p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% following 4 sequential additions of 2 different 
samples: sample 1 (red triangles) and sample 2 (black circles).  
There were also some small changes in the PDI values recorded, but the data suggests 
that multiple additions of SN-38/polymer THF stock solutions are forming new 
nanoparticle populations and are not causing disruption to the pre-existing 
population. This is validated by observations when the same co-nanoprecipitate 
regime was investigated following multiple co-nanoprecipitation in the absence of 
SN-38.  
 
Figure 4.23 Overlaid DLS size distributions for the four sequential co-nanoprecipitations of A) p(EHMA20-co-
DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% and B) 5 wt.% SN-38 loaded p(EHMA20-co-DSDMA0.80): p(PEG114-b-
HPMA100) 60:40 wt.%. 1st addition (black line), 2nd addition (blue line), 3rd addition (red line) and 4th addition (black 
dashed line). 
The derived count rate appears to remain consistent despite the polymer 
nanoparticle concentration increasing, which may seem counter-intuitive since the 
derived count rate is a calculated parameter that calculates the number of photons 
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detected. Given that the light scattered is directly proportional to the size and 
number of particles present in a sample, it would be expected that this would 
increase consistently during the multiple co-nanoprecipitation process. However, it 
is worth reiterating that these DLS measurements of the multiple co-
nanoprecipitations were all conducted at the same concentration of 1 mg mL-1, since 
the samples prepared were extremely turbid (Figure 4.24).  
 
Figure 4.24 Photographs of A) p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% sample 1 (Ai) and 
sample 2 (Aii), and B) 5 wt.% SN-38 loaded p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% sample 1 
(Bi) and sample 2 (Bii) after four sequential co-nanoprecipitations.  
The SEM images obtained after the 1st addition and 4th addition of the SN-38/polymer 
THF stock solution showed that a homogenous population of polymer nanoparticles 
was maintained throughout the study (Figure 4.25). 
 
Figure 4.25 SEM images of 5 wt.% SN-38 loaded p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) following i) initial 
first addition co-nanoprecipaiton, ii) and iii) after the fourth addition co-nanoprecipitation.  
The stability of samples generated by multiple co-nanoprecipitation was measured 
over an 8-week period via DLS following storage of samples under ambient  
conditions (Table 4.8). 
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Table 4.8 DLS analyses over an 8-week period to determine the stability of 2 individual samples: p(EHMA20-co-
DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% and 5 wt.% SN-38 loaded p(EHMA20-co-DSDMA0.80): p(PEG114-b-
HPMA100) 60:40 wt.%. 
 

















0 150 0.072 594 800 155 0.116 697 500 
1 150 0.077 668 000 150 0.096 701 350 
3 155 0.106 663 000 155 0.116 693 550 
5 150 0.084 502 250 155 0.071 605 500 
8 150 0.094 482 100 155 0.063 651 100 
 
5 wt.% SN-38 loaded 
p(EHMA20-co-DSDMA0.80): 
p(PEG114-b-HPMA100) 
0 185 0.233 626 750 185 0.204 534 400 
1 175 0.132 604 700 175 0.132 638 250 
3 170 0.083 564 250 190 0.208 675 900 
5 170 0.085 541 900 180 0.088 478 350 
8 175 0.105 514 600 180 0.160 511 800 
a Measured using DLS analysis at a concentration of 1 mg mL-1, Dz values obtained have been rounded to the nearest 5 nm. 
Minimal changes were observed for the measurements of the hydrodynamic 
diameter over the 8-week period (Figure 4.26).  
 
Figure 4.26 Graphical representation of the changes in hydrodynamic diameter over 8 weeks via DLS of 
p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% sample 1 (black, closed circle), sample 2( red, open 
circle) and 5 wt.% SN-38 loaded p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) 60:40 wt.% sample 1 (green, 
closed squares) and sample 2 (blue, open squares).  
Monomodal size distributions were obtained for the blank (no SN-38) p(EHMA20-co-
DSDMA0.80):p(PEG114-b-HPMA100) co-nanoprecipitates (Figure 4.27A). However, a 
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small secondary population ≥ 5000 nm was observed for 5 wt.% SN-38 loaded 
p(EHMA20-co-DSDMA0.80):p(PEG114-b-HPMA100) co-nanoprecipitate on the 3-week 
and 8-week measurements (Figure 4.27B). This secondary peak may be 
representative of SN-38 drug crystals that had formed during storage and it is 
important to note that after 5 weeks of sample storage, a cream coloured sediment 
was evident at the bottom of the vials, suggesting that these secondary populations 
were not stable within the dispersion (Appendix, Figure A.35). 
 
Figure 4.27 Overlaid DLS size distribution by intensity traces for A) p(EHMA20-co-DSDMA0.80): p(PEG114-b-
HPMA100) co-nanoprecipitate regime and B) 5 wt.% SN-38 loaded p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) 
co-nanoprecipitate regime measured over 8 weeks.  
The ability to increase the concentration of SN-38 loaded polymer nanoparticles via 
sequential low volume additions of the polymer-drug stock solution, coupled with 
extended stability, is very appealing. Especially since the concentration of SN-38 has 
been increased by a factor of four whilst maintaining a constant volume of water. 
This methodology is very attractive and generates an opportunity to create materials 
that can be taken forward and analysed in in vivo studies.  
4.5 Quantitative Analysis of SN-38 Release from Branched Vinyl Copolymer 
Nanoparticles Using Tritium Labelled SN-38 
One of the leading advantages of DDS from a pharmacological perspective is the 
opportunity to offer controlled drug release. It is highly desirable that the drug 
release from a DDS is slow and sustained. This temporal control provided by DDS can 
potentially allow for the maintenance of therapeutic and efficacious drug 
concentrations in the blood or at the targeted tissues.  If the release of the drug is 
too fast, this can result in a large concentration of the drug being released from the 
DDS in a short time, which is often referred to as a burst release. Such release could 
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result in premature clearance of the drug, off-site toxicities, and reduced efficacies 
as a result of inadequate concentrations of drug reaching the target tissues.  Whereas 
if the release of the drug is too slow, then the DDS could potentially be cleared from 
the body before depositing a therapeutic concentration of the drug.  
Given that the successful encapsulation of SN-38 within branched vinyl co-polymer 
nanoparticles formed via co-nanoprecipitation had been demonstrated, this offered 
the opportunity to study the release rates of SN-38 from the polymer nanoparticles. 
Therefore, release experiments were conducted to observe the release behaviour of 
SN-38 from the polymer nanoparticles.  A number of different experimental methods 
have been used for the determination of drug release profiles from dispersed 
systems including, sample and separate, continuous flow and dialysis membrane 
methods. (ref) These are typically used in combination with an analytical technique, 
such as UV-Vis spectroscopy which can be used to quantify drug concentrations.  
 Radiolabelling of SN-38 with Tritium (3H) and subsequent membrane dialysis coupled 
with liquid scintillation counting (LSC) also offers as a quantitative analytical 
technique that can be used to accurately detect concentrations of SN-38. 3H is a beta 
(β) emitting radio nuclide, which exhibits low energy (0.0186 MeV) and has a half-life 
of > 12 years. Since the β emission is of low energy, this results in low penetration 
distances in air from emitted electrons and an inability to penetrate through the top 
layer of any exposed skin. All experiments conducted using 3H-labelled SN-38 
required basic radiation protection training at the University of Liverpool and all 
experiments were conducted within the Rannard Group Radio Materials Laboratory 
under the supervision of an accredited radiation protection supervisor, Dr Helen 
Cauldbeck. The high accuracy and precision that accompanies radiometric analysis 
means that EE, drug loading and drug release rates can be accurately determined. 
4.5.1 Quantification of SN-38 Encapsulation Efficiency and Drug Loading Achieved 
During Nanoparticle Formation via Co-Nanoprecipitation  
The use of radio-experiments and LSC for the monitoring of SN-38 release allows for 
the detection of extremely low concentrations and highly accurate quantification due 
to the highly sensitive nature that is associated with experiments using radio-labelled 
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molecules. The intensity of β-emissions that are emitted from 3H nuclei per unit mass 
is referred to as the specific activity (SA). Using LSC, the total radiation (TR) from a 
sample is detected. The relationship between TR, mass of SN-38 and the SA is 
presented in Equation 4.2. This allows for the SN-38 mass to be calculated at any 
given time point.  
 
Mass of SN-38(mg) = TR (µCi) SA (µCi mg−1⁄ )  (4.2) 
Co-nanoprecipitations were conducted using 3H-labelled SN-38 containing SA ranging 
from 31.16 - 38.67 µCi mg-1. The co-nanoprecipitations for the radio-dialysis 
experiments were conducted with various branched vinyl polymers in combination 
with p(PEG114-b-HPMA100) at a composition of 60:40 wt.%, respectively. Drug loading 
of SN-38 was fixed at 5 wt.% for all co-nanoprecipitate regimes. Co-
nanoprecipitations were left for 24 hours to allow for THF evaporation. DLS analysis 
and quantification of EE and drug loading were conducted on all the samples 
prepared using 3H-labelled SN-38 and are presented with the corresponding radio-
dialysis. Analyses by LSC were conducted on co-nanoprecipitates, which allowed for 
the quantification of the accurate mass of SN-38 present. Following this, 
centrifugation was conducted on an aliquot to separate the free SN-38 dissolved in 
the aqueous media from the nanoparticles. This allowed for the EE and drug loading 
to be quantified. 
4.5.2 Determining SN-38 Release Rates via 3H Radio-dialysis  
Radio-dialysis experiments were conducted to determine the percentage release of 
SN-38 from p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) nanoparticles over 24 
hours. Dialysis as mentioned, is a well-established and useful technique to determine 
in vitro release. These were conducted using 3H-labelled SN-38 within the co-
nanoprecipitation. The 3H-labelled SN-38 polymer nanoparticles (1 mL) were added 
to a double-sided bio-dialyser, which was sealed with a 3.5 kDa molecular weight cut 
off (MWCO) membrane. This bio-dialyser was then placed into a sealed reservoir 
(100 mL) of stirred DI water at 37 °C to ensure sink conditions (Figure 4.28).  
 




Figure 4.28 Schematic representation of how the release rate of SN-38 from branched vinyl copolymer 
nanoparticles were determined over time via radio-dialysis. Branched vinyl copolymer nanoparticles were loaded 
with 3H-labelled SN-38 and added into a bio-dialyser (3.5 kDa MWCO), which was placed in DI water and stirred 
under sink conditions.  
During the release experiment, the bio-dialyser was removed and transferred to 
fresh pre-heated reservoirs at regular time intervals of: 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 
24 hours. This ensured that sink conditions were maintained and that any hazards or 
risks associated with the use of radio-labelled SN-38 were minimised as the rigid 
structure of the bio-dialyser provides more secure containment of 3H-labelled SN-38. 
An aliquot (1 mL) was removed from each reservoir and added to a scintillation 
cocktail (10 mL) to enable LSC analyses of the 3H-labelled SN-38 within the aqueous 
solution. Measuring the activity at each time point enabled the mass of SN-38 to be 
determined following its release from the polymer nanoparticles. These values were 
then used to plot a cumulative release curve against time. Given the significant 
accuracy associated with LSC analyses, it was deemed unnecessary to run the 
measurements in triplicate.    
4.5.2.1 The Impact of pH on SN-38 Release Rates  
Given that SN-38 has pH dependant behaviour, it was of interest to understand 
whether this would impact the release of the SN-38 from the branched vinyl 
copolymer nanoparticles as studies have shown that the release of SN-38 from 
chitosan nanoparticles can be impacted by pH.57 The release of SN-38 from 
p(EHMA100-co-EGDMA0.80):p(PEG114-b-HPMA100) nanoparticles at pH7 and pH 4 was 
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studied by radio-dialysis using 3H-labelled SN-38. To enable this, a co-
nanoprecipitation was conducted in the exact same manner that has previously been 
described, with a composition of 60:40 wt.% branched vinyl polymer:AB block 
copolymer ratio but with the incorporation of 3H-labelled SN-38 at a drug loading of 
5 wt.%. A turbid aqueous nanoparticle dispersion was obtained and analysed via DLS. 
A monomodal size distribution was obtained with the hydrodynamic diameter (180 
nm) and PDI (0.178) values consistent with those previously obtained for this system 
when using unlabelled SN-38, suggesting that the encapsulation of 3H-labelled SN-38 
had been successful. The EE value was also determined (92 %), which corresponded 
to a drug loading of 4.78%, consistent with the 5 wt. % which was being targeted. The 
radio dialysis experiments were conducted as before after adjusting the pH of the 
aqueous medium to pH 4 and pH 7. The cumulative release plot showed that similar 
release profiles were obtained but the release rates were different for the 
experiments performed at the two different pH values (Figure 4.29). Release profiles 
were also determined at pH7 and pH4 for non-encapsulated SN-38 (Appendix, Figure 
A.36). 
Figure 4.29 Cumulative 3H-labelled SN-38 release (%) data obtained over 24 hours via radio-dialysis of 
Chapter 4  
199 
 
p(EHMA100-co-EGDMA0.80):p(PEG114-b-HPMA100) nanoparticles at pH 4 (black, closed circles) and pH 7 (red, 
open triangles) at 37 °C.  
The release of SN-38 after 24 hours at pH 7 was 14.2%, whereas the release of SN-38 
at pH 4 after 24 hours was 17.3%. It can be postulated that the differences observed 
between the two release rates could be as a result of the shift in the equilibrium that 
exists between SN-38 lactone and carboxylate form.  As previously discussed, SN-38 
exists as a closed lactone ring at pH 4. Therefore, removing the possible ionic 
interactions that were occurring between the carboxylate form of SN-38 and the 
ester functionality on the polymer backbone or the hydroxyl group present on the 
hydrophobic segment (HPMA) of the AB block copolymer. Similar observations have 
been reported for the release of SN-38 from poly(amidoamine) dendrimers, whereby 
a difference in release rate was observed for pH 7.4 and pH 5.58 At pH 7.4, the authors 
reported that 20% of the total SN-38 had been released within 2 hours, which 
increased significantly to 85% SN-38 released in 2 hours when the pH was decreased. 
Another study conducted by Seperhri and co-workers also observed a difference in 
release rates of SN-38 from PLGA nanoparticles at different pH values.16  Release 
rates at pH 7.4 saw ~15% of SN-38 being released in 24 hours, which increased to ~ 
30% SN-38 being released in 24 hours at pH 5.2.  
DLS analysis of the 3H-labelled SN-38 loaded p(EHMA100-co-EGDMA0.80):p(PEG114-b-
HPMA100) nanoparticles after the radio-dialysis showed minimal impact on the 
nanoparticle size or stability (Dz = 174 nm, PDI = 0.183) when compared to the values 
obtained before radio-dialysis. As expected, this result suggests that the mechanism 
of SN-38 release from the branched vinyl polymer nanoparticles is most likely to be 
diffusion-based rather than erosion or degradation of the nanoparticulate structure.  
The release rate of SN-38 from p(EHMA100-co-EGDMA0.80):p(PEG114-b-HPMA100) 
nanoparticles in a changing pH environment was also studied. This experiment was 
designed to simulate what would happen to the release rate when the SN-38 loaded 
nanoparticles were administered in vivo at the initial pH of blood and as they 
progressed to the lower pH condition typically exhibited within a tumour 
microenvironment.  The radio-dialysis was conducted as described previously, but 
the pH of the reservoir was changed from pH 7 to pH 4 at the 4-hour time point. 
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SN-38 cumulative release (%) was plotted against time (Figure 4.30). The cumulative 
release graph clearly shows the presence of two different release profiles. Initially, 
there was a release profile at pH 7 where there had been a 13% cumulative release 
of SN-38 over 4 hours, but when the media was changed to pH 4 there was a subtle 
change in the release profile that is indicated by the appearance of a step-like change, 
which is highlighted on the figure with an arrow. After 24 hours, the cumulative 
release of SN-38 was 29%. This change, although only subtle, suggests that the rate 
of release of SN-38 is increased when the environment of the nanoparticles is 
changed to more acidic conditions.  Both experiments have shown that the 
percentage release of SN-38 from p(EHMA100-co-EGDMA100):p(PEG114-b-HPMA100) 
nanoparticles is dependent on the pH of the reservoir media. The faster release 
observed for pH 4 is desirable for exploiting tumour environmental factors, such as 
acidic pH, to ensure an increased concentration of SN-38 released into the tumour 
tissue. Additionally, the slow release of SN-38 at biological pH suggests that the 
nanoparticles are maintaining their structural integrity and burst release profiles are 
avoided. This is essential of any DDS if the primary aim is to release concentrations 
that are sufficient for a therapeutic effect.   




Figure 4.30 Cumulative 3H-labelled SN-38 release data obtained over 24 hours via radio-dialysis of p(EHMA100-co-
EGDMA0.80):p(PEG114-b- HPMA100) nanoparticles at pH 7 (black, closed circles) initially between 0 and 4 hour and 
then following the subsequent pH change to pH 4 (black, open circles) at 37 °C. 
4.5.2.2 The Impact of Divinyl Monomer Chemistry on SN-38 Release Rates 
Manipulating the polymer-drug interactions have also been shown to modulate the 
rate of drug release in previous reports.59 It was hypothesised that changes to the 
release rate may be observed through different polymer-drug interactions, which 
may arise following the changes to the divinyl monomer chemistry. Therefore, the 
release rates of branched p(EHMA20-co-DVMy) synthesised with different branching 
agents was investigated using radio-dialysis, were DVM represents divinyl monomer. 
The co-nanoprecipitations were performed as previously described with the 
inclusion of 5 wt.% 3H-labelled SN-38 for the following polymers: p(EHMA20-co-
DSDMA0.80), p(EHMA20-co-BPGDMA0.80) and p(EHMA20-co-EGDMA0.80) with p(PEG114-
b-HPMA100) at 60:40 wt.%, respectively. The branched polymers with the lower DPn 
of the primary polymer chains were chosen to maximise any effect that the divinyl 
monomer residue chemistries had on the polymer-drug interactions. Turbid aqueous 
nanoparticle dispersions were obtained by co-nanoprecipitation and were analysed 
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via DLS. Monomodal size distributions with hydrodynamic dimeters and PDI values 
were obtained as follows: p(EHMA20-co-DSDMA0.80) (Dz = 160 nm, PDI = 0.161), 
p(EHMA20-co-BPGDMA0.80) (Dz = 165 nm, PDI = 0.178) and p(EHMA20-co-EGDMA0.80) 
(Dz = 180 nm, PDI = 0.160). All of which were successfully loaded with 5 wt.% 3H-
labelled SN38. The physicochemical properties of these co-nanoprecipitates were 
consistent with those following the co-nanoprecipitation of non-radio labelled SN-38 
loaded co-nanoprecipitate regimes described in Chapter 4.2.1 which were as follows: 
p(EHMA20-co-DSDMA0.80) (Dz = 180 nm, PDI = 0.221), p(EHMA20-co-BPGDMA0.80) (Dz 
= 180 nm, PDI = 0.202) and p(EHMA20-co-EGDMA0.80) (Dz = 190 nm, PDI = 0.186). The 
radio-dialysis proceeded over 24 hours with the reservoir medium at pH 7. 
Cumulative release (%) plots were obtained (Figure 4.31).  
 
Figure 4.31 Cumulative 3H-labelled SN-38 release data obtained over 24 hours at pH 7 via radio-dialysis of 
p(EHMA100-co-EGDMA0.80)(black, open circles), p(EHMA100-co-DSDMA0.80) (red, crosses), p(EHMA100-co-
BPGMA0.80)(blue, open triangles): p(PEG114-b- HPMA100) nanoparticles at 37 °C. 
The 3 different branched polymers all followed the same release profile, with 
minimal differences in the cumulative release (%) of SN-38 over 24 hours. The 
cumulative release of SN-38 after 24 hours was greatest for p(EHMA20-co-
BPGDMA0.80) (17.0 %), followed by p(EHMA20-co-DSDMA0.80) (15.7 %) and p(EHMA20-
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co-EGDMA0.80) (14.9 %). The ordering of these systems in terms of cumulative 
percentage release may seem counter-intuitive, since it would be expected that the 
greater hydrogen bonding capabilities of the BPGDMA divinyl monomer residues 
would increase the polymer-SN-38 interactions and therefore slow the release. 
However, the EE for these systems were determined by radiometric analyses and 
were calculated as follows: 92%, 87% and 83% for the EGDMA, DSDMA and BPGDMA 
divinyl monomer residues, respectively. Therefore, from this observation it is 
apparent that EE has a direct effect on the rate of release. Although, the observed 
changes were only minimal and may be as a result of EE instead of differing polymer-
SN-38 interactions, this experiment has highlighted that the release of SN-38 from 
branched p(EHMA20-co-DVMy) based co-nanoprecipitates is reproducible, since 
three different stock solutions showed similar release profiles and results.  
4.5.2.3 The Impact of Higher SN-38 Concentrations Following Multiple Co-
Nanoprecipitations on the Rate of Release 
Multiple co-nanoprecipitations successfully increased the concentration of SN-38 
within 1 mL of aqueous nanoparticle dispersion (Section 4.4). The radio-dialysis of 
these dispersions with higher SN-38 concentrations (0.20 mg mL-1) was conducted to 
establish observable differences to the release of SN-38 at lower concentrations 
(0.05 mg mL-1). Multiple co-nanoprecipitations of 3H-labelled SN-38 were conducted 
as before. Turbid aqueous nanoparticle dispersions were obtained, which were 
analysed via DLS at [P]f = 1 mg mL-1. Monomodal size distributions were obtained for 
the different SN-38 concentrations, with the hydrodynamic diameters in the range of 
155 to 193 nm and the PDI values between 0.170 and 0.204. Release of SN-38 was 
monitored following the first, second, third and fourth addition of SN-38/polymer 
THF stock at SN-38 concentrations of 0.05, 0.10, 0.15 and 0.20 mg mL-1. Accurate 
quantification of SN-38 concentrations was obtained by LSC as follows: 0.0524, 
0.0902, 0.1402 and 0.1912 mg mL-1. High EE values were determined in the range of 
89-94%.  The radio-dialysis was conducted at pH 7 for 24 hours. The cumulative 
release plot showed that the same release profiles were obtained for all four 
concentrations with comparable release rates (Figure 4.32). The cumulative release 
of SN-38 after 24 hours was in the range of 13 – 16%.   




Figure 4.32 Cumulative 3H-labelled SN-38 release data obtained over 24 hours at pH 7 via radio-dialysis of 5 wt.% 
3H-labelled SN-38 loaded p(EHMA100-co-EGDMA0.80): p(PEG114-b- HPMA100) nanoparticles  with increasing SN-38 
concentrations prepared via multiple co-nanoprecipitations.  SN-38 concentrations: 0.05 mg mL-1 (black, open 
circle), 0.10 mg mL-1 (red, open triangle), 0.15 mg mL-1 (green, open diamond) and 0.20 mg mL-1 (pink, open 
square). 
4.5.3 Mathematical Modelling of SN-38 Release  
The term drug release actually refers to a multi-step complex process. Initially, drug 
molecules migrate from their original position to the outer surface of the polymeric 
system (polymer-water interface). This is then followed by the movement of the drug 
particles into the release medium.60 This in turn generates a two-stage release 
profile: the initial release from the particle surface, often described as a burst release, 
followed by the second more stable release of the drug that is dependent on the 
mechanism of release.  There are many mechanisms that control this release, which 
are usually determined by the physical or chemical characteristics of the polymer. 
The most common are diffusion, swelling or erosion based.61 Simple mathematical 
models can be employed to provide information and understanding of the drug 
release kinetics and mechanism. Solute transport from non-degradable polymers is 
mainly considered as diffusion based and drug release occurs due to a concentration 
gradient. There are several different diffusion-based models that can be used to 
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describe release profiles, such as zero order, first order and Highuci model, each of 
which are described below. 62-64 
Zero order kinetics can be described by the following relationship (Equation 4.3). 
𝐶𝑡 = 𝑘𝑡 + 𝐶0            (4.3) 
Whereby Ct represents the concentration of drug at time t, kt is the rate constant at 
time (t) and C0 is the initial drug concentration. A plot of cumulative release vs time 
would yield a straight line. If a strong correlation was observed, it would suggest that 
the rate of release is dependent on drug dissolution and not the disaggregation of 
the polymer system. 
First order kinetics can be described by the following relationship (Equation 4.4). 
𝐶𝑡 =  𝐶0 𝑒
−𝑘𝑡             (4.4) 
A plot of log (Ct) against time yields a straight line whose gradient is equal to the rate 
constant. If the release kinetics are first order, then the release rate is directly 
proportional to the concentration of the drug. It is often used to describe the 
dissolution of a poorly water-soluble drug, which is embedded in a water-soluble 
matrix. 
The Higuchi model is described by the following relationship (Equation 4.5). 
Ct =  kHt
0.5             (4.5) 
Where kH represents the Higuchi rate constant. A plot of drug concentration vs 
square root of time yields a straight line. The Higuchi model is based on several 
assumptions: the initial concentration of the drug in the formulation is higher than 
the drug thermodynamic equilibrium solubility, sink conditions are maintained, 
polymer swelling and dissolution is negligible, the drug particles are much smaller 
than the nanoparticle carrier, and finally, that the drug diffusivity does not change 
rate.  
The obtained release profiles for 5 wt.% 3H-labelled SN-38 loaded (EHMA20-co-
DSDMA0.80), p(EHMA20-co-BPGDMA0.80) and p(EHMA20-co-EGDMA0.80) with p(PEG114-
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b-HPMA100) co-nanoprecipitate regimes were analysed using the zero-order, the 
first-order and the Higuchi model (Figure 4.33).  
Linear regression analysis was employed to study the linearity of the kinetic plots and 
to determine the correlation coefficients (R2). The model that yielded the best R2 
values was the Higuchi model (≥ 0.98), followed by the zero-order kinetic model (0.89 
– 0.96). The worst fitting model was the first order kinetic model, as indicated by the 
low R2 values (0.76 – 0.89). These results suggest that the release of SN-38 was not 
concentration dependent, which is clearly advantageous when designing a DDS. It 
can be concluded from the obtained high linearity values that the mechanism of 
release has a high reliance on drug diffusion. The Higuchi model has been derived 
from Fick’s first law of diffusion and the suitability of the model fit indicates that the 
drug release is via drug diffusion over time from a homogenous environment i.e. the 
polymer nanoparticle is not degrading.  




Figure 4.33 Release kinetic plots of 5 wt.% SN-38 loaded (EHMA20-co-DSDMA0.80), p(EHMA20-co-BPGDMA0.80) and 
p(EHMA20-co-EGDMA0.80) with p(PEG114-b-HPMA100) co-nanoprecipitate regimes according to i) zero-order 
model, ii) first-order model, and iii) the Higuchi model.  
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4.6  Conclusion 
SN-38 loaded branched vinyl copolymer nanoparticles have been successfully 
prepared at a drug loading of 5 wt.% via co-nanoprecipitation. The production of 
which proved to be facile, efficient and reproducible, as demonstrated by the high 
EE values (≥ 83%) and the similarities in both particle size and PDI values across 
different batches. The drug loaded nanoparticles that were generated were of an 
acceptable particle size for the intended application and were also found to exhibit 
stability over prolonged periods of time (13 weeks). Studies were conducted to try to 
increase the drug loading beyond 5 wt.% but were unsuccessful as they resulted in 
multiple populations being observed, the formation of drug crystals and polymer 
aggregates. However, multiple co-nanoprecipitation proved to be a successful, 
simple method to increase the concentration of SN-38 within a single formulation 
whilst still targeting a 5 wt.% drug loading. The use of 3H-labelled SN-38 provided a 
highly accurate quantification platform to analyse the release rates of SN-38 from 
branched vinyl co-polymer nanoparticles via radio-dialysis. The findings from these 
studies show that the release of SN-38 from polymer nanoparticles could be 
sustained over time at a physiological relevant temperature and pH. SN-38 remained 
within the nanoparticles for 24 hours with < 16% release. Studies were also 
performed to study the effect of pH, polymer-drug interactions and initial drug 
concentration on the release rates of SN-38. It was shown that release rates were 
greater when the radio-dialysis medium was acidic in pH, which is potentially 
advantageous for a DDS to exploit the tumour environmental factors. Simple 
mathematical modelling of the obtained release profiles confirmed that the release 
was diffusion based and followed a release profile best fitted to the Higuchi model. 
The findings within this chapter highlight the promising potential and suitability of 
these SN-38 loaded nanoparticles to be considered for further in vitro and in vivo 
analysis. 
All of the attempts described above (Section 4.3) to increase the drug loading of SN-
38 within nanoparticle regimes above 5 wt.% offered limited success. However, 
whilst this value may initially seem modest, it is not uncommon that reported drug 
loadings for polymer nanoparticles do not exceed 10 wt.% 65-67 and even less 
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(1-5  wt.%) for those prepared by nanoprecipitation methods.68,69 These loading 
values are likely due to the different solubilities exhibited by the individual 
components, which lead to different precipitation times. However, one of the main 
advantages of working with SN-38 is the extreme level of potency it exhibits,70-72 
which in turn may see the reduction in the dose that would achieve an equivalent 
therapeutic effects to that of IR. 
In an attempt to estimate the possible clinical value of a 5 wt.% loaded SN-38 
containing polymer nanoprecipitate, it is useful to compare the commercial products 
that attempt to deliver the benefits of SN-38 in the clinic. Campto, the marketed 
brand of IR, is currently sold as IR hydrochloride and sorbitol at concentrations of 20 
mg mL-1 (17.33 mg mL-1 of IR).73 Currently, IR in monotherapy is dosed at a 
350 mg m-2.74 The average person is 1.75 m2, so the average dose of IR administered 
is 612.5 mg (1.75 m2 x 350 mg m-2), which equates to approximately 30.6 mL of 
Campto being required (612.5 mg; 20mgmL-1). Within this solution there is 530.73 
mg of IR (30.6 mL x 17.33 mg mL-1). Literature has shown that SN-38 is up to 1000 
times more potent than IR.72 If potency is assumed to be 1000 times greater than IR, 
the dose required to achieve the same therapeutic effect as IR would only be 0.531 
mg m-2. The concentration of the 5 wt.% SN-38 loaded formulations is 0.05 mg mL-1, 
meaning that only 10.62 mL would be required of these formulations. This sees a 
reduction of 65% of total volume of formulation required. If we take the more 
modest potency level of 100-fold higher than IR, the same calculations would equate 
to 106 mL being required of our formulation. Whilst this volume is greater than 
required for Campto, the advantage is the delivery of SN-38 as an active parent 
compound. Multiple co-nanoprecipitations increased the concentration of SN-38 
from 0.05 mg mL-1 to 0.2 mg mL-1; this would potentially reduce the administered 
volume by a factor of 4 and into the range of the Campto product if the conservative 
potency of 100-fold is correct (26.5 mL). These calculations do not consider factors 
such as metabolism and clearance rates that are drug-specific and are purely deriving 
an SN-38 equivalence basis; however, it is important to note that the formulation 
(from this perspective) does provide an ethical foundation to conduct in vivo studies 
that are described in Chapter 5. 
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In Vitro and In Vivo Pharmacological Assessment of 












5.1 Pharmacological Studies of SN-38 Loaded Co-nanoprecipitated Nanoparticles 
Polymer nanoparticles administered in vivo can initiate a myriad of different 
biological responses, as discussed in Chapter 1.4, but their overall effect, whether 
valuable or deleterious, is governed by their interactions at a cellular level.1  The 
interactions of polymer nanoparticles with cells can modulate cellular fate, induce or 
prevent mutations, initiate cell-cell communication, and modulate their cellular 
structure in a way that is largely dictated by phenomena occurring at the nano-bio 
interface.1 When in biological fluids nanoparticles can acquire different 
physicochemical properties, and typically the surface of the nanoparticle can be 
dramatically modified through the adsorption of proteins.2  This protein-corona 
alters the size and the interfacial composition of the nanoparticles, thereby creating 
a biological identity that is distinctly different to its original chemistry.3 This biological 
identity determines the physiological response including accumulation and toxicity.  
There are several factors that may affect the polymer nanoparticle’s biological 
identity:  1) its physical characteristics such as size, polydispersity, shape, charge and 
surface chemistry, 2) the nature of the physiological environment (e.g. blood type, 
cell cytoplasm, protein abundance), and 3) experimental parameters, including 
duration of exposure.4, 5  
One of the primary assessments of chemotherapeutics for cancer and their 
therapeutic utility is their ability to cause cellular death. This potency is a crucial 
parameter to consider when evaluating anti-cancer DDS. Additionally, for an anti-
cancer DDS to achieve high therapeutic efficacy and success, the intercellular fate of 
the nanoparticle is also critical. In order to evaluate how SN-38 loaded branched vinyl 
polymer nanoparticles would behave in biological environments and to assess their 
cellular toxicity, a series of in vitro and in vivo pharmacological evaluations were 
conducted using the materials described in Chapter 4. All of the pharmacological 
experiments presented within this chapter were completed by Usman Arshad in the 
Molecular and Clinical Pharmacology Department at the University of Liverpool 
under the supervision of Professors Andrew Owen and Chris Goldring; however, the 




SN-38 encapsulated nanoparticles prepared and presented in Chapter 4 were taken 
forward for in vitro analysis.   
5.1.1 Determining SN-38 Equilibration Rate via Rapid Equilibrium Dialysis   
To facilitate a quick screening of the SN-38 loaded nanoformulations that were 
described in Chapter 4, in vitro release kinetics were studied using rapid equilibrium 
dialysis (RED) devices (Figure 5.1). The RED device insert is made up of two side-by-
side compartments, one donor and one acceptor, which are separated by a cellulose 
dialysis membrane with a specified molecular weight cut-off (MWCO). The insert is 
then used within a base plate that can hold up to 48 RED device inserts, which allows 
for high throughput screening. The high surface area-to-volume ratio of the dialysis 
membrane enabled rapid equilibration and allowed any differences in equilibration 
times i.e. release rates between drug loaded formulations to be identified. SN-38 
loaded nanoparticles were added to the donor compartment and the concentration 
of SN-38 in the acceptor compartment was determined at time intervals. This was 
then used to generate a qualitative assessment of overt differences in behaviour 
between the formulations. A similar study has been reported on SDN-based DDS of 
atovaquone, an antimalarial drug.6  
 




To determine whether there were any differences in equilibration between the SN-
38 nanoformulations, 5 wt.% SN-38 loaded nanoparticles were diluted to 250 ng mL-
1 in PBS (pH 7.4) and compared to free SN-38. Free SN-38 was dissolved in DMSO 
prior to dilution with PBS, such that DMSO comprised < 1% of the final volume. To 
assess the SN-38 release kinetics, 0.5 mL of the samples were added to the donor 
compartments of 8 kDa MWCO RED inserts and 1 mL PBS was added to the acceptor 
compartments. Plates containing the inserts were placed on an orbital shake which 
was set at 37 °C. Each insert represented a single time-point and at 0.5, 1, 2, 3, 4, 5, 
6, 7, 8 and 24 hours both the acceptor fluids (1 mL) and donor fluids (0.5 mL) were 
removed. Aliquots of each time-point sample were then used to determine 
concentrations of SN-38 in each compartment using a validated liquid 
chromatography with tandem mass spectrometry (LC-MS) method. Since this 
experiment represents an equilibrium assay, the experiment was completed once 
the concentration of SN-38 in each compartment was the same (i.e. 50% of the initial 
SN-38 concentration was detected in the acceptor compartment).  Data is shown as 
the cumulative release (%) of SN-38 that has been determined to have diffused across 
the membrane at the set time-points (Figure 5.2-5.4). It is important to reiterate that 
each time-point is represented by a single insert and that the experiment is 
completed once 50 % of the total SN-38 concentration has been detected. This 
experiment differs from the radio-dialysis described in Chapter 4.5 and the two 





Figure 5.2 SN-38 cumulative release (%) data obtained over a period of 24 hours via RED of SN-38 loaded: i) 
p(EHMAn-co-EGDMA), ii) p(EHMAn-co-BPGDMA) and iii) p(EHMA-co-GDMA) branched vinyl copolymers co-
nanoprecipitated with AB block copolymer p(PEG114-b-HPMA100) (60:40 wt. % respectively), compared to free SN-





Figure 5.3 SN-38 cumulative release (%) data obtained over a period of 24 hours via RED of SN-38 loaded: i) 
p(EHMAn-co-BPGDMA), ii) p(EHMA-co-UDMA) and iii) p(EHMA-co-DSDMA) branched vinyl copolymers co-
nanoprecipitated with AB block copolymer p(PEG114-b-HPMA100) (60:40 wt. % respectively), compared to free SN-






Figure 5.4 SN-38 cumulative release (%) data obtained over a period of 24 hours via RED of SN38 loaded: i) 
p(BuMA100-co-EGDMA0.95) and ii) p(BuMA50-s-HPMA50-co-EGDMA0.95) compared to free SN-38 (grey circles). 
Where, n represents DP20 or DP100 monomer units.   
In all cases, it is evident that SN-38 loaded nanoparticles have a slower equilibration 
in comparison to free SN-38. This is consistent with previous observations from the 
radio release experiments presented in Chapter 4.5 and further suggests that very 
little free drug is present in the aqueous solution and that the majority of SN-38 is 
encapsulated within the polymer nanoparticles, since no burst release was observed. 
The equilibration profiles seem to vary between the fourteen tested SN-38 
nanoformulations, although none of the variations in polymer functionality or 





release after 24-hours. However, reducing the DPn value from 100 to 20 monomer 
units showed a reduction in the SN-38 equilibration of the SN-38 loaded polymer co-
nanoprecipitates within the 8-hour time frame for: p(EHMA20-co-EGDMA0.80) (Figure 
5.2i) and p(EHMA-co-BPGDMA0.80) co-nanoprecipitated with AB block copolymer 
p(PEG114-b-HPMA100) (60:40 wt. % respectively) (Figure 5.3i). For example, after 3 
hours equilibration time, p(EHMA100-co-EGDMA0.80) had a cumulative release of 
approximately 26 % compared to p(EHMA20-co-EGDMA0.80) which had a cumulative 
release of approximately 17 %, which equates to a reduction of approximately 34.6 
% less SN-38 released under the same conditions within the same time. Additionally, 
similar was observed for p(EHMA100-co-BPGDMA0.85) after 3 hours equilibration time, 
which had cumulative release of approximately 26 %, compared to approximately 
18 % cumulative release for p(EHMA20-co-BPGDMA0.80), a reduction of approximately 
30.8 % in SN-38 release. Since the monomer and divinyl chemistry is remaining the 
same, one of the only known differences is the polymer primary chain length and the 
subsequent mass of divinyl monomer present per unit of polymer mass. Therefore, 
it can be postulated that these reductions to the SN-38 equilibration may be due to 
a number of factors; for example, SN-38 interactions with the polymeric core of the 
nanoparticle may be affected by 1) the increased relative mass of divinyl monomer, 
2) the increase in chain-end concentration, or 3) the variation in Tg that would be 
present as the primary chain length decreases. Variations to the DPn value within the 
other polymeric systems had little effect on SN-38 equilibration.  
Five candidates were selected for further in vitro studies due to time and 
experimental constraints; however, it was difficult to identify these candidates as the 
differences in the extent of drug release was relatively small and there was no single 





Since the optimal equilibration rate for these DDS was unknown, in order to select a 
broad range of candidates for further in vitro studies, analysis of the curves was 
conducted that allowed an evaluation of the differences at specific times and 
identification of formulations that appeared to have the fastest or most delayed 
release. Comparisons of cumulative release to free SN-38 were chosen at four time 
points to provide this analysis: early time-points (0.5 and 1 hours), an intermediate 
time-point (6 hours) and the final time-point (24 hours), each of which are 
represented in Figure 5.3i-iii.  
Analysis at 0.5 hours equilibration showed that all 14 nanoformulations did not 
demonstrate a burst release as their cumulative release rates were all lower (< ~4 %) 
than that obtained for free SN-38 (~ 10%). In addition, the initial equilibration of 
these formulations was all similar, except for p(EHMA20-co-DSDMA0.75) (Figure 5.5iii) 
which had the largest SN-38 cumulative release (~ 4%). Since this suggests it has the 
fastest SN-38 release rate at this time point under these conditions, it was of interest 
to study this formulation with further in vitro studies, therefore it was selected. 
The cumulative release after 1 hour was compared, and two formulations were 
chosen: p(EHMA100-co-BPGDMA0.85) (Figure 5.5ii) and p(EHMA20-co-UDMA0.90) 
(Figure 5.5iii), which had the highest and lowest cumulative release with approximate 
values of 10 % and 3 %, respectively, compared to free SN-38 which had a cumulative 
release of approximately 17 % after 1 hour. These cumulative release values 
correspond to the “fastest” and “slowest” SN-38 release at 1 hour. 
Input from an industrial collaborator, AstraZeneca, suggested that differences within 
the first 8 hours was important for seeing in vivo differences between formulations, 
the 6-hour timepoint was therefore selected as a key determinant of potential 
benefit. Overall, p(BuMA50-s-HPMA50-co-EGDMA0.95) exhibited the highest 
cumulative release (~ 43 %) and was similar to that compared of free SN-38 (~ 44 %). 
This increased cumulative release value compared to the other formulations was 






Figure 5.5 Graphical representation of the SN-38 loaded nanoformulations cumulative release at 0.5 hour (black 





Looking at the equilibration after 24 hours, the nanoformulation with the “slowest” 
equilibration rate compared to free SN-38 was selected, which corresponded to 
p(BuMA100-co-EGDMA0.95) with a cumulative release of approximately 44 %.  The 
selection of SN-38 nanoformulations for further in vitro and in vivo studies effectively 
bracketed the range of release behaviours available within the library of materials 
generated within this programme.  The chosen candidates are presented in Table 5.1. 
Table 5.1 SN-38 nanoparticle formulations that were selected for further in vitro pharmacological assessment. 



















5.1.2 ATP assays to Determine Cytotoxicity of SN-38 Nanoformulations in 2D HCT-116, CT-
26, LoVo and DLD-1 cell lines and 3D Spheroids from HCT-116 and CT-26 
The treatment of cells with a cytotoxic compound can result in a variety of different 
cell fates such as: necrosis (accidental cell death), apoptosis (programmed cell 
death), or a decrease in cell viability. Cytotoxicity assays are widely used to determine 
how toxic compounds are to cells.7, 8 One method commonly used to assess the 
cytotoxicity is the use of adenosine triphosphate (ATP) assays, which quantify ATP 
levels. ATP can be used as a marker of cell-viability since only metabolically active 
cells produce ATP, whereas dead cells do not.9 DDS encapsulating chemotherapeutic 
agents should aim to at least maintain, if not decrease, the cell viability level 





Experiments were conducted to evaluate the cytotoxicity of the SN-38 loaded 
nanoformulations in both human and murine CRC cell lines. The cytotoxicity’s of the 
selected SN-38 loaded nanoformulations were compared against free SN-38 and IR. 
ATP assays were conducted using CellTiter-Glo® Luminsecent cell viability assays 
(Promega, UK) according to manufacturer’s instructions. Four different cell lines 
obtained from humans and mice were investigated: human colorectal cancer (HTC-
116), murine colorectal cancer (CT-26), human colorectal adenocarcinoma (LoVo), 
and Dukes’ type C colorectal adenocarcinoma (DLD-1). ATP quantification was 
measured by a luciferin-luciferase assay using a Varioscan flash fluorescent plate 
reader measuring the luminescence at 570 nm wavelength. Cell viability was 
calculated as a percentage of untreated vehicle control (DMSO – 0.1%) or blank 
nanoformulation sample and used to determine the half maximal inhibitory 
concentration (IC50) value (mean ± SD, n=3) after 48, 72, and 96-hours incubation 
time. ATP assays were conducted across a range of concentrations ([SN-38] = 0.5 to 
400 nM and [IR] = 0.01 to 100 µM), with free SN-38 and IR in solutions with 0.1% 
DMSO. The in vitro cytotoxic effect of SN-38 loaded nanoformulations, free SN-38 
and IR is presented in Figure 5.6 and Figure 5.7 A-D.  Additionally, the in vitro 
cytotoxicity of the polymer nanoparticles without SN-38 was also tested. 
For all five of the nanoformulations with no SN-38 loaded, IC50 values were not 
obtained since the blank nanoformulations were not cytotoxic at the concentration 
range used (i.e. the value for cell viability = 100 %). This is a positive observation as it 
suggests that the polymer-based nanoparticles did not disrupt any of the cellular 
membranes or elicit any toxicity. This means that any toxicity observed after the 
incorporation of SN-38 is a direct result of the inclusion of the potent payload.  
Through the incorporation of SN-38 within the nanoformulations a decrease in cell 
viability was observed, indicating that the SN-38 nanoformulations were toxic (Figure 
5.6 and 5.7). This was to be expected since SN-38 is the toxic, active metabolite of IR 
that is used clinically as a chemotherapeutic. When compared to IR, the in vitro 
cytotoxicity experiments demonstrated that the SN-38 loaded nanoparticles had 





than the IC50 values of IR (Table 5.2). The symbol X, included on Figure 5.6 and 5.7 
represents were an IC50 was not calculated within this concentration range or 
incubation time. Except, in the instance of the missing IC50  value for co-
nanoprecipitate regime, p(BuMA100-co-EGDMA0.95), after 72 hours incubation which 







Figure 5.6 In-vitro cell viability study of A) HCT 116 and B) CT 26 cancer cells after treatment with free SN-38, SN-
38 loaded: (p(BuMA100-co-EGDMA0.95):p(PEG114-b-HPMA100) 60:40 wt.%), (p(EHMA20-co-UDMA0.90):p(PEG114-b-
HPMA100) 60:40 wt.%) , p(EHMA20-co-DSDMA0.75), (p(EHMA20-co-BPGDMA0.80):p(PEG114-b-HPMA100) 60:40 wt.%) 
and (p(BuMA50-s-HPMA50-co-EGDMA0.90):p(PEG114-b-HPMA100) 60:40 wt.%) after 48 (black), 72 (red) and 96 hours 






Figure 5.7  In-vitro cell viability study of C) LoVo and D) DLD-126 cancer cells after treatment with free SN-38, SN-
38 loaded: (p(BuMA100-co-EGDMA0.95):p(PEG114-b-HPMA100) 60:40 wt.%), (p(EHMA20-co-UDMA0.90):p(PEG114-b-
HPMA100) 60:40 wt.%) , p(EHMA20-co-DSDMA0.75), (p(EHMA20-co-BPGDMA0.80):p(PEG114-b-HPMA100) 60:40  wt.%) 
and (p(BuMA50-s-HPMA50-co-EGDMA0.90):p(PEG114-b-HPMA100) 60:40 wt.%) after 48 (black), 72 (red) and 96 hours 







Table 5.2 IC50 values of SN-38 nanoformulations 1-5, free SN-38 and irinotecan on HCT-116, CT-26, LoVo and DLD-
1 cell lines after 48, 72 and 96-hour incubation times. Cell viability was determined by CellTiter-Glo® Luminsecent 















48 92 ± 3 178 ± 23 81 ± 7 178 ± 15 
p(EHMA20-co-
UDMA0.90) 
82 ± 5 - 95 ± 7 - 
p(EHMA20-co-
DSDMA0.75) 
76 ± 2 - - - 
p(EHMA100-co-
BPGDMA0.90) 




99 ± 12 - - - 
SN-38 26 ± 2 186 ± 22 51 ± 6 97 ± 3 
Irinotecan 95252 ± 391 18381 ± 1082 17914 ± 637 4259 ± 530 
p(BuMA100-co-
EGDMA0.95): 
72 - - - - 
p(EHMA20-co-
UDMA0.90) 
42 ± 5 192 ± 4 14 ± 1 43 ± 5 
p(EHMA20-co-
DSDMA0.75) 
44 ± 11 148 ± 4 19 ± 1 49 ± 1 
p(EHMA100-co-
BPGDMA0.90) 




69 ± 3 166 ± 8 76 ± 8 173 ± 14 
SN-38 10 ± 2 54 ± 18 6 ± 1 33 ± 12 
Irinotecan 2430 ± 311 12478 ± 1236 2906 ± 171 1156 ± 37 
p(BuMA100-co-
EGDMA0.95): 
96 24 ± 10 133 ± 10 24 ± 2 53 ± 1 
p(EHMA20-co-
UDMA0.90) 
22 ± 13 173 ± 14 14 ± 3 53 ± 1 
p(EHMA20-co-
DSDMA0.75) 
26 ± 4 132 ± 10 18 ± 6 30 ± 1 
p(EHMA100-co-
BPGDMA0.90) 




26 ± 2 148 ± 4 53 ± 2 71 ± 6 
SN-38 5 ± 1 51 ± 4 6 ± 1 10 ± 1 
Irinotecan 906 ± 141 2596 ± 236 926 ± 71 832 ± 120 






For example, in HCT-116 cell line, a range of low IC50 values for SN-38 loaded 
nanoformulations were obtained (76 ± 1 ≤ IC50 ≤ 99 ± 12 nM) compared to the higher 
IC50 value for IR (95253 ± 391 nM) after 48 hours incubation time. These IC50 values 
for the SN-38 loaded nanoformulations suggest that they demonstrate more than a 
1000-fold greater cytotoxic behaviour compared to IR alone.   
When compared to free SN-38 IC50 values in all four cell lines and at all three-
incubation time points, the obtained IC50 values for the five SN-38 loaded 
nanoformulations were slightly higher. For example, in HCT-116 cell lines the IC50 
values for all of the SN-38 loaded nanoformulations (18 ± 2 ≤ IC50 ≤ 27 ± 2 nM) were 
slightly higher than the IC50 value obtained for free SN-38 (5 ± 1 nM). This indicates 
that free SN-38 showed greater cytotoxicity than the SN-38 loaded nanoparticles. 
Which is indicative of a fraction of the SN-38 being within the nanoparticles and 
therefore acting as if it is a lower concentration of available free SN-38. Therefore, 
whilst the SN-38 loaded nanoformulations were slightly less cytotoxic compared to 
free SN-38, they are representative of SN-38 that can potentially be administered in 
vivo and have a significantly greater cytotoxic effect than IR. The apparent decrease 
in direct toxicity, observed for encapsulated SN-38, may offer additional advantages 
in vivo as high concentrations of IR induces intestinal toxicity and severe diarrhoea;10, 
11 the direct cause of which is believed to be associated by the reconversion of SN-38 
glucuronide, a waste metabolite of SN-38, back into SN-38 which is then retained for 
long periods in the intestine. 
In all four cell lines, a time response is observed for free SN-38, SN-38 loaded 
nanoformulations and IR. This time response indicates that cell viability continues to 
decrease with time following the initial treatment with the formulations.  Within 
error, the five different SN-38 loaded nanoformulations did not differ with any 
statistical significance in cytotoxicity behaviour following statistical analysis which 
was conducted  via a two-way ANOVA and a Holm-Šídák post-hoc analysis.  
Additional studies were also conducted using 3D spheroids created with HCT-116 and 





proportionally with increasing SN-38 concentration and tumour size was seen to 
decrease (Figure 5.8-5.13).  
 Figure 5.8 Cell viability graphs for SN-38 loaded p(EHMA20-co-UDMA0.90):p(PEG114-b-HPMA100) (60:40 wt. %)  
nanoparticles in 3D spheroids grown from HCT 116 cell lines after i) 72 hours incubation time and ii) 144 hours 
incubation time. Microscope images also displaying tumour shrinkage following the administration of the SN-38 







Figure 5.9 Cell viability graphs for SN-38 loaded p(EHMA20-co-UDMA0.90):p(PEG114-b-HPMA100) (60:40 wt. %)  
nanoparticles in 3D spheroids grown from CT-26 cell lines after iii) 72 hours incubation time and iv) 144 hours 
incubation time. Microscope images also displaying tumour shrinkage following the administration of the SN-38 





Figure 5.10 Cell viability graphs for SN-38 loaded p(EHMA100-co-BPGMA0.95):p(PEG114-b-HPMA100) (60:40 wt. %)  
nanoparticles in 3D spheroids grown from HCT 116 cell lines after i) 72 hours incubation time and ii) 144 hours 
incubation time. Microscope images also displaying tumour shrinkage following the administration of the SN-38 









Figure 5.11 Cell viability graphs for SN-38 loaded p(EHMA100-co-BPGMA0.95):p(PEG114-b-HPMA100) (60:40 wt. %)  
nanoparticles in 3D spheroids grown CT-26 cell lines after iii) 72 hours incubation time and iv) 144 hours 
incubation time. Microscope images also displaying tumour shrinkage following the administration of the SN-38 









Figure 5.12 Cell viability graphs for SN-38 loaded p(BuMA50-s-HPMA50-co-EGDMA0.95):p(PEG114-b-HPMA100) (60:40 
wt. %)  nanoparticles in 3D spheroids grown from  HCT 116 cell lines after i) 72 hours incubation time and ii) 144 
hours incubation time. Microscope images also displaying tumour shrinkage following the administration of the 








Figure 5.13 Cell viability graphs for SN-38 loaded p(BuMA50-s-HPMA50-co-EGDMA0.95):p(PEG114-b-HPMA100) (60:40 
wt. %)  nanoparticles in 3D spheroids grown CT-26 cell lines after iii) 72 hours incubation time and iv) 144 hours 
incubation time. Microscope images also displaying tumour shrinkage following the administration of the SN-38 
loaded p(BuMA50-s-HPMA50-co-EGDMA0.95): p(PEG114-b-HPMA100) (60:40 wt. %) nanoparticles at varying 
concentrations
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However, IC50 values were only obtained at 144 hours and were not obtained at 72 
hours at the tested concentration range (Figure 5.14). Again, the symbol X has been 
used to represent were IC50 was not reached within the tested concentration range. 
 
Figure 5.14 In-vitro cell viability in 3D spheroids from A) HCT 116 and B) CT 26 cancer cells after treatment with 
free SN-38 (grey bar), p(BuMA100-co-EGDMA0.95 (black bar), p(EHMA20-co-UDMA0.90)(red  bar, fine), p(EHMA20-co-
DSDMA0.75) (green bar, medium), p(EHMA20-co-BPGDMA0.80) (blue bar, coarse), p(BuMA50-s-HPMA50-co-
EGDMA0.90) (turquoise, fine check) and irinotecan (pink bar) after incubation for 144 hours. All branched 
copolymers were co-nanoprecipitated with p(PEG114-b-HPMA100) at 60:40 wt. % composition respectively. X 
represents were IC50 was not reached within the tested concentration range.  
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As depicted in Figure 5.9A, the cell viability of the HCT-116 3D spheroids was affected 
after a 144-hour incubation with each of the SN-38 loaded nanoparticles, as well as 
with free SN-38 and IR. Whereas, in the CT-26 3D spheroids, only three of the SN-38 
loaded nanoformulations: (p(EHMA20-co-UDMA0.90), p(EHMA20-co-BPGDMA0.80) and 
p(BuMA50-s-HPMA50-co-EGDMA0.90) generated an IC50 value at the tested 
concentration range. The IC50 values obtained for SN-38 loaded nanoformulations 
were significantly lower than those obtained for IR in both 3D spheroids from HCT-
116 and CT-26 cell lines (Table 5.3).  
Table 5.3 IC50 values of free SN-38 and irinotecan and five SN-38 nanoformulations, on 3D spheroids created from 
HCT-116 and CT-26 cell lines after 144-hour incubation time. Cell viability was determined by CellTiter-Glo® 






3D Spheroids  
(CT-26) 
SN-38 10 ± 5 292 ± 40 
Irinotecan 4480 ± 324 16 419 ± 247 
p(BuMA100-co-EGDMA0.95) 47 ± 3 - 
p(EHMA20-co-UDMA0.90) 25 ± 4 378 ± 14 
p(EHMA20-co-DSDMA0.75) 18 ± 1 - 
p(EHMA100-co -BPGDMA0.90) 42 ± 3 133 ± 19 
p(BuMA50-s-HPMA50-co-EGDMA0.95) 48 ± 4 229 ± 17 
Furthermore, the obtained IC50 values were lower for the 3D spheroids grown from 
HCT-116 cells compared to those obtained for the 3D spheroids grown from CT-26 
cells for all SN-38 nanoformulations, free SN-38, and IR. This may be as a result of 
better penetration of SN-38 within HCT-116 spheroids compared to CT-26 spheroids.  
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In the study using HCT-116 3D spheroids, the SN-38 loaded nanoformulations 
p(EHMA20-co-UDMA0.90) and p(EHMA20-co-DSDMA0.75) had the lowest IC50 values 
within the nanoformulation series (IC50 = 25 ± 4 and 18 ± 1 nM, respectively). The 
latter demonstrating similar values compared to unformulated SN-38 (IC50 = 10 ± 5 
nM), indicating that they are exhibiting similar cytotoxicity as the free drug. This 
observation is not that surprising since p(EHMA20-co-DSDMA0.75) also displayed the 
fastest initial equilibration rate when assessed via RED (Section 5.1.1).  
The IC50 values obtained for the SN-38 nanoformulations in the 3D spheroids from 
CT-26 cells were as follows. For SN-38 loaded:  p(BuMA100-co-EGDMA0.95) and 
p(EHMA20-co-DSDMA0.75), no IC50 value was obtained over the tested concentration 
range as previously mentioned.  The lowest IC50 value was exhibited by SN-38 loaded 
p(EHMA20-co-BPGDMA0.80) (133 ± 19 nM), which was lower than that obtained for 
free SN-38 (292 ± 40 nM) and considerably lower than that obtained for IR (16 419 ± 
247 nM). The IC50 value obtained for SN-38 loaded p(BuMA50-s-HPMA50-co-
EGDMA0.90) (229 ± 17) was similar in cytotoxicity as free SN-38. SN-38 loaded 
p(EHMA20-co-UDMA0.90) (378 ± 14 nM) was the least cytotoxic out of the SN-38 
formulations on this tested cell line.   
The IC50 values collected from both 3D spheroids cell lines, further confirm the 
superior cytotoxicity of the SN-38 loaded nanoformulations compared to IR.   
5.1.3 Determining Cellular Accumulation Ratios of SN-38 Nanoformulations 
in M1 and M2 Macrophages  
When a host is exposed to nanomaterials, phagocytes are key cellular participants in 
determining the fate of the nanoparticles within the body. In particular, macrophages 
are believed to be the first cell-type involved in the detection of nanoparticles that 
can mediate host inflammatory and immunological biological responses. When a 
nanoparticle reaches the exterior membrane of a phagocyte, interactions can occur 
between the nanoparticle and the plasma membrane components or the 
extracellular matrix. These interactions permit and facilitate entry into the cell mainly 
via endocytosis. This is a distinct process whereby nanoparticles are engulfed in 
membrane invaginations, which then bud off inside the cell to form a vesicle 
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containing the ingested nanoparticle.12 One of the main endocytosis mechanisms is 
phagocytosis. Generally, wherever nanoparticles are detected phagocytosis occurs 
ubiquitously, since macrophages play a crucial role in the defence system of the body. 
Macrophages can be divided into M1-type (classically activated) and M2-type 
(alternatively activated), both of which produce an array of cytokines, chemokines, 
hormones, proteases and polypeptide growth factors.13, 14 The role of M1 
macrophages is to function as a immune monitor, secrete pro-inflammatory 
cytokines and present antigens. Whereas, M2 macrophages primarily reduce 
inflammation by secretion of anti-inflammatory cytokines.15 The phagocytosis by 
macrophages can result in the rapid systemic clearance of the nanoparticles, which 
in-turn limits the nanoparticles ability to accumulate at the target delivery site. The 
extent of this phagocytic uptake is largely governed by the physiochemical 
characteristics of the nanoparticles, such as size, shape, and surface properties.16 
With regard to the latter, studies have shown that “stealth” surface functionalities 
such as PEG can reduce such phagocytic uptake and enhance systemic circulations 
times, as discussed in detail in Chapter 1.5. 
For the treatment of certain infection diseases such as HIV, accumulation of 
nanoparticles in macrophages is highly advantageous, since it has been shown that 
macrophages can act as latent reservoirs of the HIV virus.17-19 There are also 
emerging reports within recent literature of macrophages being targeted for anti-
cancer therapies, since macrophages are a major constituent of the tumour 
microenvironment.20-22 Within this environment, the macrophages promote pro-
tumour functions such as proliferation, angiogenesis and metathesis, so targeting of 
macrophages may prove advantageous, although there is a lot unknown about 
macrophages ontogeny as it is very much still in its infancy. In general, anti-cancer 
DDS are designed and engineered to limit and minimise the macrophage uptake in 
order to facilitate long systemic circulation times to enable high therapeutic efficacy.  
The cellular accumulation ratio (CAR) of five SN-38 loaded nanoformulations was 
investigated in M1-type and M2-type macrophages. CAR is given as the ratio of the 
intracellular to the extracellular SN-38 concentration. The CAR of the five different 
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SN-38 nanoformulations in M1 and M2 macrophages was compared directly to free 
SN-38 after a 24-hour incubation time (Figure 5.15).  
 
Figure 5.15 Cellular accumulation (ratio of cellular to extracellular concentration) of: free SN-38 (grey bar), SN-38 
loaded (p(BuMA100-co-EGDMA0.95) (black bar), SN-38 loaded (p(EHMA20-co-UDMA0.90) (red  bar, fine), SN-38 
loaded p(EHMA20-co-DSDMA0.75) (green bar, medium), SN-38 loaded p(EHMA20-co-BPGDMA0.80) (blue bar, 
coarse) and SN-38 loaded p(BuMA50-s-HPMA50-co-EGDMA0.90) (turquoise, fine check). All of which are sterically 
stabilised with AB block copolymer p(PEG114-b-HPMA100) (60:40 wt. % branched copolymer: AB block copolymer 
respectively. Macrophages were treated with 50 µM of sample for 24 hours. Values are mean ± standard 
deviation from three experiments.  
The CAR values after incubation with SN-38 loaded: p(BuMA100-co-EGDMA0.95), 
p(EHMA20-co-UDMA0.90) and p(EHMA20-co-DSDMA0.75) (0.66 ± 0.23, 0.65 ± 0.33 and 
0.62 ± 0.49, respectively) were identical within experimental error and were lower 
than the CAR value for free SN-38 (1.19 ± 0.17). This suggests that the uptake of free 
SN-38 by macrophages was greater than that of the SN-38 loaded nanoparticles, 
although not statistically significant. This decreased uptake may be as result of the 
formulation including PEG moieties, which may have reduced the protein corona 
formed compared to that of free SN-38. The CAR values obtained for SN-38 loaded: 
p(EHMA20-co-BPGDMA0.80) and p(BuMA50-s-HPMA50-co-EGDMA0.90) (1.48 ± 0.28 and 
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1.278 ± 0.41) were similar to that of free SN-38. These 2 formulations also exhibited 
the two highest cumulative release of SN-38 when tested by RED, as discussed in 
Section 5.1.1. The increased equilibration compared to the other 3 formulations may 
also explain the increased accumulation within macrophages: if the 
nanoformulations release more SN-38 or present more SN-38 at the surface of the 
particle, then they may have a greater protein corona that would subsequently 
trigger an increase in macrophage uptake.  Despite being similar to SN-38 uptake, it 
was observed that formulating SN-38 within polymer nanoparticles did not increase 
macrophage uptake.  
5.1.4 In vivo PK Studies  
 A pharmacokinetic study was conducted with 5 wt.% SN-38 loaded p(EHMA20-co-
DSDMA0.80):p(PEG114-b-HPMA100) 60:40 wt.% co-nanoprecipitate, which was 
administered to healthy male BALB/c mice at [SN-38] = 0.40 mg mL-1. BALB/c 
represents an albino, immunodeficient inbred mouse strain, which serves as a useful 
murine model in cancer therapy research.23 This material was selected due to the 
fact that it had the lowest CAR value following the in vitro study involving M1 and M2 
macrophages (Section 5.1.3), which suggested that it would likely have the greatest 
systemic circulation time following intravenous administration.  
Unfortunately, due to undue stress the mice were sacrificed after administration and 
before any evaluation could be conducted, which is concerning from the perspective 
of the future application of this material. Investigations have been initiated in order 
to provide an explanation for the failure of the in vivo study, however, due to the 
COVID-19 pandemic these were unable to be completed before the completion of 
this thesis.  
5.2 Conclusion 
The pharmacological behaviour of fourteen different SN-38 loaded nanoformulations 
were assessed. RED assays were used as a rapid screening process to evaluate the 
SN-38 release rates of these formulations compared to free SN-38. All fourteen of 
the SN-38 nanoformulations showed no evidence of any burst release and it was 
shown that the formulations have a reduced equilibration compared to free SN-38 
within 8 hours of equilibration time. This observation provides further validation that 
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the vast majority of the SN-38 concentration is encapsulated within the nanoparticles 
as previously demonstrated through encapsulation efficiency calculations (Chapter 
4, Section 2.2). 
Although the equilibration profiles of the nanoformulations were slightly different, 
they did not differ significantly between the fourteen samples and it was shown that  
variations in polymer functionality and brancher chemistry had little influence on SN-
38 release under these conditions. However, it was indicated that variations to DPn 
value may modulate SN-38 release rate through increased polymer-drug 
interactions, although it is currently unclear why this variation has an impact in this 
way. It is recognised that a more comprehensive study with more varying DPn values 
would be required before drawing on that conclusion.  
Five nanoformulations were chosen to progress with further in vitro cytotoxicity and 
cellular uptake studies: p(BuMA100-co-EGDMA0.95), p(EHMA100-co-BPGDMA0.85), 
p(EHMA20-co-UDMA0.90), p(EHMA20-co-DSDMA0.75) and p(BuMA50-s-HPMA50-co-
EGDMA0.95), all co-nanoprecipitated with AB block copolymer p(PEG114-b-HPMA100) 
at a compositional ratio of 60:40 wt. % respectively. These were chosen based on 
their “slow and fast” equilibration rates at four chosen time points compared to free 
SN-38 and the other SN-38 nanoformulations. 
Cytotoxicity studies of these five formulations demonstrated that the corresponding 
non-loaded polymer nanoparticles were not cytotoxic, which is a highly 
advantageous attribute and suggestive that the material is suitable and safe for its 
intended application as described in Chapter 1, Section 4.1. The studies confirmed 
that through the encapsulation of SN-38 within the polymer nanoparticles that a 
decrease to cellular viability was observed and therefore an increase in the material’s 
cytotoxic behaviour. This observation was consistent with what was expected since 
SN-38 is reported to have anti-cancer properties. Additionally, it also demonstrated 
that all five of the SN-38 nanoformulations had superior cytotoxicity compared to IR 
with extremely low IC50 values in nM being obtained for all five of the SN-38 
nanoformulations. This result is extremely promising and combined with the fact that 
the formulations represent SN-38 that could be directly administered intravenously 
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indicates that these nanoformulations have potential to act as SN-38 DDS with 
encouraging in vitro anti-cancer properties.  This was then further reiterated when 
further cytotoxicity studies were conducted in 3D spheroids which also 
demonstrated that the five SN-38 nanoformulations had extremely low IC50 values 
and had the ability to cause tumour shrinkage under these tested conditions.  Again, 
it was highlighted that the SN-38 nanoformulations were significantly more toxic 
than IR further validating the desire to be able to formulate and deliver SN-38 
directly.  
The CAR values were determined for the five SN-38 loaded nanoformulations. 
through in vitro macrophage uptake studies. Interestingly, three of the SN-38 loaded 
nanoformulations: p(BuMA100-co-EGDMA0.95), p(EHMA20-co-UDMA0.90) and 
p(EHMA20-co-DSDMA0.75) all co-nanoprecipitated with AB block copolymer p(PEG114-
HPMA100) (60:40 wt. % composition) all demonstrated lower cellular uptake (0.66 ± 
0.23, 0.65 ± 0.32 and 0.62 ± 0.49, respectively) compared to free SN-38 (1.19 ± 0.17). 
This reduced cellular uptake may be as a result of the reduced recognition by the 
macrophages caused through the incorporation of the PEG functionalities from the 
AB block copolymer. But it is unclear at this stage why the other two SN-38 
nanoformulations: p(EHMA100-co-BPGDMA0.90) and p(BuMA50-s-HPMA50-co-
EGDMA0.95) with AB block copolymer p(PEG114-HPMA100) showed similar uptake (1.48 
± 0.28 and 1.28 ± 0.41 respectively) to that of free SN-38. However, it is worth noting 
that although there were differences observed there was no statistical significance. 
Positively, it was seen that encapsulating SN-38 within polymer nanoparticles did not 
increase the cellular accumulation, i.e., the macrophage uptake was not increased, 
and the polymer nanoparticles do not increase the cellular interaction with 
macrophages. 
The failing of the in vivo PK studies of SN-38 loaded nanoformulation p(EHMA20-co-
DSDMA0.75):p(PEG114-b-HPMA100) (60:40 wt. % respectively) at this stage is unclear  
and although concerning given the intended application of the SN-38 DDS, 
investigations will resume following the return of research from COVID19. However, 
despite this, the initial preliminary results from the in vitro work are still suggestive 
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that these SN-38 nanoformulations have the capability to act as DDS of the currently 
un-administrable SN-38. 
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The main objective of this research was to encapsulate the anti-cancer drug SN-38, 
within a novel polymeric based drug delivery platform and assess its applicability as 
a biologically, and clinically, relevant therapy candidate. At the highest level, this has 
been successfully achieved and the results presented within this thesis have shown 
that a wide variety of sterically stabilised branched vinyl polymer nanoparticles 
loaded with SN-38 can be prepared, with relative ease, high efficiency and 
reproducibility via co-nanoprecipitation. Additionally, it was demonstrated through 
radiometric analysis and in vitro studies that these polymer nanoparticles may be 
potentially useful as drug delivery systems of SN-38. This research has also provided 
an understanding of how the chemistry of the polymers and the subsequent core of 
the nanoparticles may govern the success of the encapsulation and how it can 
modulate the drug release. Furthermore, it has also highlighted and allowed the 
identification of a number of factors within the polymerisation and co-
nanoprecipitation processes which influence the successful formation of the 
polymers and nanoparticles, respectively.   
Methanolic ATRP proved to be a robust synthetic technique which allowed for the 
synthesis of a wide range of polymeric materials with well-defined architectures 
including, linear homo and statistical copolymers, statistical branched and AB block 
copolymers, with varying degrees of polymerisation. The synthetic versatility which 
ATRP exhibited allowed for various different chemical compositions to be 
synthesised with relative ease and control, through the incorporation of different 
vinyl, divinyl monomers and initiators, expanding on previously reported materials. 
It also facilitated the generation of a novel library of soluble hydrophobic branched 
materials, which were obtained via a ‘modified Strathclyde approach’. As expected, 
an influence on the polymer’s physical properties, specifically the glass transition 
temperature and polarity were observed when varying the chemistries and 
architectures. Which in turn, also influenced the success of drug encapsulation and 
varied release profiles which will be discussed below. 
Before the encapsulation of SN-38, further essential studies were required to gain an 




nanoprecipaiton, in the context of this new polymer library. Findings from both the 
nanoprecipitation and co-nanoprecipitation studies confirmed that high molecular 
weight branched copolymers were an essential requirement in the formation of 
stable and highly monodispersed aqueous nanoparticle dispersions. Furthermore, 
the failing of the vast majority of the polymers during the sole nanoprecipitation 
experiments also emphasised the importance of the presence of an AB block 
copolymer to provide steric stabilisation; as confirmed during the initial co-
nanopreciptation studies, undertaken with p(PEG114-b-HPMA100) and branched 
polymers: p(HPMA100-co-EGDMA0.90), p(BuMA100-co-EGDMA0.95) and p(EHMA100-co-
EGDMA0.80).  
During these studies it was determined that the optimal composition ratio required 
between branched vinyl polymer and AB block copolymer was ≥ 40 wt.% of AB block 
copolymer to provide sufficient steric stabilisation upon dilution and exposure to salt 
whilst also facilitating the successful formation of monodisperse nanoparticles within 
the ideal size range for anti-cancer DDS (< 200 nm). It was also highlighted that 
variation of this ratio had a direct impact on particle size, whereby increasing the % 
wt. of AB block copolymer decreased the particle hydrodynamic diameter, which 
provides a future formulation strategy to reduce the nanoparticle hydrodynamic 
diameter. Additionally, it was observed that this ratio also governed the success of 
the co-nanoprecipitations, which was entirely dependent on the chemical nature of 
the monomer residue within the branched polymer backbone. It was observed that 
p(EHMA100-co-EGDMA0.80) nanoprecipitates required a much larger content of 
p(PEG114-b-HPMA100) (≥ 70 wt.%), compared to the p(BuMA100-co-EGDMA0.95) 
nanoprecipitates (≥ 40 wt.%) in order to achieve colloidal stability.   
Following these findings, it was assumed that the nanoprecipitates of the EHMA-
based polymers would not be suitable for DDS due to the larger content of AB block 
copolymer required to provide steric stability.  However, interestingly, when pyrene 
was encapsulated during the co-nanoprecipitation process it was shown that whilst 
there was almost no impact on the size and dispersity of the polymer nanoparticles, 
the presence of a hydrophobic guest macromolecule seemed to influence the overall 




EGDMA0.80). This observation was somewhat surprising and was further observed 
when the guest molecule was   substituted with SN-38, which also appeared to aide 
nanoparticle formation. Unexpectedly, it transpired that all the polymers involving 
EHMA monomer residues ultimately became the lead candidates for successful SN-
38 loaded nanoparticle regimes and subsequent pharmacological studies.  
For the first time, the complimentary chemistry of the B segment of the AB block 
copolymer, to the branched vinyl polymer core, was shown as not being a 
prerequisite to produce sterically stabilised nanoparticles, and it was observed that 
by varying of the hydrophobic segment of the AB block copolymer an impact on the 
core polarity was seen.  This new-found ability to manipulate and tune both the 
chemistry of the branched polymer and the AB block copolymer and, in-turn, the core 
of the nanoparticle is very appealing when considering a new drug delivery 
nanocarrier and provides an expansion to the scope of co-nanopreciptation to 
produce branched vinyl copolymer nanoparticles, which seek to complement guest 
drug molecule chemistries.  
All the studies conducted proved that the co-nanoprecipitation approach provided a 
fast and efficient route to sterically stabilised, highly monodisperse, aqueous vinyl 
polymer nanoparticles. This was achieved without the need for any additives, such 
as polymeric surfactants within the aqueous phase. In vitro cytotoxicity studies of 
blank unloaded branched vinyl copolymer nanoparticles confirmed that these 
materials did not cause any decrease in cell viability, which is a critical feature of any 
potential DDS and means that they are fit for their intended purpose. 
The applicability of the co-nanoprecipitation technique for the generation of guest 
loaded sterically stabilised aqueous polymer nanoparticles was demonstrated via low 
loading of hydrophobic guest molecule pyrene which, thanks to its fluorescent 
chemical nature, characterised the internal polarity of the nanoparticles i.e. 
hydrophobicity of the core, was varied through copolymerisation of different vinyl 
and divinyl monomers into the polymers and also through the incorporation of 




Again, when SN-38 was encapsulated, minimal changes to nanoparticle size, 
monodispersity, charge and stability were observed. However, the success of the 
encapsulation was largely dictated by the chemistry of the vinyl monomer residue 
and a strong dependency on EHMA was observed. One possible explanation of this 
dependency, may arise from the observation that the core of nanoparticles 
consisting of EHMA polymers, was found to be the least polar and therefore most 
hydrophobic, meaning that it is more suited as a host environment for SN-38. 
Additionally, it was observed that the most successful SN-38 loaded formulations all 
contained the AB block copolymer, p(PEG114-b-HPMA100).  
The maximum SN-38 drug loading achieved under the studied conditions was 
determined to be 5 wt. % with respect to total mass. Efforts were made to increase 
this value through increasing the SN-38 concentration in the THF solvent phase, via 
pH variations and SN-38 drug modifications; however, all were unsuccessful. 
Alternatively, as per the hypothesis laid out in Chapter 1, investigations were 
conducted into whether drug loading could be optimised and influenced through 
manipulations to core chemistries, specifically through varying the divinyl monomer, 
but again minimal impact was observed.  Whilst this value may appear to be modest, 
it is worth reiterating the extreme potency SN-38 exhibits compared to the prodrug 
irinotecan (up to a 1000- fold increase) and that SN-38 is not currently directly 
administered due to its extreme hydrophobicity and instability, therefore, these 
systems are still an attractive option for clinical treatments. This SN-38 drug loading 
value is also particular noteworthy, since this drug loading achieved through co-
nanopreciptation of SN-38 is higher than those previously reported using alternative 
nanoformulation techniques.1  
Successful multiple co-nanopreciptation allowed for the concentration of SN-38 to 
be increased (four-fold), whilst maintaining the nanoparticles hydrodynamic 
diameter, dispersity and stability, without any additional chemical adaptations or 
modifications to the polymeric nanoparticles. This was the first demonstration of a 




Increasing the drug concentration via such a simple methodology only strengthens 
the attractiveness of these SN-38 loaded nanoparticle systems from a 
pharmacological perspective, since it means that the administered dose required for 
therapy would be reduced. Even at the lowest SN-38 concentration ([SN-38] = 0.05 
mg mL-1), an impressive dosing volume reduction of 65 % was determined for the SN-
38 loaded nanoparticles compared to Campto (marketed product of IR), when the 
potency of SN-38 is assumed to be 1000- fold greater than IR. When a highly 
conservative potency value of SN-38 is used (100- fold), the total volume of 
formulation required does increase (106 mL), compared to Campto (30.6 mL), but 
this value is not thought to be unrealistic for infusion from a clinical perspective. 
Whilst it is noted that this may not be ideal from a formulation perspective, it is worth 
reiterating that the conversion of IR to SN-38 does vary considerably between 
patients and that these SN-38 loaded nanoparticle formulations provide the unique 
advantage of directly administrating aqueous SN-38, something which is not 
currently reported. Additionally, the determined value for total volume required was 
reduced significantly (26.5 mL), when the concentration of SN-38 was increased four-
fold ([SN-38] = 0.20 mg mL-1) via multiple co-nanopreciptation, assuming SN-38 has 
100-fold increased potency. This new determined value is within the range of the 
Campto product.  
Of course, it is recognised that these values determined are subjective and do not 
consider factors such as metabolism and clearance rates, but they do help to provide 
some context into the relevance of these SN-38 nanoformulations as clinical DDS 
which may help to direct future work. This SN-38 potency was also highlighted when 
it was determined that the SN-38 nanoformulations had superior cytotoxicity 
compared to prodrug IR during in vitro cytotoxicity studies. 
In addition to this, the attractiveness of these SN-38 loaded nanoparticles were 
further validated through a series of different radiometric analyses and in vitro 
experiments. Radio dialysis highlighted that the majority of SN-38 mass (> 83 %) was 
encapsulated within the core, since no burst release was observed unlike many 
reported DDS, and that the branched vinyl copolymer nanoparticles retained 




38 retained at pH 7 and 82.7 % SN-38 retained at pH4). Therefore, this suggests that 
the SN-38 concentration within the branched vinyl copolymer nanoparticles would 
remain significant over time and would potentially allow for the nanoparticles to 
accumulate at the intended delivery site via EPR effect and deliver a sufficient 
concentration of SN-38 to maximise their therapeutic effectiveness. It was also 
established through modelling of the release rate data, that SN-38 release from the 
polymer nanoparticles was entirely diffusion based. 
A subtle pH dependency was determined through the release profiles and it was 
observed that by decreasing the pH from 7 to 4, saw the release rate of SN-38 
increase. This was particularly interesting as it suggested that the polymer 
nanoparticles may release more SN-38 at the tumour site, an obvious benefit, since 
it is characteristically a lower pH condition than typically exhibited from blood. 
It was hypothesised that SN-38 release from the polymer nanoparticles may have 
been manipulated and altered through the variations to core chemistry, and in turn 
variations in polymer Tg and polarity. However, despite varying equilibration profiles 
being obtained during RED, no significant difference was observed for the varying 
chemistries and since the majority of successful formulations involved the vinyl 
monomer residue, EHMA, studying the real impact of varying core polarity on drug 
release was not possible. However, it was observed that shorter primary polymer 
chain lengths may cause slower drug release.    
An additional positive effect of the incorporation of an AB block copolymer and 
subsequent PEG moieties, was observed when a reduced cellular accumulation ratio 
was determined for SN-38 loaded: p(BuMA100-co-EGDMA0.95), p(EHMA20-co-
UDMA0.90) and p(EHMA20-co-DSDMA0.75) all co-nanoprecipitated with AB block 
copolymer p(PEG114-HPMA100) (60:40 wt. % composition) compared to free SN-38. 
This suggests that there was a reduction in cellular uptake, potentially caused 
through the reduced recognition of the nanoparticles from the stealth characteristics 
PEG provides. Despite this not being consistently observed across all the 
formulations, positively, it can be confirmed that encapsulating SN-38 within polymer 




The work presented within this thesis shows that aqueous branched vinyl copolymer 
nanoparticles prepared via a simple formulation strategy, co-nanoprecipaiton, can 
act as a suitable DDS for the direct delivery of SN-38 with promising potential. This 
ability to formulate an aqueous SN-38 formulation at clinically viable drug 
concentrations may facilitate a more convenient and efficient delivery of SN-38 and 
would remove the need to utilise the currently administered prodrug IR.  SN-38 
polymer nanoparticles detailed within literature reports predominantly focus on the 
utilisation of polyesters, specifically PLGA, for the synthesis of nanoparticles, whereas 
here it has been demonstrated, for the first time that methacrylate-based polymers 
are also suitable. This may help to overcome some of the disadvantages associated 
with the use of PLGA nanoparticles as drug carriers such as: unpredictable 
degradation profile of PLGA, which has been shown to affect the activity of the 
encapsulated drug and the poor drug loading and burst release.2, 3  
Although the primary objective of this study was successfully met, the study did 
present some limitations. First of all, although a wide library of materials was 
generated, the scope of the project was limited to the chemistries which were 
explored and it may have been that alternative, more beneficial chemistries were 
missed i.e. the chemistry chosen may not have been broad enough or the right 
chemistry for SN-38. However, the chemistries studied here do provide good 
foundational knowledge to build from.  Furthermore, SN-38 was difficult and 
complex to work with, due to its instability with pH change and the extremely limited 
solubility exhibited by SN-38. These complexities of SN-38 may have prevented the 
true impact of the designed chemical variations and their influence on drug 
encapsulation, release and pharmacological behaviour to be seen.  
6.2 Future Work 
The work presented within this thesis has shown that co-nanoprecipitation has 
provided a reliable and fast method to generate sterically stabilised SN-38 loaded 
branched vinyl nanoparticles with reproducibility and high efficiency. However, there 
are multiple different avenues which could be explored should the research in this 





• Further in vivo investigations to gain detailed understanding into the off-site 
accumulation of the polymer nanoparticles within lung tissue.  
• Making the internal nanoparticle core chemistry more like SN-38.  
o Incorporating complimentary SN-38 chemistries within the polymer 
core through monomer and initiator design may promote and increase 
polymer-drug interactions. In turn, this may increase the drug loading 
and modulate drug release.  
• Expanding the scope of the chemistry library further through the use of 
different vinyl monomers which vary more significantly in pendant group 
functionality. 
o This variation may permit the influence of these changes to drug 
encapsulation and release to be observed if the library of the 
monomers used was extended.  
• Applicability of the formulation technique in a scaled-up setting. 
• Encapsulating an alternative anti-cancer drug (e.g. docetaxel, paclitaxel and 
doxorubicin)  
o Utilising the same chemistry discussed but co-nanoprecipitating with 
an alternative drug which is not limited by its extreme hydrophobicity 
and instability. This may provide opportunity to gain more detailed 
understanding into: 1) what limits drug loading capacity, 2) whether 
the effect of chemical manipulation i.e. physicochemical properties 
have on the pharmacological behaviour (e.g. drug release).  
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Butyl methacrylate (BuMA, contains 10 ppm monomethyl ether hydroquinone as 
inhibitor 99%), 2-ethyl hexyl methacrylate (EHMA, 99%), 2-hydroxypropyl 
methacrylate (HPMA, 97% mixture of isomers, contains 180-220 ppm monomethyl 
ether hydroquinone as inhibitor), copper (I) chloride (Cu(I)Cl, 99%), α-bromo 
isobutyryl bromide (EBiB 99%), 2,2’–bipyridine (bpy, 99%), anhydrous methanol 
(anhydrous MeOH, 99.8%), aluminium oxide (activated, neutral), deuterated 
chloroform (CDCl3, 98.8 atom %), ethylene glycol dimethacrylate (EGDMA, 98%), 
bisphenol A dimethacrylate (BPDMA, > 98%), bisphenol A glycerolate dimethacrylate 
(BPGDMA, 98%), bis(2-methacryloyl)oxyethyl disulphide (DSDMA, contains 6000 
ppm hydroquinone as inhibitor, 99%), Diurethane dimethacrylate (UDMA, mixture of 
isomers contains 225 ± 25 ppm topanol as inhibitor, ≥ 97%), Glycerol dimethacrylate 
(GDMA, mixture of isomers, contains 200 ppm monomethyl ether hydroquinone as 
inhibitor, 85%), poly(ethylene glycol) monomethyl ether (Mn ~5,000 g mol-1),  pyrene 
(98%), dithiothreitol (DTT), basic aluminium oxide and Dowex marathon exchange 
beads were purchased from Sigma Aldrich. Anhydrous triethylamine (TEA, 99%), 4-
(dimethylamino) pyridine (DMAP, 99%) and all solvents were analytical grade and 
purchased from Fisher scientific and used as received.   
7-ethyl-10-hydroxycamptothecin (SN-38) was purchased from Chemleader 
Biochemical. SN-38 as purchased was sent to RCTritec, Switzerland for direct 
tritiation (H/T exchange). Tritiated SN-38 was stored in a THF solution until used. THF 
was removed before experiments were conducted. ProSafe+ scintillation cocktail 
was purchased from Meridian Biotechnologies Ltd. and was added to radio samples 
before LSC. All materials were used as received. SN-38 Pentanoate was synthesised 
and supplied by Dr Andrew Dwyer, PDRA in the department of chemistry at the 
University of Liverpool. 
7.2 Instrumentation  
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded in chloroform-
d, methanol-d4, DMSO-d6 or D2O using a 400 MHz Bruker Avance spectrometer 
operating at 400 and 100 MHz, respectively. Chemical shifts (δ) are reported in parts 





Triple detection size exclusion chromatography (SEC) was conducted using either: i) 
a Malvern Viscotek instrument equipped with a GPC max VE2001 auto-sampler, two 
viscotek T6000 columns (and a guard column), a refractive index (RI) detector VE3580 
and a dual 270 detector (light scattering and viscometer), or ii) a Malvern Viscotek 
equipped with D6000 columns (and a guard column) and a triple detector array 
TDA305 (refractive index, light scattering and viscometer). Analysis was conducted 
using a mobile phase of either i) DMF (containing 0.01 M lithium bromide) at 60 °C, 
or ii) THF (containing 2 v/v % TEA), at 35 °C both at a flow rate of 1 mL min-1. Polymer 
thermal characteristics were analysed using differential scanning calorimetry (DSC), 
utilising a DSC Discovery instrument using a T4P calibration of samples held within 
Tzero pans. Samples were analysed at temperatures between -90 and 270 °C under 
a nitrogen atmosphere at a pressure of 0.1 MPa with a heating rate of 5 °C min-1. 
Dynamic light scattering (DLS) measurements and zeta potentials were performed 
using a Malvern Zetasizer Nano ZS instrument with a wavelength of 630 nm. 
Measurements were performed at 25 °C at a nanoparticle concentration of 1 mg mL-
1 unless stated otherwise. Dispersions were measured without additional filtration or 
centrifugation, unless stated otherwise, in a polystyrene disposable fluorometric 
cuvette (size measurements) or a disposable capillary zeta flow cell (zeta 
measurements). Size measurements were obtained as an average of 3 individual 
measurements and were rounded to the nearest 5 nm. Scanning electron microscopy 
(SEM) images were obtained using a Hitachi S-4800 FE-SEM and a Tescan FIB SEM 
S8000G. Aqueous nanoparticle samples were prepared for analysis by dropping 10 
μL sample (0.5 mg mL-1) onto a silicon wafer, which was mounted on an aluminum 
stub with silver electroconductive paste. Samples were placed in a desiccator 
overnight and allowed to dry at ambient temperature and then chromium sputter-
coated (120 mA for 60 seconds). Fluorescence spectra were obtained using a 
Shimadzu RF-5301PC spectrofluorophotometer.  Emission spectra for pyrene were 
recorded between 300 and 500 nm.  An excitation wavelength of λex = 335 nm was 
used for all studies, as well as an excitation slit width of 2.5 nm and an emission slit 
width of 2.5 nm with a scan rate of 60 nm min-1. Electrospray ionisation (ESI) mass 
spectrometry data were recorded in the Mass Spectrometry Laboratory at the 





ionisation and direct infusion syringe pump sampling. All materials were diluted with 
methanol. Elemental analyses were obtained from a Thermo FlashEA 1112 series 
CHNSO elemental analyser. All radiation measurements were carried out using a 
liquid scintillation counter (Packard Tri-Carb 3100TR; Isotech) and radio-TLC analysed 
on an AR-2000 radio-TLC imaging scanner (Bioscan Inc.) 
7.3 Experimental Methods 
7.3.1 Chapter 2  
7.3.1.1 General Synthesis of p(BuMA)100 via ATRP  
Prior to use, anhydrous MeOH and BuMA were deoxygenated via gentle bubbling 
with Ar for 60 minutes. In a typical ATRP synthesis of p(BuMA)100, bpy (0.110 g, 0.704 
mmol, 2 eq.), BuMA (5 g, 35.2 mmol, 100 eq.), was added to an oven dried round-
bottomed flask (25 mL) equipped with an argon inlet/outlet and a magnetic stirrer 
bar. Anhydrous MeOH was added (6.58 mL, 50 wt.% based on total solid mass) and 
the solution was degassed via Ar sparge for 30 minutes. Copper catalyst Cu(I)Cl (0.038 
g, 0.352 mmol, 1 eq.) was added rapidly to the flask forming a brown coloured 
solution, and the reaction was further degassed for 5 mins. EBiB (52 µL, 0.352 mmol, 
1 eq.) was rapidly injected into the solution and the Ar inlet and outlet was removed. 
The reaction flask was inverted and shaken, the septum was sealed with grease and 
flask was swiftly submerged into a preheated oil bath (50 °C). The reactions 
proceeded as homogeneous solution, for 72 hours. The polymerisation was 
terminated by exposure to air and a small sample was removed to calculate the 
monomer conversion by 1H-NMR (CDCl3) (Figure 7.1). The reaction mixture was 
diluted further with the addition of THF, forming a bright green coloured solution. 
The polymer was then purified by passing the sample through a neutral alumina 
column to remove the copper catalytic system. Excess THF was removed under 
vacuum to concentrate the sample before precipitation from THF into ice cold MeOH, 
yielding a white solid, which was dried in a vacuum oven (40 ˚C, 24 hours) The 
resulting polymer was characterised by 1H NMR in CDCl3 (Figure 7.2) and TD-SEC with 








Figure 7.1 Crude 1H-NMR (CDCl3) taken to allow for the quantification of monomer conversion achieved during 




Figure 7.2 1H-NMR (CDCl3) of pure p(BuMA)100. 
This method outlined was also used for the synthesis of p(BuMA)20, p(EHMA)20, 
p(EHMA)100, p(HPMA)20 and p(HPMA)100. The polymerisation of EHMA, became 
biphasic as the polymerisation progressed. Due to this biphasic nature of the EHMA 
polymerisation, termination occurred through the exposure to air and the addition 
of CDCl3 so that a homogenous solution could be formed before collecting a crude 
1H-NMR sample. Purification by precipitation of HPMA based polymer occurred in ice 





7.3.1.2 Determination of p(BuMA)60 Polymerisation Kinetics  
Kinetic studies were performed by taking samples from the polymerisation of 
p(BuMA)60 under positive Ar pressure. The polymerisation was prepared as stated in 
Section 7.3.1.1. Aliquots were analysed by 1H NMR (CDCl3) to determine the 
conversion and by TD-SEC with a mobile phase of THF/TEA 98:2 v/v % after the 
catalyst was removed from the samples by passing through a small neutral alumina 
column. Monomer conversion was determined by NMR spectroscopy using crude 
samples of the reaction medium. Integrals of the vinyl protons of the unreacted 
monomer (5.55 ppm and 6.10 ppm) were compared with the integrals of the CH2 
signal adjacent to the ester group of both the polymer repeat units and the monomer 
(3.95 ppm and 4.15 ppm, respectively). 
7.3.1.3 Synthesis of poly(ethylene glycol) mono-functional ATRP macro-initiator 
(MeO-PEG114-Br) 
Poly(ethylene glycol) methyl ether, MeO-PEG114-OH (32.15 g, 6 mmol, 1 eq.) was 
added to anhydrous toluene (100 mL) in the presence of TEA (1.21 g, 12 mmol, 2 eq.) 
in a two necked round-bottomed flask fitted with a dropping funnel, an Ar 
inlet/outlet and a magnetic stirrer bar. The reaction mixture was heated to 40 °C to 
help solublise the MeO-PEG114-OH. After 30 minutes of heating and stirring, MeO-
PEG114-OH was full dissolved. The reaction mixture was then left to cool to ambient 
temperature. α-bromoisobutyryl bromide (23.76 g, 12 mmol, 2 eq.) diluted with 
toluene (20 mL) was placed into the dropping funnel. The reaction was placed in an 
ice bath and the α-bromoisobutyryl bromide solution was added slowly over 30 mins. 
The ice bath was removed and the reaction mixture was left to stir at ambient 
temperature for 24 hours. Upon return, the reaction mixture had formed a white 
precipitate (triethylamine salt Et3NH+Br-) which provided indication of the reaction 
progress. A hot filtration (50 ˚C) was performed using small amounts of hot toluene 
to wash the salt. The reaction medium was filtered through a short basic alumina 
column with toluene as the eluent and concentrated on the rotary evaporator. The 
resulting product was diluted in THF and purified by precipitation into room 
temperature hexane to yield a fine white powder. Solvent was removed by 
decantation. The precipitation step was repeated, and the product was finally dried 





functional macro-initiator (MeO-PEG114-Br) (white powder, 21 g, 66%) was confirmed 
by 1H NMR in CDCl3, and TD-SEC with a mobile phase of DMF (containing 0.01 M 
lithium bromide).  
7.3.1.4 Synthesis of PEG114 AB block Copolymer p(PEG114-b-BuMA100) by Cu-ATRP. 
Prior to use, anhydrous MeOH and BuMA were deoxygenated via gentle bubbling 
with Ar for 60 minutes. In a typical reaction, targeting a number average DPn of 100 
monomer units for BuMA, using MeO-PEG114-Br macroinitiator (1.81 g, 0.352 mmol, 
1 eq.), BuMA (5 g, 35.2 mmol, 100 eq.) and bpy (0.11 g, 0.704 mmol, 2 eq.) were 
added to a round bottomed flask (25 mL) equipped with an Ar inlet/outlet and a 
magnetic stirrer bar. Anhydrous MeOH (50 wt.%, based on total solid mass, 8.79 mL) 
was added and the solution was degassed via Ar sparge for a further 15 minutes. 
Cu(I)Cl (0.035 g, 3.52 mmol, 1 eq.) was rapidly added to the flask and the reaction 
medium turned dark brown immediately. The reaction mixture was further degassed 
for 60 seconds, sealed with grease and submerged into a preheated oil bath (50 ˚C). 
The reaction was allowed to proceed for 72 hours. The polymerisations were cooled 
and terminated by exposure to air and a small sample was removed and diluted with 
CDCl3 to determine the monomer conversion (1H-NMR, Figure 7.3). The reaction 
mixture was diluted with the addition of DCM. The copper catalytic system was 
removed by passing the polymer solution through a neutral alumina column using 
DCM as the mobile phase. The resulting solution was concentrated in-vacuo and the 
AB block copolymer was purified by precipitation from THF into ice-cold diethyl ether 
and dried in vacuo at 40 ˚C for 24 hours. The resulting AB block copolymer was 
characterised by 1H NMR (CDCl3) and TD-SEC with a mobile phase of THF/TEA (98:2% 
v:v). The procedure outlined above was followed for the synthesis of p(PEG114-b-








Figure 7.3 1H-NMR (CDCl3) of p(PEG114-b-BuMA100). 
7.3.1.5 General Synthesis of EGDMA branched copolymer via methanolic ATRP 
(BuMA, HPMA and EHMA) 
Prior to use, anhydrous MeOH and all monomers were deoxygenated via gentle 
bubbling with Ar for 60 minutes. In a typical reaction, targeting a number average 
DPn of 100 monomer units for BuMA, the branched copolymer, p(BuMA100-co-
EGDMA0.95), was synthesised and purified using the procedure described above for 
linear p(BuMA100) with the addition of the branching agent/ divinyl co-monomer 
EGDMA. In brief, BuMA (5 g, 35.2 mmol, 100 eq.), EGDMA 66.3 mg, 0.342 mmol, 0.95 
eq. wrt.to initiator amount), bpy (0.110 g, 0.704 mmol, 2 eq.) were added to a round 
bottom flask (25 mL) equipped with an Ar inlet/outlet and a magnetic stirrer bar. 
Anhydrous MeOH (50 wt.%, based on total solid mass, 6.67 mL) was added and the 
solution was degassed via Ar sparge for a further 30 minutes.  Cu(I)Cl (34.8 mg, 0.352 
mmol, 1 eq.) was added rapidly, forming a dark brown coloured solution. The 
reaction mixture was purged further with Ar for 30 minutes. EBiB (51.7 µL, 0.361 
mmol, 1 eq.) was injected into the reaction mixture, and the reaction mixture was 
further purged with Ar for approximately 1 minute. The Ar inlet and outlet were 
removed from the flask, which was then inverted, sealed with grease and submerged 
into a pre-heated oil bath (50 ˚C). The reaction was allowed to proceed for 72 hours. 
The polymerisation was terminated by exposure to air and a small sample removed 
to calculate the monomer conversion by 1H-NMR (CDCl3). The reaction mixture was 
diluted using CHCl3, which rapidly turned bright green in colour. The solution was 





concentrated in vacuo. The branched copolymer was then purified by precipitation 
from THF into ice-cold MeOH to yield white solid powder. The supernatant was 
decanted and the residual powder was dried in vacuo at 40 ˚C for 24 hours. The 
resulting branched material was characterised by 1H NMR in CDCl3 and TD-SEC with 
a mobile phase of THF/TEA eluent (98/2 v/v %).  
7.3.1.6 General Synthesis of statistical linear copolymers via methanolic ATRP 
(BuMA, HPMA and EHMA) 
In a typical ATRP synthesis of a linear statistical copolymer p(BuMA50-s-HPMA50) 
targeting DPn = 100 monomer units overall, anhydrous MeOH and all monomers were 
deoxygenated via gentle bubbling with Ar for 60 minutes prior to use. BuMA (1 g, 
7.08 mmol, 50 eq.), HPMA (1.02 g, 7.08 mmol, 50 eq.) and bpy (44.36 mg, 0.284 
mmol, 2 eq.) were added to an oven dried round-bottomed flask (10 mL) equipped 
with an Ar inlet/outlet and a magnetic stirrer bar. Anhydrous MeOH was added (2.63 
mL, 50 wt.% based on total solid mass) and the solution was degassed via Ar sparge 
for 30 minutes. Copper catalyst Cu(I)Cl (0.0140 g, 0.142 mmol, 1 eq.) was added 
rapidly to the flask forming a brown coloured solution, and the reaction was further 
degassed for 5 mins. EBiB (20.8 µL, 0.142 mmol, 1 eq.) was rapidly injected into the 
solution and the Ar inlet and outlet was removed. The reaction flask was inverted 
and shaken, the septum was sealed with grease and the flask was swiftly submerged 
into a preheated oil bath (50 °C). The reactions proceeded as homogenous solutions, 
except for p(BuMA50-s-EHMA50) which became biphasic as the polymerisation 
progressed towards the late stages. Reactions proceeded for up to 72 hours and the 
polymerisations were terminated by exposure to air. In the cases of homogenous 
reaction mixtures, a small sample was removed for 1H-NMR (CDCl3 or MeOD) analysis 
to determine monomer conversion followed by the addition of THF to the reaction 
medium. The biphasic polymerisation was diluted with CDCl3 to allow for a crude 
sample to be taken for 1H-NMR analysis to determine monomer conversion.  All the 
polymers were purified by passing the samples through a neutral alumina column to 
remove the copper catalytic system. Excess THF (or CHCl3) was removed under 
vacuum to concentrate the sample before precipitation from THF into ice cold MeOH, 





polymers were characterised by 1H NMR in CDCl3 and TD-SEC with a mobile phase of 
THF/TEA (98/2 v/v %) using a narrow and broad poly(styrene) standard calibration. 
7.3.1.7 General Synthesis of statistical branched copolymer via methanolic ATRP 
(BuMA, HPMA and EHMA) 
The synthesis and purification of statistical branched copolymers followed the same 
procedure as that described for linear p(BuMA50-s-HPMA50), but with the inclusion of 
EGDMA divinyl monomer. BuMA (2.50 g, 17.6 mmol, 50 eq.), HPMA (2.54 g, 
17.6  mmol, 50 eq.), EGDMA (62.8 mg, 3.168 mmol, 0.9 eq.) and bpy (0.110 g, 0.704 
mmol, 2 eq.) were added to a reaction flask (25 mL) fitted with a magnetic stirrer bar 
and an Ar inlet and outlet. Anhydrous MeOH (50 wt.% wrt. total solid mass, 6.71 mL) 
was added and the solution was degassed via Ar sparge for 30 minutes. Copper 
catalyst Cu(I)Cl (34.8 mg, 0.352 mmol, 1 eq.) was added rapidly to the flask forming 
a brown coloured solution, and the reaction was further degassed for 5 mins. EBiB 
(68.7 µL, 0.352 mmol, 1 eq.) was rapidly injected into the solution and the Ar inlet 
and outlet was removed. The reaction was then carried out in an identical manner to 
that described in section 7.3.1.7 with precipitation of polymer into ice-cold hexane. 
The resulting polymer was characterised by 1H NMR in CDCl3 and TD-SEC with a 
mobile phase of THF/TEA (98/2 v/v%) using a narrow and broad poly(styrene) 
standard calibration. 
7.3.1.8 General Synthesis of branched EHMA copolymers with varying divinyl 
monomers (BPGDMA, BPDMA, DSDMA, UDMA, GDMA) 
Prior to use, anhydrous MeOH and EHMA monomer were deoxygenated via gentle 
bubbling with Ar for 60 minutes. In a typical reaction, targeting a number average 
DPn of 20 monomer units for p(EHMA20-co-UDMA0.90), EHMA (2 g, 10 mmol, 20 eq.), 
UDMA (0.2139 g, 0.4545 mmol, 0.90 eq. wrt. to initiator amount) and bpy (0.1567 g, 
1.01 mmol, 2 eq.) were added to a round bottomed flask (25 mL) equipped with an 
Arinlet/outlet and a magnetic stirrer bar. Anhydrous MeOH (50 wt.%, based on total 
solid mass, 3.24 mL) was added and the solution was degassed via Ar sparge for a 
further 30 minutes.  Cu(I)Cl (49.6 mg, 0.502 mmol, 1 eq.) was added rapidly, forming 
a dark brown solution. The reaction mixture was purged further with Ar for 30 
minutes. EBiB (73.7 µL, 0.502 mmol, 1 eq.) was injected into the reaction mixture, 





Ar inlet and outlet were removed from the flask, which was then inverted, sealed 
with grease and submerged into a pre-heated oil bath (50 ˚C). The reaction was 
allowed to proceed for 48 hours, and become biphasic as the reaction progressed. 
The polymerisation was terminated by exposure to air and the reaction medium was 
diluted using CDCl3 to give a bright green and homogenous mixture. The mixture was 
passed over a neutral alumina column to remove the catalytic complex and 
concentrated in vacuo. The branched copolymer was then purified by precipitation 
from THF into ice-cold MeOH to yield white powder. The supernatant was decanted, 
and the residual polymer was dried in vacuo at 40 ˚C for 24 hours. The resulting 
branched material was characterised by 1H NMR in CDCl3 and TD-SEC with a mobile 
phase of THF/TEA eluent (98/2 v/v %).  
7.3.2 Chapter 3  
7.3.2.1 Aqueous nanoparticle formation  
7.3.2.2 Sole Nanoprecipitations 
During a typical sole nanoprecipitation experiment, polymeric material (50 mg) was 
dissolved in 10 mL of analytical grade THF in a glass vial and sealed. The vial was 
placed on a roller mixer at ambient temperature for 18-24 hours to allow for 
complete solubilisation. The polymer concentration within this stock was [P]0 = 5 mg 
mL-1. The polymer/THF stock solution (1 mL) was rapidly added to a glass vial 
containing deionized water (5 mL) which was stirring (450 rpm). This mixture was 
then left for 24 hours at ambient temperature to allow for THF evaporation, resulting 
in an aqueous nanoparticle dispersion at final polymer concentration [P]f = 1 mg mL-
1. These nanoparticle dispersions were assessed initially by visual observation for any 
signs of sedimentation or polymer aggregates. DLS analysis of the aqueous 
dispersions (1 mL) was then performed to obtain the hydrodynamic diameter and 
zeta potential measurements. This method was used for the sole nanoprecipitations 
of: linear homopolymers, branched copolymers, AB block copolymers and statistical 
linear and branched copolymers.  
7.3.2.3 Co-nanoprecipitations  
During a typical co-nanoprecipitation targeting a weight fraction of 40 wt.% AB block 





weighed out (20 mg of AB block copolymer and 30 mg of hydrophobic polymer) into 
a glass vial followed by the addition of THF (10 mL). The solutions were sealed and 
placed on a roller mixer for 24 hours to allow for solubilisation. The polymer 
concentration within this stock solution was [P]0 = 5 mg mL-1. The polymer/THF stock 
solution (1 mL) was added to a glass vial containing stirring (450 rpm) deionized water 
(5 mL). This mixture was then left for 24 hours at ambient temperature to allow for 
THF evaporation, resulting in an aqueous nanoparticle dispersion at final polymer 
concentration [P]f = 1 mg mL-1. These nanoparticle dispersions were assessed initially 
by visual observation for any signs of sedimentation or polymer aggregates. DLS was 
then used to obtain the hydrodynamic diameter and zeta potential measurements.  
 
7.3.2.4 Varying the Weight Compositional Ratio of Each Polymeric Component 
Within Co-nanoprecipitation 
Co-nanoprecipitation studies were conducted using branched copolymer and AB 
block copolymer weight percentages of: 100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 
40:60, 30:70, 20:80, 10: 90 and 0:100. A total mass of 50 mg of material was weighed 
out into a glass vial followed by the addition of THF (10 mL). The solutions were 
sealed and placed on a roller mixer for 24 hours to allow for solubilisation. Polymer 
concentration within this stock was [P]0 = 5 mg mL-1. The polymer/THF stock solution 
(1 mL) was added to a glass vial containing stirring (450 rpm) deionized water (5 mL). 
This mixture was then left for 24 hours at ambient temperature to allow for THF 
evaporation, resulting in an aqueous nanoparticle dispersion at final polymer 
concentration [P]f = 1 mg mL-1. These nanoparticle dispersions were assessed initially 
by visual observation for any signs of sedimentation or polymer aggregates. DLS was 
then used to obtain the hydrodynamic diameters. This method was used for the co-
nanoprecipitations of p(HPMA100-co-EGDMA0.90), p(BuMA100-co-EGDMA0.95) and 
p(EHMA100-co-EGDMA0.80) with p(PEG114-b-HPMA100). Samples were left at ambient 
temperature on the benchtop for 10 days and DLS measurements were repeated to 





7.3.2.5 Nanoparticle Stability to Addition of PBS 
Five THF stock solutions of p(HPMA100-co-EGDMA0.90): p(PEG114-b-HPMA100) were 
prepared with compositional ratios varying from 100:0 – 50:50 wt.%, respectively. 
The polymer concentration within this stock solution was 5 mg mL-1. The polymer-
THF stock solution (1 mL) was added to stirring DI water (5 mL, 450 rpm) to produce 
a final polymer concentration of 1 mg mL-1, and THF was allowed to evaporate 
overnight. Initial Dz, PDI and derived count rate values were determined via DLS prior 
to dilution.  PBS (pH 7.4) was added over a 100-fold dilution factor to produce 
polymer concentrations at 0.5, 0.25, 0.1 and 0.01 mg mL-1. The aqueous nanoparticle 
dispersions were sealed and placed on a roller mixer overnight following dilution and 
then assessed initially by visual observations for any sign of polymer aggregation or 
sedimentation and then via DLS at [P]f = 1 mg mL-1.  
7.3.2.6 SEM Sample Preparation of Nanoparticles 
In a typical preparation of a sample for SEM analysis, aqueous nanoparticle 
dispersion (1 mL, 1 mg mL-1) was added to a glass vial containing deionised water (1 
mL) to give a diluted aqueous nanoparticle dispersion at a concentration of 0.5 mg 
mL-1 . Aqueous nanoparticle dispersion (10 µL) was dropped onto a silicon wafer, 
which was mounted on an aluminum stub with silver DAG and left to dry overnight 
in a desiccator. Dried samples were chromium sputter-coated (120 mA for 60 
seconds).   
7.3.2.7 Encapsulation of the Hydrophobic Guest Molecule Pyrene 
In a typical encapsulation of pyrene, a stock solution of pyrene was prepared in 
acetone (0.1 mg mL-1). The stock solution (300 μL, 0.1 mg mL-1) was added to a glass 
vial and the acetone was allowed to evaporate overnight to leave pyrene dye (30 μg). 
For a typical co-nanoprecipitation targeting a 60:40 wt.% composition, p(HPMA100-
co-EGDMA0.95) (18 mg), p(PEG114-b-HPMA100) (12 mg) and THF (6 mL) were added to 
the vial to give [P]0 = 5 mg mL-1 and [pyrene]0 = 5 µg mL-1. The solution was sealed 
and placed on a roller mixture for 24 hours for complete solubilisation. The pyrene 
loaded nanoparticles were then prepared by rapid addition of 
copolymers/pyrene/THF (1 mL) into vigorously stirring deionised water (5 mL, 450 





THF evaporation leading to a [P]f = 1 mg mL-1 and [pyrene]f = 1 μg mL-1. Samples were 
assessed initially by visual observations to look for any signs of visible polymer 
aggregation or sedimentation, then the samples were assessed via DLS.  
7.3.2.8 Evaluating the Stability of Pyrene Loaded p(EHMA100-co-EGDMA0.80): 
p(PEG114-b-HPMA100) Nanoparticles to PBS Addition  
A stock solution of pyrene was prepared in acetone (0.1 mg mL-1). The stock solution 
(300 μL, 0.1 mg mL-1) was added to glass vials and the acetone was allowed to 
evaporate overnight to leave pyrene dye (30 μg). Five stock solutions of p(EHMA100-
co-EGDMA0.80): p(PEG114-b-HPMA100) were prepared with compositional ratios 
varying from 100:0 – 50:50 wt.%, respectively. The polymer concentration within this 
stock solution was 5 mg mL-1. The solution was sealed and placed on a roller mixture 
for 24 hours for complete solubilisation. The pyrene loaded nanoparticles were then 
prepared by rapid addition of copolymers/pyrene/THF (1 mL) into vigorously stirring 
deionised water (5 mL, 450 rpm). The mixture was left for 24 hours at ambient 
temperature to ensure complete THF evaporation leading to a [P]f = 1 mg mL-1 and 
[pyrene]f = 1 μg mL-1. Samples were assessed via DLS before addition of PBS. 
Following this, PBS (pH 7.4) was added over a 100-fold dilution factor to produce 
polymer concentrations at 0.5, 0.25, 0.1 and 0.01 mg mL-1. The aqueous nanoparticle 
dispersions were sealed and placed on a roller mixer overnight following dilution and 
then assessed initially by visual observations for any sign of polymer aggregation or 
sedimentation and then via DLS at [P]f = 1 mg mL-1.  
7.3.3 Chapter 4 
7.3.3.1 Preparation of Aqueous SN-38 Loaded Nanoparticles (5 wt.% drug loading) 
Before conducting the co-nanoprecipitation experiments, a stock solution of SN-38 
was prepared in THF (1 mg mL-1). During a typical co-nanoprecipitation, 2.5 mL of the 
SN-38 stock solution was added to a vial and to this, 30 mg of a branched copolymer 
and 20 mg of AB block copolymer were added and dissolved in 7.5 mL of THF. The 
solution was tightly sealed and placed on a roller mixer overnight to ensure complete 
solubilisation. SN-38/polymer THF stock (1 mL, [P]0= 5 mg mL-1) was added rapidly to 
stirring DI water (5 mL). The mixture was left for 24 hours at ambient temperature to 





nanoparticles ([P]f = 1 mg mL-1 and [SN-38] = 0.050 mg mL-1. These nanoparticle 
dispersions were assessed initially by visual observation for any signs of 
sedimentation or polymer aggregates. DLS was then used to obtain the 
hydrodynamic diameter and zeta potential measurements. The same procedure was 
followed when targeting drug loading values of 2.5, 6, 7.5, 10, 20 and 30 wt.%. 
7.3.3.2 Determining the Encapsulation Efficiency of SN-38 During Co-
Nanoprecipitation via UV-Vis Spectroscopy 
SN-38 loaded aqueous nanoparticle dispersions were prepared as previously 
described in Section 7.3.3.1. An aliquot of SN-38 loaded aqueous nanoparticle 
dispersion (1 mL, [P]f = 1 mg mL-1) was added to a glass vial and rapidly cooled using 
liquid N2 and H2O was removed via freeze drying over 48 hours. The same SN-38 
loaded aqueous nanoparticle dispersion (1.5 mL, [P]f = 1 mg mL-1) was added to an 
Amicon® ultra-15 centrifugal filter unit (MWCO = 3 kDa) with a regenerated cellulose 
membrane and placed under high centrifugation (6000 xg, 20 °C) for 60 minutes. The 
filtrate (1 mL), located in the bottom compartment of the centrifugal filter unit, was 
removed and added to a glass vial. DI H2O (1 mL) was added to the top compartment 
and the sample was placed under high centrifugation (6000 xg, 20 °C) for 30 minutes. 
The SN-38 loaded nanoparticles were washed a further 2 times. The aliquots (total 
volume = 4 mL) were combined and rapidly cooled under liquid N2 and freeze dried 
for 72 hours. Following the removal of H2O, both the filtrate and unfiltered SN-38 
loaded aqueous nanoparticle monoliths were re-solvated with a known volume of 
inhibitor-free THF.  The SN-38 mass concentration was determined from the UV-Vis 
absorption at 390 nm, using a pre-established SN-38 calibration curve, which was 
prepared for SN-38 from 8 standard THF stock solutions obtained over 0.1 μg mL-1 to 
15 μg mL-1. SN-38 encapsulation efficiency was determined by using Equation 7.1. 
Where, [SN-38]total represents the SN-38 concentration determined prior to 
ultracentrifugation and [SN-38]free represents the SN-38 concentration determined 
from the filtrate following the ultracentrifugation.  
EE (%) = (
[SN−38 total]−[SN−38 free]
[SN−38 total]





7.3.3.3 Stability of SN-38 Loaded Nanoparticles   
SN-38 loaded nanoparticle formulations of p(BuMA100-co-EGDMA0.95): p(PEG114-b-
HPMA100) (2.5 wt.% SN-38) and p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) (2.5 
and 5 wt.% SN-38) were prepared as described in Section 7.3.3.1, with composition 
of branched polymer: AB block copolymer at 60:40 wt.%, respectively. Initial Dz, PDI, 
derived count rate and zeta potential measurements were obtained via DLS following 
THF evaporation after 24 hours.  Nanoparticle dispersions were then stored out of 
direct light at ambient temperature, and the measurements repeated after 7 days 
and 13 weeks of storage.  
7.3.3.4 Reproducibility Studies on SN-38 Loaded Nanoparticles   
Three independent co-nanoprecipitations of 5 wt.% SN-38 loaded p(EHMA100-co-
EGDMA0.80): p(PEG114-b-HPMA100) at 60:40 wt.% compositions were conducted under 
identical conditions from three different stock solutions as previously described in 
Section 7.3.3.1. Dz, PDI, derived count rate and zeta potential measurements were 
obtained via DLS after THF evaporation after 24 hours.   
7.3.3.5 Modifying pH of Nanoprecipitation Environment  
SN-38 loaded co-nanoprecipitation regimes were prepared as described in Section 
7.3.3.1, but the pH of the deionised water was altered to pH 4 by the addition of 
H2SO4 (aq.) (1 M). SN-38/polymer THF stock solution (1 mL, [P]0 = 5 mg mL-1) was added 
rapidly to stirring water (5 mL, pH 4). The mixture was left for 24 hours at ambient 
temperature to ensure complete THF evaporation to yield SN-38 loaded aqueous 
polymer nanoparticles ([P]f = 1 mg mL-1 and [SN-38] = 0.050 mg mL-1. These 
nanoparticle dispersions were assessed initially by visual observation for any signs of 
sedimentation or polymer aggregates. DLS was then used to obtain the 
hydrodynamic diameter and zeta potential measurements.  
7.3.3.6 Multiple Co-nanoprecipitations 
During a typical multiple co-nanoprecipitation, a THF stock solution of 5 wt.% SN-38 
loaded p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) was prepared as described 
in Section 7.3.3.1, at 60:40 wt.% composition of branched polymer: AB block 
copolymer, respectively, and a concentration of polymer = 5 mg mL-1. The SN-





sample was left to stir for 24 hours to allow for THF evaporation. To this aqueous 
nanoparticle dispersion, SN-38/polymer-THF stock solution (1 mL) was then added 
again with rapid stirring and left for 24 hours. A further two additions were made in 
the same manner, to generate aqueous SN-38 loaded nanoparticle dispersions with 
[P]f = 4 mg mL-1 and [SN-38] = 0.20 mg mL-1. Dz, PDI and derived count rate values 
were determined via DLS measurements.   
7.3.3.7 Assessment of 3H-Labelled SN-38 Radio Purity via Radio Thin-Layer 
Chromatography 
Thin-layer chromatography (TLC) analysis was conducted on SN-38 in order to 
establish a suitable eluent system and Rf values; these were determined to be ethyl 
acetate (100%) and Rf1 = 0.25 and Rf2 = 0.88 associated with the open and closed 
lactone form of SN-38. Using the same mobile phase, radio-TLC was conducted to 
check radio purity of 3H-labelled SN-38, which was ran in parallel to unlabelled SN-
38. TLC plate was dried and analysed using a radio-TLC imaging scanner which 
generates Rf values via digital counting of 3H isotopes. The Rf values obtained for the 
radio-labelled and unlabelled SN-38 were compared and found to be in good 
agreement.  
7.3.3.8 Preparation of 3H-SN-38 Loaded Branched Vinyl Copolymer Nanoparticles 
via Co-Nanoprecipitation  
3H-SN-38 loaded nanoparticles were prepared targeting a SN-38 drug loading of 5 
wt.% using a compositional ratio of branched polymer: AB block copolymer at 60:40 
wt.%, respectively. Total solid mass was 50 mg and [P]0 = 5 mg mL-1.   For a typical co-
nanoprecipitation of 5 wt.% 3H-SN-38 loaded p(EHMA100-co-EGDMA0.80): p(PEG114-b-
HPMA100), a stock solution of 3H labelled SN-38 (5-135 µL, 5.418-37.133 µCi mg-1) was 
prepared in EtOH and added to a glass vial and left at ambient temperature overnight 
to allow complete EtOH evaporation. A stock solution of p(EHMA100-co-EGDMA0.80): 
p(PEG114-b-HPMA100) was prepared in THF ([P]0 = 5 mg mL-1), sealed and placed on a 
roller mixer for 24 hours. To the glass vial containing dried 3H-SN-38, an aliquot of 
polymer stock solution was added; the glass vial was then sealed and the contents 
were mixed using a vortex mixer for approx. 1 minute.  Co-nanoprecipitation was 
conducted by rapidly adding this solution (1 mL) into stirring DI water (5 mL), and the 





and to yield 3H-SN-38 loaded p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) 
nanoparticles with [P]f = 1 mg mL-1 which were analysed by DLS.  
7.3.3.9 Determining Radiometric Encapsulation Efficiency  
The encapsulation efficiency of 3H-SN-38 loadings was determined by using LSC to 
obtain the total mass of SN-38 present within the aqueous nanoparticle dispersions 
prepared as described in Section 7.3.3.11. Following this, the aqueous nanoparticle 
dispersions (0.5 mL, [P]f = 1 mg mL-1) were placed in centrifugal tubes and centrifuged 
(14 000 rpm, 1 hour). The filtrates were collected and analysed via LSC, which 
determined the mass of the free SN-38 present. Encapsulation efficiencies were 
calculated using Equation 7.2. 
EE (%) =  
(Total mass of SN−38)−(Free SN−38)
(Total mass of SN−38)
 x 100 (7.2) 
 
7.3.3.10 Determining SN-38 Release Rates via 3H Radio-dialysis at pH 7 and pH 4 
SN-38 release rates were determined at pH 7 and pH 4 using radio dialysis of 
p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) aqueous nanoparticle dispersion. 
The 3H-SN-38 loaded nanoparticle dispersion was prepared as described in Section 
7.3.3.11, with a targeted SN-38 loading of 5 wt.% and [P]f = 1 mg mL-1. Loaded 3H-SN-
38 p(EHMA100-co-EGDMA0.80): p(PEG114-b-HPMA100) (1 mL) nanoparticle dispersion 
was added to a double-sided dialyser (MWCO = 3.5 kDa regenerated cellulose 
membrane). This was placed in a preheated (37 °C) glass jar containing DI water (100 
mL, pH 7), which was then placed in a preheated oil bath and stirred (100 rpm). SN-
38 release rate was monitored at pre-determined time points of 0.5, 1, 2, 3, 4, 5, 6, 
7, 8 and 24 hours. At each time point the bio-dialyser was removed and added to a 
new jar with pre-heated H2O (100 mL). SN-38 release rate was determined using LSC 
after removing an aliquot (1 mL) from each independent time point reservoir and 
adding scintillation cocktail (10 mL). The release rate of SN-38 was also determined 
in an identical manner at pH 4, with the only difference being the pH of the DI water 
in the reservoir was acidified to pH4 using 1 M HCl(aq.). Cumulative release was  
calculated using Equation 7.3. 
Cumulative Release (%) = (
(concentration drug release)t
(total drug concentration) t=o





7.3.3.11 Determining SN-38 Release Rates via 3H Radio-dialysis with a pH step 
change from pH 7 to pH 4.  
SN-38 release rates from 5 wt.% 3H-SN-38 loaded p(EHMA100-co-EGDMA0.80): 
p(PEG114-b-HPMA100) nanoparticles were determined as per Section 7.3.3.13.  
However, at the time point of 4 hours, the pH of the water in the reservoir was 
changed from pH 7 to pH 4.   
7.3.3.12 Determining SN-38 Release Rates via 3H Radio-dialysis of 5 wt. % 3H-SN-38 
loaded p(EHMA20-co-DSDMA0.80), p(EHMA20-co-BPGDMA0.80) and p(EHMA20-co-
EGDMA0.80): p(PEG114-b-HPMA100) Nanoprecipitate Regimes 
SN-38 release rates from 5 wt.% 3H-SN-38 loaded p(EHMA20-co-DSDMA0.80), 
p(EHMA20-co-BPGDMA0.80) and p(EHMA20-co-EGDMA0.80) with p(PEG114-b-HPMA100) 
at 60:40 wt.%, respectively, were determined using radio-dialysis following the same 
method outlined in Section 7.3.3.13. 
7.3.3.13 Determining SN-38 Release Rates via 3H Radio-dialysis of Increased 1H-SN-
38 Drug Concentrations  
Multiple co-nanoprecipitations of 5 wt.% loaded 3H-SN-38 p(EHMA20-co-EGDMA0.80): 
p(PEG114-b-HPMA100) with a compositional ratio of 60:40 wt.%, respectively, were 
conducted. A SN-38/polymer-THF stock solution was prepared and co-
nanoprecipitated as described in Section 7.3.3.11 to produce four samples. Each 
sample would be used to monitor the release at the corresponding addition number 
(i.e. the sample that was analysed after the first stock addition did not receive an 
additional subsequent addition). Release studies were conducted via radio-dialysis 
with SN-38 concentrations of 0.05, 0.10, 0.15 and 0.20 mg mL-1 after THF evaporation 
at pH 7, 37 °C.  
7.3.4 Chapter 5 
7.3.4.1 Pharmacology Studies  
As discussed throughout, pharmacology assessment of various co-nanoprecipitated 
materials was conducted by Usman Arshad, supervised by Joanne Sharp and Helen 
Box. The SN-38 encapsulated materials were studied to assess their release rates, 
cellular accumulation in macrophages and cytotoxicity to HTC-116, CT-26, LoVo, DLD-





7.3.4.2 Materials  
Dulbecco’s Modified Eagles Medium (DMEM), Hanks buffered saline solution (HBSS), 
Trypsin-EDTA, bovine serum albumin (BSA), Formic acid (FA), 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent), acetonitrile (ACN) and all 
general laboratory reagents were purchased from Sigma (Poole, UK). Foetal bovine 
serum (FBS) was purchased from Gibco (Paisley, UK). The CellTiter-Glo® Luminescent 
Cell Viability Assay kit was from Promega (UK). The 24-well HTS transwell plates were 
obtained from Corning (New York, USA). The 96-well black walled, flat bottomed 
plates were from Sterilin (Newport, UK). Rotenone, 2-deoxyglucose, chlorpromazine 
hydrochloride, dansylcadaverine, indomethacin, genistein, dynasore hydrate were 
all purchased from Sigma Aldrich. 
7.3.4.3 In vitro Release of SN-38 via Rapid Equilibrium Dialysis  
Candidates from physicochemical characterisation were progressed to in vitro 
release kinetics using a rapid equilibrium dialysis setup. SN-38 NPs were diluted to 
250 ng ml-1 in PBS (pH 7.4). Free SN-38 was dissolved in DMSO prior to dilution with 
PBS, such that DMSO comprised < 1% of final volume. To assess release, 0.5 mL of 
samples were added to the donor compartment of an 8 kDa MWCO rapid equilibrium 
dialysis inserts (ThermoFisher Scientific) and 1 mL PBS was added to the acceptor 
compartment. Plates containing the inserts were placed on an orbital shaker 
(Heidolph Rotomax 120; 100 rpm, 48 hours, 37  ± 1 °C). Each insert represented a 
single time-point and at specified time intervals both acceptor (1 mL) and donor fluid 
(0.5 mL) were removed. Aliquots of each timed sample were then used to determine 
levels of SN-38 in each compartment using a validated LC-MS method. Data are 
shown as the % release of SN-38 (diffused across the membrane). 
7.3.4.4 In vitro Cytotoxicity 
The cytotoxicity of selected nano-formulations was tested on CT26, DLD-1, HCT116 
and LoVo colorectal cancer cell lines. The toxicity was also compared to irinotecan 
and free SN-38 solution in 0.1% DMSO. Monolayer cells were seeded on 96-well 
plates at density of 2000-5000 cells/well and incubated for 24 hours at 37 °C under 
5% CO2. Additionally, HCT116 (1250 cells/well) and CT26 (1000 cells/well) were 





incubation, the medium was replaced with increasing NP and free SN-38 
concentrations (0.5 to 400 nM) or irinotecan (0.01 to 100 µM) and left for 24-144 
hours. Cell viability was measured using the CellTiter-Glo® Luminsecent cell viability 
assay (Promega, UK) according to manufacturer’s instructions. Luminescence was 
then measured at 570 nm wavelength using a Varioscan flash fluorescent plate 
reader. Cell viability was calculated as a percentage of untreated vehicle control 
(DMSO – 0.1%) or blank NP samples and used to determine an IC50 value (mean ± SD, 
n = 3). 
7.3.4.5 Macrophage Uptake 
Monocytes were isolated by ficoll plaque separation of buffy coats purchased from 
the NHS Blood and Transfusion Service. The CD14+ monocytes were then 
differentiated into M1/M2 macrophages using macrophage generation media DXF. 
Macrophages (1 x 106) were plated out in 6 well plates and treated (50 µM) for 24 
hours with the various nano-formulations. Both extracellular and intracellular 
(following lysis with H2O) levels of SN-38 were quantified using the LC MS/MS 























Figure A.1 1H-NMR (CDCl3,400 MHz) of BuMA monomer.  
 








Figure A.3 1H-NMR (MeOD,400 MHz) of HPMA monomer. 
 
 






Figure A.5 1H-NMR (CDCl3, 400 MHz) of p(PEG114-b-EHMA100). 
 






Figure A.7 1H-NMR (MeOD, 400 MHz) of p(HPMA100-co-EGDMA0.95).  
 







Figure A.9 DSC thermogram obtained for p(EHMA20). 
 






Figure A.11 DSC thermogram obtained for p(HPMA100). 
 
Figure A.12 DSC thermogram obtained for p(BuMA100). 
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Figure A.13 DSC thermogram obtained for p(HPMA100-co-EGDMA0.90). 
 







Figure A.15 DSC thermogram obtained for p(EHMA100-co-EGDMA0.80). 
 






Figure A.17 DSC thermogram obtained for p(EHMA20-co-EGDMA0.80). 
 
Figure A.18 DSC thermogram obtained for p(BuMA50-s-EHMA50). 
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Midpoint type: Half height 
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Figure A.19 DSC thermogram obtained for p(HPMA50-s-EHMA50). 
 
Figure A.20 DSC thermogram obtained for p(BuMA50-s-HPMA50).
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Figure A.21 DSC thermogram obtained for p(BuMA50-s-HPMA50-co-EGDMA0.90). 
 






Figure A.23 DSC thermogram obtained for p(BuMA50-s-EHMA50-co-EGDMA0.95). 
 
 






Figure A.25 DSC thermogram obtained for p(PEG114-b-BuMA100). 
 







Figure A.27 DSC thermogram obtained for p(EHMA20-co-UDMA0.80). 
 
Figure A.28 DSC thermogram obtained for p(EHMA20-co-DSDMA0.80). 
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Figure A.29 DSC thermogram obtained for p(EHMA20-co-BPDMA0.85). 
 
Figure A.30 DSC thermogram obtained for p(EHMA20-co-GDMA0.85). 
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Table A.1 DLS analyses of p(HPMA100-co-EGMDA0.90) co-nanoprecipitates varying in wt. % of p(PEG114-b- HPMA100) 
from 0 – 50 wt.%, respectively, following the serial dilution with PBS addition at 0.10 & 0.01 mg mL-1.  
Polymer Concentration Wt.% of Branched 
Polymer 




(nm) PDI Derived 
count rate 
(kcps) 
0.10 mg mL-1 
(PBS) 
100 0 Polymer aggregation 
90 10 Polymer aggregation 
80 20 160 0.098 51 200 
70 30 80 0.129 12 255 
60 40 60 0.133 5400 
50 50 240 0.307 6000 
0.01 mg mL-1 (PBS) 
100 0 Polymer aggregation 
90 10 Polymer aggregation 
80 20 160 0.142 6000 
70 30 85 0.235 1300 
60 40 125 0.350 850 








Figure A.31 Size distribution by intensity of p(EHMA100-co-EGMDA0.90) and 10 wt. % AB block copolymer p(PEG144-












Table A.2 DLS and zeta potential analyses of aqueous nanoparticle dispersions produced via co-nanoprecipitation 
of the AB block copolymer, p(PEG114-b-HPMA100), with branched p(EHMA) varying in divinyl monomer residue 








Figure A.32 1H-NMR (DMSO-D6, 400 MHz) of SN-38.  
  AB Block copolymer: p(PEG114-b-HPMA100) 









(kcps)a ζ (mV)b 
20 
GDMA 165 0.131 574 300 -11.9 
UDMA 160 0.084 765 000 -7.79 
100 
GDMA 165 0.104 689 500 -8.45 
UDMA 160 0.038 627 900 -10.4 
a Measured using DLS analysis at a concentration of 1 mg mL-1. b Obtained via measurement of the electrophoretic mobility of 






Figure A.33 13C-NMR analysis of SN-38 (DMSO-d6,400 MHz). 
 
Figure A.34 UV-Vis calibration curve for SN-38 absorbance at wavelength of 390 nm, concentration range of 0 


















UV Calibration Curve of SN-38 




Figure A.35 A photograph of 5 wt. % SN-38 loaded p(EHMA20-co-DSDMA0.80): p(PEG114-b-HPMA100) co-
nanoprecipitate regime with increased SN-38 concentration and polymer concentration after 5 weeks following 
the multiple nanoprecipitation.  
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